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Abstract 
Kidney cancer accounts for 2-3% of adult malignancies with clear cell renal cell 
carcinoma (ccRCC) being the most common histological subtype (70-80% of cases). 
Interestingly, ccRCCs show a highly distinct metabolic phenotype making this disease 
stand out amongst other cancer types. The underlying causes of the aberrant metabolism 
in ccRCC are not fully understood, but metabolic transformation could provide novel 
strategies for targeted therapies in this disease. The pVHL tumour suppressor is located 
on chromosome 3p21, which is frequently lost in ccRCC. pVHL is a negative regulator 
of the Hypoxia-inducible factor (HIF), which orchestrates the cellular response to 
oxygen deprivation and might contribute to the aberrant metabolic phenotype of ccRCC 
cells. 
In order to reveal metabolic weaknesses in ccRCC, a customised RNAi screen targeting 
230 different metabolic enzymes, regulators and nutrient transporters was performed. 
The screen was performed in a panel of 5 ccRCC pVHL-null cell lines and included 
their counterparts with reconstituted pVHL, in order to also identify potential 
vulnerabilities that depend on VHL function. With this approach, several genes that are 
essential for ccRCC cell viability but dispensable for the survival of non-malignant 
renal epithelial cells were identified. It was found that ccRCC cell lines are highly 
sensitive to ablation of components of the glutathione-dependent reactive oxygen 
species (ROS) detoxification system. Silencing of enzymes of the glutathione 
biosynthesis pathway or different glutathione peroxidases (GPXs) severely impaired 
cell viability. One of the precursors of glutathione biosynthesis is glutamate, which is 
generated from glutamine by glutaminase (GLS). Interestingly, there is evidence that 
ccRCCs are highly dependent on the MYC oncogene, which induces many enzymes 
within the glutaminolysis pathway. Indeed, we found that glutamine starvation or 
chemical inhibition of GLS reduced proliferation and viability of ccRCC cells, 
confirming the importance of this pathway in ccRCC. 
In conclusion, the study reported in this thesis provides insight into the metabolic 
dependencies of ccRCC cells and emphasises the need for a solid anti-oxidant system 
for ccRCC cell survival and proliferation. Concomitantly, the reliance of ccRCC cells 
on glutamine and glutathione is a vulnerability that could potentially be exploited for 
diagnostic and/or therapeutical applications. 
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1.1  Cancer – cell proliferation out of control 
Under normal conditions, cell proliferation is a highly controlled process required for 
tissue growth and regeneration. Cell proliferation is stimulated through growth factors 
such as epidermal growth factor (EGF), platelet-derived growth factor (PDGF), insulin-
like growth factor (IGF), vascular endothelial growth factor (VEGF), tumour growth 
factor α (TGF-α) or other mitogens and inhibited by growth inhibitory factors, such as 
TGF-β. Growth factors engage intracellular signalling cascades that eventually lead to 
regulation of gene expression and modulation of the cell cycle. Moreover, if the cell 
senses stress or accumulated damage, such as DNA breaks, lipid oxidation or protein 
misfolding, cell cycle checkpoints get induced and stall cell cycle progression to 
provide time for damage repair. Is the damage beyond repair, apoptosis (the best 
described form of programmed cell death) is induced to remove the faulty cell from the 
system. 
Cancer cells are fast proliferating cells that are literally ‘out of control’. They display 
increased growth factor signalling through increased expression of activating mutations 
in components of growth factor signalling pathways. Furthermore, cancerous cells 
acquired means to overrule cell cycle regulation, most often through mutations in p53, 
and evade apoptosis. A summary of common phenotypes, 10 have been defined so far, 
that contribute to malignant transformation from normal cells to tumour cells is depicted 
in Figure 1.1 and is described in more detail in the Hallmarks of Cancer (Hanahan and 
Weinberg, 2011, Hanahan and Weinberg, 2000). 
 
 
 
 
 
 
 
 
Figure 1.1: The Hallmarks of Cancer 
Schematic overview of events frequently 
occurring in the process of malignant 
transformation and important in tumour 
maintenance. Events can be cell intrinsic, 
arise from extrinsic stimuli or are mediated 
through cell-cell interactions. Schematic was 
modified after (Hanahan and Weinberg, 
2011) with permission. 
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Two signalling cascades frequently deregulated in cancer, the RAS/MAP kinase and the 
PI3K/AKT/mTOR pathway, are initiated by growth factor binding to a suitable growth 
factor receptor tyrosine kinase (RTK). Subsequent phosphorylation/activation events 
eventually lead to changes in gene expression promoting cell survival, growth and 
proliferation (Figure 1.2) (Cully et al., 2006). 
 
 
 
Figure 1.2: Frequently deregulated 
growth factor signalling in cancer cells 
Schematic of receptor tyrosine kinase (RTK) 
downstream signalling to promote cell 
growth, proliferation and survival. Upon 
stimulation through growth factors (GF), 
RTKs activate RAS or PI3K through 
phosphorylation. The PI3K/AKT cascade 
leads to cell cycle progression via inhibition 
of GSK3 resulting in the stabilisation and 
activation of c-Myc. Inhibition of FOXO 
proteins by AKT also leads to cell cycle 
progression. Activation of the mTOR pathway 
by AKT induces protein translation, ribosomal 
biogenesis and cell growth, while inhibition of 
pro-apoptotic BCL2 proteins promotes cell 
survival. The RAS/MAP kinase cascade 
stimulates cell growth and proliferation via 
positively regulating the mTOR pathway and 
c-MYC, respectively. Highlighted in red are 
proteins that are frequently upregulated in 
cancer; highlighted in green are proteins that 
are often activated in tumours due to genetic 
mutations and highlighted in blue, PTEN, is 
frequently lost in cancer. 
 
1.2  Cancer – cellular metabolism rewired 
Metabolic requirements differ according to the cell type. In resting differentiated cells, 
metabolism is tuned to generate enough energy to maintain structural integrity and fulfil 
the cells’ physiological role. If the cellular function is production or storage of certain 
substances, the metabolic network is adapted accordingly. In contrast, proliferating cells 
adapt their metabolism towards generation of macromolecules such as proteins, lipids 
and nucleic acids, which are needed for cellular growth and division (Thompson et al., 
2005, Vander Heiden et al., 2009). Adequate nutrient supply is essential for execution 
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of metabolic reactions. Nutrients, i.e. carbohydrates, amino acids and fatty acids, are 
taken up through food and, following resorption in the gut, are transported with the 
blood to sites of consumption, where they are taken up by the cells through specific 
transporters. Furthermore, cells rely on sufficient oxygen supply, also provided by the 
blood stream. Under normal conditions, nutrient and oxygen supply is warranted 
through an elaborate and efficient vascular system. Growing solid tumours, however, 
can outgrow the vasculature resulting in inefficient nutrient supply and hypoxic areas.  
 
1.2.1 Cancer cells are hooked on aerobic glycolysis  
During the 1920s, Otto Warburg observed that cancer cells displayed high glucose 
consumption rates concomitant with high lactate secretion rates, a sign of high 
glycolytic flux (Warburg, 1956a, Warburg, 1956b). This would not be surprising would 
it not have occurred under ample oxygen conditions. In normal, differentiated cells, 
under ample oxygen conditions, the tricarboxylic acid (TCA) cycle with associated 
oxidative phosphorylation (OXPHOS) along the electron transport chain (ETC) in the 
mitochondria is the main site of adenosine triphosphate (ATP, cellular energy-storing 
molecule) generation (Figure 1.3A). Glycolysis, the multi-step conversion of glucose to 
pyruvate, is prevalent in situations when oxygen is limited as it is an anaerobic process 
(Figure 1.3A and Figure 1.4). Glycolysis generates less ATP than oxidative 
phosphorylation but ATP generation is faster (Curi et al., 1988). While conversion of a 
single glucose molecule to CO2 yields a total of ~36 ATP molecules (corresponding to 2 
ATP, 8 NADH, 2 FADH2) via the mitochondrial TCA cycle and OXPHOS; the net 
yield from glycolysis for a glucose molecule is only 2 ATP and 2 NADH molecules. 
Concluding that cancer cells have dysfunctional mitochondria, Warburg defined cancer 
as a metabolic disease and cancer-characteristic aerobic glycolysis ever since became 
known as the Warburg Effect (Warburg, 1956b) (Figure 1.3B).  
This cancer-characteristic high rate of glucose uptake that exceeds the glucose uptake of 
resting cells formed the basis of 2-fluoro-2-deoxy-D-glucose (18F)-positron emission 
tomography ([18F]-FDG-PET), a diagnostic method for detection of tumour lesions in 
the body (Som et al., 1980, Kelloff et al., 2005). 18F-FDG is a glucose analogue coupled 
to a positron-emitting radioactive fluorine-18 isotope, which, once it is taken up by a 
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cell, is trapped in the cell cytoplasm following hexokinase (HK)-mediated 
phosphorylation and can be visualised using PET scanning technology. 
 
 
Figure 1.3: Glucose utilisation for energy production in differentiated and proliferative 
tissue 
(A) Under normal oxygen conditions, differentiated, non-proliferating cells use the tricarboxylic acid 
(TCA) cycle with associated oxidative phosphorylation via the electron transport chain (ETC) as main 
energy source to fuel cellular homeostasis and function. Only if oxygen levels get low in the 
microenvironment, cells switch to anaerobic glycolysis. (B) In contrast, proliferating cells and cancer 
cells often show the so-called Warburg Effect, whereby they mainly rely on glycolysis independent of the 
oxygen concentration in the microenvironment. In terms of ATP/energy production glycolysis is less 
efficient, however, intermediates from glucose catabolism serve as precursors for many macromolecules. 
Actively cycling cells may switch to an increased glycolytic flux to accommodate for efficient cell mass 
accumulation, which enables cell growth and division. 
 
Although Warburg’s theory of cancer being a metabolic disease was proven wrong in 
the 1960s with the establishment of genetic mutations being causal for tumourigenesis, 
it took scientists almost 30 years from Warburg’s initial observation to realise the 
importance of metabolism in the context of cancer. In recent years, cancer metabolism 
gained increasing appreciation so much that it was included in the revised version of the 
Hallmarks of Cancer (Figure 1.1) (Hanahan and Weinberg, 2000, Hanahan and 
Weinberg, 2011). 
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1.2.2 Glycolysis provides precursors for anabolic processes  
One reason for why cancer cells operate on such high glycolytic rates is the high 
demand of building blocks for macromolecules (Lunt and Vander Heiden, 2011, 
Moreno-Sanchez et al., 2007). Intermediates of glycolysis serve as precursors for the 
biosynthesis of nucleotides, amino acids (AAs) or phospholipids. Glucose-6-phosphate 
(G6P) and fructose-6-phosphate (F6P) for example are precursors for purine and 
pyrimidine biosynthesis via the oxidative arm of the pentose phosphate pathway (PPP). 
In addition, theses reactions generate NADPH as by-product, which is essential for 
maintaining cellular redox homeostasis, as it is an important cofactor for enzyme-
mediated redox reactions (Figure 1.4). The glycolytic intermediate 3-phosphoglycerate 
(3PG) is a precursor of serine, which itself is a substrate/precursor for purine and 
pyrimidine, glycine and cysteine as well as sphingolipids and folate, connecting 
glycolysis with the PPP, AA biosynthesis and one-carbon metabolism (Locasale, 2013) 
(Figure 1.4). Another glycolytic intermediate, glyceraldehyde-3-phosphate, is converted 
to glycerol-3-phosphate and phosphatidic acid and supports phospholipid synthesis, 
while pyruvate can be converted into alanine (Figure 1.4).  
 
With glycolysis having such a central role in macromolecule biosynthesis, it is not 
surprising that cancer cells found a way to circumvent the tight regulation of this 
process, often through upregulation of glycolytic enzymes due to aberrant 
transcriptional regulation.  
In many caner cells, enhanced glucose uptake necessary for increased glycolytic flux is 
accommodated through upregulation of glucose transporters (GLUT1-5), especially of 
GLUT1 and GLUT3 (Yamamoto et al., 1990). Hexokinase 2 (HK2), one of the four 
glycolytic enzyme isoforms (HK1-3 and GCK) that commits glucose to the glycolytic 
pathway through irreversible conversion to G6P, is also frequently upregulated in 
different cancer cells (Peng et al., 2008, Wolf et al., 2011).  
The rate-controlling reversible conversion of F6P to fructose-2,6-bisphosphate (F2,6BP) 
and back is mediated by bifunctional 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatases (PFKFBs). F6P is an allosteric activator of phosphofructokinase 1 
(PFK1), which converts F6P into F1,6BP and enhances glycolytic flux. The ATP-
dependent phosphorylation of F6P is catalysed by the PFK2 activity, while F2,6BP 
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dephosphorylation is carried out by the FBPase activity. There are four members of the 
PFKFB homodimeric enzyme family, PFKFB1-4. All but PFKFB3 have equal PFK2 
and FBPase activity, while in the PFKFB3 isoform the PFK2 activity dominates (Okar 
and Lange, 1999, Okar et al., 2001). Many cancer types show high expression of 
PFKFB3 as adaptation to sustain high-rate glycolysis (Atsumi et al., 2002, Kessler et al., 
2008, Minchenko et al., 2005). However, metastatic prostate cancer cells rely on the 
PFKFB4 FBPase activity to provide the PPP with substrates for NADPH production to 
sustain cellular redox balance (Ros et al., 2012). 
Under hypoxic conditions, pyruvate is converted into lactate instead of entering the 
TCA cycle in mitochondria. The conversion to lactate is catalysed by lactate 
dehydrogenase (LDH). There are two LDH isoforms, LDHA and LDHB, and LDHA 
has been found upregulated in several tumour types (Augoff and Grabowski, 2004, 
Fantin et al., 2006, Koukourakis et al., 2009).  
GLUT1/3, PFKFB3 and LDHA are targets of the transcription factor hypoxia inducible 
factor 1 (HIF-1), which regulates a metabolic switch from oxidative respiration to 
anaerobic glycolysis in response to low oxygen levels. HIF activity is often aberrantly 
high in cancers and will be discussed in more detail below. 
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Figure 1.4: Overview of the main metabolic activities in cancer cells 
The main metabolic pathways that contribute to the production of macromolecules in mammalian cells 
are nucleotide synthesis, the pentose phosphate pathway, glycogen and serine synthesis, glutaminolysis, 
cholesterol synthesis, fatty-acid synthesis and elongation/desaturation. The enzymes involved in these 
pathways are shown in bold, those induced in response to hypoxia are marked with an asterisk. Metabolic 
enzymes in the TCA cycle, fumarate hydratase (FH) and succinate dehydrogenase (SDH), can act as 
tumour suppressors. 2-hydroxyglutarate (2-HG) is produced from α-ketoglutarate (α-KG) by the mutant 
forms of isocitrate dehydrogenase 1 (IDH1) and IDH2 enzymes that are found in cancer (grey dashed 
arrow). Reductive carboxylation of α-KG by IDH1 and IDH2 produces citrate for lipid synthesis in 
hypoxic cells (black dashed arrow). ACC, acetyl-CoA carboxylase; ACLY, ATP citrate lyase; ACO, 
aconitase; CA9, carbonic anhydrase 9; CoA, coenzyme A; CS, citrate synthase; FASN, fatty-acid 
synthase; F1,6BP, fructose-1,6-bisphosphate; F2,6BP, fructose-2,6-bisphosphate; F6P, fructose-6-
phosphate; GLS, glutaminase; GLUD, glutamate dehydrogenase 1; GOT, glutamic-oxaloacetic 
transaminase; GSH, glutathione; G1P, glucose-1-phosphate; G6P, glucose-6-phosphate; G6PD, G6P 
dehydrogenase; HIF, hypoxia inducible factor; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; 
KEAP, kelch-like ECH-associated protein 1; LDHA, lactate dehydrogenase A; MDH, malate 
dehydrogenase; ME1, malic enzyme 1; NRF2, nuclear factor (erythroid-derived 2)-like 2; PDH, pyruvate 
dehydrogenase; PDHK1, pyruvate dehydrogenase kinase; PEP, phosphoenolpyruvate; PFK, 
phosphofructokinase; PHD, prolyl hydroxylases; PHGDH, phosphoglycerate dehydrogenase; PKM2, 
pyruvate kinase M2; PL, phospholipids; ROS, reactive oxygen species; SCD, stearoyl-CoA desaturase; 
TAG, triacylglycerides. Figure and legend taken from and modified after (Schulze and Harris, 2012) with 
permission. 
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1.2.3 Glutaminolysis provides precursors for anabolic processes 
Besides glucose, glutamine, the most abundant AA, is another important cellular carbon 
source for anabolic processes and additionally provides nitrogen for the synthesis of 
non-essential AAs and nucleotides. Following uptake by the cell through specialised 
transporters such as solute carrier family 1 member 5 (SLC1A5), glutamine is converted 
to glutamate and ammonia via glutaminase (GLS). The process by which glutamine is 
shunted into other metabolic pathways following conversion to glutamate is termed 
glutaminolysis. The transcriptional programme of mitochondrial glutaminolysis is 
regulated by the proto-oncogenen c-MYC. Consequently, MYC transformed cells are 
referred to as glutamine addicted, as glutamine withdrawal is highly detrimental to 
theses cells, even more than glucose withdrawal (Dang, 2009, Dang, 2012, Wise et al., 
2008, Yuneva et al., 2007). 
The amino-group of glutamate can be transferred to oxaloacetate, in a reaction catalysed 
by glutamic-oxaloacetic transaminase (GOT), to form aspartate. Alternatively, 
glutamate can be converted to α-ketogluterate (α-KG) by glutamate dehydrogenase 
(GLUD). α-KG can then enter the mitochondria to replenish the TCA cycle for 
ATP/energy generation or to generate TCA cycle intermediates required for 
biosynthetic processes, such as citrate, a process called anaplerosis (DeBerardinis et al., 
2007). However, α-KG can also undergo isocitrate dehydrogenase (IDH)-mediated 
reductive decarboxylation (NADPH-dependent) to directly yield citrate, a precursor of 
fatty acid synthesis (DeBerardinis et al., 2007, Mullen et al., 2012). There are three IDH 
isoforms, IDH1-3, with IDH1 being mainly cytoplasmic, while the other two are 
localised to the mitochondrial compartment. Hypoxic cancer cells and clear cell renal 
cell carcinoma cells were found to make use of this reductive glutamine metabolism for 
lipogenesis (Mullen et al., 2012, Wise et al., 2008). 
 
1.2.4 Cancer cells reactivate de novo lipid synthesis 
Apart from hepatocytes and adipocytes, most cells within the adult human body are not 
capable of lipogenesis but rely almost exclusively on external lipid supply, in form of 
free fatty acids (fFAs) or low-density lipoproteins (LDLs), via the blood stream. The 
expression of enzymes involved in de novo lipid synthesis is mostly regulated by sterol 
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regulatory element (SRE)-binding proteins (SREBP) (Eberle et al., 2004, Horton, 2002). 
SREBPs are basic-helix-loop-helix-leucine zipper transcription factors, that come in 
three isoforms: SREBP1a, SREBP1c and SREBP2, whereby the two SREBP1 isoforms 
are generated through alternative splicing of the same gene locus (Brown and Goldstein, 
1997). Although all isoforms have largely overlapping functions, SREBP1c mainly 
regulates fatty acid, triacylglycerol and phospholipid synthesis, while SREBP2 controls 
cholesterol synthesis (Bengoechea-Alonso and Ericsson, 2007, Horton, 2002). The 
activation of all SREBP isoforms is cholesterol dependent and SREBPs are processed, 
accumulate in the nucleus and become transcriptionally active when cholesterol is 
limited (Espenshade et al., 2002). In addition, SREBP1 is also activated upon insulin-
stimulated PI3K/AKT/mTORC1 signal transduction, linking the regulation of protein 
synthesis with lipid production (Li et al., 2010, Porstmann et al., 2008, Peterson et al., 
2011, Yecies and Manning, 2011). Moreover, the finding that p53 can cooperate with 
SREBP2 to drive transformation in breast epithelial cells by inducing enzymes of the 
mevalonate (cholesterol) pathway links lipogenesis to tumourigenesis (Freed-Pastor et 
al., 2012). Indeed, reports have shown, that cancer cells reactivate de novo lipid 
synthesis even in the presence of ample exogenous lipid supply and present increased 
expression of enzymes involved in lipid synthesis such as ATP citrate lyase (ACLY), 
acetyl-coA carboxylase (ACC) and fatty acid synthase (FASN) (Medes et al., 1953, 
Menendez and Lupu, 2007, Yahagi et al., 2005, Yoon et al., 2007). The exact role of 
lipid synthesis in cancer still needs to be explored, but it is reasonable to assume that 
lipogenesis contributes to generation of biological membranes, energy via FA-
oxidation/β-oxidation, protein modifications and second messengers to support cell 
growth and proliferation (Santos and Schulze, 2012, Baenke et al., 2013). 
 
1.2.5 Pentose Phosphate Pathway is important for sustaining redox 
balance 
The PPP is split into two phases: the oxidative and the non-oxidative arm. In the 
oxidative part, G6P is firstly converted to 6-phosphoglucono-δ-lactone by glucose-6-
phosphate dehydrogenase (G6PD), generating one molecule of nicotinamide adenine 
dinucleotide phosphate (NADPH). Next, the lactone is hydrolysed by 6-
phosphogluconolactonase (PGLS) to 6-phosphogluconate (6PG). Finally, ribulose-5-
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phosphate (R5P) is generated through decarboxylation of 6PG by 6-phosphogluconate 
dehydrogenase (6PGD), yielding another NADPH molecule. In the oxidative PPP arm, 
R5P is converted back to the glycolysis intermediates F6P by transaldolase (TALDO) or 
to glyceraldehyde-3-phosphate by transketolase (TKTL) (Figure 1.4).  
The PPP is particularly important in proliferating cells to guarantee the supply of 
riboses for nucleotide biosynthesis and DNA replication. In resting, non-cycling cells, 
the PPP becomes rewired to produce mainly NADPH as the demand for nucleotides 
drops. However, the oxidative PPP branch is one of only four reactions that generate the 
co-factor NADPH in the cytosol. The conversion of malate to pyruvate by malic 
enzyme 1 (ME1) and the conversion of isocitrate to α-KG by IDH1 and the one-carbon 
metabolism are the other sources of NADPH (Fan et al., 2014, Lewis et al., 2014). 
NADPH, besides nicotinamide adenine dinucleotide (NADH), is important for cellular 
redox homeostasis as it serves as reducing agent in many enzyme-mediated redox 
reactions. The relative ratios of NADPH/NADP+ and NADH/NAD+ are indicators of 
cellular redox state (Feron, 2009). In the context of cancer metabolism, it has been 
suggested that NADPH production is rate-limiting for proliferation (Vander Heiden et 
al., 2009). One reason for this is the high NADPH amount needed for de novo lipid 
synthesis (14mol NADPH per 1mol palmitoyl-CoA), the other for being essential for 
the recycling of glutathione, the most abundant non-enzymatic antioxidant in the cell.  
 
1.3  HIF signalling pathway 
Many solid tumours display hypoxic areas, i.e. areas where the partial oxygen pressure 
is below that of normal surrounding tissue, as they outgrow the local vascular system 
(Bristow and Hill, 2008). In the developing organism hypoxia is a driver for 
vascularisation but it can also contribute to the maintenance of cells in an 
undifferentiated state (Covello et al., 2006). Hypoxia is also important in wound healing 
as it promotes keratinocyte migration to the lesion and subsequent epithelial restoration 
(Benizri et al., 2008). Hence, cells developed an oxygen sensing and context-dependent 
responding system. The main cellular response to low oxygen tensions is orchestrated 
by hypoxia-inducible factor (HIF). HIF is a heterodimeric transcription factor consisting 
of the constantly expressed HIF-1β subunit, also known as aryl hydrocarbon receptor 
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nuclear translocator (ARNT), and the oxygen-sensitive HIF-α subunit. There are three 
HIF-α subunits: HIF-1α, HIF-2α and several splice variants of HIF-3α. 
Both, HIF-α and ARNT contain a basic helix-loop-helix (bHLH) domain followed by a 
Per/ARNT/Sim (PAS) domain in the N-terminus, which are essential for DNA binding 
and heterodimerisation (Jiang et al., 1996). HIF-1/2α have two transactivation domains, 
one in the C-terminus (CAD) and one in the N-terminus (NAD), while HIF-3α lacks the 
CAD and ARNT only has one transactivation domain (TAD) in the C-terminus 
(Semenza, 1999a, Gu et al., 1998, Hara et al., 2001, Maynard and Ohh, 2004, Semenza, 
1999b). Furthermore, the HIF-α subunits contain a unique oxygen-dependent 
degradation (ODD) domain. Under hypoxic conditions (molecular oxygen tensions 
below local homeostatic oxygen concentrations), HIF-α is stable, translocates to the 
nucleus, binds to ARNT and recruits transcriptional co-activators p300/CBP to its CAD. 
The HIF transcription factor complex binds to hypoxia-response elements (HRE, 5’-
RCGTG-3’) in target enhancer/promoter sequences of numerous genes (>800 already 
identified) inducing a transcriptional programme to adapt to hypoxia (Xia et al., 2009, 
Schodel et al., 2011, Semenza, 2011). HIF upregulates genes involved in angiogenesis 
and erythropoiesis (e.g. VEGFA, PDGF, inducible nitric oxide synthase (iNOS) and 
erythropoietin (EPO)) to enhance reoxygenation by increasing blood supply. In addition, 
HIF also induces glycolytic enzymes (e.g. GLUT1/3, HK2, PDHK1, PFKFB3 and 
LDHA) to reduce oxygen consumption via energy/ATP production (Bertout et al., 2008, 
Kaelin, 2008, Porporato et al., 2011). Under normoxic conditions, prolyl hydroxylase 
domain-containing proteins, PHD1-3, catalyse the hydroxylation of conserved proline 
residues within the ODD domain (P402 and P564), marking HIF-α for proteasomal 
degradation (Bruick and McKnight, 2001, Jaakkola et al., 2001). PHD1-3, members of 
the α-KG-dependent oxygenase superfamily, are also referred to as oxygen sensors, as 
their enzymatic activity strongly depends on molecular oxygen tension. Apart from 
oxygen and α-KG, PHD activity is dependent on ascorbate and Fe2+ (Schofield and 
Ratcliffe, 2004). Contrary, cytosolic accumulation of succinate, fumarate and ROS has 
inhibitory effects on PHD activity (Kaelin and Ratcliffe, 2008, Selak et al., 2005). In 
addition, the HIF-1α isoforms can also be hydroxylated on a specific aspargine residue 
(A803) in the CAD by factor inhibiting HIF-1 (FIH1) (Mahon et al., 2001). 
The prolyl-hydroxylated HIF-α subunit is recognised by the von Hippel-Lindau protein 
(pVHL) (Maxwell et al., 1999). pVHL is part of a hydroxylated prolyl-motive specific 
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E3 ubiquitin ligase, a complex that comprises, apart from pVHL, of elongin B, elongin 
C and cullin-2. pVHL is considered to be a tumour suppressor gene, as germline 
mutation in the VHL gene causes familial von Hippel-Lindau disease, a hereditary 
cancer syndrome. Clear cell renal cell carcinomas (ccRCC), the most common subtype 
of renal cancer, is characterised by heterozygous loss of the VHL gene located on the 
short arm of chromosome 3 (3p26-25) (Latif et al., 1993). VHL mutations analysed so 
far all seem to impair either the ubiquitin ligase complex assembly or binding to the 
HIF-α substrate (Kishida et al., 1995, Lonergan et al., 1998, Clifford et al., 2001, 
Knauth et al., 2006, Li et al., 2007). Hence, loss of pVHL leads to loss of pVHL-
mediated degradation of HIF-α via the 26S proteasome, resulting in HIF stabilisation 
and activation of HIF-target genes. ccRCC thus represents a pseudo-hypoxic state in 
which angiogenesis and glycolysis are promoted even in the presence of ample oxygen 
in the microenvironment (Figure 1.5). Consequently, ccRCC is a suitable model to 
study HIF signalling and metabolic remodelling. 
 
 
Figure 1.5: HIF pathway regulation under normoxic and hypoxic conditions and in ccRCC 
(A) Under normoxic conditions, HIF-α is hydroxylated on conserved proline residues by prolyl-
hydroxylases (PHDs). This phosphorylation pattern is recognised by pVHL, a component of an E3-
ubiquitin ligase complex, which ubiquinates HIF-α and targets it for proteasomal degradation. (B) If 
oxygen levels drop, PHDs cannot longer hydroxylate HIF-α, so that it is stabilised and can translocate to 
the nucleus where it binds to ARNT and p300/CBP and induces transcription of target genes involved in 
vascularisation and glycolysis. (C) Most ccRCCs lack functional pVHL and, although HIF-α is 
hydroxylated by PHDs, the E3-ubiquitin ligase complex is not able to mark it for degradation. HIF 
accumulates, translocates to the nucleus and induces a transcriptional program in adaptation to hypoxia 
despite ample oxygen in the microenvironment. 
 
Although HIF-1α and HIF-2α have overlapping functions in that they both induce a 
cellular response to a hypoxic environment, they also differentially regulate distinct 
subsets of genes in a context dependent manner (Hu et al., 2002, Raval et al., 2005). 
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HIF-1α has been found to be induced quickly upon oxygen deprivation and orchestrates 
an immediate acute response to hypoxia. To tune down oxygen consumption, HIF-1α 
induces a metabolic switch from oxidative phosphorylation to glycolysis. HIF-2α, on 
the other hand, is induced during prolonged hypoxia and activates angiogenesis by 
inducing VEGF and EPO expression. HIF-2α was also found to induce the stem cell 
factor OCT4 (Covello et al., 2006), transforming growth factor α (TGFα) and cyclin D1 
(Raval et al., 2005) as well as mTORC1 activity (Elorza et al., 2012). Furthermore, 
ccRCCs expressing both HIF-α isoforms show increased MAP kinase and 
PI3K/AKT/mTOR signalling, while ccRCCs expressing only the HIF-2α isoform reveal 
hyperactive c-MYC (Gordan et al., 2008). 
Interestingly, there is evidence for the two HIF-α isoforms antagonising each other. Not 
only do the two isoforms reciprocally regulate each other’s protein levels (Mandriota et 
al., 2002, Raval et al., 2005) but they also have opposing effects on c-MYC activity 
(Gordan et al., 2007a, Gordan et al., 2007b, Gordan et al., 2008, Koshiji et al., 2004, 
Zhang et al., 2007). c-MYC, a transcription factor regulating cell cycle progression but 
also mitochondrial biogenesis and respiration, is upregulated in 40% of human cancers. 
While HIF-1α inhibits, HIF-2α promotes c-MYC activity. Apart from being able to 
induce the expression of MXI, a repressor of c-MYC activity (Ferber et al., 2012), HIF-
1α can also negatively regulate c-MYC through promoting its proteasomal degradation 
(Zhang et al., 2007) or by replacing c-MYC from its binding partner Sp1, thereby 
increasing transcription of p21 amongst others (Koshiji et al., 2004). 
Both HIF-α isoforms can interact with the c-MYC binding partner MAX, but these 
interactions lead to opposing effects. HIF-1α inhibits c-MYC/MAX complex formation 
leading to cell cycle arrest by inducing expression of the negative cell cycle regulators 
p21 and p27, and reducing the expression of the positive regulators cyclin D2 and E2F.  
Contrary, HIF-2α stabilises c-MYC by complexing with MAX, causing a dose-
dependent stabilisation of the c-MYC/MAX complex and an induction/repression of 
cyclin D2, E2F1, p21 and p27 promoting cell cycle progression and proliferation 
(Gordan et al., 2007a, Gordan et al., 2007b). In keeping with this observation, it has 
been suggested, that HIF-2α acts as driver in pVHL-defective ccRCC tumourigenesis, 
as HIF-1α expression decreases in the course of tumour development due to frequent 
loss of HIF-1α on chromosome 14q, while HIF-2α expression increases concomitantly 
and can override pVHL’s tumour suppressor activity (Kondo et al., 2002, Mandriota et 
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al., 2002, Maranchie et al., 2002, Raval et al., 2005, Keith et al., 2012). Moreover, 
preclinical models have shown that ablation of HIF-2α is sufficient to suppress tumour 
formation by pVHL-defective ccRCC cells (Kondo et al., 2002, Zimmer et al., 2004). 
Finally, a genome-wide association study provided evidence that HIF2A/EPAS 
polymorphisms can be linked to the risk of renal carcinoma (Purdue et al., 2011). 
In contrast to the other two HIF-α isoforms, not much is known about HIF-3α so far. 
Lacking the CAD it has been suggested that it is less potent in transcriptional regulation 
than HIF-1/2α in the human kidney (Hara et al., 2001). Instead, it has been shown that 
the alternatively spliced variant HIF-3α4 that lacks ODD, NAD and CAD has a negative 
effect on HIF-1α transcriptional response. Furthermore, the same study showed that 
mRNA levels of this HIF-3α isoform were downregulated in most of the tested primary 
ccRCC tumour specimens, and an important role of HIF-3α4 in inhibiting ccRCC 
tumourigenesis was suggested (Maynard et al., 2005). 
 
1.4  Clear cell renal cell carcinoma - ccRCC 
1.4.1 ccRCC – Incidence, prognosis and treatment 
Kidney cancer accounts for ~2% of all cancers yearly diagnosed worldwide (Figure 
1.6A) (Ljungberg et al., 2011). In the UK from 2000-2002 to 2009-2011, kidney cancer 
incidences increased 27% in men and 38% in women, making it the 8th/9th most 
frequent cancer type in men/women, respectively (Cancer Research UK statistics) 
(Figure 1.6C). Kidney cancer incidence is higher in men than in women and is rare 
below the age of 50 but frequent in patients above 60. The overall survival rate for 
kidney cancer is low (56% for 5-year and 50% for 10-year survival; Figure 1.6B), due 
to the lack of early symptoms and diagnostic markers and frequent resistance towards 
conventional radiation and chemotherapy. Kidney cancer is often only diagnosed in an 
advanced disease stage, or after metastases have already formed (25-30%). Hence, 
initial treatment is partial or radical nephrectomy, depending on size and staging of the 
tumour. In some cases, surgical excision can be accompanied or replaced with more 
targeted therapies. Sunitinib (Sutent; RTK inhibitor), Pazopanib (Votrient; RTK 
inhibitor), interferon (if cancer is very small) are considered first line drug treatments, 
whereas Bevacizumab (Avastin; recombinant humanised monoclonal antibody against 
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VEGFA), Temsirolimus (Torisel; mTOR inhibitor), Everolimus (Afinitor; mTOR 
inhibitor), Sorafenib (Nexavar; tyrosine kinase inhibitor) and interleukin 2 are given to 
patients with metastatic phenotype and disease reoccurrence (Singer et al., 2013). 
 
Figure 1.6 Kidney cancer statistics 
(A) Worldwide kidney cancer incidence and mortality rates. Copied from (Ljungberg et al., 2011). (B) 
Age-standardised one-, five-and ten-year net survival for selected cancers in adults (aged 15-99), England 
and Wales, 2010-2011; Prepared by Cancer Research UK; Original data sources: Cancer Research UK 
Cancer Survival Group, London School of Hygiene and Tropical Medicine. Personal communication, 
2014; (C) The 20 most commonly diagnosed cancers: 2000-2002 and 2009-2011. Percentage change in 
European age-standardised incidence rates per 100,000 population (male and females, UK); Prepared by 
Cancer Research UK; Original data sources: 1. Office for National Statistics. Cancer Statistics: 
Registrations Series MB1. http://www.ons.gov.uk/ons; 2. Welsh Cancer Intelligence and Surveillance 
Unit. http://www.wcisu.wales.nhs.uk; 3.Information Services Division Scotland. Cancer Information 
Programme. www.isdscotland.org/cancer; 4. N. Ireland Cancer Registry. www.qub.ac.uk/nicr. 
 
Kidney cancer can be split into two main cancer types: renal cell carcinoma (RCC) and 
urothelial cell carcinoma (UCC) of the renal pelvis. RCC, an adenocarcinoma 
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originating from the proximal convoluted tubule epithelium (site of waste transport 
from blood to urine) is the most common kidney cancer in adults and accounts for 90-
95% of all cases; UCC accounts for most of the remaining cases. Histologically, there 
are four distinguishable RCC sub-types: conventional or clear cell RCC (ccRCC), the 
most common subtype accounting for 75% of all RCC cases, papillary RCC (15% of 
cases), chromophobic RCC (5% of cases) and collecting duct RCC (2% of cases). 
ccRCC can be subdivided further into hereditary and sporadic ccRCC. Underlying 
hereditary ccRCC is the von Hippel-Lindau (VHL) disease, a rare autosomal-dominant 
tumour syndrome resulting from germ line mutations in the VHL gene on chromosome 
3p25. Individuals with VHL disease develop highly vascularised tumours in multiple 
organs - depending on the location of the mutation, but 45% of them develop ccRCC 
(Clifford et al., 2001, Hoffman et al., 2001, Lonser et al., 2003, Neumann and Bender, 
1998). Non-familial ccRCC also show a high frequency of bi-allelic VHL inactivation 
(Kim and Kaelin, 2004, Kondo et al., 2002). Risk factors associated with sporadic 
ccRCC include hypertension, obesity, smoking and, especially, continuous dialysis 
following cystic renal disease. 
 
1.4.2 Metabolic and epigenetic reprogramming is characteristic for 
ccRCC tumourigenesis 
The Cancer Genome Atlas (TCGA) Research Network recently published a 
comprehensive molecular characterisation of ccRCC resulting from the analysis of 
≥ 400 primary nephrectomy specimens from ccRCC patients; with overlapping and 
complimentary findings published by Sato and colleagues at the same time confirming 
the universality of these events in ccRCC pathogenesis. 
One of their findings was the observation that, although, somatic copy number 
alterations (SCNAs) occurred at fewer sites compared to other tumour types, the 
observed SCNAs frequently involved entire chromosome arms or chromosomes as 
opposed to focal alterations (Cancer Genome Atlas Research, 2013). It was confirmed 
that fractional loss of chromosome 3p, was the most frequent event, observed in 91% of 
all samples (Zbar et al., 1987). In addition to VHL, chromosome 3p also comprises 
genes encoding PBRM1, BAP1 and SETD2, three chromatin and histone modifying 
proteins that were recently identified to be frequently altered in ccRCC (Dalgliesh et al., 
Chapter 1: Introduction 
 32 
2010, Guo et al., 2012, Varela et al., 2011). The previously reported fractional loss of 
chromosome 14q, including the pVHL target HIF1A (Shen et al., 2011), was found in 
almost half of the cases. Loss of HIF1A was suggested to drive more aggressive 
tumours in ccRCC, contrary to what has been observed in other tumour types (Semenza, 
2003, Shen et al., 2011). The previously reported focal gain of chromosome 5q was 
confirmed in 67% of the cases, whereby 5q35 was refined as region of interest (Presti 
and Carroll, 1991, Presti et al., 1991a, Cancer Genome Atlas Research, 2013). Finally, 
the study from Sato and colleagues identified a gain of chromosome 7q in 41% of cases 
and 20% of cases show a loss of 8p with or without loss of 8q (Sato et al., 2013). In 
addition to these sites of accumulated events of focal loss/gain, more sporadic losses or 
amplifications of specific loci were found. Gene losses include CUL3 on 2q36, 
CDKN2A (p16) and CDKN2B on 9p21 and PTEN on 10q23, while MDM4, a p53 
regulator, on 1q32, c-MYC on 8q24 and JAK2 on 9p24 were gained. Furthermore, 
whole-exome sequencing revealed 19 significantly mutated genes, including VHL, 
PBRM1, SETD2, KDM5C, BAP1, ATM, P53, PTEN, PIK3CA, MTOR and TET2 
highlighting the contribution of metabolic regulators and DNA modifying enzymes in 
ccRCC tumourigenesis (Cancer Genome Atlas Research, 2013, Sato et al., 2013). 
Several integrative pathway analyses pointed out that besides the HIF1A/ARNT also 
the MYC/MAX, SP1, FOXM1 and JUN/FOS transcriptional response are hyperactive 
in ccRCC (Cancer Genome Atlas Research, 2013). With respect to signalling cascades, 
the PI3K/AKT/MTOR axis was found to be impaired in 28% of the analysed core set 
samples. This impairment was based on mutually exclusive gene alterations with 
respect to copy number alterations, somatic mutations and mRNA expression (Cancer 
Genome Atlas Research, 2013, Sato et al., 2013). 
Analysis of protein and mRNA expression levels as potential predictive marker for 
clinical outcome reiterated that a shift towards increased lipogenesis as result of reduced 
levels of AMPK and its complex components together with increased ACC levels 
correlate with poor prognosis (Tong et al., 2011). In addition, downregulation of TCA 
cycle genes, particularly pyruvate dehydrogenase 4 (PDHK4), dihydrolipoamide S-
acetyltransferase (DLAT), aconitase 2 (ACO2) and α-KG dehydrogenase (OGDH) and 
upregulation of PPP genes, especially G6PD, PGLS, TKT and TALDO as well as 
increased glutamine import via SLC1A5 also correlate with worse clinical outcome 
(Figure 1.7) (Cancer Genome Atlas Research, 2013). 
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Figure 1.7: Molecular correlates of patient survival involve metabolic pathways 
When viewed in the context of metabolism, the molecular survival correlates highlight a widespread 
metabolic shift, with tumours altering their usage of key pathways and metabolites (red and blue shading 
representing the correlation of increased gene expression with worse or better survival respectively, 
univariate Cox based on extended cohort). Worse survival correlates with upregulation of pentose 
phosphate pathway genes (G6PD, PGLS, TALDO and TKT), fatty acid synthesis genes (ACC and FASN), 
and PI(3)K pathway enhancing genes (MIR21). Better survival correlates with upregulation of AMPK 
complex genes, multiple TCA cycle genes and PI(3)K pathway inhibitors (PTEN, TSC2). Additionally, 
specific promoter methylation events, including hypermethylation of PI(3)K pathway repressor GRB10, 
associate with outcome. (Figure and legend was adapted from (Cancer Genome Atlas Research, 2013)). 
 
Furthermore, a systems biology approach that applied genome-scale metabolic 
modelling of cancer cells, revealed that ccRCC has a unique metabolic phenotype that 
distinguishes this disease from other cancer types in that ccRCCs displayed unique 
alterations in nucleotide, one-carbon and glycerophospholipid metabolism with regard 
to transcript and protein level (Gatto et al., 2014). Moreover, these alterations were 
associated with recurrent loss of heterozygosity (LOH) in multiple metabolic genes 
adjacent to VHL, suggesting that it is not exclusively the pVHL/HIF axis that initiates 
tumour formation and contributes to the distinct ccRCC metabolic phenotype. 
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1.4.3 ccRCC mouse models  
Evidence for pVHL not being the exclusive driver of ccRCC was provided by several 
studies aiming to generate ccRCC mouse models. For example, attempts to recapitulate 
ccRCC tumourigenesis in mouse by inactivating Vhl in kidney epithelia only resulted in 
a mild phenotype (Frew and Krek, 2008, Hsu, 2012). More promising results were 
obtained through a conditional Vhl knockout mediated by a proximal tubule-specific 
phosphoenolpyruvate carboxykinase (Pepck)-Cre driver, which resulted in renal 
microcysts in ~25% of mice (Rankin et al., 2006). In addition, conditional ablation of 
Vhl outside of the proximal tubule using Cre recombinase expression under the Ksp-
cadherin-promoter (distal tubules and collecting duct-specific expression) resulted in 
hydronephrosis but no further abnormalities (Shao et al., 2002). Only combined Ksp1.3-
Cre –mediated ablation of Vhl and Pten led to hyper-proliferation of the urothelium and 
multiple epithelial tubule cysts in the kidney cortex and medulla (Frew et al., 2008), 
suggesting that ablation of VHL alone is unable to drive tumour formation. A recent 
study by Pritchett and colleagues showed that conditional ablation of Vhl in collecting 
ducts and distal tubules using Hoxb7-driven Cre recombinase expression resulted in 
highly penetrant tubular phenotypes, interstitial inflammation and fibrosis after 2 
months (Pritchett et al., 2014). Furthermore, knockout of Hif-1α in addition to Vhl was 
able to rescue this phenotype (although fibrosis only modestly), while double knockout 
of Vhl and Hif-2α did not alter the phenotype, hinting to an important role of HIF-1α in 
kidney cancer initiation (Pritchett et al., 2014). Indeed, the so-called TRACK 
(transgenic model of cancer of the kidney) mouse model was found to recapitulate 
ccRCC histological morphology (Fu et al., 2011). TRACK mice express a constitutively 
active triple mutant (P402A, P564A and N803A) human HIF-1α under the type 1 γ-
glutamyl transpeptidase (GGT or γGT) promoter, which is expressed exclusively in the 
kidney proximal tube. TRACK mice show distorted tubular structures and accumulation 
of ‘clear’ cells in the outer renal cortex (30-50% coverage). These kidney lesions 
resemble human VHL disease on histological (accumulation of lipids and glycogen in 
the cytoplasm in ‘clear’ cells) and molecular (increased expression of HIF-1α 
downstream targets CAIX, Glut-1 and VEGF) level. These data support the conclusion 
that constitutively active HIF-1α is a driving force in ccRCC tumourigenesis.  
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Aim 
The aim of this study was to investigate potential metabolic vulnerabilities of clear cell 
renal cell carcinoma (ccRCC). To identify these vulnerabilities, a screening approach 
was taken. The applied functional screen comprises of an siRNA library targeting 240 
metabolite transporters and metabolic enzymes and regulators. With loss of functional 
pVHL being a central characteristic in ccRCC, identification of possible metabolic 
vulnerabilities that are dependent on pVHL loss was one of the aims. Another aim was 
finding potential correlations between different metabolic vulnerabilities and the 
different HIF-α isoforms, as they clearly have distinguishable roles in ccRCC 
tumourigenesis. In the following, the questions that will be addressed are: 
 
• What differences and commonalities do different ccRCC cell lines show with 
regards to HIF-α isoform expression and stabilisation? How does reintroduction 
of functional pVHL change this pattern? 
• What differences and commonalities do different cell lines show in their 
dependencies to different nutrients and energy/ATP producing pathways? Does 
reintroduction of functional pVHL influence this behaviour? 
• Does the loss of any other metabolic enzyme, metabolic regulator or metabolite 
transporter synergise with the loss of pVHL or correlate with one HIF-α 
isoform or the other to negatively influence the survival and proliferation of 
ccRCC cells? 
• How do the identified genes cause loss of cell viability? What is the underlying 
mechanism? Is there a pattern emerging when comparing the different ccRCC 
cell lines? 
•  How can the identified vulnerability be exploited?  
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2.1  Cell culture 
2.1.1 Cell lines 
The 5 isogenic clear cell Renal Cell Carcinoma (ccRCC) cell lines RCC4, UMRC2, 
A498, 786-O, 769-P, which either contain a pVHL-expression construct or an empty 
vector (EV) were obtained from the laboratory of William Kaelin Jr. (Iliopoulos et al., 
1995). The parental ccRCC cell lines RCC4, UMRC2, A498, 786-O as well as CAKI1, 
TK10, A.704, UMRC3, ACHN and HEK293 were obtained from the LRI Clare Hall 
Cell Services facility. 769-P, CAKI2, UO31 were a gift from Marco Gerlinger, 
Translational Cancer Therapeutics, CRUK LRI. Finally, the HPV-16 transformed but 
non-tumourigenic proximal tubular cell line HK-2 (Cat. No. CRL-2190TM) was 
purchased from the American Type Culture Collection (ATCC). 
 
2.1.2 Culture conditions 
All ccRCC cell lines were maintained in DMEM supplemented with 4.5 g/l D-Glucose, 
0.11 g/l Sodium Pyruvate (Gibco), 4mM Glutamine (Clare Hall Cell Services facility), 
100Units/ml Penicillin / 100 µg/ml Streptomycin (Gibco), 10% Fetal Bovine Serum 
(FBS) (Gibco, Cat. No. 10270-106). HK-2 cells were maintained in Keratinocyte-Serum 
Free Medium (KSFM) with L-Glutamine (Gibco, Cat. No. 17005-034) supplemented 
with 5 ng/ml Human Recombinant EGF and 50 ng/ml Bovine Pituitary Extract (BPE) 
(both Gibco, Cat. No. 37000-015) and were grown on collagen-coated cell culture 
dishes (BD Bioscience, Cat. No. 734-0280). All cell lines were maintained in a humid 
incubator at 37°C and 5% CO2 for 6-8 weeks before they were discarded and exchanged 
with newly thawed cells.  
Only HK-2 cells are sensitive to trypsin and need pelleting (centrifugation for 5 min at 
1000rpm) and removal of the trypsin-containing supernatant (SN) before transferring to 
a new petri dish. 
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2.1.3 Culture of cell lines in hypoxic conditions 
For treatment of cell lines in hypoxic conditions, cells were placed into a hypoxia 
chamber (Ruskinn Invivo2 500, Bridgend, UK). All ccRCC cell lines were cultured 
under 0.1% oxygen conditions if not stated differently for the indicated time periods. 
Upon plating, cells were usually allowed to attach before placing them into the hypoxia 
chamber. 
 
2.1.4 Storage and recovery of cells 
All cancer cell lines were cryo-preserved in freezing medium containing 50% FBS, 
40% full growth medium and 10% Dimethyl sulfoxide (DMSO, Sigma). HK-2 cells 
were frozen in full growth medium (KSFM) containing 7.5% DMSO. 
Following trypsinisation, cells were spun down for 5 min at 1000rpm to remove 
residual trypsin, resuspended in the appropriate freezing medium and distributed to 
cryogenic vials (Nunc, ThermoFisher Scientific) in 1 ml aliquots. Cells were gradually 
frozen in isopropanol-containing cryogenic freezing containers (Nalgene, ThermoFisher 
Scientific) at -80°C before they were transferred to liquid nitrogen tanks for long-term 
storage. 
For recovery, cryogenic vials containing frozen cells were placed in a 37°C water bath 
for ~3 min to thaw. Cell suspensions were then transferred to 5 ml pre-warmed culture 
medium, spun down for 5 min at 1000 rpm to remove residual DMSO. Obtained cell 
pellet was resuspended in fresh culture medium and transferred to appropriate tissue 
culture vessels. Cells were media changed the next day in order to remove dead cells. 
Cells were passaged at least twice after thawing before they were used for an 
experiment.  
  
2.1.5 Determination of live cell number 
For plating a given cell number in experimental set-ups, cells were counted either using 
a Vi-CELL® XR Cell Viability Analyzer (Beckman Coulter) or a Countess® Automated 
Cell Counter (Invitrogen). Most of the time, the Vi-CELL® was used for ccRCC cell 
counting. For this automated cell counting device, 500 µl cell suspension following 
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trypsinisation were transferred into a Vi-CELL® sample vial and placed in the 
instrument for cell number determination using the ‘Default’ setting. 
The Countess® Automated Cell Counter was used for HK-2 cells and for determining 
cell numbers for the screen as it requires less cell suspension volume as the Vi-CELL®. 
For this, following trypsinisation, 10 µl cell suspension was mixed well with 10 µl 
Trypan Blue (0.4%, Invitrogen). 10 µl of this mix was transferred to a disposable 
counting chamber (Invitrogen) which was inserted into the Countess® device for cell 
number determination.  
 
2.1.6 Starvation of ccRCC cell lines 
For starvation/nutrient –dependency studies, DMEM lacking glucose, glutamine and 
sodium-pyruvate was obtained from the LRI Clare Hall Cell Services facility. This 
medium was supplemented before usage with 100 Units/ml Penicillin / 100 µg/ml 
Streptomycin (Gibco), 10 % FBS and one or any combination of the following 
nutrients: 25 mM D-glucose (Invitrogen), 1 mM sodium pyruvate (Gibco), 4 mM 
glutamine (Clare Hall Cell Services facility). Both regular and dialysed FBS 
(Invitrogen) were used and is indicated, respectively. 
  
For lipid starvation, DMEM was supplemented before usage with 25mM D-glucose 
(Invitrogen), 1 mM sodium pyruvate (Gibco), 4 mM glutamine (Clare Hall Cell 
Services facility) and 10 % regular FBS was substituted with either 1 % lipoprotein-
deficient FCS (LPDS, Bioscience UK) or 10 % lipid depleted FBS (LDS). LDS was 
generated using Liposorb™ resin from Calbiochem (Darmstadt, DE) according to 
manufacturer’s instructions. 
 
For starvation experiments, cells were plated in 96-well plates at 2000 cells/well in 
100 µl common growth medium. The next day, cells were washed 2x in PBS before 
addition of 200 µl DMEM with the desired nutrient supplementation. Cells were 
maintained at 37°C/ 5% CO2 during the duration of the experiment. After 96 h, cells 
were fixed over night at -20°C with 80% ice-cold EtOH (in ddH2O). 
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2.2  siRNA transfections 
A list of siRNAs used in this study can be found in Table 2.1. 
2.2.1 Reverse siRNA transfection for cell viability experiments 
In order to determine the effect on cell viability upon ablating a specific gene, siRNA 
transfection was employed. A reverse siRNA transfection protocol was performed in 
black clear bottom 96-well plates (BD Falcon) using 37.5 nM of siRNA (Dharmacon 
siGENOME® set of 4 upgrade; 2 nM were resuspended in 100 µl 1x siRNA-buffer for a 
final stock concentration of 20 µM before mixing a small aliquot of the 4 individual 
oligonucleotides in a 1:1:1:1 ratio to obtain a SMARTpool, all ThermoFisher Scientific) 
and 0.1 µl (0.2 µl for HK-2 cells) Dharmafect2 transfection reagent (Dharmacon, 
ThermoFisher Scientific) per 100 µl reaction volume per well. 
Briefly, for a 96-well format 0.1875 µl siRNA SMARTpool (20µM stock) were mixed 
with 9.8 µl OptiMEM (Invitrogen) and incubated for 5 min. Meanwhile, 0.1 µl of 
Dharmafect2 transfection reagent (0.2 µl for HK-2 cells) were mixed with 9.9 µl 
OptiMEM (9.8 µl for HK-2 cells) and then added to the siRNA/OptiMEM mix, 
vortexed and incubated for at least 20 min (for up to 2 h) before transferring 20 µl of 
this siRNA/Dharmafect2/OptiMEM to a well of a 96-well plate. In parallel, cells were 
trypsinised, counted (ccRCCs with Vi-CELL® and HK-2 with Countess®) and 
resuspended in a volume of culture medium (containing 10 % FBS) that would yield a 
cell concentration of 25 cells per µl. 80 µl of this cell suspension was then added on top 
of the 20 µl siRNA/Dharmafect2/OptiMEM transfection mix. After plating, the plates 
were kept for ≥ 30 min at RT before placing them in a humid 37°C/5 % CO2 incubator. 
Approximately 24 h later, 100 µl fresh culture medium was added to the cells. Cells 
were fixed 96 h post transfection by aspirating the culture medium, adding 100 µl 
-20°C-cold 80 % EtOH/ddH2O and keeping them at least over night at -20°C. 
 
 
Chapter 2: Materials and Methods 
 41 
2.2.2 Reverse siRNA transfection for total RNA and protein extractions 
Transfections aimed for total RNA and/or protein extractions were performed in 6-well 
plates according to the protocol as described in 2.2.1, with adapted transfection reagent 
amounts used per well. For a 6-well plate, 2.6 µl siRNA SMARTpool were mixed with 
147.4 µl OptiMEM and incubated for 5 min. In the meantime, 1.5 µl Dahrmafect2 
transfection reagent (3 µl for HK-2 cells) were mixed with 148.5 µl OptiMEM (147 µl 
for HK-2 cells). siRNA and Dharmafect2 mix were then added together, vortexed and 
incubated for ≥ 20 min before transferring the 300 µl to a well. In parallel, cells were 
trypsinised, counted and resuspended in culture medium (containing 10 % FBS) so that 
a suspension with 125 cells/µl was achieved. 1.2 ml of this cell suspension was added 
on top of the 300 µl siRNA/Dharmafect2/OptiMEM transfection mix. Following plating, 
plates were kept for ≥ 30 min at RT, before placing them in a humid 37°C/5 % CO2 
incubator. Approximately 24 h later, 1 ml fresh culture medium was added to the cells. 
To check knockdown (KD) efficiency, cells were lysed 48 h post transfection. 
 
In case of time course analyses, cells were transfected all at the same time and harvested 
24, 48, 72, 96, 120 hours post transfection or as specified in the respective figure legend.  
 
2.2.3 Reverse siRNA transfection of two genes simultaneous 
For co-silencing of two genes simultaneously, procedure as described in 2.2.1 and 2.2.2 
was followed using half the concentration, i.e.18.75 nM (cell viability, 96-well plate) or 
1.3 nM (RNA/protein extraction, 6-well plate) of each of the siRNA SMARTpools in 
order to keep the final siRNA concentration in the transfection reaction at 37.5 nM per 
100 µl and 2.6 nM per 1.5 ml. In these experiments, the single (control) knockdowns 
were complemented 1:1 with scrambled siRNA. 
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Table 2.1: siGENOME siRNAs used in this study 
Gene Symbol Entrez Gene ID Pool Number Duplex Number Sequence 
CAT 847 MU-010021-01 
D-010021-01 
D-010021-02 
D-010021-03 
D-010021-04 
CACAUGACAUUACCAAAUA 
GGAAUCCAGUUAAUUACUU 
GAGCACAGCAUCCAAUAUU 
GGACAUCGCCACAUGAAUG 
CPT1A 1374 MU-009749-02 
D-009749-01 
D-009749-02 
D-009749-05 
D-009749-18 
GAGAGAACCUCAUCAAUUU 
GAAGAAGGAUACAGAAGUG 
GGACAGCUACGCCAAAUCU 
UGACAACGAUGUACGCCAA 
CPT1B 1375 MU-010266-01 
D-010266-04 
D-010266-17 
D-010266-18 
D-010266-19 
CAAGUAACUAUGUGAGUGA 
GAUCAUGUAUCGCCGUAAA 
GGACUGAGACUGUGCGUUC 
CAUGAUUGCAGGCGAGAAC 
FOXO1 2308 MU-003006-03 
D-003006-05 
D-003006-06 
D-003006-07 
D-003006-21 
CCAGGCAUCUCAUAACAAA 
CCAGAUGCCUAUACAAACA 
GGAGGUAUGAGUCAGUAUA 
AGGACAAUAAGUCGAGUUA 
FOXO3 2309 MU-003008-02 
D-003008-05 
D-003008-07 
D-003008-21 
D-003008-22 
CGAAUCAGCUGACGACAGU 
GUACUCAACUAGUGCAAAC 
CAGUAAAGAGGUACGAAAA 
UGCAUUAACUUGCGGUAUU 
FOXO4/MLLT7 4303 MU-003016-02 
D-003016-05 
D-003016-06 
D-003016-07 
D-003016-08 
GGACUGGACUUCAACUUUG 
CCACGAAGCAGUUCAAAUG 
GAGAAGCGACUGACACUUG 
GACCAGAGAUCGCUAACCA 
G6PD 2539 MU-008181-02 
D-008181-01 
D-008181-02 
D-008181-03 
D-008181-05 
GAGAGUGGGUUUCCAGUAU 
CAACAUCGCCUGCGUUAUC 
CGUGAGGCCUGGCGUAUUU 
UGACCUACGGCAACAGAUA 
GCLC 2729 MU-009212-03 
D-009212-03 
D-009212-05 
D-009212-06 
D-009212-20 
CUUCUAAGCCGGAUCAUAU 
GAGUAUGGGAGUUACAUGA 
UGAGGGAGUUUAUCGCAAA 
CAAGAAAUAUCCGACAUAG 
GLS 2744 MU-004548-00 
D-004548-01 
D-004548-02 
D-004548-03 
D-004548-04 
AGACAUGGUUGGUAUAUUAUU 
UGAAUAAGAUGGCUGGUAAUU 
GGUGGUUUCUGCCCAAUUAUU 
GAAUAACACUCCCAUGGAUUU 
GPX1 2876 MU-008982-00 
D-008982-01 
D-008982-02 
D-008982-03 
D-008982-04 
GCAAGGUACUACUUAUCGA 
UGAAUUCCCUCAAGUACGU 
GGAGAACGCCAAGAACGAA 
GCAACCAGUUUGGGCAUCA 
GPX2 2877 MU-011675-00 
D-011675-01 
D-011675-02 
D-011675-03 
D-011675-01 
GAACGAGCAUCCUGUCUUC 
GAAGGUAGAUUUCAAUACG 
CAGGAGAACUGUCAGAAUG 
GCAGGGCCGUGCUGAUUGA 
GPX3 2878 MU-006485-01 
D-006485-01 
D-006485-02 
D-006485-03 
D-006485-04 
GUACGGAGCCCUCACCAUU 
GGAUGUCAAUGGAGAGAAA 
AGGAAGAGCUUGCACCAUU 
GAGGCUUUGUCCCUAAUUU 
GPX4 2879 MU-011676-01 
D-011676-01 
D-011676-03 
D-011676-04 
D-011676-17 
CAACGUGGCCUCCCAGUGA 
GUAACGAAGAGAUCAAAGA 
CGUCAAAUUCGAUAUGUUC 
GCUGCGUGGUGAAGCGCUA 
GPX5 2880 MU-009445-01 
D-009445-03 
D-009445-04 
D-009445-17 
D-009445-18 
GCAAGCACAUCCUCUUCGU 
UGGCGUACUUGAAGCAAUU 
AGGCCAUCGCACUUAAUAA 
GGGAGGAUUUGUACCUAGU 
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Gene Symbol Entrez Gene ID Pool Number Duplex Number Sequence 
GPX6 257202 MU-019309-00 
D-019309-01 
D-019309-02 
D-019309-03 
D-019309-04 
GCAAGCACGUCCUGUUUGU 
GCAGUUCAAUACCCACUAG 
GCGAGGAGUACAUCCAAUU 
AUAGGAAGGUGGAUUGCAA 
GPX7 2882 MU-009875-01 
D-009875-01 
D-009875-02 
D-009875-03 
D-009875-04 
GAAGCGAGAAGACUUAUAA 
ACAAGGAGAUUGAGAGCUU 
GCACCUACAGUGUCUCAUU 
GGACUUCUACGACUUCAAG 
GPX8 493869 MU-034902-01 
D-034902-17 
D-034902-18 
D-034902-19 
D-034902-20 
GUAUAAAGGCAAAGUUUCA 
CUAAAAUUCCUCAAACCUA 
GGUUAGACAAGUGAUCAUA 
GUGUAUGACUGAAAUUUCU 
GSR 2936 MU-009647-01 
D-009647-01 
D-009647-02 
D-009647-03 
D-009647-04 
GAACACAGCUGUCCACUCU 
GAUUAUGGCUUUCCAAGUU 
GAUACGGCAUGAUAAGGUA 
UCAAUUGGCGUGUUAUUAA 
GSS 2937 MU-009586-00 
D-009586-01 
D-009586-02 
D-009586-03 
D-009586-04 
CAAAGAAGCUGGCAAGAUC 
CGACGAACAUUUGAAGAUA 
CUACAUGCCUCGUCAGUAC 
GCAUCUACUUCGAACCAAA 
LMNA 4000 MU-004978-01 D-001050-01 GGUGGUGACGAUCUGGGCU 
ME1 4199 MU-009348-02 
D-009348-02 
D-009348-03 
D-009348-19 
D-009348-05 
CAUCUGACAUUGAGAAAUU 
AGUAAGAGGUUCUGAAUAU 
CCUUGCAGCUCUUCGAAUA 
GGUAAAUUGGCUCUAUAUA 
MYC 4609 MU-003282-07 
D-003282-14 
D-003282-15 
D-003282-16 
D-003282-35 
AACGUUAGCUUCACCAACA 
GGAACUAUGACCUCGACUA 
GAACACACAACGUCUUGGA 
CUACCAGGCUGCGCGCAAA 
NFE2L2 4780 MU-003755-02 
D-003755-01 
D-003755-02 
D-003755-04 
D-003755-05 
 
PDHK1 5163 MU-005019-00 
D-005019-01 
D-005019-02 
D-005019-03 
D-005019-04 
GGAAGUCCAUCUCAUCGAAUU 
GGAACACCAUGCCAACAGAUU 
GAUCAGAAACCGACACAAUUU 
GAUCAGUGAAUGCUUGUGAUU 
PLK1 5347 MU-003290-01 
D-003290-05 
D-003290-06 
D-003290-07 
D-003290-08 
CAACCAAAGUCGAAUAUGA 
CAAGAAGAAUGAAUACAGU 
GAAGAUGUCCAUGGAAAUA 
CAACACGCCUCAUCCUCUA 
SEPSECS 51091 MU-015559-00 
D-015559-01 
D-015559-02 
D-015559-03 
D-015559-04 
CAAGAUGUAUCCAGGAAGA 
CCAAAGGCAAAGUAUAUUA 
AAGGGUGCCUGAUAGAUUA 
GGCUCGAGUUGGUAGAAUA 
SLC1A5 6510 MU-007429-01 
D-007429-02 
D-007429-03 
D-007429-17 
D-007429-18 
GGAUGUGGGUUUACUCUUU 
GUUCUGGUCUCCUGGAUCA 
GAGAGGAAUAUCACCGGAA 
CAGUCAACCUCCCGGUCGA 
SLC7A9 11136 MU-007619-02 
D-007619-02 
D-007619-04 
D-007619-05 
D-007619-18 
UCAAUUACAUCACAGAAGA 
GAAGCUACGUCCAGAACAU 
GACAUAAACUCGUUAGUCA 
CGUGAUGACUGCCACCGAA 
SLC7A11 23657 MU-007612-01 
D-007612-01 
D-007612-02 
D-007612-03 
D-007612-04 
GGAAGUCUUUGGUCCAUUA 
GGAGUUAUGCAGCUAAUUA 
GGGAACAACUAUAAAGAAA 
UGACAAAUGUGGCCUACUU 
SLC16A4 9122 M-007406-00 
D-007406-01 
D-007406-02 
D-007406-03 
D-007406-04 
GACAGGAGCCCUUAUAUUA 
GAAACACACUGCCAUGAGA 
GAAGAAAGUGAUAAGGUUA 
UGACAUACUUGGAGAGAAA 
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Gene Symbol Entrez Gene ID Pool Number Duplex Number Sequence 
SOD1 6647 MU-008364-01 
D-008364-05 
D-008364-06 
D-008364-07 
D-008364-08 
UCGUUUGGCUUGUGGUGUA 
ACAAAGAUGGUGUGGCCGA 
GUGCAGGGCAUCAUCAAUU 
UUAAUCCUCUAUCCAGAAA 
SOD2 6648 MU-009784-02 
D-009784-03 
D-009784-04 
D-009784-19 
D-009784-20 
AAAGAUACAUGGCUUGCAA 
GUAAUCAACUGGGAGAAUG 
ACCAGGAGGCGUUGGCCAA 
GGAUUGAUGUGUGGGAGCA 
TXNRD2 10587 MU-009089-01 
D-009089-01 
D-009089-03 
D-009089-04 
D-009089-17 
GAAAGAGAUUCUGCUGUCA 
UGGGAGGCCUGAUCCAAGA 
GCCGAUCACAUCAUCAUUG 
GCACACGGUUUGCGGCGUU 
UBB 7314 MU-013382-01 
D-013382-01 
D-013382-02 
D-013382-03 
D-013382-17 
GCCGUACUCUUUCUGACUA 
GUAUGCAGAUCUUCGUGAA 
GACCAUCACUCUGGAGGUG 
CCCAGUGACACCAUCGAAA 
RISC-free siRNA 
  
D-001220-01 N/A 
siGENOME non-
targeting 
siRNA1 
siRNA2 
siRNA3 
siRNA4 
 
 
 
 
 
 
 
 
D-001210-01 
D-001210-02 
D-001210-03 
D-001210-04 
 
 
AUGAACGUGAAUUGCUCAA 
UAAGGCUAUGAAGAGAUAC 
AUGUAUUGGCCUGUAUUAG 
UAGCGACUAAACACAUCAA 
On TARGET Plus 
(siOTP, non-
targeting) 
siControl1 
siControl2 
siControl3 
siControl4 
 
 
 
 
 
 
 
D-001810-01 
D-001810-02 
D-001810-03 
D-001810-04 
 
 
 
UGGUUUACAUGUCGACUAA 
UGGUUUACAUGUUUUCUGA 
UGGUUUACAUGUUUUCCUA 
UGGUUUACAUGUUGUGUGA 
 
2.3  siRNA screening 
2.3.1 Determination of optimal transfection reagent 
The UMRC2, A498, 786-O, and 769-P isogenic cell line pairs as well as the HK-2 cells 
were screened with a library of 23 transfection reagents (TR) (Table 2.2) by Dr. Ming 
Jiang from the CRUK LRI High Throughput Screening (HTS) facility in search for the 
optimal transfection reagent. For this, cells were reverse transfected on a 96-well plate 
format with 37.5 nM LaminA/C using the TR library at two different concentrations 
(0.1 µl and 0.3 µl). 48 h post transfection, cells were fixed with 80% -20°C-cold ethanol 
over night at -20°C. Cells were then stained with an antibody against LaminA/C (see 
Table 2.5 for details) and DAPI. Immunofluorescence intensities of LaminA/C as 
readout for knockdown efficiency and number of positive DAPI-stained nuclei as 
readout for cell number, was computed using a Cellomics ArrayScan VT (Thermo 
Scientific). 
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Table 2.2: Transfection reagents used in this study 
Transfection Reagent Manufacturer 
CodeBreaker™ Promega 
DharmaFect 1 ThermoFisher Scientific 
DharmaFect 2 ThermoFisher Scientific 
DharmaFect 3 ThermoFisher Scientific 
DharmaFect 4 ThermoFisher Scientific 
DreamFect Gold Oz Biosciences (Marseille, France) 
FuGENE® Promega 
GeneEraser™ Agilent 
GeneSilencer® Genlantis (San Diego, CA, USA) 
HiPerFect® Qiagen (Germantwon, MD, USA) 
INTERFERin® Polyplus (Illkirch, France) 
Lipofectamine Invitrogen 
Lipofectamine™ 2000 Invitrogen 
Lipofectamine™ 
RNAiMAX Invitrogen 
Lullaby® Oz Biosciences 
METAFECTENE® Cambio (Cambridge, UK) 
N-TER™ Nanoparticle Sigma-Aldrich 
Oligofectamine™ Invitrogen 
RiboJuice™ Merck Millipore 
siIMPORTER™ Merck Millipore 
siLentFect Bio-Rad 
siPORT™ Amine Ambion 
siPORT™ NeoFX™ Ambion 
TransIT-siQUEST® Mirusbio (Madison, Wi, USA) 
TransIT-TKO® Mirusbio 
 
2.3.2 Screening protocol 
Day 2 prior to screening 
All 10 cell lines used in the screen were passaged under standard tissue culture 
conditions into 2× 75 cm2 flasks and incubated at 37ºC, 5% CO2 for 2/3 days to let the 
cells reach 90% confluence. 
(Note: A 1:4 split from 90 % confluence into 75 cm2 flask, allows 90% confluence 
within 48 h with a total of ~5-8×106 live cells per 75 cm2.) 
 
Day of screening 
The aliquoted siRNA library containing 10 µl of 375 nM siRNA/Hank’s Buffer Salt 
Solution (HBSS) mix were thawed for 20 min at room temperature (RT) and 
centrifuged for 1 min at 1500 rpm. 10 µl of the transfection reagent mix (0.1 µl 
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Dharmafect2/OptiMEM (Invitrogen)) was added to each well of each plate used at the 
time using a WellMate 8-channel microplate dispenser (ThermoFisher Scientific). 
While the plates with the 20 µl siRNA/HBSS:Dharmafect2/OptiMEM transfection mix 
were left to incubate for 20 min at RT, the cells were prepared. One cell line pair was 
processed at the time. Cells were rinsed with PBS, trypsinised and centrifuged for 5 min 
at 1000 rpm to remove the trypsin. Cells were counted using the Countess® and 
resuspended in 100 ml freshly prepared growth medium yielding a cell density of 
2.5×104 cells/ml. 80 µl of this cell suspension per well was dispersed over the nine 96-
well plates constituting the siRNA library (3 plates in triplicates) using a WellMate 
(speed = high). The final reaction volume was 100 µl per well with a final siRNA 
concentration of 37.5nM.  
(Note: RCC4, UMRC2 and 786-O ± pVHL were transfected on one day and A498 and 
769-P ± pVHL were transfected a week later.) 
 
Day 1 post screening 
100 µl freshly prepared full growth media was added per well using a WellMate   
(speed = 3).  
 
Day 4 post screening 
96 hours post reverse siRNA transfection, cells were fixed with 100 µl/well of 80%  
-20°C-cold EtOH. Therefore, the culture medium was aspirated using a microplate 
washer (Bio Tek) and 100 µl/well of ice-cold EtOH was added using a WellMate 
(speed = 3). Plates were sealed and stored at -20°C until ready to process further. 
 
Day X post screening 
The plates were processed in two batches: 3 pairs (i.e. 54 plates) in the morning and 2 
pairs (i.e. 36 plates) in the afternoon. Using a microplate washer, EtOH was aspirated 
and cells were washed 3x with 100 µl PBS, RT. Subsequently, a WellMate dispersed 
30 µl/well DAPI solution (100 ng/ml in PBS) (speed = 1) and cells were incubated for 
1 h. Next, the staining solution was aspirated and the cells were washed 2x with 100 µl 
PBS using a microplate washer. Finally, 100 µl PBS was added with a WellMate 
(speed = 1). Plates were sealed with aluminium foil and fed into an Acumen X3 laser 
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scanning imaging cytometer (TTP Labtech, Hertfordshire, UK) to determine DAPI 
staining intensity as readout for cell number. 
 
2.3.3 Screen data analysis 
The raw cell number values obtained from the Acumen X3 were analysed by Dr. 
Rebecca Saunders from the CRUK LRI HTS facility using the cellHTS2 software 
package (Bioconductor) (Boutros et al., 2006). Firstly, raw cell number values were 
centred to the respective plate median based only on sample wells without inclusion of 
the 16 control wells. Next, Z-Scores were calculated using the median absolute 
deviation (MAD) of the population. A Z-Score(MAD) close to 0 indicates that the given 
measurement is very similar to the median of the population, a negative Z-Score(MAD) 
indicates a loss in cell number while a positive Z-Score(MAD) represents a gain in cell 
number compared to the population median. Z-Scores(MAD) ≤ -1.7 and ≥ 1.7 were 
considered to indicate significant effects on cell number compared to the population 
median. These Z-Score(MAD) values were used to define hits in the course of the screen 
data analysis. For screen quality evaluation, Spearman Rank Correlation analyses were 
performed on a plate-by-plate basis of the individual replicates to check for 
reproducibility within the experiment. A Spearman Rank factor above 0.65 was 
considered to indicate good correlation.  
For more details on the screen analysis and quality control see Chapter 4, sections 4.3.2 
and 4.3.3. 
 
2.4  Small molecule inhibitor treatment 
Drug response studies were performed in a 96-well plate format. Cells were plated at a 
cell density of 2000 cells/well in 100 µl growth medium. The next day, 100 µl/well of 
fresh growth medium containing the respective drug in twice the concentration than 
desired was added to the cells. Cells were incubated with the respective drug for 72 h 
before over night fixation at -20°C in 100 µl 80% ice-cold EtOH. Fixed cells were 
washed 2x with 150 µl PBS, stained with 50 µl DAPI (100 ng/ml)/PBS solution for 
≥ 20 min, washed again 2x in 100 µl PBS before adding a final 100 µl PBS. Plates were 
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then sealed and analysed for cell number counts using an Acumen X3 laser scanning 
imaging cytometer. 
A complete list with small molecule inhibitors and other chemicals used to treat cells in 
this study is depicted in Table 2.3. 
 
Table 2.3: Chemical inhibitors, small molecules and supplements used for cell treatment 
Reagent Supplier Solvent Stock solution Description 
(+)-Etomoxir sodium salt hydrate Invitrogen DMSO 100 mM CPT1 inhibitor -> inhibits β-oxidation 
2-Deoxy-D-Glucose Sigma Aldrich ddH2O 1 M Glucose analogue 
4-hydroxy-2,2,6,6-tetramethyl-
piperidine-N-oxyl (TEMPOL) Sigma-Aldrich ddH2O 1 M 
Antioxidant; 
SOD2 mimetic  
Antimycin A DMSO DMSO 100 mM ETC Complex III inhibitor 
Bezafibrate Sigma-Aldrich DMSO 500 mM PPARα agonist 
BPTES Sigma-Aldrich DMSO 10 mM GLS inhibitor 
BrdU Sigma-Aldrich PBS 30 mM  
BSO Sigma-Aldrich ddH2O 100 mM GCLC inhibitor 
Carbonyl cyanide-4-(trifluoro-
methoxy)phenyl hydrazone 
(FCCP) 
Sigma-Aldrich DMSO 20 mM Disruption of mitochondrial membrane potential 
Carnitine Sigma-Aldrich ddH2O 50 mM Supports β-oxidation 
Cdk4/6 inhibitor  DMSO 25 mM Induces cell cycle arrest in G1 
D-Glucose Sigma-Aldrich ddH2O 
10% 
(355 mM)  
DMOG Sigma Aldrich DMSO 1 M PHD inhibitor 
Doxirubicine  ddH2O 100 µM 
Intercalates into the DNA and 
causes DNA damage 
Ebselen Sigma Aldrich DMSO 100 mM Antioxidant; GPX mimetic 
L-Glutathione reduced Sigma-Aldrich ddH2O  Antioxidant Hydrogen peroxide Sigma-Aldrich ddH2O 30 wt% Reactive oxygen species 
L-Cysteine hydrochloride, non-
animal source, anhydrous Sigma-Aldrich ddH2O  Amino acid 
MG-132 Calbiochem ddH2O 20 mM Proteasome inhibitor 
N-Acetyl-L-cysteine (NAC) Sigma-Aldrich ddH2O 1 M 
Antioxidant; 
Precursor for Cysteine 
Sodium Palmitate Sigma-Aldrich   Fatty acid Oligomycin A Invitrogen DMSO 100 mM ATP synthase inhibitor 
Pyocyanin Sigma-Aldrich DMSO 100 mM ROS generator 
Rotenone  DMSO 10 mM ETC Complex I inhibitor 
Sodium pyruvate Sigma-Aldrich ddH2O 100 mM  
Luperox® TBH70x Tert-Butyl 
Hydroperoxide Sigma-Aldrich ddH2O 70 wt% Reactive oxygen species 
α-Ketoglutaric acid (α-KG) Sigma-Aldrich ddH2O  TCA cycle intermediate 
 
2.5  Kinetic Caspase-3/7 Apoptosis assay 
For analysis of real time apoptosis induction following siRNA treatment, a 
CellPlayerTM Kinetic Caspase-3/7 Apoptosis Assay Kit (Essen Bioscience, Cat no. 
4440) was employed. This reagent is a fusion of an activated caspase-3/7 motif (DEVD) 
to NucView™488, a DNA intercalating dye. Just before placing cells in an Essen 
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BioScience IncuCyte™ system, the Caspase-3/7 substrate was added as a 1:500 dilution 
directly to the medium (10 µM final concentration). This inert, non- fluorescent 
substrate is cell permeable and its cleavage upon induction of apoptosis results in a 
green fluorescent DNA dye. Quantification of fluorescence accumulation was analysed 
using the IncuCyte™ FLR object counting algorithm. 
 
2.6  Fluorescence-activated cell sorting (FACS) analysis 
2.6.1 Cell cycle analysis 
Cell cycle analysis was performed using the intercalating fluorescent agent propidium 
idodide (PI, Ex/Em = 535/617 nm) to measure DNA content using FACS. 
Cells were reverse transfected with 37.5 nM SMARTpool siRNA targeting GPX1 and 
GPX3 in a 6-well format. For harvesting, cells were trypsinised, spun down at 1000 rpm 
for 5 min and washed 1x PBS before fixing in ice-cold 70 % EtOH over night at 4ºC. 
Before FACS analysis, cells were washed 2x in ice-cold PBS and treated with 50 µl 
ribonuclease (100 µg/ml, Sigma) for 5 min to ensure staining of only DNA. Cells were 
subsequently stained with 200 µl PI (50 µg/ml in PBS, Sigma) and analysed 
immediately on an LSRII flow cytometer. 
 
2.6.2 BrdU pulse-chase analysis 
For tracing cell cycle duration, 5-bromo-2-deoxyuridine (BrdU) –pulse chase analysis 
was performed. Therefore, cells were incubated with 30 µM BrdU for 15 min (labels 
cells in S-phase), then washed 2x with PBS and replenished with fresh medium. Cells 
were trypsinised, washed 2x in PBS and fixed in 70% EtOH over night at 4ºC 
immediately for time point 0 h and then after 2, 4, 6 and 8 h. Immunofluorescence (IF) 
against DNA-incorporated BrdU (anti-BrdU antibody, Becton Dickinson) was 
performed following antigen retrieval with 2 M Hydrochloric acid (1:4 HCL in ddH2O); 
PI staining was complenmetary. Fluorescent intensity was analysed on a FORTESSA 
FACS analyser.  
NOTE: Cell cycle analysis, i.e. PI staining and IF against BrdU and subsequent FACS 
analysis was performed by members of the LRI FACS laboratory. 
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2.6.3 Reactive oxygen species (ROS) detection 
(A) H2DCFDA 
1.5x105 cells were reverse transfected with 37.5 nM siRNA for 48 h in a 6-well format. 
Treatment with 1 mM H2O2 for 10 min prior to H2DCFDA addition was used as a 
positive control for ROS induction. Cells were incubated with 5 µM cell permeable 6-
carboxy-2',7'-dichlorodihydrofluorescein diacetate (Carboxy-H2DCFDA; 
Ex/Em = 495/529 nm; Molecular Probes), a chemically reduced, acetylated form of 
fluorescein that is used as an indication of the presence of reactive oxygen species 
(ROS), for 30 min at 37ºC in the dark. Stained cells were then trypsinised, washed 1x in 
PBS to remove residual trypsin and media and resuspended in 300 µl cold PBS. 
Immediately before analysing on an LSRII FACS analyser, DAPI was added to exclude 
dead cells. Cells were kept on ice and in dark while waiting to be analysed. 
 
(B) Cellular ROS/Superoxide detection (Abcam, ab139476) 
30 min prior trypsinisation cells were treated with 200 µM Pyocyanin (a ROS inducer) 
and AntimycineA (superoxide inducer) respectively, as positive control for 
ROS/Superoxide induction. Cells were washed 2x in PBS and incubated with the 
ROS/Superoxide fluorescent dye combination for 30 min at 37°C and in the dark. Cells 
do not need to be washed to remove residual dye, but were analysed directly with an 
LSRII FACS analyser. The green ROS probe requires Ex/Em = 490/525 nm 
(Fluorescine), while the orange Superoxide probe requires Ex/Em = 550/620 nm 
(Rhodamine) filter sets for detection. 
 
2.7  Immunocytochemistry to detect DNA damage 
Accumulation of phospho-Histone H2A.X (γ-H2A.X) and 53BP1 as result of the DNA 
damage response can be used as readout for DNA damage.  
Cells were transfected with 37.5 nM siRNA targeting GPX1, GPX3 and SOD1 for 96 h 
in a 96-well format. 6 h before fixation, untransfected cells were treated with 250 nM 
doxyrubicine, a DNA intercalating agent causing DNA damage, as positive control. 
Cells were fixed for 2 h in a 50:50 mix of methanol/acetone at -20°C. Following 
fixation, cells were washed 2x with PBS before incubation in blocking solution (3% 
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BSA/0.1% Tween20 in PBS) for 1 h at RT or over night at 4°C. Blocking solution is 
then replenished with 30 µl staining solution, i.e. blocking solution containing 53BP1 
(rabbit, H300, Santa Cruz; 1:200 dilution) and γH2A.X (mouse, millipore; 1:400 
dilution) antibody. Cells were incubated under constant shaking for 1.5 h at RT. Cells 
were washed 3x in PBS before adding the secondary fluorescent antibody (Alexa 
Flour® rabbit and mouse 488 and 594) for 1 h at room temperature. Cells were washed 
3x in PBS, replenished with 100 µl PBS and subjected for analysis using a Celomics 
ArrayScan VT (Thermo Scientific) and the accompanying Thermo Scientific HCS 
studio: Cellomics Navigator Version 6.4.4 software.  
 
2.8  Lipid droplet analysis 
For basal cytoplasmic lipid droplet analysis, 4000 cells/well were plated in a 96-well 
format and fixed 48 h later with 80 % ice-cold EtOH over night at -20°C. After fixation, 
cells were washed 2x with PBS before adding staining solution containing 1:10000 Nile 
Red (Life Technologies, stock: 1 mg/ml in DMSO) and 1:5000 DAPI (Sigma, stock: 
5 mg/ml) in PBS for 15-30 min, RT. Cells were washed 2x with PBS, replenished with 
100 µl PBS and subjected for analysis using a Celomics ArrayScan VT (Thermo 
Scientific) with associated Thermo Scientific HCS studio: Cellomics Navigator Version 
6.4.4 software. 
  
2.9  Nucleic acid manipulations 
2.9.1 Extraction of total RNA 
Total RNA was extracted from cells using an RNeasy Mini Kit (Qiagen) according to 
the manufacturer's instructions for extraction of animal cells. Cells were lysed with RLT 
buffer and disrupted by centrifugation in shredder columns (QIAshredder, Qiagen). The 
obtained RNA was eluted in 20-40 µl nuclease-free water (Ambion) and RNA 
concentration was measured using a NanoDrop spectrophotometer (ThermoFisher 
Scientific). RNA was stored at -80ºC. 
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2.9.2 Complementary DNA synthesis 
Total RNA was used to generate its complementary DNA (cDNA) with SuperScript II 
reverse transcriptase, Oligo dT12-18 and RNaseOUT (Invitrogen). Reverse transcription 
was performed according to the first-strand cDNA synthesis protocol (Invitrogen). 
Briefly, 1 µg RNA was mixed with 1 µl of 10 mM dNTPs (Invitrogen), 1 µl Oligo 
dT12-18 primer (500 µg/ml; Invitrogen) and nuclease-free water (Ambion) up to a total 
volume of 12 µl. This mix was heated for 5 min at 65ºC and then cooled for 5 min on 
ice before adding 8 µl RT reaction mix (Invitrogen) to each sample. Reactions were 
thoroughly mixed and incubated at 42ºC for 1.5h. 
RT reaction mix 
4 µl 5x first strand buffer  
2 µl DTT (0.1 M)  
1 µl RNAseOUT (40 units/µl) 
1 µl SuperScript II reverse transcriptase (200 units/µl)  
 
Finally, cDNA was diluted to a final concentration of 10 ng/µl with nuclease-free water 
(Ambion). 
 
2.9.3 Quantitative real time qPCR (RT-qPCR) 
Quantitative real time PCR (RT-qPCR) is based on a PCR, where the amplified product 
is measured after each cycle by a fluorescence detector for amplification (7900HT Fast 
Real-Time PCR System, Applied Biosystems). Here, the SYBR Green I dye 
(Platinum® SYBR® Green qPCR SuperMix-UDG with ROX, Invitrogen) was used as 
fluorphore, which binds to double-stranded DNA during the elongation phase. To avoid 
unspecific fluorophore binding, each run included a standard melting curve programme 
(90ºC-65ºC) and a dissociation curve was produced (SDS2.3 software) as reference for 
internal quality control. A dissociation curve plots the ratio of fluorescence intensity 
and temperature over time for each PCR product analysed. The more identical products 
present, the more the curve ascends until it reaches a peak. This peak indicates the 
maximal dissociation ratio within the melting curve. 
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RT-qPCRs were performed on 96-well plates and each reaction mix included 
12.5 µl  Platinum® SYBR® Green qPCR SuperMix-UDG with ROX 
2.5 µl   QuantiTect Primer (10 pmol/µl; Quiagen) 
10 µl  cDNA (10 ng/µl) 
 
Table 2.4 gives a full list of qPCR primers used in this study. 
 
RT-qPCR analysis is based on the number of PCR cycles that are needed to accumulate 
a certain threshold of fluorescence, the so-called cycle threshold (CT) obtained for a 
sample. The CT value is proportional to the logarithm of initial amount of the 
mRNA/cDNA of the gene of interest in a sample. To compare relative RNA levels of a 
gene of interest among different samples, determination of RNA levels of the 
housekeeping gene ACTB (ecodes β-actin) was included in each set of RT-qPCRs for 
normalisation purposes. The difference in cell cycle numbers, ΔCT, were compared to 
each other (Livak and Schmittgen, 2001). 
RT-qPCR conditions 
50°C  2 min 
95°C  5 min 
  95°C  15 sec  
60°C  1 min  40x 
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Table 2.4: Qiagen QuantiTect Primer used in this study 
Gene 
symbol Protein 
Catalogue 
number 
ACTB  b-Actin QT01680476 
BAX Bcl-2-associated X proteine QT00031192 
CAT Catalase QT00079674 
CDKN1A p21/WAF1/CIP1 QT00062090 
CDKN1B p27/Kip1 QT00998445 
CPT1A Carnitine palmitoyltransferase IA QT00082236 
CPT1B Carnitine palmitoyltransferase IB QT00057036 
FOXO1 Forkhead box transcription factor of the O class 1 QT00044247 
FOXO3 Forkhead box transcription factor of the O class 3 QT00031941 
FOXO4 Forkhead box transcription factor of the O class 4 QT00029141 
G6PD Glucose-6-phosphate dehydrogenase QT00071596 
GCLC Glutamate-cysteine ligase catalytic subunit QT00037310 
GLS Glutaminase QT00019397 
GPX1 Glutathione peroxidase 1 QT00203392 
GPX2 Glutathione peroxidase 2 QT00200039 
GPX3 Glutathione peroxidase 3 QT00062279 
GPX4 Glutathione peroxidase 4 QT00067165 
GPX5 Glutathione peroxidase 5 QT00044744 
GPX6 Glutathione peroxidase 6 QT01677088 
GPX7 Glutathione peroxidase 7 QT00009492 
GPX8 Glutathione peroxidase 8 QT00032347 
GSR Glutathione reductase QT00038325 
GSS Glutathione synthetase QT00014413 
MYC  QT00035406 
NFE2L2 Nuclear respiratory factor 2, NRF2 QT00027384 
PDHK1 Pyruvate dehydrogenase kinase 1 QT00069636 
PMAIP1/ 
NOXA1 Phorbol-12-myristate-13-acetate-induced protein 1 QT00074438 
PPARGC1B PGC1B QT00081865 
PRDX2 Peroxiredoxin 6 QT00000098 
PUMA/BBC3 53 upregulated modulator of apoptosis (PUMA) or Bcl-2-binding component 3 (BBC3) QT00082859 
RAD51  QT00072688 
SCAP SREBP cleavage activating protein QT00197764 
SCD Stearoyl-CoA desaturase-1 QT01669521 
SEPSECS O-phosphoseryl-tRNA(Sec) selenium transferase QT00048342 
SLC1A5 Solute carrier family 1 (neutral amino acid transporter), member 5 QT00083909 
SLC7A11 solute carrier family 7 (anionic amino acid transporter light chain, xc- system), member 11 QT00002674 
SLC7A9 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 9 QT00057778 
SOD1 Cu/Zn superoxide dismutase QT01671551 
SOD2 Mn superoxide dismutase QT01008693 
TFAM Mitochondrial transcription factor A QT00012782 
TOMM20 Translocase of outer mitochondrial membrane 20 homolog (yeast) QT00088914 
TP53 p53 QT00060235 
VEGFA Vascular endothelial growth factor A  QT01682072 
XRCC6 Ku70 QT00036064 
 
Note: Lyophilised qPCR primers were resuspended in 1.1 ml TE (pH 8.0) to obtain 10x 
stock dilutions. 
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2.9.4 Single-nucleotide polymorphism (SNP) analysis of part of 
chromosome 3p 
Genomic DNA was extracted using a DNeasy Blood and Tissue Kit (Quiagen) 
according to the manufacturers protocol. DNA concentrations were measured using a 
NanoDrop spectrophotometer (ThermoFisher Scientific). 250 ng/ml DNA were 
subjected to a targeted PCR with the following commercially available SNP primers 
(Invitrogen): 
 D3S2450, D3S4420,  D3S2947E, D3S4351, D3S1317, 
 D3S1351, D3S1259 D3S1211, D3S1581, D3S36 
To each sample DNA, 8 µl PCR reaction mix and nuclease-free water to a final volume 
of 25 µl was added. 
 PCR reaction mix 
2.5 µl  10x Buffer 
0.2 µl  dNTPs (2.5mM each) 
0.1 µl  primer pair (200µM) 
   5 µl  reagent Q (comes with Taq polimerase; Quiagen) 
0.2 µl  Taq polymerase (Quiagen) 
 
  PCR conditions 
  94°C  5 min 
  94°C  1 min 
  55°C  1 min   35x 
  72°C  1 min 
  72°C  10 min 
    4°C  ∞ 
 
The PCR product was cleaned up using a QIAquick PCR Purification kit following the 
manufacturer’s guidelines. 
For the sequencing reaction, to 4 µl of the cleaned PCR product 8 µl BigDye® 
Terminator (BDT, provided by the LRI Equipment Park), 1 µl sequencing primer 
(20 µM) and 7 µl ddH2O was added. 
Sequencing conditions 
  96°C  5 min 
  96°C  1 min 
  50°C  1 min   35x 
  60°C  1 min 
    4°C  ∞ 
The obtained results were analysed using GeneMapper software 5 (Applied Biosystems). 
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2.10  Protein manipulations 
2.10.1 Protein quantification using Sulforhodamine B (SRB) assay 
To determine cellular protein content as means of normalisation where cell number 
readout was not possible, sulforhodamine B staining was performed. This method was 
adapted from (Vichai and Kirtikara, 2006) and was mainly performed on a 96-well 
format. Supernatant/media was aspirated from cells before adding ice-cold 10 % tri-
chloro-acetic acid (TCA in milliQ H2O) in PBS for fixation for ≥1 h at 4ºC. Cells were 
washed 2x with 100 µl/well ddH2O and air-dried over night at RT. The following day, 
50 µl/well of a 0.4 % Sulforhodamine B in 1 % acetic acid solution was added and 
incubated for 30 min at RT constantly shaking. Cells were washed 2x in 1 % acetic acid 
and dried completely before adding 100 µl/well 10 mM TRIS (pH 8) for 15 min at RT 
constantly shaking to re-solubilise the protein-bound Sulforhodamine B. Luninescence 
at 530, 565 and 690 nm was measured using a SpectraMax 190 plate reader (Molecular 
Devices, Sunnyvale, CA, USA) and SoftMax Pro software. Note: a cell-free, media 
only –containing well was always included in order to determine background SRB 
levels. For cell mass determination, the following calculation was performed: 
λ570 - λ690 (background of respective well) - average protein background 
 
2.10.2 Protein quantification using Bradford assay 
In order to load equal amounts of protein samples on SDS-polyacrylamide gels, protein 
concentrations were determined using Bradford reagent (Bio-Rad Protein Assay). BSA 
was used to generate a standard curve (0, 2, 4, 6, 8, 10, 12, 14 µl BSA (0.025 µg/µl) + 
250 µl Bradford reagent, respectively, for 0, 0.4, 0.8, 1.2, 1.6, 2.0, 2.4, 2.8 µg/µl BSA). 
Bradford reagent was diluted 1:5 in ddH2O and 250 µl were added per well to 10 µl 1:5 
protein sample dilution (in ddH2O). After 5 min incubation constantly shaking at RT, 
the absorbance at λ = 595 nm was measured on a SpectraMax 190 plate reader using 
the SoftMax Pro software (Molecular devices). 
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2.10.3 Preparation of cell lysates for immunoblots 
Medium was aspirated and cells were washed 2x with cold PBS prior to lysis with 100-
200 µl cold TNET buffer supplemented with protease (Complete, EDTA free, Roche) 
and phosphatase (PhosStop, Roche) inhibitors and DTT. After incubation on ice for 
20 min constantly shaking, cells were scraped using cell scraper (Sarstedt; Newton, NC 
USA) and collect cell lysates were centrifuged at 13000 rpm for 10 min at 4°C. 
Supernatants were carefully transferred into new tubes. Protein lysates were stored at  
-80°C until further use. 
TNET lysis buffer pH7.5 
  1 %  NP-40 
  20 mM Tris-HCL (pH 7.5) 
  137 mM NaCl 
  10 %  Glycerol 
  2 mM  EGTA 
  1 mM  DDT  
 
NuPage loading dye (4x) was added to 10-15 µg protein lysates for protein denaturing. 
TNET buffer was used to equalise total volumes of cell lysates used for separation on 
sodium dodecyl sulphate (SDS)-gels. The mixture was vortexed followed by a 10 min 
incubation period at 70°C. 
  NuPage Loading Dye 
  8 %  SDS 
  200 mM TRIS Base 
  40 %  Glycerol 
  0.01 g/l Bromphenol Blue 
  2 %  β-Mercaptoethanol 
  1 mM  DDT 
 
2.10.4 Sodium dodecyl sulphate (SDS) –PAGE 
SDS-page is a common method used to analyse cellular protein contents. This 
technique allows separation of proteins based on their molecular weight. The detergent 
SDS is not only used to denature the proteins but it also imparts a uniform charge to 
them. Therefore, proteins will separate solely based on size and not charge. In this 
study, only pre-cast 4-12 % Novex®- NuPage TRIS-glycine SDS-page gradient gels 
(Invitrogen) were used in Bio-Rad electrophoresis chamber systems. 
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The following running buffers were used: 
20x NuPAGE® MOPS Running Buffer  20x NuPAGE® MES Running Buffer 
pH 7.7 (Novex/leife technologies, NP0001) pH 7.3 (Novex/life technologies, NP0002) 
50 mM MOPS    50 mM MES 
50 mM TRIS Base   50 mM TRIS Base 
0.1 %  SDS    0.1 %  SDS 
1 mM   EDTA    1 mM  EDTA 
 
The pre-stained full-range protein marker RPN800E (Amersham) was used as 
molecular size standard to determine approximate protein sizes. Protein separation was 
performed at 150 V for ± 90 min. 
 
2.10.5 Westerm Blotting 
Immunoblotting is a commonly used method to transfer proteins separated by 
denaturing gel electrophoresis onto a membrane. SDS gradient gels obtaind in 2.10.4 
were transfered onto an Immobilon-P membrane (Merck Millipore) using an 
electrophoretic transfer cell (Bio-Rad). Briefly, PVDF membranes were activated by a 
quick rinse in methanol followed by two quick washes with transfer buffer. All other 
components for the blot were equilibrated in transfer buffer while preparing the 
sandwich. The transfer was carried out at 250 mA for 120 min, Membranes were 
blocked in 5% milk/TBS for 0.5-1 h at RT constantly shaking to prevent unspecific 
binding of antibodies to membranes. Incubation with primary antibody (1:1000 dilution 
in 3% BSA/Azide/Tris buffered saline/Tween20 (TBST)) occurred over night at 4°C 
constantly shaking. The following day the primary antibody solution was removed and 
membranes were washed 2x 5 min in 5 % milk/TBST and 3x 5 min in 0.1 % TBST 
constantly shaking. Then, secondary antibody conjugated to horseradish-peroxidase 
(HRP) (1:2000 dilution in 5 % milk/TBST) was added for 45 min at RT under constant 
shaking. Visualisation of protein bands occurred by chemiluminescence using an 
Amersham ECL detection kit (GE Healthcare) on Medical X-ray films (Hyperfilm, GE 
Healthcare), which were developed using an automatic X-ray film processor (JP-33, 
JPI Healthcare Solutions, Planview, NY, USA). 
Composition of used buffers are listed below: 
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Transfer Buffer 
250 mM Glycine 
25 mM  TRIS Base 
10 %  Methanol 
 
TRIS-buffered saline (TBS), pH 7.4  TBST, pH 7.4 – wash buffer 
137 mM NaCl     500 ml  TBS 
25 mM TRIS Base    0.1 %  Tween 20 
 
Blocking solution 
5 %  Semi-skimmed milk powder 
500 ml  TBS 
0.1 %  Tween20 
 
Western blot stripping buffer, pH 2.5 
1 M  Glycine 
2 %  SDS 
to adjust pH HCl, conc. 
 
Table 2.5 lists all antibodies used in this study. 
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Table 2.5: Antibodies used in this study 
Primary Antibody Host Predicted size 
[kDa] 
Clone Cat No Manufacturer 
53BP1 Rabbit 220 H300 Sc-22760 Santa Cruz 
ACC Rabbit 280  3662 Cell Signalling 
ACLY Rabbit 120  4332S Cell Signalling 
AKT Rabbit 60  9272 Cell Signalling 
BCL-2 Mouse 26    
BrdU Mouse    BD Bioscience 
c-Myc Mouse 57-65 9E10 ♯21 M4439 Sigma-Aldrich 
CDK2 Rabbit 33 78B2 2546 Cell Signalling 
CDK6 Mouse 36 DCS83 3136 Cell Signalling 
Cyclin A Rabbit 54 H-432 Sc-751 Santa Cruz 
Cyclin D1 Mouse 36  Sc-20044 Santa Cruz 
ERK1/2 Rabbit 42/44  9102 Cell Signalling 
FASN Mouse 265 23 610962 BD Bioscience 
GPX1 Rabbit 22 C8C4 3286 Cell Signalling 
GSK3α/β Mouse 47/51  368662 Calbiochem 
HA.11 – HA-tag Mouse  16B12 MMS-101P Covance 
HIF-1α Mouse 120 54/HIF1α 610959 BD Bioscience 
HIF-2α Rabbit 120  NB100-122 Novus 
LAMINA/C Mouse ~70 636 Sc-7292 Santa Cruz 
MEK1/2 Rabbit 45  9122 Cell Signalling 
MitoProfile® Total 
OXPHOS human WB 
antibody cocktail 
Mouse I – 18, II – 29, III – 48, IV – 22, V - 54  ab110411 Abcam 
mTOR Rabbit 289  2972 Cell Signalling 
p16  16 JC8  CRUK in house 
p21/WAF1/CIP1 Rabbit 21  Sc-397 Santa Cruz 
p27/Kip1 Mouse 27  610241 BD Transduction lab 
p53 Mouse 53 DO-7 610984 Dako 
pACC (S79) Rabbit 280  3661S Cell Signalling 
pACLY (S455) Rabbit 120  4331 Cell Signalling 
pAKT (S473) Rabbit 60  9271S Cell Signalling 
pAKT (T308) Rabbit 60  9275 Cell Signalling 
PARP Rabbit 116 (FL) / 89 (cleaved)  9542 Cell Signalling 
pERK1/2 (T202/Y204) Mouse 42/44 E10 9106 Cell Signalling 
pGSK3α/β (S21/9) Rabbit 47/51 S21/9 9331 Cell Signalling 
pHistone H2A.X (S139) Mouse 15  05-636 Merck Millipore 
pP38 (T180/Y182)  38    
PPARγ Mouse 55 E-8 Sc-7273 Santa Cruz 
pRb (S780) Goat 107/140  Sc-12901 Santa Cruz 
pS6 (S235/236) Rabbit 32  2211 Cell Signalling 
pS6 (S240/244) Rabbit 32  2215 Cell Signalling 
PTEN Rabbit 54  9552 Cell Signalling 
Rb Rabbit 107/140 C-15 Sc-050 Santa Cruz 
S6 Ribosomal protein Rabbit 64 5G10 2217 Cell Signalling 
SOD1 Mouse 18 71G8 4266S Cell Signalling 
SOD2 Rabbit 25  SOD-110 Stressgen 
SREBP1 Mouse 125, 70 2A4 557036 BD PharMingen 
SREBP2 Mouse 120 1C6 557037 BD PharMingen 
TOMM20 Rabbit 20  Sc-11415 Santa Cruz 
β-Actin-HRP Mouse 45 AC-15 A3854 Sigma-Aldrich 
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Secondary Antibody Host Cat No Manufacturer 
ECLTM Anti-mouse IgG-HRP  Sheep NA931V GE Healthcare 
ECLTM Anti-rabbit IgG-HRP Donkey NA934V GE Healthcare 
Alexa Fluor® 488 anti-rabbit- IgG Donkey A21206 Life Technologies 
Alexa Fluor® 594 anti-mouse- IgG Goat A11005 Life Technologies 
 
2.11  Metabolic Manipulations  
2.11.1 Measurements of Oxygen Consumption Rate (OCR) and 
Extracellular Acidification Rate (ECAR) 
Oxygen consumption and lactate secretion are physiological symptoms that go with 
active cellular metabolism, more specifically, the ratio is an indicator of how glycolytic 
or respiratory cells are. The Seahorse Bioscience Extracellular Flux (XF) Analyser 
(Seahorse Bioscience, Massachusetts, USA) is a valuable tool to evaluate cellular 
oxygen consumption rates (OCRs) and extracellular acidification rates (ECARs) the 
latter of which are supposed to correlate with lactate secretion. 
Cells were plated on 96-well XF Cell Culture Microplates (seahorse Bioscience) in 
80 µL culture medium the day before assaying. Appropriate plating cell numbers need 
to be determined beforehand, as these are crucial for successful analysis. Cells were 
seeded so that they were 100 % confluent at time of analysis. Note also, that the XF 
sensor cartridge (Seahorse Bioscience) needs to be hydrated in 200 µl/well XF Calibrant 
solution (pH 7.4) (Seahorse Bioscience) over night at 37°C in a CO2-free incubator 
(Seahorse Bioscience). The next day, assay medium was freshly prepared by 
supplementation of plain XF Assay Medium (Seahorse Bioscience) with the necessary 
nutrients. This medium was also used to prepare 10x drug concentrations and was 
distributed to the appropriate injection ports on the XF sensor cartridge for injection 
during the assay. The sensor cartridge was then placed into the XF Analyser for 
calibration. In the meantime, cells were washed carefully in assay medium, replenished 
with the appropriate amount of this and incubated at 37°C for ≥ 30 min in the CO2-free 
incubator to deacidify the medium. Following calibration, the XF Cell Culture 
Microplate was inserted into the XF analyser for flux analysis. Compositions for the 
respective assay media used for the different assays together with the respective 
treatments are listed in Table 2.6, and a standard flux analysis protocol is depicted in 
Table 2.7. 
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Table 2.6: Media composition and drug concentrations for OCR/ECAR measurements 
Assay Glycolysis Respiratory 
capacity 
β-Oxidation 
vs. Glycolysis 
β-Oxidation 
Medium XF assay medium modified DMEM  
(no Glucose, 2 mM Glutamax; Part no: 102352-000) 
Krebs-Henseleit Buffer (KHB) 
(111 mM NaCl, 4.7 mM KCl, 
2 mM MgSO4, 1.2 mM Na2HPO4) 
Supplements 25 mM Glucose 10 mM Glucose 2.5 mM Glucose 
10 mM Sodiumpyruvate 1 mM Sodium pyruvate 0.5 mM Carnitine 
Added drugs 
(in order) 
25 mM Glucose 1.3 µM Oligomycin 50 µM Etomoxir 100 µM Sodium palmitate 
1.3 µM Oligomycin 0.4 µM FCCP 25 mM Glucose 50 µM Etomoxir 
50 mM 2-DG    
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Table 2.7: Standard Seahorse Bioanalyser protocol for 3 injections 
Protocol Steps 
Command Time (min) Port 
Calibrate 0.00   
Equilibrate     
Mix 3.00   
Wait 1.00   
Measure 4.00   
Mix 3.00   
Wait 1.00   
Measure 4.00   
Mix 3.00   
Wait 1.00   
Measure 4.00   
Mix 3.00   
Wait 1.00   
Measure 4.00   
Inject   A 
Mix 3.00   
Wait 3.00   
Measure 4.00   
Mix 3.00   
Wait 1.00   
Measure 4.00   
Mix 3.00   
Wait 1.00   
Measure 4.00   
Inject   B 
Mix 3.00   
Wait 3.00   
Measure 4.00   
Mix 3.00   
Wait 1.00   
Measure 4.00   
Mix 3.00   
Wait 1.00   
Measure 4.00   
Inject   C 
Mix 3.00   
Wait 3.00   
Measure 4.00   
Mix 3.00   
Wait 1.00   
Measure 4.00   
Mix 3.00   
Wait 1.00   
Measure 4.00   
EndProtocol     
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2.11.2 Measurement of intracellular glutathione levels 
To determine basal intracellular gluthathion in ccRCC cells and in HK-2 cells, a 
Gluthathione Fluorometric Assay Kit (BioVision, Cat. No. K264-100) was employed 
according to the manufacturer’s guidelines. In brief, quick handling and keeping the 
samples cold/on ice as much as possible is essential. Cells were plated on 10 cm tissue 
culture dishes and shock-frozen on dry ice 48 h later for lysis. Cells were stored at -
80°C until processed. Following collection of the lysed cells via a cell scraper and 
further mechanical disruption using a 21 G syringe, cell lysates were quickly transferred 
to pre-prepared perchloric acid (PCA) and vortexed to obtain a homogenous mixture. 
After 5 min on ice, emulsions were centrifuged at 4°C for 2 min at 13000 rpm, to 
collect the supernatant. Ice-cold 6 N KOH was added in a 1:2 ratio to the PCA-
preserved sample, incubated for 5 min on ice and spun down for 2 min at 13000 rpm at 
4°C. A 6th of each sample supernatant was transferred to a 96-well plate for (a) reduced 
glutathione (GSH), (b) oxidised GSSG and (c) total glutathione detection. To detect 
GSSG, samples were first pretreated with 10 µl GSH quencher for 10 min at RT and 
then with 10 µl reducing agent to destroy any excessive quencher and convert GSSG to 
GSH. The latter treatment applies also for determination of total glutathione. In parallel 
a GSH, GSSG and GSH+GSSG standard was prepared the same way including a 
reagent only containing background control. To start the reaction, 10 µl o-
phthalaldehyde (OPA) was added and mixed well. After ~40 min incubation at RT, 
OPA fluorescence (Ex/Em = 340/420 nm) was detected using a PHERAstarPlus-plate 
reader (BMG Labtech). 
To calculate GSH amountst, the background was subtracted, the standard curves were 
plotted (RFU vs. GSH standard) and the sample values were applied to the standard 
curves to obtain glutathione amounts. 
For being able to compare across samples, GSH, GSSG and total glutathione levels 
were normalised to total protein concentrations used in the assay. Protein concentrations 
were determined using Bradford protein quantification assay. 
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2.11.3 Measurement of GPX activity 
To determine how GPX activity compares between ccRCC and HK-2 cells, GPX 
activity was measured using a Glutathione Peroxidase Assay Kit (Abcam, ab102530) 
according to the manufacturer’s guidelines. Briefly, cells were plated on 10 cm tissue 
culture dishes and harvested 48 h later by shock-freezing on dry ice. Cells were further 
mechanically disrupted by passing several times through 21G syringes before 
centrifugation at 10000 rpm for 15 min at 4°C, to collect the supernatant. 25 µl of each 
sample was transferred to a well on a 96-well plate (in duplicates) including a positive 
(purified GPX) and a negative (reagents only) control and volume was brought to 50 µl 
with Assay buffer). A standard curve was prepared as displayed in Table 2.8, and 
NADPH autoflourescence was measured (Ex/Em = 340/420 nm). 
 
Table 2.8: NADPH standard curve          Reaction Mix per well 
     33 µl Assay buffer 
  3 µl NADPH solution (40mM) 
  2 µl Glutathione reductase solution 
  2 µl GSH solution   
 
 
 
 
40 µl reaction mix was added to each sample containing well. The reaction was started 
with addition of 10 µl Cumene Hydroperoxide following 15 min incubation. Changes in 
NADPH conversion were recorded manually every minute for 20 min using an Envision 
plate reader. GPX activity was calculated as follows: 
 
          NADPH decrease over time  
GPX activity = ----------------------------------------------------- X sample dilution = nmol/min/ml = mU/ml 
             Δ time [min] x pretreated sample volume  
   added into the reaction well [ml] 
 
With one unit being defined as amount of enzyme needed to cease the oxidation of 
1 µmol of NADPH to NAD+ per minute under assay kit conditions at 25°C. 
For being able to compare across samples, the obtained GPX activity values were 
normalised to total protein concentrations used in the assay. Protein concentrations were 
determined using Bradford protein quantification assay. 
ml NADPH 
standard 
(1 mM) 
nmol/well 
NADPH 
standard 
µl assay 
buffer 
0 0 100 
20 20 80 
40 40 60 
60 60 40 
80 80 20 
100 100 0 
120 120 0 
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2.12  Data analysis 
2.12.1 Analysis of quantitative experiments  
Data are usually presented as mean values and the error bars represent either the 
standard deviation (SD) or standard error of the mean (SEM) as described in the figure 
legend. All quantitative data was analysed and graphed up using GraphPad Prism 6.0 
(GraphPad software). Drug dose response curves were generated using the 
“log(inhibitor) vs. response – variable slope (four parameters)” analysis and IC50 
values were extracted from the accompanied table of XY coordinates. For statistical 
analysis, when the different ccRCC cell line behaviours were compared to HK-2 cell 
behaviour, 2-way ANOVA analysis with Dunnett multiple comparison testing was 
carried out. The same is true for time courses or some dose response curves, when 
different time points were compared to t0 or vehicle control treatment. Indicated p-
values (or asterisks) were obtained as stated in the respective figure legends and are 
corrected for multiple comparison testing. Only p-values ≤ 0.05 were considered to be 
statistically significant with *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.005; ****, p ≤ 0.001. 
 
2.12.2 Analysis of ccRCC TCGA dataset 
TCGA kidney renal cell carcinoma data were downloaded from the cBioPortal website 
(http://www.cbioportal.org/public-portal/), via Bioconductor's "cgdsr" package 
(Jacobsen, 2013). Processed RNA-seq expression signals (kirc_tcga_rna_seq_v2_mrna) 
and clinical data (kirc_tcga_rna_seq_v2_mrna) were gathered for a selection of genes 
(GPX1, GPX3, SOD1, GLS, GCLC, GCLM, GSS, GSR, G6PD, SLC1A5, SLC7A9 and 
SLC7A11). 
 
Single gene survival analysis 
For each selected gene, expression across patient samples were categorised into high, 
medium and low expression groups based on 1/3 and 2/3 quantiles. Kaplan-Meier 
survival curves were plotted for the resulting groups. The effect of expression on overall 
survival was then assessed using a Cox proportional hazard model from the Biocoductor 
package “survival”.  
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3.1  Introduction 
ccRCC is characterised by high intratumoural heterogeneity (Gerlinger et al., 2012a). 
Furthermore, as described above, sporadic and hereditary ccRCC is characterised by a 
heterogeneous loss of DNA fragments on the short arm of chromosome 3, which 
harbours VHL amongst others. The gene product of this gene, pVHL encodes an E3 
ubiquitin ligase whose most prominent target is the α-subunit of the heterodimeric HIF 
transcription factor (Maxwell et al., 1999). HIF orchestrates a metabolic switch from 
oxidative respiration to anaerobic glycolysis and stimulates vascularisation in response 
to hypoxic stress. ccRCC cells are presenting a pseudo-hypoxic state, in which HIF is 
constitutively active despite the presence of ample oxygen levels, leading to a highly 
glycolytic phenotype of this cancer subtype (Figure 1.5). 
Apart from VHL, other adjacent genes are lost in the course of ccRCC tumourigenesis, 
many of which are involved in metabolic processes. In a systems-biology approach, it 
has been found that ccRCC metabolism is distinct from that of other cancer types and 
that ccRCC cells have highly compromised nucleotide, inositol and 
glycerol(phospho)lipid metabolism (Gatto et al., 2014). 
To fully appreciate the heterogeneity of ccRCC, for the studies described in the 
following, a cell line panel of 12 ccRCC cell lines and one non-tumourigenc kidney 
epithelial cell line, HK-2, was assembled. This panel comprises eight cell lines that have 
endogenously lost functional pVHL (RCC4, UMRC2, A498, 786-O, 769-P, CAKI2, 
UMRC3 and A704) and four cell lines that still express endogenous pVHL (TK10, 
CAKI1, ACHN and UO31). 
 
In order to study pVHL function in the context of ccRCC, a selection of isogenic 
ccRCC cell lines was obtained from the laboratory of Prof. William Kaelin (Dana-
Farber Cancer Institute, Boston, MA). These cell lines had been generated by 
introducing a wild type VHL allele (pBABE-puro-HA-VHL) into different established 
ccRCC cell lines that lack endogenous functional pVHL. As control, parental cells were 
transfected with the empty vector backbone (EV). Five isogenic cell line pairs, namely 
RCC4 EV, RCC4 VHL, UMRC2 EV, UMRC2 VHL, A498 EV, A498 VHL, 786-O EV, 
786-O VHL, 769-P EV and 769-P VHL, were obtained to carry out a functional siRNA 
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screen to identify metabolic enzymes that show synthetic lethal interactions with pVHL 
(see Chapter 4). In this section, both the parental cell lines as well as the isogenic cell 
line pairs will be examined for their HIF-expression patter, respiratory and glycolytic 
profile as well as specific nutrient dependencies.  
 
3.2  LOH of chromosome 3p fractions is common in ccRCC cell 
lines 
Fractional LOH of chromosome 3p is a common characteristic of ccRCC cells. In order 
to establish the LOH pattern within the cell line panel, the 12 ccRCC cell lines were 
analysed for single-nucleotide polymorphisms (SNP) along the short arm of 
chromosome 3 from 3p26.1 to 3p13 spanning ~70.5Mb (Figure 3.1A). All of the cancer 
cell lines that are known to have lost functional pVHL were found to have only one 
copy of all the SNP markers tested (LOH of 3p26.1 to 3p13). Surprisingly, ACHN, 
known to express functional pVHL, showed the very same pattern (Figure 3.1B). In this 
case, LOH of chromosome 3p must not be accompanied by VHL mutation on the other 
allele, leaving one functional VHL copy for transcription. In contrast, all other cell lines 
known to express functional pVHL (HK-2, TK10, CAKI1 and UO31) were found to 
have a patchy SNP pattern towards the distal part of the 3p chromosome arm, with some 
stretches being scored as heterozygous (Figure 3.1B). Interestingly, the non-
tumourigenic HK-2 cells but also positive blood sample controls (Ctr. I and Ctr. II) are 
not fully heterozygous for the whole 3p chromosome, but show LOH towards the 
proximal centromere stretch.  
Chapter 3: Metabolic characterisation of ccRCC cell lines 
 70 
 
Figure 3.1: Heterozygous loss of a substantial stretch of chromosome 3p is common in 
ccRCC cells. 
(A) List of single-nucleotide polymorphism (SNP) markers tested on the ccRCC cell line panel to 
examine loss of heterozygosity (LOH) along the indicated stretch of chromosome 3p. VHL, commonly 
lost in ccRCC lies within marker D3S1317. (B) Summary of SNP array analysis on genomic DNA of 
ccRCC and HK-2 cells. Ctr. I and Ctr. II are blood DNA samples from healthy patients, which were 
kindly provided by Andrew Rowan, Translational Cancer Theapeutics, CRUK LRI. Blue cells indicate 
LOH, red cells indicate heterozygosity (HET); UD, undetermined. 
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3.3  Profiling of ccRCC cells for HIF stabilisation and hypoxia 
tolerance 
3.3.1 ccRCC cell lines express either both HIF-α isoforms or only HIF-2α 
As pVHL is a negative regulator of the transcription factor HIF, basal HIF expression 
and transcriptional activity was examined in the ccRCC cell lines. ccRCC cell lines that 
have lost functional pVHL clearly show higher basal levels of HIF-α protein expression 
compared to cells that express functional pVHL (Figure 3.2A). A498 cells were found 
to express a truncated form of HIF-1α protein. This truncated form has recently been 
described and shown to lack the domains encoded by exons 2-6, resulting in a ΔHIF-1α 
isoform with reduced tumour suppressor function (Shen et al., 2011). Furthermore, in 
786-O and 769-P cells, no expression of HIF-1α was detectable. Interestingly, only cell 
lines that show stabilisation of HIF-1α also display increased levels of pyruvate 
dehydrogenase kinase 1 (PDHK1) mRNA (Figure 3.2B), an established HIF-1α 
transcriptional target (Kim et al., 2006). A498, 786-O, 769-P and all cell lines 
expressing functional pVHL show low levels of PDHK1 mRNA (Fig. 3.2B). Non-
tumourigenic HK-2 cells show similar basal HIF-1α protein levels as pVHL-null 
ccRCC cells and moderate expression of PDHK1. Levels of HIF-2α were low in these 
cells (Figure 3.2B). 
 
Figure 3.2: ccRCC cells express different levels of HIF-1α and HIF-2α 
(A) The indicated ccRCC cell lines and HK-2 cells were analysed for basal HIF-1α and HIF-2α protein 
expression. β-Actin serves as loading control. (B) HIF-1α activity was assessed by measuring mRNA 
abundances for its downstream target pyruvate dehydrogenase kinase 1 (PDHK1). Bar graphs depict 
average of duplicate measurements normalised to ACTB and relative to HK-2 ± SD. Number above HK-2 
bar represents average ΔCT value for comparison. 
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With regard to the isogenic cell line pairs, all pVHL-null cell lines showed the same 
pattern of HIF-α isoform expression as the parental cell lines (Figure 3.3). In contrast, 
the pVHL-expressing cells show a substantial reduction in HIF-α expression. This was 
especially prominent for HIF-2α in RCC4, A498 and 786-O cells. Moreover, detection 
of exogenous pVHL showed strong overexpression in RCC4 and A498 cells, while 786-
O and 769-P cells show moderate expression. Only weak expression of pVHL could be 
detected in UMRC2 cells. 786-O and 769-P cells seem to express pVHL at endogenous 
levels (Figure 3.3A). 
As expected, expression of the HIF target gene vascular endothelial growth factor A 
(VEGFA) is modulated in a pVHL-dependent manner, while expression of PDHK1 was 
modulated only in the HIF-1α expressing cell lines RCC4 and UMRC2 (Figure 3.3B). 
 
 
Figure 3.3: Exogenous pVHL represses HIF-α stabilisation and activity 
(A) Basal HIF-1α, HIF-2α and HA-tagged pVHL expression in isogenic cell line pairs. HEK293 cells 
were used as positive control. (B) HIF activity was assessed by measuring mRNA abundances for its 
downstream targets pyruvate dehydrogenase kinase 1 (PDHK1) and vascular endothelial growth factor A 
(VEGFA). Bar graphs depict average of duplicate measurements normalised to ACTB and relative to  
HK-2 ± SD. Number above HK-2 bar represents average ΔCT value for comparison. 
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3.3.2 MG-132, DMOG and hypoxia stabilise HIF-α protein in VHL 
reconstituted cell lines  
In order to evaluate the capacity of stabilising HIF-α isoforms in pVHL expressing 
versus pVHL deficient ccRCC cells, cells were treated with the proteasome inhibitor 
MG-132 to prevent proteasomal degradation of HIF-α. MG-231 treatment resulted in 
substantial HIF-1α and HIF-2α accumulation both in all pVHL expressing and lacking 
cell line pairs, although HIF-α levels were higher in cells lacking pVHL (Figure 3.4B). 
769-P cells express very low levels of HIF-2α, which was increased following MG-132 
treatment. The observation that proteasome inhibition also resulted in accumulation of 
HIF-α protein in pVHL-null cells, hints to the existence of degradation systems other 
than the pVHL-mediated regulation.  
A more specific way of examining HIF-α stabilisation is achieved by inhibiting the 
activity of the negative regulators of HIF-α, the PHDs, using the competitive inhibitor 
dimethyloxallyl glycine (DMOG). The isogenic cell line pairs as well as CAKI2, 
CAKI1, TK10, UO3 and HK-2 cells were treated with DMOG and analysed for HIF-α 
accumulation. DMOG treatment was as efficient in inducing HIF-α accumulation as 
MG-132 treatment in all cell lines tested (Figure 3.4C). Contrary to MG-132, DMOG 
only increased HIF-1α levels in pVHL containing RCC4 and UMRC2 cells, confirming 
the specificity of the treatment. HK-2 cells were found to have a quite large HIF-1α 
pool, and DMOG treatment increased HIF-1α protein levels even above the levels of 
RCC4 cells, which display the largest amount of HIF-1α protein among the cancer cell 
lines (Figure 3.4C). DMOG treatment in pVHL expressing cells results in HIF-2α levels 
similar to those in untreated EV cells without causing any additional increase in cells 
lacking pVHL (Figure 3.4C). 
Finally, isogenic cell lines together with HK-2 cells were subjected to oxygen 
deprivation for short (6 h) and long (24 h) term in order to mimic the actual HIF 
activating environment and to assess HIF-α accumulation. In pVHL-expressing cells, 
HIF-1α and HIF-2α protein levels were increased after 6 h exposure to 0.1% oxygen but 
declined to almost basal levels after 24 h of oxygen deprivation (Figure 3.4D). This 
transient induction could indicate the possibility of adaptation to long-term hypoxia 
exposure. While RCC4 and A498 EV cells maintained their basal HIF-1α and HIF-2α 
levels upon short and long term oxygen deprivation, 786-O EV cells showed a reduction 
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of HIF-2α protein after 24 h in hypoxia. Moreover, UMRC2 EV cells seemed to 
gradually lose both HIF-1α and HIF-2α expression over time in hypoxia, again 
suggesting adaptation mechanisms. Interestingly, the non-tumourigenic HK-2 cells 
strongly upregulated both HIF-1α and HIF-2α in hypoxia and maintained these high 
levels over at least 24 h of oxygen deprivation. No induction of HIF-1α or HIF-2α 
protein could be detected in 769-P cells (Figure 3.4D). 
 
 
 
Figure 3.4: HIF-α stabilisation in isogenic ccRCC cells upon treatment with MG-132 and 
DMOG 
(A) Schematic depicting HIF signalling and degradation and highlighting some ways of interfering with 
the pathway to stabilise HIF protein. (B) HIF-α protein leves and pVHL in pVHL-isogenic ccRCC cell 
line pairs upon treatment with 25 µM MG-132, a proteasome inhibitor, for 2 h. (C) HIF-α and pVHL 
protein levels in ccRCC isogenic cell lines, CAKI2, CAKI1, TK10, UO31 and HK-2 cells upon treatment 
with the PHD competitive inhibitor DMOG (1 mM) for 4 h. (D) HIF-α and pVHL protein levels upon 
short (6 h) and long (24 h) term incubation in 0.1% oxygen. (B-D) β-actin serves as loading control. 
 
Taken these data together, pVHL-reconstituted cells showed the expected regulation of 
the HIF-α isoforms. pVHL-expression resulted in lower basal expression of HIF-1α and 
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HIF-2α protein but this negative effect could be reversed by treatment with MG-132 or 
DMOG. Moreover, these cell lines also showed induction of HIF-α in hypoxia. The 
non-tumourigenic HK-2 cells, surprisingly, showed substantial basal HIF-1α 
accumulation, which was enhanced in hypoxia and maintained over longer oxygen 
deprivation. 
 
3.3.3 ccRCC cells are more sensitive to 0.1% than 0.5% oxygen 
conditions independent of pVHL expression 
To assess the tolerance of the isogenic ccRCC cell lines as well as HK-2, TK10 and 
CAKI1 cells towards oxygen deprivation, cell proliferation was monitored over five 
days in oxygen-deprived conditions. Supply with 0.5% and 0.1% oxygen were 
compared to normoxia (21% oxygen). For the first 2-3 days, proliferation of most of the 
cancer cell line pairs and HK-2 cells did not differ much between the different oxygen 
conditions (Figure 3.5A). Around day 3-4, proliferation rates dropped significantly in 
0.5% oxygen for all but the 769-P cell line pairs as well as for TK10 cells. Surprisingly, 
RCC4 and UMRC2 cells expressing pVHL had slightly higher proliferation rates in 
normoxic conditions than their pVHL-lacking counterparts. Only A498 pVHL-null cells 
outgrew their pVHL-expressing partners. Notably, in hypoxia, the respective pairs had 
similar growth kinetics. The 786-O and 769-P cell line pairs showed very similar growh 
rates in both normoxic and hypoxic conditions (Figure 3.5A). 
Decreasing the oxygen supply even further to 0.1% significantly reduced cell 
proliferation from day 2 onwards in all cell lines (Figure 3.5B). The respective cell line 
pairs showed similar growth rates, although RCC4 and 769-P pVHL-expressing cells 
grew faster than their pVHL-deficient partners. 
In summary, ccRCC cells were relatively tolerant towards oxygen deprivation to a level 
of 0.5% for several days. However, levels below this oxygen concentration seemed to 
be stressful for the cells and resulted in ~50% growth inhibition. Furthermore, previous 
observations could be confirmed that showed that, despite slowing down tumour growth 
in vivo, re-expression of pVHL does not inhibit ccRCC cell proliferation in vitro (Chen 
et al., 1995, Iliopoulos et al., 1995). 
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Figure 3.5: Proliferation rates of isogenic ccRCC cell line pairs under hypoxic conditions 
The 5 isogenic cell lines as well as TK10, CAKI1 and HK-2 cells were plated in a 96-well format. The 
next day, one half of the cells were placed in a regular incubator, the other half was placed in a hypoxia 
chamber with (A) 0.5% or (B) 0.1% oxygen supply. Parallel plates of cells were fixed every 24 h over a 
time course of 5 days. Graphs represent average endpoint cell numbers of 4 wells (A) / 8 wells (B) ± SD. 
Red / blue asterisks indicate statistically significant differences in proliferation under normoxic / hypoxic 
conditions when pVHL expressing cells were compared to pVHL-null cells. Black / grey asterisks 
indicate statistically significant cell number differences in pVHL-null / pVHL-expressing cells when 
survival was compared in normoxia vs hypoxia (2-way ANOVA analysis with Bonferroni multiple 
comparison testing; *, p ≤ 0.05; ****, p ≤ 0.001). 
 
3.4  Profiling of ccRCC cell lines for nutrient utilisation 
3.4.1 ccRCC cells are highly glycolytic 
Due to a constitutively active HIF pathway, ccRCC cells are known to be highly 
glycolytic. To examine how variable the different ccRCC cell lines are in this respect 
and if there is a HIF-α isoform-specific pattern or a difference between pVHL 
expressing cell lines compared to pVHL-null cells, cells were analysed for their 
glycolytic profile using a Metabolic Flux Analyzer (Seahorse Biosciences). This 
instrument measures simultaneously oxygen consumption rates (OCR) and extracellular 
acidification rates (ECAR) in real time, thereby providing a readout for mitochondrial 
respiration and cellular proton secretion. Proton secretion is likely to be an indicator of 
the export of lactate produced from glucose through glycolysis (Figure 3.6A). After 
measurement of basal ECAR, cells were subsequently treated with glucose to stimulate 
glycolysis, the ATP synthase inhibitor Oligomycin to determine the maximal glycolytic 
capacity and with 2-deoxyglucose (2-DG) to inhibit glycolysis (Figure 3.6B).  
The slowest proliferating cell line of the panel, A704, showed the highest basal 
glycolytic rate when compared to the average basal ECAR. 786-O, UMRC3, CAKI1 
and UO31 cells were significantly more glycolytic than average, while 769-P and A704 
cells were significantly less glycolytic (Figure 3.6D). None of the cancer cell lines 
showed a glycolytic capacity or a glycolytic reserve that was above average.  
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Figure 3.6: ccRCC cells are highly glycolytic 
(A) Flow diagram illustrating the several intermediates that glucose (a 6-carbon unit) is subsequently 
converted to, ultimately resulting in pyruvate (a 3-carbon unit). Pyruvate can either be shuttled to the 
mitochondria to enter the TCA cycle for mitochondrial respiration, or it can be converted to lactate by 
lactate dehydrogenase (LDH) when oxygen levels are low (hypoxia). Lactate secretion results in 
extracellular acidification due to the symport of protons. (B) Schematic illustrating the ECAR profile that 
can be obtained when cells are sequentially treated with glucose (stimulates glycolysis), the ATP synthase 
inhibitor Oligomycin (to determine maximal glycolytic capacity) and 2-deoxyglucose (2-DG, an inhibitor 
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of glycolysis). This schematic was obtained with permission from the Seahorse Bioscience website. (C) 
Using a Seahorse XFe96 Bioanalyzer, the extracellular acidification rate (ECAR) of the different ccRCC 
cells was determined. Cells were plated in a 96-well plate format the day before analysis in full growth 
medium. For analysis, growth medium was replaced with assay medium containing 25mM glucose, 2mM 
Glutamax and 10mM sodium pyruvate. Cells were placed into the instrument and basal ECAR was 
determined. Subsequently, glucose, Oligomycin and 2-DG were added. Graphs represent average of at 
least 5 wells normalised either to cell mass (CM, left hand graph) or to the last basal rate (right hand 
graph) ± SD. (D) Bar graph summarising, apart from average basal ECAR rates, also average glycolytic 
rate, maximal glycolytic capacity and the glycolytic reserve ± SD. These rates were calculated according 
to (B) from last rates for each treatment in (C). Asterisks indicate statistical difference of the respective 
rate for a given cell line compared to the general average for this rate (dotted lines in respective colour 
shading) (2-way ANOVA with Dunnett multiple testing analysis; * p ≤ 0.05). 
 
3.4.2 ccRCC cells have high respiratory capacity 
The mitochondrial respiratory capacity was determined using a Seahorse Bioanalyzer. 
For this, upon measuring basal OCR levels, ccRCC and HK-2 cells were subsequently 
treated with Oligomycin and FCCP. Oligomycin inhibits ATP synthase and, in this case, 
serves to measure ATP-production. FCCP leads to proton leakage and disruption of the 
mitochondrial membrane potential along the electron transport chain (ETC) and allows 
measurement of the maximal cellular respiratory capacity (Figure 3.7A-B). 
Surprisingly, only RCC4, UMRC2, A704 and UO31 cells showed significantly lower 
basal respiration compared to HK-2 cells, while all other cell lines showed comparative 
or even significantly higher basal respiration; 769-P and TK10 cells being an example 
of the latter. 769-P and TK10 cells also had the highest respiratory capacity, although 
all but UMRC2, UMRC3 and UO31 cells showed significantly higher respiratory 
capacity than HK-2 cells (Figure 3.7D). Hence, the spare respiratory capacity of HK-2 
cells is very limited and apart from CAKI2, UMRC3 and UO31 much higher in the 
cancer cells. Interestingly, ATP production resulting from this respiratory pattern 
seemed to be similar in ccRCC and HK-2 cells. Only 769-P and TK10 cells displayed 
significantly higher and A704 cells significantly lower ATP production than HK-2 cells 
(Figure 3.7D). 
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Figure 3.7: ccRCC cells have a higher respiratory capacity than HK-2 cells 
(A) Schematic illustrating the different components of the mitochondrial electron transport chain (ETC). 
The ETC is fuelled with electrons from NADH and FADH2, which are generated through subsequent 
oxidation of glucose-derived pyruvate in the TCA cycle. Oxygen functions as an electron acceptor within 
the ETC. When oxygen concentrations are low (hypoxia), pyruvate can be alternatively converted into 
lactate, which is secreted from the cell. (B) Schematic illustrating the oxygen consumption rate (OCR) 
profile that can be obtained when treating cells with the ATP synthase inhibitor Oligomycin, the 
uncoupler FCCP and the mitochondrial poisons Antimycin A (complex III inhibitor) and Rotenone 
(complex I inhibitor). This schematic was obtained with permission from the Seahorse Bioscience 
website. (C) Using a Seahorse XFe96 Bioanalyzer, OCR levels of ccRCC and HK-2 cells were 
determined. Cells were plated the day before analysis in full growth medium. For analysis, growth 
medium was replaced with assay medium containing 25mM glucose, 2mM Glutamax and 10mM sodium 
pyruvate. After determination of basal OCR, Oligomycin and FCCP were added subsequently to the cells 
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and changes in OCR were recorded. Graphs summarise mean measurements ± SD of at least 5 replicate 
wells normalised to cell mass (CM, left hand graph) or the last basal rate (left hand graph) and are 
representative of at least 3 independent experiments. (D) Bar graph summarising average basal 
respiration, maximal and spare respiratory capacity, as well as ATP production ± SD. These were 
calculated according to (B) from last rates for each treatment in (C). Asterisks indicate statistical 
difference of the respective rate compared to HK-2 cells (dotted lines in respective colour shading) (2-
way ANOVA with Dunnett multiple testing analysis; * p ≤ 0.05). 
 
Assessment of mitochondrial OxPhos complexes revealed that, although all ccRCC cell 
lines expressed similar levels of complex III and V, expression of complex I and IV was 
more heterogeneous (Figure 3.8). 769-P cells consistently expressed the highest levels 
of all complexes, potentially explaining their high OCR. RCC4 cells expressed very low 
levels of complexes I and IV, while CAKI2 and UMRC3 cells express relatively low 
levels of complex IV (Figure 3.8). pVHL-expressing cell lines, including HK-2 cells, 
expressed on average lower levels of complex I compared to pVHL-null cells. At the 
same time, pVHL cells expressed higher levels of c-MYC compared to cell lines that 
lost functional pVHL. TOMM20, a mitochondrial transmembrane protein transporter, 
was used to evaluate differences in mitochondrial mass across the cell line panel and 
revealed that pVHL-null cells have presumably in average more mitochondrial mass 
(with exception of A704 cells) than pVHL-expressing cells (Figure 3.8). Expression of 
TOMM20 correlated, at least to some extend, with PGC1-α protein levels, a 
transcriptional regulator involved in mitochondrial biogenesis (Scarpulla, 2011), while 
it inversely correlated with c-MYC expression (Figure 3.8), another driver of 
mitochondrial biogenesis (Li et al., 2005, Zhang et al., 2007, Kim et al., 2008). 
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Figure 3.8: pVHL-null cells have lower c-MYC but higher PGC1α and TOMM20 protein 
levels 
Cells were plated in a 6-well plate format and lysed 48 h later for protein extraction. Whole protein 
lysates were analysed for representative subunits of the different electron transport chain complexes 
(OxPhos) as well as for PGC1α and c-MYC, transcription factors known to drive mitochondrial 
biogenesis and TOMM20, an indicator for mitochondrial mass. β-Actin serves as loading control. 
 
Next, respiration in the five isogenic cell line pairs was evaluated using the same 
technique. Figure 3.9A shows representative respiration profiles for the isogenic cell 
lines. Interestingly, only the RCC4 isogenic cell line pair showed a significant 
difference in basal respiration, maximal and spare respiratory capacity although the 
resulting ATP production seemed to be similar. All other ccRCC cell line pairs seemed 
to have comparative respiratory properties (Figure 3.9B). 
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Figure 3.9: pVHL-null ccRCC cells tend to have a higher respiratory capacity than their 
pVHL-reconstituted counterparts 
Using a Seahorse XFe96 Bioanalyzer, mitochondrial respiration rates (OCR) were determined for the 5 
isogenic cell lines. Cells were plated the day before analysing in full growth medium. For analysis, 
growth medium was replaced with assay medium containing 25 mM glucose, 2 mM Glutamax and 
10 mM sodium pyruvate. Subsequently, Oligomycin and FCCP were added. (A) Representative graphs 
summarise average of at least 5 wells ± SD normalised to cell mass (CM). (B) Bar graph summarising 
average basal respiration, maximal and spare respiratory capacity, as well as ATP production ± SD. These 
rates were calculated from the last rates for each treatment in (A) of 3 independent experiments. Asterisks 
indicate statistical difference of the respective rate between the isogenic cell line pairs (2-way ANOVA 
with Bonferroni multiple testing analysis; * p ≤ 0.05). 
 
It has been proposed that HIF-1α regulates mitochondrial biogenesis in pVHL-deficient 
renal carcinoma cells by inhibition of c-MYC transcriptional activity (Zhang et al., 
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2007). When comparing mRNA expression levels, only pVHL-expressing RCC4 and 
786-O cells showed a small increase in PGC1β, TFAM and TOMM20 mRNA 
compared to their respective VHL-deficient counterpart (Figure 3.10). In contrast, 
UMRC2, A498 and 769-P showed no VHL-dependent variation in expression of these 
factors. These mRNA data do not unambiguously reflect what could be seen on protein 
levels (Figure 3.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: pVHL-null cells show similar mRNA levels of mitochondrial biogenesis driver 
Cells were plated in a 6-well plate format and lysed 48 h later for total RNA extraction. RNA was reverse 
transcribed and cDNA was analysed for the abundance of c-MYC, PGC1β and TFAM, transcription 
factors driving mitochondrial biogenesis, and the mitochondrial amino acid transporter TOMM20 by RT-
qPCR. Bars represent average of duplicate measurements normalised to ACTB and data are displayed 
relative to mRNA levels in HK-2 cells. Error bars indicate SD. Number above the HK-2 bar indicates 
average ΔCT value for comparison. 
 
3.4.3 ccRCC cells depend on glucose and glutamine for proliferation but 
not on pyruvate 
Glucose is one of the main nutrients used for energy production, both via glycolysis and 
via mitochondrial oxidative metabolism. Pyruvate, the canonical substrate that feeds 
into the TCA cycle, is the end product of glycolysis. However, glutamine is another 
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substrate that can feed into the TCA cycle after it is converted into glutamate and 
subsequently α-ketoglutarate (α-KG) (Figure 3.11A). Moreover, glucose and glutamine 
also act as carbon sources for the synthesis of macromolecules. To delineate which of 
these three nutrients, glucose, pyruvate and glutamine, serves as preferred energy and 
carbon source in ccRCC cells, cell proliferation was monitored in an IncuCyte life cell 
imaging system under nutrient deprived conditions. Cells were supplied with medium 
lacking glucose, pyruvate or glutamine or combinations thereof. It should be noted that 
HK-2 cells were grown in DMEM rather than their generic growth medium KSFM. 
This might explain the apparent differences in growth between full medium and nutrient 
depleted medium (Fig. 3.11B). As can be appreciated from Figure 3.11C-G, all ccRCC 
cells, independent of pVHL expression, were severely sensitive to glucose withdrawal. 
Moreover, deprivation of glutamine caused an even more dramatic reduction in 
proliferation. In contrast, lack of pyruvate did hardly affect any of the ccRCC cell lines. 
Another interesting observation was the fact that, in the nutrient deprived situation, all 
cell lines displayed an initial growth burst over the first 24-48 h, even exceeding the 
proliferation rate of cells grown in full medium. This could be an overcompensation 
effect, potentially mediated by the induction of autophagy, which might be initially 
beneficial but is detrimental in the long run because cell intrinsic resources get depleted. 
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Figure 3.11: ccRCC cells are dependent on glucose and glutamine for proliferation but 
not pyruvate 
(A) Schematic depicting the main nutrients, glucose and glutamine (and the intermediate pyruvate) for 
energy production via glycolysis, mitochondrial respiration or glutaminolysis, respectively. (B-G) 
2000 cells/well of the 5 isogenic ccRCC cell lines and HK-2 cells were plated in standard culture medium 
in a 96-well format. The next day, cells were transferred into medium containing 10 % dialysed FBS and 
either glucose, glutamine or sodium pyruvate (respective right hand panel) or a combination of glutamine 
and sodium pyruvate (‘- glucose’ condition), glucose and sodium pyruvate (‘- glutamine’ condition) or 
glutamine and glucose (‘- sodium pyruvate’ condition) (respective left hand panels). Plates were placed in 
an IncuCyte live cell imager and monitored for proliferation every 3 h for 5 days. Graphs represent 
average confluence measurement of 3 wells ± SD for each time point recorded. 
 
3.5  Profiling of ccRCC cell lines for growth factor dependencies 
3.5.1 Serum starvation has a stronger anti-proliferative effect on pVHL-
expressing ccRCC cells with lost HIF-1α 
Seen that ccRCC cells are heavily dependent on glucose and glutamine supply, it was 
considered whether they are also dependent on constant growth factor supply and 
whether presence or absence of functional pVHL affect growth factor dependency. To 
examine this, the isogenic cell line pairs together with HK-2 cells were monitored in an 
IncuCyte life cell imaging system for growth kinetics in growth medium containing 1% 
or 10% FCS. The growth curves depicted in Figure 3.12 show that only in the RCC4 
and 769-P isogenic cell line pairs, cells expressing pVHL were growth inhibited 
compared to their matched EV cell line. Moreover, while proliferation of 786-O EV, 
UMRC2 and A498 EV cells was not affected by serum deprivation, both RCC4 cell 
lines, 769-P EV and HK-2 cells exhibited a strong reduction in their proliferation rate 
when serum starved (Figure 3.12). 
Interestingly, RCC4 and UMRC2 cells, which both express HIF-1α and HIF-2α, did not 
show significant difference in serum dependency between cells lacking functional 
pVHL and those in which the protein had been re-expressed. In contrast, in the 786-O 
and 769-P isogenic cell line pairs, both expressing only the HIF-2α isoform, slow down 
of proliferation upon serum starvation occured in a pVHL-dependent manner (Figure 
3.12). This suggests that these cells require serum-derived growth factors when HIF-2α 
is inhibited by the re-expression of pVHL. 
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Of note: HK-2 cells are normally maintained in serum-free keratinocyte medium 
supplemented with recombinant EGF and bovine pituitary gland extract. For this 
analysis, HK-2 cells were transferred into DMEM supplemented with 10% or 1% FCS. 
 
The observation that ccRCC cell lines were on the whole only inhibited in their 
proliferation over the 5 day time course but did not significantly arrest and die, suggests 
that they can sustain an efficient autocrine signalling system for self-preservation. 
 
 
Figure 3.12: pVHL-expressing ccRCC cells with lost HIF-1α expression are more sensitive 
to serum withdrawal than their counterparts 
2000 cells/well of the 5 isogenic cell lines and HK-2 cells were plated in standard culture medium in a 
96-well format. The next day, the culture medium was replaced with 200 µl/well freshly prepared culture 
medium supplemented with either 10 % or 1 % FBS. Plates were placed in an IncuCyte life cell imaging 
system and monitored for proliferation every 3 h for 5 days. Graphs represent average confluence 
measurement of 3 wells (except for HK-2 cells, full medium one well only) ± SD for each time point 
recorded. 
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3.5.2 ccRCC cells show heterogeneous basal PI3K/AKT and MAPK 
protein expression and activation patterns 
Most cancer cells have deregulated growth factor signalling leading to uninhibited cell 
growth and proliferation. To assess whether the observed growth inhibition upon serum 
starvation is due to differential growth factor signalling, ccRCC cell lines were analysed 
for expression of components of the PI3K/AKT and MAP kinase pathway. Only the 
RCC4 and 769-P isogenic cell line pairs showed a difference in AKT, mTOR and S6 
protein expression or phosphorylation. While pVHL seemed to repress AKT/mTOR/S6 
pathway activity in RCC4 cells, this pathway was inhibited in 769-P cells by the 
absence of pVHL (Figure 3.13B). Furthermore, 786-O cells do not express PTEN and, 
hence, showed strong AKT activation (Figure 3.13B). Also, it seems as if phospho-
GSK3α is generally higher in pVHL-expressing cells (Figure 3.13B).  
Comparison of AKT and MAPK pathway activity amongst all ccRCC cell lines 
revealed that despite normal PTEN expression, A498 and the non–tumourigenic HK-2 
cells closely followed 786-O cells in their levels of AKT phosphorylation (Figure 
3.13C). Furthermore, although all ccRCC and HK-2 cells showed similar amounts of 
ERK2 expression and activation, levels of (phospho-)ERK1 were heterogeneous: 786-O, 
769-P and CAKI1 cells showed low levels of phospho-ERK1, while they were above 
average in A498, CAKI2 and UO31 cells (Figure 3.13C). 
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Figure 3.13: ccRCC cells only show minor pVHL-dependent differences in the activation 
state of signalling pathways but show substantial cell line heterogeneity 
(A) Schematic of receptor tyrosine kinase (RTK) downstream signalling to promote cell growth, 
proliferation and survival. The PI3K/AKT cascade leads to cell cycle progression via inhibition of GSK3 
resulting in the stabilisation and activation of c-MYC. Activation of the mTOR pathway by AKT induces 
protein translation, ribosomal biogenesis and cell growth, while inhibition of pro-apoptotic BCL2 
proteins promotes cell survival. RTKs also activate the ERK/MAP kinase cascade via RAS to stimulate 
cell growth and proliferation via positively regulating the mTOR pathway and c-MYC respectively. (B) 
The 5 isogenic cell lines and HEK293 were analysed for the indicated proteins and phospho-sites to 
examine basal protein expression and phosphorylation status. β-Actin serves as loading control. (C) The 
parental ccRCC cell lines and HK-2 cells were analysed for the indicated proteins and phospho-sites to 
examine basal protein expression and activation status. β-Actin serves as loading control. pVHL-
expressing cell lines are marked in blue while VHL deficient cell lines are marked in red. 
 
3.6  Profiling ccRCC cell lines for lipid utilisation 
3.6.1 ccRCC cells only partially rely on exogenous lipid supply 
Despite growth factors, serum also contains the lipid fraction cells can source from if 
needed. To distinguish whether growth inhibition upon serum starvation is due to 
limiting growth factors or if it is rather caused by a limitation in lipid supply, ccRCC 
and HK-2 cells were monitored for 5 days for their proliferation rates in an IncuCyte 
live imaging system in growth medium containing lipid depleted serum (LDS). As can 
be seen from Figure 3.14, the respective cell line pairs have distinct growth patterns. 
What all of them but UMRC2 cells have in common, though, is the initial growth spurt 
within the first 24-48 h in which cells in LDS outgrew cells in conventional FCS that 
was also observed when cells were glucose or glutamine starved. In 786-O and 769-P 
cells (both express only HIF-2α) lacking pVHL this growth spurt seemed to be even 
more extreme than in pVHL-reconstituted cells. The RCC4, UMRC2 and 769-P 
isogenic pairs shared a similar pattern in that cells lacking pVHL expression, after the 
initial growth spurt, adapted the same growth rate in LDS as pVHL-null cells had in 
conventional FCS; the respective pVHL-null cells reduced their growth rate by ~50%. 
UMRC2 cells do not seem to be limited in their proliferation by lack of external lipid 
and lipoprotein supply independent of their pVHL status and neither do A498 pVHL-
null cells. A498 pVHL-expressing cells proliferated even faster in lipid deficient serum 
as compared to full serum. Both 786-O cell lines had inhibited growth rates without 
external lipid supply, whereby pVHL-expressing cells were more impaired than pVHL-
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null cells. Interestingly, HK-2 cells seemed to have a growth advantage in lipid-
deprived medium as they proliferated almost twice as fast as cells in full serum.  
Taken together, it seems as if RCC4, 786-O and 769-P cells rely to some extent on 
extrinsic lipid supply as they grew slower under lipid-starved conditions, while UMRC2 
cells are lipid self-sufficient. Contrary, A498 and HK-2 cells prefered a lipid-free 
environment for enhanced growth. Furthermore, all cells showed an initial growth burst 
over the first 24-48 h independent of pVHL expression.  
 
Figure 3.14: ccRCC cells are partially dependent on external lipid supply 
2000 cells/well of the 5 isogenic cell lines and HK-2 cells were plated in standard culture medium in a 
96-well format. The next day, the culture medium was replaced with 200 µl/well freshly prepared full 
growth medium containing either 10 % regular FCS or 10 % lipid depleted FCS (LDS). Plates were 
placed in an IncuCyte live cell imaging system and monitored for proliferation every 3 h for 5 days. 
Graphs represent average confluence measurement of 3 wells (except for HK-2 cells, full medium one 
well only) ± SD for each time point recorded. 
 
3.6.2 Expression of de novo lipid synthesis enzymes negatively correlate 
with the proliferation pattern seen under lipid deprived conditions 
In lipid depleted growth medium, RCC4, A498 and 769-P cells lacking pVHL had 
higher proliferation rates than their pVHL-expressing counterparts. Contrary, 786-O 
pVHL-expressing cells showed more proliferation than their pVHL deficient partners in 
these conditions. Cancer cells have been shown to reactivate de novo lipid synthesis 
even in the presence of ample exogenous lipid supply and present increased expression 
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of enzymes involved in lipid synthesis such as ATP citrate lyase (ACLY), acetyl-coA 
carboxylase (ACC) and fatty acid synthase (FASN) (Medes et al., 1953, Menendez and 
Lupu, 2007, Yahagi et al., 2005, Yoon et al., 2007). To see if there is any correlation 
between tolerance towards limited lipid supply and intrinsic de novo lipid synthesis, 
ccRCC cells were examined for their basal lipid synthesis enzyme expression. 
Moreover, expression of SREBP1 and SREBP2 were also established. SREBPs are 
important for cellular lipid homeostasis. There are two SREBP isoforms, SREBP1 and 
SREBP2. While SREBP1 mainly regulates genes involved in de novo fatty acid 
synthesis, SREBP2 regulates genes involved in cholesterol biosynthesis (Brown and 
Goldstein, 1997) (Figure 3.15A). 
What can be taken from Figure 3.15B is that tolerance towards limiting lipid 
concentration seems to correlate with expression of de novo lipid biosynthesis enzymes. 
UMRC2 cells showed high levels of SREBP1, SREBP2, ACC and FASN expression, 
while A498 cells displayed high levels of ACLY phosphorylation, which increases the 
activity of this enzyme. Although expression of lipid biosynthesis enzymes does not 
directly translate into lipid synthesis rates, this observation suggests that cells with 
higher basal rate of de novo lipid synthesis could be protected from variations in 
extrinsic variations in lipid supply. There was also some VHL-dependent regulation. 
SREBP1 protein levels as well as downstream targets ACC, FASN and ACLY were 
higher in UMRC2, A498 and 769-P cells expressing pVHL compared to their pVHL-
deficient counterparts (Figure 3.15B). However, this did not correlate with the 
sensitivity of the cells towards lipid deprivation. No obvious pVHL-dependent 
difference could be seen on mRNA level for the desaturase SCD, although levels were 
slightly lower in the ccRCC cells compared to the HK-2 cells; UMRC2 cells form an 
exception (Figure 3.15C).  
The parental cell lines showed similar expression patterns as the isogenic cell lines. 
ccRCC cell lines that maintain functional pVHL expression displayed on average higher 
levels of FASN and ACLY but also higher phospho-ACC than pVHL-deficient ccRCC 
cell lines (Figure 3.15D). Interestingly, HK-2 cells, which showed enhanced 
proliferation in delipidated growth medium, expressed comparatively low basal levels 
of SREBP1 but relatively high levels of PPARγ, FASN and ACC protein when cultured 
in standard growth medium (Figure 3.15D). 
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Figure 3.15: Expression of fatty acid biosynthesis enzymes in ccRCC cell lines 
(A) Schematic of fatty acid and cholesterol biosynthesis: An acetyl-group is split from citrate and is 
conjungated to CoA by ATP citrate lyase (ACLY) and can then be used for fatty acid or cholesterol 
biosynthesis. Conversion of acetyl-CoA to malonyl-CoA by acetyl-CoA carboxylase (ACC) produces the 
substrate for fatty acid synthase (FASN), which condenses acetyl-CoA and malonyl-CoA to form the 
growing acyl-chain. Steroyl-CoA desaturase (SCD) introduces a double carbon bond in saturated fatty 
acids to generate mono-unsaturated fatty acids. Transcription factors of the sterol element binding protein 
family (SREBPs) are the main transcriptional regulators of de novo lipid biosynthesis. (B) The 5 isogenic 
cell lines and HEK293 cells were plated in standard culture medium and whole cell lysates were analysed 
for the indicated proteins and phospho-sites to assess protein expression and activity levels. β-actin serves 
as loading control. (C) The 5 isogenic cell lines and HK-2 cells were plated in standard culture medium. 
Total mRNA was reverse transcribed and generated cDNA was analysed for mRNA abundance for SCD 
via RT-qPCR. Bar graphs represent average of 2 replicate measurements normalised to ACTB ± SD and 
data are displayed relative to HK-2 mRNA levels. Number above HK-2 bar represents average ΔCT value 
for comparison. (D) The parental ccRCC and HK-2 cells were plated in standard culture medium and 
whole cell lysates were analysed for the indicated proteins and phospho-sites to assess protein expression 
and activity levels. β-actin serves as loading control. 
 
3.6.3 Isogenic ccRCC cells are sensitive to Bezafibrate treatment in a 
pVHL-specific manner 
Having seen that ccRCC cells show varying sensitivity to lipid withdrawal, it was 
considered whether treatment with the peroxisome proliferator-activated receptor α 
(PPARα) agonist Bezafibrate would also modulate this effect. The transcription factor 
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PPARα is activated when cellular/organismal energy levels drop, e.g. under prolonged 
starvation. PPARα positively regulates genes involved in fatty acid transport, binding 
and activation as well as genes involved in peroxisomal and mitochondrial β-oxidation 
and ketogenesis (Buzzai et al., 2005). 
Under full serum conditions, there was a tendency of cells expressing pVHL and both 
HIF-α isoforms (RCC4, UMRC2 and A498 to some extend) to show higher sensitivity 
towards Bezafibrate treatment than their pVHL-deficient counter parts. However, the 
reverse was observed for cell lines expressing only the HIF-2α isoform (especially 769-
P). HK-2 cells were tolerant towards all drug concentrations tested (Figure 3.16A).  
Under lipid-depleted conditions, all cells were dramatically more sensitive towards 
Bezafibrate treatment, with HK-2 and UMRC2 pVHL-expressing cells showing the 
highest sensitivity (Figure 3.16B), suggesting PPARα hyperactivity causing more 
problems than it solves in ccRCC cells, but especially in the non-tumourigenic HK-2 
cells, under lipid deprivation. 
 
 
Chapter 3: Metabolic characterisation of ccRCC cell lines 
 96 
Figure 3.16: Dose response of the PPARα agonist Bezafibrate under full serum or lipid-
depleted conditions 
2000 cells/well of the 5 isogenic cell lines and HK-2 cells were plated in standard culture medium in a 
96-well format. The next day, cells were transferred into medium supplemented with either (A) 10% 
regular FCS or (B) 10% lipid depleted FCS (LDS) and the indicated concentrations of Bezafibrate and 
incubated for 72 h. Dose response curves (left-hand panel) were modelled in Graphpad Prism 6 to 
measured endpoint cell numbers (average values obtained from 3 different wells ± SD). Bar graphs 
(center panel) represent Bezafibrate IC50 values extracted from dose-response curves. (C) Table 
summarising R2 values of goodness-of-fit for the modelled dose-response curve to the collected data 
points. 
 
3.6.4 Isogenic cells differ in their levels of lipid droplet content 
ccRCC obtained its name from the observation that ccRCC cells appear clear under the 
microscope due to deposition of glycogen, phospholipids and neutral lipids, particularly 
cholesterol esters, in the cytoplasm (Gebhard et al., 1987). To investigate if 
reintroduction of functional pVHL affects the accumulation of lipid droplets, isogenic 
ccRCC cell lines were analysed for intracellular lipid droplets (LDs). The most obvious 
observation was that UMRC2 and A498 cells had the highest cellular LD density, 
whereby 769-P and CAKI1 cells had the lowest. Furthermore, all isogenic cell line pairs 
but 769-P cells also displayed differential LD accumulation. However, while in RCC4 
and 769-P cells the LD density was higher in the pVHL-null cells, in the UMRC2 and 
A498 pairs it was higher in the pVHL-expressing cells (Figure 3.17B top graph). 
Compared to their counterparts, RCC4 and 769-P pVHL-null cells did not only have 
less but also smaller LDs, while UMRC2 pVHL-expressing cells had larger LDs. In 
A498 and 769-P cells, LDs were similar in size independent of pVHL-status (Figure 
3.17B center and bottom graph). 
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Figure 3.17: Isogenic ccRCC pairs differ in their cytoplasmic lipid droplet accumulation 
The five isogenic cell lines were analysed for basal lipid droplet properties under standard growth 
conditions. (A) Representative images of ccRCC isogenic, TK10 and CAKI1 cells, grown in standard 
culture medium in a 96-well format, stained for lipid droplets (LDs) with the lipophilic dye Nile Red 
(green pseudo colour) and chromatin with DAPI (blue pseudo colour). Scale bar, 50 µm. (B) 
Quantification of LD number, size and intensity per cell. Bar graphs represent average of at least 
duplicate wells ± SD. Asterisks indicate statistical difference of LD number, size and intensity in the 
isogenic ccRCC pairs (multiple t-test, Holm-Sidak method, *, p ≤ 0.05). 
Chapter 3: Metabolic characterisation of ccRCC cell lines 
 98 
3.6.5 Palmitate addition lowers ECAR, which can be restored by Etomoxir 
treatment 
As was shown before, both nutrient starvation as well as lipid depletion resulted in an 
initial growth spurt of the ccRCC cells. One explanation would be, that due to the large 
amount of stored lipids, ccRCC cells could mobilise these lipid stores for energy 
generation via β-oxidation. β-oxidation takes place in the mitochondria or peroxisomes 
and is a gradual breakdown of fatty acids (FAs) to yield acetyl-CoA, which serves as 
substrate for the TCA cycle and subsequent ATP generation via oxidative 
phosphorylation. Cellular FAs first need to be activated by carnitine palmitoyl-
transferase 1 (CPT1), which attaches a carnitine moiety that is needed for the shuttling 
of acetyl-chains to the mitochondria. Once in the mitochondria, CPT2 removes the 
carnitine moiety and releases the FA to the β-oxidation cascade (Figure 3.18A).  
 
 
Figure 3.18: ccRCC cells express much higher CPT1A mRNA levels than HK-2 cells  
(A) Schematic illustrating β-oxidation initiation via carnitine-coupled shuttling of fatty acids into the 
mitochondrial matrix and the subsequent catabolic degradation cascade. (B) The 5 isogenic cell lines and 
HK-2 cells were plated in standard culture medium. Total mRNA was reverse transcribed and generated 
cDNA was analysed for mRNA abundance for CPT1A via RT-qPCR. Bar graph represents average of 2 
replicate measurements normalised to ACTB ± SD and data are displayed relative to HK-2 mRNA levels. 
Number above HK-2 bar represents average ΔCT value for comparison. 
 
In ccRCC cells, CPT1A mRNA levels are highly upregulated compared to HK-2 cells. 
Furthermore, at least in RCC4, UMRC2 and 786-O pVHL-expressing cells, expression 
of CPT1A mRNA was almost twice as high as in their pVHL-null counterparts (Figure 
3.18B), indicating increased β-oxidation activity with pVHL expression in these cells. 
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To verify this initial observation, in an initial experiment, the ccRCC isogenic cell lines 
were assessed for their capacity to use lipids as fuel source using a Seahorse Bioscience 
Analyzer. OCR and ECAR were measured upon injection of palmitate to stimulate β-
oxidation followed by treatment with Etomoxir, an inhibitor of CPT1 and thereby β-
oxidation. Surprisingly, no increase in OCR upon injection of palmitate could be 
observed in any of the isogenic ccRCC cells (Figure 3.19A,C), but a clear decrease in 
ECAR rates in all but A498 and 786-O pVHL-expressing and CAKI1 cells (Figure 
3.19B,C). Although addition of palmitate did not increase mitochondrial respiration, it 
seemed to drive conversion of pyruvate into lactate as opposed to shuttling it into the 
mitochondria for subsequent respiration. This phenotype was reversed upon addition of 
Etomoxir, which led to a significant decrease in OCR in most of the cell lines (Figure 
3.19A,C) accompanied by an increase in ECAR rates in most of the cell lines to higher 
or lesser extent, except for the A498 isogenic cell line pair, CAKI1 and HK-2 cells 
(Figure 3.19B,C). The fact that palmitate did not stimulate OCR in these cells could 
indicate that either the amount added was too low or that these cells already have 
sufficient FA supply to carry out β-oxidation, possibly through utilisation of lipids 
stored within lipid droplets, so that a potential effect could be masked. 
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Figure 3.19: Palmitate addition decreases ECAR in ccRCCs, which can be reversed 
through Etomoxir treatment  
(A-B) OCR and ECAR determination following palmitate and Etomoxir addition using an XFe96 
Seahorse Bioanalyzer. Cells were plated the day before analysing in full growth medium. For analysis, 
growth medium was replaced with Krebs-Henseleit assay medium containing 2.5 mM glucose and 
0.5 mM carnitine. Subsequently, sodium-palmitate to stimulate β-oxidation and Etomoxir, a β-oxidation 
inhibitor, were added at the indicated time points. Graphs represent (A) average OCR and (B) average 
ECAR measurements of at least 5 wells normalised to cell mass (CM) ± SD. (C) Bar graph summarising 
average rates from last measurement for each treatment in (A) and (B). Asterisks indicate statistical 
difference between basal OCR/ECAR levels and those resulting from addition of palmitate and 
differences that result from addition of Etomoxir following palmitate treatment (2-way ANOVA with 
Bonferroni multiple testing analysis; *, p ≤ 0.05). 
 
3.6.6 ccRCC cells are sensitive to CPT1A but not CPT1B ablation, while 
either supports HK-2 cell proliferation 
As Etomoxir was significantly affecting OCR in ccRCC cells, the longer-term effects of 
Etomoxir treatment on cell viability were examined. Increasing doses of Etomoxir had 
hardly any effect on cell survival in ccRCC cells but had a negative effect on HK-2 cells 
(Figure 3.20A). This suggests that over a longer period β-oxidation might be dispensible 
in ccRCC cells but not in HK-2 cells. As this result was quite unexpected, inhibition of 
β-oxidation was also investigated by silencing the expression of the two CPT1 isoforms 
CPT1A (liver) and CPT1B (muscle) using siRNA. Surprisingly, RNAi-mediated 
ablation of either CPT1 isoform resulted in the opposite effect as the one seen following 
Etomoxir treatment: CPT1 depletion procured a growth advantage to HK-2 cells 
compared to the ccRCC cells (Figure 3.20B). Furthermore, while CPT1A silencing had 
in average a negative effect on ccRCC cell numbers compared to control silencing, 
siCPT1B had hardly any effect (Figure 3.20B). Taking into accaount that ccRCC cells 
showed high CPT1A mRNA levels in comparison to HK-2 cells (Figure 3.18B), there is 
the possibility that ccRCC cells express and rely mainly on CPT1A in contrast to HK-2 
cells. However, the high tolerance of ccRCC cells to Etomoxir suggest that further 
experiments are needed to establish the importance of β-oxidation for energy supply and 
cell survival in ccRCC cells. 
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Figure 3.20: ccRCC cells are resistant to Etomoxir treatment, but ablation of either 
CPT1A or CPT1B has a negative effect on ccRCC compared to HK-2 cell viability  
(A) 2000 cells/well of the indicated ccRCC and HK-2 cell lines were plated in standard culture medium 
in a 96-well format. The next day, full growth medium supplemented with Etomoxir was added to yield 
the indicated concentratins. Cells were incubated for 72 h. Dose response curves were modelled in 
Graphpad Prism 6 to measured endpoint cell numbers (average values obtained from 3 different 
wells ± SD). (B) 2000 cells/well of the indicated ccRCC cell lines and HK-2 cells were reverse 
transfected with siRNA SMARTpools targeting CPT1A or CPT1B in a 96-well format for 96 h. Bar 
graphs represent average of 3 wells and are normalised to the negative RISC-free (RF) control. Error bars 
represent SD. Asterisks indicate statistical difference in endpoint cell number between ccRCC cell lines 
and HK-2 cells (2-way ANOVA with Dunnett multiple testing analysis; ****, p ≤ 0.001). 
 
3.7  Discussion 
Otto Warburg defined cancer as a metabolic disease (Warburg, 1956b, Warburg, 1956a), 
a statement, which is likely to be more relevant for ccRCC than for many other cancer 
types. ccRCC cells have constitutively active HIF expression and activity (Figure 3.2-
3.4), and are highly glycolytic (Figure 3.6). Moreover, these cells require both glucose 
and glutamine as nutrients and show substantial growth retardation when deprived of 
these nutrients (Figure 3.11). Intriguingly, ccRCC cells also have a high respiratory 
capacity (Figure 3.7) and their mitochondrial metabolism cannot only be fuelled with 
glucose-derived pyruvate but also with fatty acids via β-oxidation, suggesting that they 
utilise several metabolic pathways to facilitate their growth.  
What became clear from the metabolic characterisation that was undertaken in this 
study is that ccRCC can tolerate most of the tested metabolic insults. ccRCC cells 
continue to proliferate under serum starvation (Figure 3.12), in lipid-deprived 
conditions (Figure 3.14) or under almost anoxic experimental conditions (Figure 3.5) 
for several days. Hence, this cancer type must have developed a highly dynamic 
metabolic network that can quickly adapt to different metabolic conditions. But, 
crucially, ccRCC cells displayed less tolerance to nutrient stress conditions as depletion 
of glucose or glutamine was highly detrimental to cancer cell proliferation and survival 
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(Figure 3.11). These findings suggest that pathways integral to glucose and glutamine 
utilisation and metabolism are essential for ccRCC growth. And this could be 
considered an Achilles heel in ccRCC. Dietary restriction of these nutrients is not 
feasible, thus targeting essential components of these pathways could have potent anti-
cancer activity in ccRCC. 
 
It is likely that these cells can satisfy at least some of their energy demand through β-
oxidation, fuelled by the large amounts of lipids stored in their cytoplasm; as ccRCCs 
are histochemically defined by the presence of lipid droplets (Gebhard et al., 1987). 
Interestingly, apart from the liver, the kidney cortex is the only other site within the 
mammalian body where gluconeogenesis (GNG) can take place. GNG is the process of 
generating glucose from non-carbohydrate structures such as pyruvate, lactate, glycerol, 
but also fatty acids in times of fasting. GNG is an energy consuming process and is 
often connected with ketosis, a state where the main energy source is liver-derived 
ketone bodies, consisting of acetoacetate and β-hydroxybutyrate. It is thus possible that 
ccRCC cells could utilise GNG to convert lipid-derived carbon into glucose to provide 
riboses for DNA synthesis. Also, ccRCC cells could mobilise stored glycogen to 
replenish the glucose pool. However, these potential alternative mechanisms cannot 
support ccRCC cell survival after long-term glucose withdrawal. Further analysis will 
be necessary to gain deeper insight in lipid droplet contribution to ccRCC proliferation. 
 
One possibility to identify specific metabolic dependencies in different cancer types is 
provided by a systems biology approach that models all possible metabolic reactions 
within a cancer cells. Using this approach, it has been found recently that ccRCC 
displays a unique metabolic network that is associated with LOH of chromosome 3p. 
Moreover, nucleotide, one-carbon, and glycerophospholipid metabolism was found to 
be severely compromised in ccRCC cells (Gatto et al., 2014). As glucose is the main 
precursor of the synthesis of nucleotides, limiting glucose levels would impair 
nucleotide generation to a critical point in ccRCC cells, thereby inhibiting cell 
proliferation. Also, glucose could be feeding the serine biosynthesis pathway. Serine 
has recently been found to be essential for breast cancer carcinogenesis (Maddocks et 
al., 2013) as serine-depletion induced oxidative stress, particularly in p53-deficient cells. 
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It is now well appreciated that, apart from glucose, glutamine is an essential nutrient for 
cancer cells, as glutamine depletion is detrimental for many cancer cells including 
ccRCC cells (Fuchs and Bode, 2006, Gordan et al., 2007a, Yuneva et al., 2007, Vander 
Heiden et al., 2011). However, the discrete mechanism of glutamine-dependent survival 
is not clearly defined and is under examination by several research groups. Glutamine is 
the most abundant amino acid in the cellular microenvironment (DeBerardinis and 
Cheng, 2010). Its uses stretch from energy production as substrate for the TCA cycle to 
contributing nitrogen for nucleotide synthesis and to being a component of glutathione, 
the most abundant non-enzymatic cellular anti-oxidant. As glutamine is a non-essential 
amino acid, i.e. can be produced by the cell, the question arises why ccRCC cells 
depend on external glutamine supply. As with other cancer types, ccRCC cells have 
been found to have enhanced levels of c-MYC expression, which drives cell cycle 
progression and mitochondrial biogenesis (Gordan et al., 2007a, Tang et al., 2009). One 
possibility is that ccRCC cells depend on glutamine for nucleotide biosynthesis to 
maintain cell proliferation.  
 
So far, it has been shown that ccRCC cells, although growth inhibited, maintained some 
level of proliferation even after serum depletion (Figure 3.12), suggesting efficient 
production of autocrine growth factors. Indeed, Franovic and colleagues showed that 
HIF-2α expression allows autonomous growth of cancer cells in vivo and in vitro by 
activation of epidermal growth factor receptor (EGFR) and insulin-like growth factor 
receptor type I (IGF1R) signalling (Franovic et al., 2009). However, this observation 
was specific for HIF-2α and not observed with the HIF-1α isoform. In accordance with 
this observation, results from the isogenic cell line panel showed that HIF-2α -
expressing ccRCC cells were less able to tolerate serum starvation than their pVHL-null 
counterparts (Figure 3.12), suggesting that HIF-2α induces autocrine growth factor 
signalling to maintain proliferation even under exogenous growth factor withdrawal. 
 
Overall, the pVHL-isogenic models employed in this study proved to modulate HIF 
expression and response to oxygen deprivation in a VHL-dependent fashion, as 
expected (Figure 3.4 and 3.5). Furthermore, pVHL expression was shown to enhance 
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the respiratory capacity of cells (Figure 3.9) while other metabolic tracts such as 
adaptation to nutrient and lipid deprivation were unaffected by the presence or absence 
of pVHL (Figure 3.12 and 3.14), reinforcing the possibility that only a limited amount 
of the typical metabolic characteristics of ccRCC may depend on pVHL expression. 
Besides pVHL expression, the presence of different HIF-α isoforms also influences 
metabolic characteristics, as sensitivity to serum starvation is decreased in HIF-2α only 
expressing ccRCC cells (Figure 3.12). 
To elucidate the extend by which pVHL or the different HIF-α isoforms condition 
metabolic vulnerabilities within the core glucose, amino acid and fatty acid metabolism, 
the isogenic ccRCC cells were subjected to a customised metabolic RNAi screen, which 
is described in the next chapter.  
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4.1  Introduction 
4.1.1 Synthetic lethality 
Two genes/proteins are synthetic lethal, when loss of either of them individually has no 
effect on cell viability, while simultaneous loss of both leads to cell death (Kaelin, 
2005). In order to maintain viability despite the possibility of genetic loss of a 
functional gene either due to the accumulation of random mutations or exposure to 
genotoxic environmental stress, organisms employ compensatory mechanisms to 
balance genetic variations. Compensation may occur in form of another protein of the 
same or a related family that can carry out the same function as the lost gene, or another 
pathway stepping in leading to the same net result/phenotype through a different system.  
 
 
Figure 4.1: Principle of synthetic 
lethality 
Loss of either Gene A or Gene B on 
its own does not affect cell survival. 
However, loss of both genes 
simultaneously is detrimental for the 
cell. 
 
Exploring synthetic lethality within the context of a specific genetic makeup can 
elucidate compensatory relationships with other gene products, cellular pathways or 
biochemical processes. In case the gene/protein of interest is frequently mutated or lost 
and involved in a disease syndrome, identified (compensatory) relationships can then be 
exploited for treatment through developing drugs that disrupt this link. 
Investigating synthetically lethal relationships between activated proto-oncogenes or 
mutations in tumour suppressors using genetic screens is an effective approach in 
cancer research. This strategy can identify essential processes that are required for the 
survival of cancer cells with a given genetic background. Synthetic lethal targets can 
provide novel therapeutic windows for drug development. Targeting synthetic lethal 
processes should not affect cells without the mutation and therefore result in less 
harmful side effects than those caused by classical chemotherapies. 
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4.1.2 The concept and mechanism of RNA interference 
RNA interference (RNAi) mediated by either micro RNA (miRNA) or small interfering 
RNA (siRNA) is an important, evolutionary conserved cellular mechanism to regulate 
gene expression post transcriptionally on messenger RNA (mRNA) levels. Furthermore, 
RNAi plays an important role for the immune response against invading parasitic 
nucleic acids such as viruses and transposons. 
miRNAs are cell endogenous RNA molecules and are directly transcribed as pre- 
miRNA stem-loop structures in the nucleus. In contrast, siRNAs are exogenously- 
derived double stranded RNA (dsRNA) fragments that can originate for example from 
retroviruses. Once these dsRNAs are in the cytoplasm, they are recognised by the 
endoribonuclease Dicer, which cleaves them into short dsRNA fragments of 20-25 base 
pairs in length with a two-nucleotide 3’ overhang on each end (Preall et al., 2006, 
Vermeulen et al., 2005). Dicer also facilitates the activation of the RNA-induced 
silencing complex (RISC). This muliprotein complex incorporates one strand of the 
miRNA or siRNA dsRNA fragments, the so-called ‘guide strand’ while the other so-
called ‘passenger strand’ is degraded. Distinction of guide and passenger strand is 
performed by the RISC’s catalytically active RNase Argonaute and is based on the 
thermodynamic stability of the 5’ end (Preall et al., 2006). The incorporated guide 
strand serves as template for the recognition of complementary mRNA, which, upon 
binding to the RISC complex, gets degraded by Argonaute resulting in decreasing levels 
of this mRNA species (Figure 4.2). At least for short-lived proteins, reduced mRNA 
levels will ultimately result in decreased protein levels. 
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Figure 4.2: Mechanism of RNA interference (RNAi) 
Schematic overview of the RNAi mechanism: (A) When extracellular small interfering RNA (siRNA) or 
double stranded RNA (dsRNA) from e.g. viruses enters a cell, it is recognised by the cytoplasmic 
endoribonuclease Dicer, which cleaves them into short dsRNA fragments (20-25 bp long with 2 nt 
3’ overhang), ready to be further processed by the RNA-induced silencing complex (RISC). One strand of 
these dsRNA fragments (guide strand) is incorporated into RISC and serves as template for recognition of 
complementary mRNA. Upon successful matching of mRNA and RISC incorporated guide strand, the 
mRNA is degraded by RISC’s RNase Argonaute (ARGO2). The same Dicer-/RISC-dependent RNAi 
mechanism takes effect for endogenously generated micro RNAs (miRNAs). (B) miRNAs are transcribed 
directly from the genome by RNA polimerase II (Pol II) as primary miRNA (pri-miRNA), which is 
further processed by the RNase complex Pasha/Drosha. The resulting precursor miRNAs (pre-miRNAs) 
are actively shuttled from the nucleus to the cytoplasm via Exportin 5. Once in the cytoplasm, pre-
miRNAs are cleaved by Dicer and lead to RISC-mediated mRNA degradation. 
 
4.1.3 The pVHL-isogenic ccRCC cell system to study synthetic lethality 
We used the five isogenic cell line pairs RCC4, UMRC2, A498, 786-O and 769-P 
received from William Kaelin’s laboratory that were characterised in the previous 
Chapter to carry out a functional siRNA screen to identify metabolic enzymes that show 
synthetic lethal interactions with pVHL. A similar approach targeting a small subset of 
the human kinome has already been performed successfully in the Kaelin laboratory, 
where two of these isogenic cell line pairs, RCC4 and 786-O, were transfected with an 
shRNA library targeting 88 kinases (Bommi-Reddy et al., 2008). In this study, CDK6, 
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MET and MEK1 were identified as potential synthetic lethal interactors of pVHL as 
shRNA-mediated silencing of these proteins resulted in preferential killing of the RCC4 
and 786-O pVHL-null cells compared to their pVHL-reconstituted counterparts. In the 
case of CDK6, the shRNA-mediated effect on killing in pVHL-/- cells could be 
confirmed with a small-molecule Cdk4/6 inhibitor, suggesting that novel VHL-specific 
therapeutic targets can be identified using RNAi screens in ccRCC (Bommi-Reddy et 
al., 2008).  
 
This chapter will describe a customised functional metabolic screen, whose primary aim 
was the identification of novel metabolic genes that are synthetic lethal with pVHL in a 
panel of the five pVHL-isogenic ccRCC cell line pairs: RCC4, UMRC2, A498, 786-O 
and 769-P ± VHL respectively. 
 
4.2  Screen Optimisation 
Based on previous experience, the efficiency of siRNA transfection using different 
transfection reagents (TR) can show large variations between different cell lines. To 
determine optimal transfection efficiency while minimising cell toxicity, a series of 
optimisation experiments was performed in collaboration with Dr. Ming Jiang in the 
LRI High Throughput Screening (HTS) facility. 
 
4.2.1 Optimisation of duration of siRNA-mediated gene silencing  
Determining the timing of the screen was straightforward and based on the nature of the 
screen as well as previous experience. siRNA-mediated gene knockdown (KD) occurs 
quickly after transfection. It is likely that the target mRNA gets depleted within the first 
24 h post-transfection and, depending on the stability of the targeted protein, protein 
depletion should be achieved after approx. 48-72 h. At the same time, siRNA-mediated 
KD is only transient as siRNA is not very stable and gets depleted with every cell 
duplication. Therefore, the siRNA-mediated effect is diminishing over time and 
untransfected cells could outgrow the cultures if the assay continues for too long. For 
the screen shown here, cells were incubated for 96 h post-transfection to ensure efficient 
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target depletion and detect potential detrimental effects on proliferation and survival of 
the transfected cells.  
 
4.2.2 Starting cell number 
As readout for the screen, measurement of cell viability at the endpoint of the 
experiment 96 h post transfection was chosen. Cell number was determined using an 
Acumen® eX3 laser-scanning microplate cytometer (TTP Lab Tech Ltd.), which detects 
DAPI-stained nuclei. In order to detect a good dynamic range of effects on cell number, 
optimisation of initial cell plating densities was performed. Cells were plated to ensure 
exponential growth during the experiment to detect maximal effects of gene silencing 
on proliferation without reaching confluence at the end of the assay as this affects 
accurate discrimination of individual nuclei and could result in skewed data. At the 
same time, sufficient cell numbers had to be reached to reliably detect small differences 
in cell number.  
As the different cell lines have specific growth kinetics, different cell numbers of the 
isogenic cell line pairs were plated on 96-well plates and cell proliferation was 
monitored using an IncuCyteTM kinetic live-cell imaging system (Essen BioScience). 
The growth curves over 4 days depicted in Figure 4.3 show that all ccRCC cell lines are 
highly proliferative and duplicate approx. every 36 h. As already seen from the cell 
characterisation, ectopic expression of pVHL does not negatively affect cell 
proliferation in the isogenic cell line pairs in vitro.  
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Figure 4.3: Growth kinetcs of isogenic ccRCC cell line pairs  
(A) The 5 isogenic cell line paires were plated at a density of 2000 (black), 3000 (dark grey) or 4000 
(light grey) cells/well in a 96-well plate format. Cells were monitored in an IncuCyte live cell imaging 
system. Data acquisition occurred every 2 h. (B) Growth curve comparison of the respective isogenic cell 
line pairs for the plating density of 2000 cells/well extracted from (A) that was chosen for the screen and 
subsequent experiments. Data points show mean of duplicate wells ± SD. 
 
The live-cell imaging results could be confirmed with a time course cell mass assay. 
Tested were starting cell numbers between 1000 and 8000 cells/well on a 96-well plate 
format. Also this assay narrowed down the suitable plating densities to 2000 or 4000 
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cells/well. In this range, all cell lines were close to confluence but still exhibit 
exponential growth on day 4 when left untreated (Figure 4.4). 
 
 
Figure 4.4: Cell mass-based growth kinetcs of isogenic ccRCC cell line pairs 
(A) The 5 isogenic cell line pairs as well as HEK 293 cells were plated at at a density of 1000 (black), 
2000 (dark grey), 4000 (lighter grey) or 8000 (light grey) cells/well in a 96-well plate format. Cells were 
fixed with 10 % TCA every 24 h and cellular protein content was subsequently measured using a 
sulforhodamine B protein assay. (B) Growth curve comparison of the respective isogenic cell line pairs 
for the plating density of 2000 cells/well extracted from (A), which was chosen as starting cell number 
for the screen and subsequent experiments. Data points show mean of triplicate wells ± SD. 
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4.2.3 Optimisation of transfection reagent 
siRNA is delivered to the cells using a lipid-based transfection reagent (TR), which 
forms micelles enclosing the siRNA-containing solution to be delivered in its centre. 
This liposome-like structure fuses with the cell membrane and discharges its cargo into 
the cytoplasm. There are many different TRs on the market and a suitable TR had to be 
identified that would deliver siRNA efficiently and ideally to all cell lines while having 
the least toxic effect. In collaboration with the LRI High throughput Screening Service, 
23 different TRs were tested in two concentrations (0.1 µl and 0.3 µl per 100 µl 
transfection reaction volume) to transfect the cell lines with an siRNA SMARTpool 
against the non-essential nuclear envelope protein Lamin A/C (Elbashir et al., 2001, 
Thaker et al., 2010) in a 96-well format. 48 h post transfection, cells were analysed for 
Lamin A/C expression measuring immunofluorescence (IF) intensities and for endpoint 
cell numbers by counting DAPI-positive nuclei.  
Figure 4.5 holds the transfection results for the isogenic UMRC2 and 769-P cell lines. 
For completion, Figure 4.6 shows the transfection reagent results for parental A498 and 
786-O cells, which were analysed in the contest of another screen the HTS facility 
performed, as well as the transfection results for the non-tumourigenic renal epithelial 
HK-2 cell line. Finally, Figure 4.7 summarises the transfection results for each cell line 
with the ten most promising TRs. 
Across the ccRCC cell lines tested, 0.1 µl DharmaFect2, DharmaFect3, DharmaFect4 or 
Lullaby showed the most promising results. Compared to non-transfected cells, 
transfection with these reagents reduced Lamin A/C intensity considerably and had no 
major effect on cell viability (Figure 4.5 - 4.7).  
 
Based on the results of this optimisation, DharmaFect2 (Dh2) was chosen for the screen 
as it showed good knockdown efficiency and low toxicity across the cell line panel 
(Figure 4.7). 
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Figure 4.5: Screening of transfection reagents I 
4000 cells/well of the VHL-isogenic UMRC2 and 769-P cell line pairs were reverse transfected in 
duplicates with 37.5 nM siRNA SMARTpool against the non-essential nuclear envelope protein 
Lamin A/C using a panel of 23 different transfection reagents in a 96-well plate format. Upon fixation 
48 h post transfection, cells were stained for Lamin A/C and DAPI and analysed for lamin A/C immuno-
flourescence intensity (upper panel) and cell number (lower panel) using a Cellomix® ArrayScan® VTI 
HCS Reader (Thermo Scientific). Bars represent mean of duplicate wells ± SD. Note: The cell number 
data represent the analysed fraction of cells that were analysed for Lamin A/B intensity. These fractions 
are representative for the whole well. These experiments were performed by Ming Jiang from the High 
Throughput Screening facility at the LRI. 
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Figure 4.6: Screening of transfection reagents II 
4000 cells/well of parental A498 and 769-P as well as the non-tumourigenic HK-2 cells were reverse 
transfected in duplicates with 37.5 nM siRNA SMARTpool against the non-essential nuclear envelope 
protein Lamin A/C using a panel of 23 different transfection reagents in a 96-well plate format. Upon 
fixation 48 h post transfection, cells were stained for Lamin A/C and DAPI and analysed for lamin A/C 
immuno flourescence intensity (upper panel) and cell number (lower panel) using a Cellomix® 
ArrayScan® VTI HCS Reader (Thermo Scientific). Bars represent mean of duplicate wells ± SD. Note: 
The cell number data represent the analysed fraction of cells that were analysed for Lamin A/B intensity. 
These fractions are representative for the whole well. These experiments were performed by Ming Jiang 
from the High Throughput Screening facility at the LRI. 
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Figure 4.7: Screening of transfection reagents III 
4000 cells/well of the 5 VHL-isogenic ccRCC cell line pairs were reverse transfected with 37.5 nM 
siRNA SMARTpool against the non-essential nuclear envelope protein Lamin A/C using the ten most 
promising transfection reagents from the panel tested (see Figure 4.5 & 4.6) in a 96-well plate format. 
Upon fixation 48 h post transfection, cells were stained for Lamin A/C and DAPI and analysed for 
lamin A/C immuno flourescence intensity (respective upper panel) and cell number (respective lower 
panel) using a Cellomix® ArrayScan® VTI HCS Reader (Thermo Scientific). Bars represent mean of 
duplicate wells ± SD. Note: The cell number data represent the analysed fraction of cells that were 
analysed for Lamin A/B intensity. These fractions are representative for the whole well. These 
experiments were performed by Ming Jiang from the High Throughput Screening facility at the LRI. 
 
4.2.4 Optimisation of transfection controls 
Defining suitable controls is very important to obtain reliable results from an siRNA 
screen. There are two sorts of controls: a) Negative controls that give information about 
the baseline cellular response to the transfection procedure. Ideally, these should have 
almost no effect on cell viability and can be used for normalisation. b) Positive controls 
that should cause significant cell death and that can be used an indicator for transfection 
efficiency. As negative controls, siRNAs that are either non homologous to the human 
genome (siControl 1-4 (siC1-4) and siOTP1-4) or are chemically modified so that they 
are not recognised by the RISC complex (RISC-free, RF) were used. As positive 
controls, siRNAs targeting the polyubiquitin precursor ubiquitin B (UBB) or the mitotic 
regulator polo-like-kinase 1 (PLK1) were chosen. Both proteins are vital in human cells 
and their ablation results in substantial cell death by apoptosis. Furthermore, cells were 
treated with the transfection reagent Dh2 alone. Figure 4.8 illustrates the responses of 
the different cell lines to the individual negative control-siRNAs (siC1 - siC4 and 
siOTP1 - siOTP4) as well as to the positive control-siRNA (siUBB SMARTpool). 
Although only the siC1-4 and siOTP1-4 pools were used in the screen and subsequent 
experiments, this experiment shows the effect that the individual control sequences have 
in the different cell lines. All negative control-siRNAs had some negative effect on cell 
viability. However the different siOTP sequences showed only a minor reduction in cell 
number compared to the different siC1-4 sequences (Figure 4.8). As will be shown in 
further experiments, pooling the individual siC1-4 and siOTP1-4 sequences diminishes 
the negative effect on cell number. As expected, silencing of UBB resulted in a > 90% 
loss of cell viability in all cell lines. 
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Figure 4.8: Effect of positive and negative siRNA transfection controls on ccRCC cells 
2000 or 4000 cells/well of the 5 VHL-isogenic ccRCC cell lines were reverse transfected with 37.5 nM of 
the individual negative control-siRNA sequences and the siRNA SMARTpool against UBB using 0.1 µl 
of DharmaFect2 transfection reagent in a 96-well format. Cells were fixed 96 h post transfection, DAPI 
stained and analysed for cell number using an Acumen laser scanning microplate cytometer. Bars 
represent mean of triplicate wells ± SD. 
 
4.2.5 Pilot screen 
Having optimised assay duration, transfection conditions, initial plating density and 
transfection controls, a mini pilot screen was performed. In this test screen, siRNAs 
targeting 4 metabolic genes that were predicted thought to have differential effect on the 
5 pVHL-isogenic ccRCC cell line pairs were used in addition to positive and negative 
control siRNAs. These genes were monocarbxylate transporter 4 (MCT4 or SLC16A3) 
(Gerlinger et al., 2012b), c-MYC (Gordan et al., 2007b) as well as the HIF-targets 
pyruvate dehydrogenase kinase 1 (PDHK1) and malic enzyme 1 (ME1) Also, this 
experiment was used to finalise the seeding density for the screen. 2-3 independent 
experiments were performed using two different batches of cells at different passage 
numbers to examine the consistency and reproducibility of transfection efficiency in the 
5 isogenic cell line pairs. Reassuringly, the variability between the different 
experiments was relatively low, with the positive controls siUBB and siPLK1 
consistently leaving only about 10 % viable cells after 96 h of transfection (Figure 4.9). 
The isogenic cell line pairs showed similar behaviour towards the negative controls, 
although the effect differed between different cell lines. With regard to the 4 target 
genes tested, a reduction in cell numbers was observed across the cell line panel (Figure 
4.9). However, none of these genes showed an obvious differential effect between 
pVHL-expressing and pVHL-null cells.  
In hindsight, it would have been wise to include one of the kinases (MET, MEK1 and 
particularly CDK6) that were positively identified to have a pVHL-differential effect in 
the shRNA screen carried out by Bommi-Reddy and colleagues (Bommi-Reddy et al., 
2008). Inclusion of these kinases could have helped to make a better judgement of what 
range a differential effect on cell number between the isogenic cell line pairs can be 
expected. 
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Figure 4.9: Summary of pilot screen 
2000 or 4000 cells/well of the 5 VHL-isogenic ccRCC cell line pairs were reverse transfected with 
37.5 nM siRNA SMARTpools targeting the indicated genes in a 96-well format. Cells were fixed 96 h 
post transfection, DAPI stained and analysed for cell number using an Acumen laser scanning microplate 
cytometer. Bars represent mean cell numbers of 3 independent experiments in triplicate wells each for 
2000 cells/well seeding density and 2 independent experiments with triplicate wells each for 
4000 cells/well seeding density with SEM as error bar. 2-way ANOVA (with Bonferroni multiple testing 
analysis) did not reveal any differential proliferation effect between pVHL-expressing and pVHL-null 
ccRCC cells for the four genes tested: c-MYC, PDHK1, ME1 and MCT4. Note: The different 
experiments were performed a) with different freezing batches and b) at different cell passages. 
 
4.3  Functional metabolic siRNA screen of five pVHL-isogenic 
ccRCC cell line pairs 
4.3.1 Screen setup and execution 
In order to explore novel metabolic dependencies and regulations that are essential for 
cancer cell growth and survival, an siRNA library targeting 240 metabolic enzymes, 
regulators and nutrient transporters involved in central carbon metabolism was designed 
(Figure 4.10A) by a former postdoc in the lab, Dr Claudio Santos. This customised 
siRNA library was purchased from Dharmacon and the siRNA SMARTpools and 
controls are distributed over three 96-well plates. The plate layout is depicted in Figure 
4.10B. The screen was performed in the 5 VHL-isogenic ccRCC cell lines in triplicate, 
resulting in a total of 90 assay plates that were processed in two batches. A detailed 
protocol for the screen execution can be found in Chapter 2: Materials and Methods. 
Figure 4.10C illustrates the screening process in a flow diagram. 
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Figure 4.10: Screen Setup 
(A) Overview of processes and relative distriburtion of the 240 genes targeted with the customised 
Dharmacon siGenome siRNA library. (B) Plate layout of the custom siRNA library. The 240 
SMARTpools are distributed over three 96-well plates. Each plate additionally includes 16 wells with 
positive (blue) and negative (red) controls. (C) Flow diagram of the screening process performed in this 
study.  
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4.3.2 Normalisation of primary screen data 
Comparison of data from different cell lines requires normalisation of raw screen results 
to exclude bias. This initial data analysis was performed by Dr. Rebecca Saunders (LRI 
High Throughput Screening Service) using the cellHTS2 software package 
(Bioconductor) (Boutros et al., 2006). Raw cell number values were first centred to the 
respective plate median including only the sample wells while excluding the 16 control 
wells. The plate median was chosen over the plate mean as the screen comprises of only 
a relatively small number of genes targeted and the latter would be more sensitive to 
outliers. Subsequently, a Z-Score transformation was applied to the plate-normalised 
cell numbers for each cell line. A Z-Score represents the number of standard deviations 
(SDs) that a given individual measurement differs from the population mean. In this 
screen, the Z-Score was calculated using the median absolute deviation (MAD) of the 
population. A Z-Score(MAD) value close to 0 indicates that the given measurement is 
very similar to the median of the population, a negative Z-Score value indicates a loss in 
cell number while a positive Z-Score(MAD) represents a gain in cell number compared to 
the population median. Z-Score(MAD) values ≤ -1.7 and ≥ 1.7 are considered to indicate 
significant effects on cell number compared to the population median. These Z-
Score(MAD) values were used to define hits in the course of the screen data analysis. 
 
4.3.3 Evaluation of screen quality  
Following normalisation, the screen quality was evaluated. First, the plate medians of 
the individual replicates were compared to each other on a plate-by-plate basis using 
Spearman Rank Correlation to check for reproducibility of the effect within the 
experiment. The boxplots in Figure 4.11 illustrate the raw and Z-Score(MAD)-
transformed cell number value distributions (excluding positive and negative controls) 
for each plate and replicate for each of the ten cell lines. The associated table depicts the 
range of the calculated Spearman Rank Factors for each cell line and plate. A Spearman 
Rank Factor ≥ 0.65 is considered to indicate good correlation while smaller values are 
considered to indicate low or no correlation. The box plots and the Spearman Rank 
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Factors shown in Figure 4.11 indicate that reproducibility was good for the A498 and 
769-P isogenic pairs, but only moderate for the other three cell line pairs.  
Based on the relatively low Spearman Rank Factor for UMRC2 EV and RCC4 VHL, 
the screen was repeated for these two cell lines. The reproducibility of all 3 plates 
increased for RCC4 VHL (termed RCC4 VHL II from here onwards) but only of 
plate ♯1 for the UMRC2 EV cell line (further referred at as UMRC2 EV II) (Figure 4.11 
bottom). For all further analyses, these repeat experiments were included as additional 
replicates. 
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Figure 4.11: Overview of raw and Z-Score(MAD)-normalised cell number values for each of 
the three replicates and plates 
Boxplots represent the range of median raw (pink, respective left-hand panel) and Z-Score(MAD)-
normalised (blue, respective right-hand panel) sample cell numbers for each of the three plates for the 
screened cell lines. Error bars indicate cell number range. The table at the bottom of the figure 
summarises range of Spearman Correlation Factors obtained for each cell line when each of the three 
replicates of one plate was compared to each other replicate (comparison of normalised data). Values 
≥ 0.7 are considered to represent good correlation and with that good reproducibility. Note: RCC4 VHL 
and UMRC2 EV cells were re-screened and the results were included in this Figure (RCC4 VHL II and 
UMRC2 EV II) and subsequent analyses. 
 
Next, performance of positive and negative controls was evaluated. As can be seen from 
the graphs in Figure 4.12, the individual values for each control cluster together for 
most of the cell lines, indicating that variability in transfection efficiency was low. Also, 
apart from 786-O VHL and the RCC4 cell line pair, negative controls separated well 
away from the positive controls, indicating achievement of a good dynamic range in 
response to RNAi. 
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Figure 4.12: Performance of negative and positive controls in the screen 
The scatterplots show raw, Z-Score(MAD)-transformed and RISC-free-normalised (POCRF) cell number 
values for all individual control wells, their median ± range. Controls from all plates are pooled. In most 
cases, positive controls (blue) separate well away from negative controls (red/orange/yellow). 
Note: RCC4 EV and UMRC2 VHL have twice as many data points as the repeated screen values were 
integrated in this analysis. 
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Finally, Figure 4.13 gives an overview of the variability of the individual replicates 
across the three screen plates for each cell line (excluding controls), while the 
histograms in Figure 4.14 show the distribution of the overall cell number Z-
Scores(MAD) (including controls) for the individual cell lines. 
  
Figure 4.13: Profiles of individual replicates for isogenic ccRCC cell lines screened 
Box plots represent raw (A), control-normalised (% of control, POC) (B) or Z-Score(MAD)-transformed (C) 
cell number values excluding positive and negative controls. 
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Figure 4.14: Overview of Z-Score(MAD)-distribution for the individual ccRCC cell lines 
All replicate Z-Score(MAD) values for each cell line were used for the Z-Score(MAD) distribution analysis 
including positive and negative controls. Histograms were generated with GraphPad Prism 6. 
 
In conclusion, evaluation of the screen quality implied the involvement of some 
technical issues during the screen execution process and it was advised to be cautious 
when interpreting the results. As a result, high stringency was applied during data 
analysis and the effects of potential hits were confirmed by independent validation 
experiments. 
 
4.3.4 Analysis of screen results 
Unsupervised clustering analysis was performed with the median Z-Scores(MAD) values 
(excluding controls) to see how the cell lines and genes tested relate to each other. The 
dendrogram in Figure 4.15 shows that the cell lines clustered as isogenic pairs rather 
than according to pVHL-status. Noticeably, UMRC2 cells clustered away from the 
other ccRCC cell line pairs, potentially as these cells are described as having polygonal 
rather than epithelial cell morphology (according to ATCC tissue bank). The siRNAs 
separated into two main clusters: cluster I comprises of siRNAs that have a negative 
effect on cell number. Sub-cluster IA contains siRNAs with the most detrimental effect 
across most cell lines. Cluster II consists of siRNAs that enhance cell viability with sub-
cluster IIB having the strongest positive effect across most cell lines (Figure 4.15).  
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Figure 4.15: Unsupervised hierarchical cluster analysis of siRNA screen data 
The median Z-Scores(MAD) of the three replicates for each cell line were subjected to an unsupervised 
clustering analysis using Cluster 3.0 and Java TreeView 1.1.6r2 software applications. The resulting 
heatmap revealed two main clusters: cluster IA, comprised of genes that had a negative effect on cell 
viability for most cell lines, while cluster IIB comprised of genes that had a positive effect on cell 
proliferation. 
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siRNAs that clustered in IA target genes within the glycolytic pathway (ALDOA/B, GPI, 
PKM2, HK2, PFKM, ENO3, PFKFB1, PKLR), the TCA cycle (ACO1, MDH2, DLAT, 
SUCLG2, DLD) and triacyl-glyceride / fatty acid and cholesterol biosynthesis (AGPAT6, 
PPAP2C, SCD, MCAT, PMVK, CYP51A1, MVD, FDFT1, DHCR24). Furthermore, this 
cluster also harbours siRNAs targeting members of the glutathione peroxidase (GPX) 
family (GPX1, GPX3 and GPX7), subunits of the mitochondrial NADH dehydrogenase, 
which constitutes Complex I of the electron transport chain (ETC) (MT-ND3, MT-ND4 
and MT-ND6) and the transcription factor (TF) c-MYC (Figure 4.15). 
Interestingly, sub-cluster IIB showed a similar representation of pathways affected as 
seen for sub-cluster IA. This may indicate that knocking down different isoforms of the 
same enzyme or ablating different enzymes within the same pathway can either result in 
loss of viability or enhanced cell survival/proliferation. In the glycolytic pathway, 
knocking down ENO1, ENO2, GAPDH or PFKL lead to cell number increase. The 
depletion of some proteins in the cholesterol biosynthesis pathway (MVK, HSD17B7, 
GGPS1, ACAT1, IDI1, SQLE, FDPS) also seemed to have an overall positive effect on 
cell numbers. Within the TCA cycle, it was siRNA against SDHB, IDH2, IDH3B, FH, 
PDK3, CS, PDP1 and PDP2 that seemrd to increase cell numbers. This cluster also 
included two other components of Complex I of the ETC, namely MT-ND2 and MT-
ND5 as well as two isoforms of the HIF-α subunit, HIF-1α and HIF-2α/EPAS (Figure 
4.15). 
With regard to genes that had a general positive or negative effect on ccRCC cell 
viability, disturbance of glycolysis, the TCA cycle and triacyl-glyceride / fatty 
acid / cholesterol biosynthesis seemed to be the most effective.  
 
4.3.5 Comparative analysis to detect VHL-synthetic lethality 
To detect VHL-synthetic lethal genes, two approaches were taken. Firstly, a cell line 
specific approach for which the Z-Score(MAD)-transformed data of the five isogenic cell 
line pairs were compared to each other individually. Correlation graphs for the isogenic 
cell line pairs are displayed in Figure 4.16. Tables listing genes that passed the threshold 
of Z-Score(MAD) ≤ -1.7 are shown in Figure 4. 17 in ranked order. 
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A498 and 769-P isogenic cell line pairs showed good correlation (R2A498 = 0.87 and 
R2769-P = 0.72) (Figure 4.16), indicating that reintroduction of a wt VHL gene has no 
major effect on their sensitivity towards ablation of metabolic genes. Nevertheless, 
some siRNAs showed differential effects depending on VHL status in these cells. In 
particular, A498-EV cells were sensitive to ablation of GAPDHS, TKTL1 and DHCR24, 
while A498-VHL cells showed reduced proliferation after silencing of GLS, AGXT2, 
ME2 and PKM2. For 769-P-EV cells, silencing of c-MYC, CHLA, AGXT, PGD, PFKM, 
PFKFB1, PC, AGPAT6, GALK2, GALT, DHCR7, G6PD or PFKP had a strong negative 
effect on cell proliferation, while NSDHL and SLC25A10 were essential to 769-P-VHL 
cells (Figure 4.17). An effect was called differential when a significant reduction in cell 
number was observed in one cell line for each pair, while the effect in the isogenic 
counterpart was either not significant or the difference between the two effects was 
≥ 0.2. 
The RCC4, UMRC2 and 786-O cell line pairs diverged in their response to RNAi-
mediated gene silencing as their R2 correlation values were low (Figure 4.16). However, 
these pairs did not show many VHL-dependent differential effects. In the case of RCC4, 
which displayed the strongest diversity, pVHL-null cells were sensitive to depletion of 
GALT, ND6, DHCR24, GNPNAT1, PFKFB1, PGD, ALDOA and GPX4. RCC4 
pVHL-expressing cells showed reduced cell numbers after silencing of HK2, PRKAA2, 
GCK, PRKAG3, GAPDHS, DLAT, PKM2 and MLXIPL. UMRC2 cells lacking pVHL 
were sensitive to depletion of PFKFB1 and ENO3, while UMRC2 pVHL-expressing 
cells required ODC1, GPX7, PRKAB1, GCK, ME2 and IDH3G. Finally, for 786-O 
cells, silencing of PGM1, ODC1, CAD, AGPAT4, OGDH, DHCR24, ME2, UMPS, 
GAPDHS and PFKFB1 negatively affected proliferation only for pVHL-null cells, 
while depletion of UAP1, PLD2, GALT, GALK2 and PC reduced proliferation of 
pVHL-expressing cells (Figure 4.17). 
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Figure 4.16: Correlation of Z-Scores(MAD) for each of the 5 isogenic ccRCC cell line pairs 
Median Z-Scores(MAD) of the three replicates for each cell line pair were plotted against each other and a 
Spearman Correlation analysis was performed. R2 values for each cell line pair correlation is given. A 
cut-off of Z-Score(MAD) ≤ -1.7 and ≥ 1.7 was set to define genes having a significant reduction in cell 
number. Highlighted in blue are genes that when silenced resulted in loss of viability; highlighted in 
orange are siRNA-targeted genes that resulted in a cell number gain according to the set cut-off. 
 
A small number of siRNAs showed a selective effect in more than one isogenic cell line 
pair. Depletion of DHCR24 for example had a strong negative effect on viability of 
RCC4, A498 and 786-O pVHL-null cells but not in their pVHL-expressing counterparts. 
Similar effects were observed for PFKFB1 in RCC4, UMRC2, 786-O and 769-P pVHL-
null cell lines. Some siRNAs, such as siME2, had a specific negative effect in the 
UMRC2 and A498 VHL-reconstituted cell lines but also in 786-O pVHL-null cells and 
in both 769-P cell lines (Figure 4.17). In these cases, genes were not considered as 
differential hits.  
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Figure 4.17: Summary of cell line-specific siRNAs with negative effect on cell viability 
Tables summarising siRNA-targeted genes that showed cell number loss with Z-Score(MAD) ≤ -1.7. 
Highlighted in bright blue are genes that when silenced have a significant negative effect exclusively in 
the EV or in the VHL cell line of the respective isogenic cell line pairs, Highlighted in dark blue are 
genes that have overlapping negative effects in the repeated RCC4 VHL and UMRC2 EV sample sets. 
Knockdown of c-MYC, SLC16A8 and PRKAG3 (italic labelling) are detrimental for most of the cell 
lines tested. 
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As second approach, data from all five pVHL-null cell lines and all five VHL-
reconstituted cell lines were pooled and their median Z-Scores(MAD) were compared in 
order to investigate potential global VHL-dependent effects on ccRCC cell survival 
(Figure 4.18). Surprisingly, the list of siRNAs negatively regulating ccRCC cell 
viability was relatively short. siRNA-mediated gene silencing showed a consistent 
selective negative effect on cell number only for six genes, namely PGD, ALDOA, 
PFKFB1, GALK1, GPI and AGPAT6 in pVHL-null ccRCC cells. In contrast, siRNAs 
targeting PKM2, ME2 and MLXIPL, were identified to have a selective detrimental 
effect on pVHL-reconstituted cell lines.  
 
 
Figure 4.18: Correlation of Z-Scores(MAD) with respect to pVHL-status 
Median Z-Score(MAD) from all pVHL-null and all VHL-reconstituted cell lines were plotted againt each 
other. Highlighted in blue are genes that when silenced resulted in loss of viability; highlighted in orange 
are siRNA-targeted genes that resulted in a cell number gain according to the set cut-off (Z-Score(MAD) ≤ -
1.7). The associated tables list siRNAs that had a strong global negative effect on either EV or VHL cells. 
Highlighted in bright blue / turquoise are EV / VHL specific genes. 
 
4.3.6 Comparative analysis to detect HIF-α isoform-specific correlations 
As the screened cell line panel consists of cell lines showing variations in HIF-α 
isoform expression, the screen data was also analysed with regard to correlation of cell 
number loss with HIF-α status. RCC4 and UMRC2 cells express both HIF-1α and HIF-
2α, while 786-O and 769-P express only HIF-2α. A498 cells were excluded from this 
analysis as they express only a truncated form of HIF-1α and HIF-2α (see Figure 3.3).  
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Median cell number Z-Scores(MAD) of RCC4 and UMRC2 pVHL-null cells were pooled 
and plotted against the median cell number Z-Scores(MAD) of 786-O and 769-P pVHL-
null cells (Figure 4.19). A differential hit was defined as showing a significant reduction 
in cell number (Z-Score(MAD) ≤ -1.7) in one condition (HIF-1/2α) but not in the other 
(HIF-2α). A substantial number of siRNAs showed HIF-2α-specific cell number loss 
without affect HIF-1/2α-expressing cells. These siRNAs targeted PRKAG3, PPAP2C, 
SLC16A8, ME2, MLXPL, DHCR24, GALK2, CHKA, LOC441996, GALT, ND6 and 
ODC1. In contrast, only five genes seemd to be essential for HIF-1/2α expressing cell 
lines: GPX3, UMPS, GALK1, AGPAT6 and ENO3.  
 
 
Figure 4.19: Correlation of Z-Scores(MAD) with respect to HIF-α-isoform expression 
Replicate Z-Scores(MAD) of RCC4 and UMRC2 pVHL-null cells were pooled for the HIF-1/2α set and 
replicate Z-Scores(MAD) of 786-O and 769-P cells were pooled for the HIF-2α set. The respective medians 
were plotted against each other. Highlighted in blue are genes that when silenced resulted in loss of 
viability; highlighted in orange are siRNA-targeted genes that resulted in a cell number gain according to 
the set cut-off (Z-Score(MAD) ≤ -1.7). The associated tables list siRNas that had a strong negative effect (Z-
Score ≤ -1.7) on either HIF-1/2α- or HIF-2α-expressing cells. Highlighted in turquoise / bright blue are 
HIF-1/2α- / HIF-2α-specific genes. 
 
Several of the genes that came up in this differential analysis had been previously 
identified in the other pVHL-comparative analyses (Figure 4.16 - 4.18). None of the 
siRNAs identified as differential killers, affected exclusively pVHL-null cells and only 
the siRNA pool targeting the muscle-specific isoform of pyruvate kinase, PKM2, which 
catalyses the final step in glycolysis, effectively killed only pVHL-harbouring cells 
making it a pVHL-specific hit (Figure 4.20). HIF-2α-expressing cells seemed to be 
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particular sensitive to siRNA-mediated gene silencing as targeting CHKA, DHCR24, 
GALT, LOC441996, ND6, ODC1 and PPAP2C turned out to be detrimental for this cell 
population. Ablation of the glycolytic enzyme enolase 3 (ENO3) and the pentose 
phosphate pathway enzyme UMPS on the other hand were detrimental specifically for 
HIF-1/2α-expressing cells (Figure 4.20). Finally, all four pools were sensitive to 
depletion of the transcription factor c-MYC and the Complex I component MT-ND3 
making these siRNAs the over all strongest killers.  
 
Figure 4.20: Overlap of 
negative Z-Score(MAD) when 
comparing pVHL- and HIF-α- 
isoform-specific hits 
Venn diagram visualising the 
overlap or distinctiveness of 
siRNAs targeting the indicated 
genes that have strong negative 
effects in one or more of the 
analysed pooled populations. 
Illustration was produced using 
the online tool venny 
(http://bioinfogp.cnb.csic.es/tools/
venny/index.html). 
 
 
4.3.7 Validation screen of selected genes 
To test the validity and reproducibility of the differential targets identified in the screen, 
a series of validation experiments was performed. Table 4.1 summarises the genes 
tested for knockdown and the results obtained. Due to the smaller number of siRNAs 
used for this validation screen, it was not feasible to perform a Z-Score analysis. Thus, 
cell numbers after siRNA-mediated gene silencing were normalised to the respective 
negative control (RISC-free). The cut-off for strong negative effects was set stringently 
to ≤ 0.5 % of control (POCRF). The overall effects of gene silencing in these validation 
experiments were much stronger compared to the initial screen. Silencing of many of 
the genes tested decreased cell numbers substantially in most of the cell lines (Table 
4.1). 
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Table 4.1 Summary heat-map of 
validation screen 
Gene ablation effects from the screen 
were re-evaluated in a secondary 
validation screen. Heat map represents 
RISC-free (RF)-normalised endpoint 
cell numbers (POCRF) for the individual 
isogenic cell line pairs obtained 
following 4 days siRNA treatment on a 
96-well plate format. 
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Figure 4.21: Summary of cell line-specific siRNAs with negative effect on cell viability 
from validation silencing experiments 
Tables summarise genes that when knocked down resulted in sever cell number loss with POCRF ≤ 0.5. 
Highlighted in bright blue are siRNAs that have a significant negative effect exclusively in EV or VHL 
cells of the respective isogenic cell line pairs. Marked in bold are siRNAs that reproduce the cell line-
specific detrimental effect from the screen. 
 
With respect to pVHL-specific silencing effects, the same approach was taken as for 
identifying differential effects in the primary screen. The gene ranks (POCRF ≤ 0.5) for 
the individual cell lines can be found in Figure 4.21. Surprisingly, although there was an 
increased amount of siRNAs identified with detrimental outcome on cell number 
compared to the initial screen, their overlap is limited. PFKFB1 (6-phosphofructo-2-
kinase/fructose-2,6-biphosphatase 1), PRKAB1 (protein kinase, AMP-activated, beta 1), 
and PFKM (phosphofructokinase, muscle) for example were the only genes that when 
knocked down maintained their unique negative effect on cell number in RCC4 EV, 
UMRC2 VHL, and 769-P EV cells, respectively. Apart from those three, many of the 
siRNAs that scored as cell line specific pVHL-differential did not hold up their negative 
effects, because in the validation experiment the counterpart became sensitive to the 
respective gene ablation to a similar extent, hence abolishing the differential effect 
(Figure 4.21). A similar scenario could be observed for the more global pVHL-
differential analysis, where all pVHL-null cell lines were pooled and their mean was 
compared to the mean of the pooled pVHL-expressing cell lines. Galactokinase 2 
(GALK2) was the only gene that when silenced was more detrimental for pVHL-
expressing cells (Figure 4.22A).  
 
Analysis to identify specific cell number loss correlation with HIF-α-isoform expression, 
revealed a much better reproducibility for siRNAs that preferentially affected HIF-2α 
only expressing cells: siMYC, siME2, siALDOA, siGALK2 and siLOC441996 
maintained their effect indicating a strong link between these genes and HIF-2α (Figure 
4.22B). Indeed, it is now established that ccRCC cell lines are c-MYC-driven and that 
HIF-2α directly cooperates with c-MYC to drive at least cell cycle-affecting genes 
(Gordan et al., 2007a). 
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Figure 4.22: Summary of genes with pVHL- or HIF-α isoform-specific effect on cell 
viability  
(A) Tables summarising genes that upon siRNA-mediated silencing resulted in severe cell number loss in 
a pVHL-specific manner with POCRF ≤ 0.5. Highlighted in bright blue / turquoisse are genes that have a 
significant negative effect exclusively in EV / VHL cells. (B) Tables summarising genes that upon 
siRNA-mediated silencing resulted in severe cell number loss according to HIF-α isoform status POCRF 
≤ 0.5. Highlighted in bright blue / turquoisse are genes that have a significant negative effect exclusively 
in HIF-1/2α- / HIF-2α only- expressing cells. Marked in bold are genes that reproduce the differential 
detrimental effect that was seen in the initial screen. (C) Venn-diagram illustrating the overlap or 
distinctiveness of siRNAs-targets that have strong negative effects in one or more of the analysed pooled 
populations. Diagram was generated using the online software tool venny (http://bioinfogp.cnb.csic.es/ 
tools/venny/index.html). 
 
Amongst the most detrimental siRNAs across most of the cell lines were those targeting 
the AMPK subunit PRKAG3, the transcription factor c-MYC, several genes involved in 
fatty acid, triacyl-glyceride and cholesterol metabolism (ME1, CHPT1, PPAP2C, 
HMGCS2, PMVK, DHCR24) and genes involved in ROS detoxification (GPX1, GPX3, 
GPX4 and SOD1). In addition, the glycolytic enzymes GPI, ALDOA, the lactate 
transporter SLC16A8, the TCA cycle enzyme ME2 and two AKT isoforms, AKT1 and 
AKT2 were also identified as being essential for ccRCC cell survival. All of these genes 
comprised the final gene hit list (Table 4.2). In this case, having the monocarboxylate 
transporter MCT4 amongst the genes that are essential for ccRCC cell survival served 
as a positive control, because this gene was previously found in another screen 
investigating ccRCC disease (Gerlinger et al., 2012b). 
 
 
Table 4.2 Final Hit list 
List extracted from Table 4.1 
summarises siRNA-targeted 
genes that showed strong 
negative effects on cell 
proliferation upon silencing in 
all ccRCC cells tested. 
Numbers represent obtained 
POCRF values. Highlighted in 
red are genes that were chosen 
for follow-up investigations. 
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4.4  Screen discussion and follow up 
The main objective of the functional genomics approach was to identify pVHL-
synthetic lethal metabolic genes that affected ccRCC cell viability. Although some 
siRNAs were found to have pVHL-dependent effects, these were largely cell line 
specific and it was not possible to identify solid pVHL-synthetic lethal genes that 
affected all ccRCC cell lines (Figure 4.16 – 4.18). The differential effects seen in 
individual cell lines, predominantly in the RCC4 cell line pair, were neither substantial 
nor exclusive in that all cell lines that showed a differential effect showed it in the same 
direction. In addition, many of the tested differential hits were either not reproducible or 
inconsistent when trying to validate them further (Figure 4.21 and 4.22).  
 
One of the reasons for not being able to identify strong differential gene effects might 
be due to the high variability between the individual replicates observed in the screen 
(Figure 4.11). This internal variability might mask potential real differential effects 
between cell lines. Indeed, in the subsequent smaller validation screen, variability 
between technical replicates was minimal and the number of hit genes increased. 
Unfortunately, no siRNAs could be identified within the validation screen that had a 
substantial differential effect on cell viability. This might result from the high cut off 
threshold, which was set to ≤ 50 % of RISC-free control silencing (POCRF), but the aim 
was to identify genes whose ablation had a strong biological impact. Unfortunately, we 
missed to include the top hit kinases, MET, MEK1 and particularly CDK6, that were 
identified as potential synthetic lethal interactors of pVHL in the shRNA screen carried 
out by Bommy-Reddy and colleagues (Bommi-Reddy et al., 2008) and which would 
have provided us with a positive control for our pVHL-differential hit analysis. 
Also, we cannot discount that differential hits common to all cell line pairs could have 
been identified if the readout of the screen would have been changed i.e. if tested for 
changes in migration or invasion or if a metabolic readout such as redox-flux would 
have been chosen. 
Aside from potential technical issues and high cut off thresholds, it cannot be excluded 
that the screen itself was not ideal to detect pVHL-synergistic genes. Although ccRCCs 
show a prominent metabolic phenotype, which was shown to distinguish them from 
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other cancer types (Gatto et al., 2014), the metabolic screen library the isogenic cell 
lines were subjected to is relatively small, with only 240 target genes. The library could 
potentially be expanded to encompass more metabolic genes relevant for VHL-synthetic 
lethality in the ccRCC-specific context. Subjecting the ccRCC cell lines to a whole 
genome screen might have yielded more results.  
Furthermore, as mentioned in the introduction, there is increasing evidence, that 
ccRCCs are highly heterogeneous and acquire subclonal genetic alterations during 
tumour progression (Gerlinger et al., 2012a, Martinez et al., 2013). To accommodate 
this heterogeneity, a panel of 5 isogenic pairs was used for screening. Although the cell 
lines have some commonalities such as a high glycolytic phenotype (Figure 3.6), high 
respiratory capacity (Figure 3.7) and show high sensitivity to glutamine and glucose 
withdrawal (Figure 3.11) when compared to non-tumourigenc HK-2 cells, these 
commonalities varied somewhat amongst the different ccRCC cell lines and could be 
the consequence of their distinct genetic backgrounds (for more details, see catalogue of 
somatic mutations in cancer (COSMIC; http://cancer.sanger.ac.uk/cancergenome/ 
projects/cell_lines/)). This genetic heterogeneity may make it difficult to identify 
common ccRCC-synthetic lethal relationships, which could be validated in vivo.  
 
Identification of genes that decreased cell numbers in a HIF-α isoform specific manner 
yielded a small number of genes that were predominantly HIF-2α specific. No 
convincing genes were found to have a more pronounced effect in cells expressing both 
HIF-α isoforms (Figure 4.19). Amongst the HIF-2α-specific genes was c-MYC, which 
is in line with reports of HIF-2α:c-MYC cooperation for induction of a transcriptional 
programme that drives cell proliferation in hypoxia (Gordan et al., 2007a, Gordan et al., 
2007b). With regard to the other genes, LOC441996, ME2, ALDOA and GALK2, 
although silencing of these showed higher cell number loss in HIF-2α-expressing cells, 
their ablation per se had a strong negative effect on the whole cell line panel (Figure 
4.20 and 4.22). Hence, the relevance of this specificity is not clear but their increased 
importance in HIF-2α driven tumours might be able to be resolved more easily in 
longer-term assays where differences would be larger. 
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A final conclusion that can be made from the siRNA screen is that although VHL 
loss/mutation is unequivocally an early and important event in ccRCC initiation and 
growth (Gerlinger et al., 2012a), the subsequent alterations that take place as a 
consequence of HIF loss mean that re-addition of functional pVHL alone is able to 
change the respiratory capacity of the cells for example but would be unable to rewire 
the subtle metabolic differences that have developed in each of the tumours which the 
cell lines were derived from. 
 
As the screen revealed a promising number of genes, whose depletion resulted in 
convincing and reproducible negative effects on cell number in most, if not all, ccRCC 
cell line pairs (Table 4.2), it was decided to focus on this set of genes for further 
investigations. Furthermore, by comparison with the non-tumourigenic HK-2 renal 
epithelial cell line, cancer-specific effects might be identifiable. 
 
A promising lead for further investigation in ccRCC appeared to be within the ROS 
detoxification system, with a special focus on the glutathione peroxidase family, as 
silencing of several members of this family (GPX1, GPX3, GPX4, GPX7) repeatedly 
came up as particularly detrimental for the ccRCC cell lines tested while having little or 
no effect in the non-tumourigenic renal epithelial HK-2 cells as will be shown in the 
following. 
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5.1  Introduction 
5.1.1 Adaptable redox balance is essential for cancer cell proliferation 
and survival 
Cellular redox homeostasis is maintained by the balance between the generation and 
elimination of reactive oxygen species (ROS). ROS species are constantly generated as 
by-products in metabolic processes whenever electron leakage occurs and electrons are 
transferred to an oxygen atom instead of a carbon or a phosphate molecule. Processes 
that can produce oxygen radicals include the mitochondrial electron transport chain 
(ETC) and endoplasmic reticulum (ER) stress (Santos et al., 2009, Higa and Chevet, 
2012) (Figure 5.1). In addition, active enzyme-catalysed ROS production occurs 
through the function of specific metabolic enzymes, such as cytochrome P450 
(CYP450) (Hanukoglu, 2006), lipoxygenase (LOX), cyclooxygenase (COX) as well as 
NADPH oxidase (NOX, membrane-bound), xanthine oxidase (XO) and nitric oxide 
synthase (NOS) (Keisari et al., 1983, Los et al., 1995) (Figure 5.1). ROS species include 
hydrogen peroxide (H2O2), the superoxide anion (O2-), the very reactive hydroxyl 
radical (OH, generated from H2O2 in the presence of Fe2+ through a Fenton reaction), 
organic hydroperoxides (ROOH) and highly reactive alcoxy and peroxy radicals (RO, 
ROO). Due to dynamic changes in ROS species present in the cellular milieu and the 
lack of tools to detect and quantitatively measure these changes, ROS is often used to 
summarise H2O2 and O2- only. Sequestering these ROS species are various endogenous 
antioxidants such as glutathione (GSH), thioredoxin (TRX) and NADPH (provides the 
reducing equivalents for regeneration of these antioxidants), as well as dietary 
antioxidant compounds, which can be supplemented exogenously, such as vitamin C 
(ascorbate), vitamin E (tocopherol family), β-carotene (a carotenoid) and the non-metal 
selemnium (Se). These antioxidants harbour intrinsic redox capacity in either thiol 
groups (GSH and TRX) or in their, sometimes multiple, double bonds (vitamin C and E, 
β-carotene) and are less substrate-specific than endogenous ROS-detoxifying enzymes 
like superoxide dismutase (SOD), catalase (CAT, predominantly in peroxisomes), 
glutathione peroxidase (GPX), glutathione transferase (GST), glutaredoxin (GRX), and 
peroxiredoxin (PRX). Some of these enzymes use GSH as co-substrate (Figure 5.1). 
Chapter 5: The glutathione redox system is essential for ccRCC cell survival 
 152 
SODs are the only enzymes that can convert highly reactive O2- into less reactive H2O2, 
which can then be converted to water by CAT, GPXs and other enzymes. There are 
three SOD isoforms: mitochondrial MnSOD/SOD2 and cytoplasmic and extracellular 
Cu/ZnSOD (SOD1 and SOD3 respectively) covering the main cellular compartments of 
O2- generation (Figure 5.1). 
 
 
Figure 5.1: Cellular enzymatic ROS generation and detoxification systems 
Reactive oxygen species (ROS) are usually generated as by-products from the electron transport chain at 
complex I and III (CI, CIII) or the endoplasmic reticulum (ER). But ROS can also be actively generated 
by enzymes such as nitric oxide synthase (NOS), NADPH oxidases (NOX), cyclooxygenase 2 (COX2) or 
heme oxygenase (HMOX). Opposed to these ROS generating enzymes are ROS scavenging enzymes 
(bold labelling) such as superoxide dismutases (SODs) that convert O2- to H2O2, which is further 
converted to water by catalase (CAT), glutathione peroxidases (GPXs), thioredoxins (TRXs) and 
peroxyredoxins (PRXs). GSH, reduced glutathione; GSSG, oxidised glutathione; GSR, glutathione 
reductase; TRXR, thioredoxin reductase. Highlighted in orange are ROS producers; highlighted in blue 
are non-enzymatic antioxidants and co-substrates for redox-active enzymes, which are highlighted in bold 
lettering. 
 
The master regulator of antioxidant response to oxidative stress is the ubiquitously 
expressed transcription factor nuclear factor erythroid 2-related factor 2 (NRF2). Under 
normal conditions, NRF2 is bound to Kelch-like ECH-associated protein 1 (KEAP1) 
restraining it to the cytoplasm. Furthermore, KEAP1, a BTB-containing protein acts as 
an adaptor for cullin 3 (CUL3) binding, which, together with the E3 ubiquitin ligase 
RING-box protein 1 (RBX1), form a BCR E3 ubiquitin ligase complex. This E3 
ubiquitin ligase complex polyubiquitinates NRF2, thereby marking it for proteasomal 
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degradation. In response to oxidative stress, KEAP1 gets oxidised and the binding to 
NRF2 is lost, enabling NRF2 translocation to the nucleus where it activates the 
transcription of its downstream targets (Taguchi et al., 2011). NRF2 drives the 
expression of the two subunits of γ-glutamylcysteine synthetase (γ-GCL): GCLC 
(catalytic subunit) and GCLM (modifying subunit). γ-GCL is the rate-limiting enzyme in 
GSH production. NRF2 also controls the supply of cysteine by controlling the 
expression of the cystine/glutamate antiporter solute carrier family 7 member 11 
(SLC7A11 or XCT) (Sasaki et al., 2002). Cysteine is the rate-limiting substrate not only 
for GSH production, but also for the generation of selenocysteine, a special amino acid 
incorporated in the catalytic centre of several enzymes, including some involved in ROS 
scavenging (e.g. GPXs and TRX reductase (TRXR)). In addition, NRF2 positively 
regulates NADPH-producing enzymes such as malic enzyme 1 (ME1), glucose-6-
phosphate dehydrogenase (G6PD) and isocitrate dehydrogenase (IDH) (Mitsuishi et al., 
2012). Other NRF2 targets include TXNRD1, PRDX1 (Kim et al., 2007), GPX2, and 
several GSTs, heme oxygenase (decycling) 1 (HMOX1), components of the ferritin 
complex (ferritin light chain (FTL) and ferritin heavy chain (FTH)) (Chorley et al., 
2012) and NAD(P)H quinone oxidoreductase 1 (NQO1). 
 
Other important transcriptional regulators of antioxidant proteins are forkhead 
transcription factors of the O subgroup (FOXOs). In mammals, there are four FOXO 
isoforms: FOXO1, FOXO3, FOXO4 and FOXO6. FOXOs are regulated through 
phosphorylation by AKT, which causes their exclusion from the nucleus and subsequent 
proteasomal degradation. Although most FOXO target genes are predominantly 
associated with cell cycle arrest and apoptosis (van der Horst and Burgering, 2007), 
FOXO3 and FOXO4 are involved in ROS detoxification, as they regulate the expression 
of SOD2, CAT and sestrin 3 (Kops et al., 2002a, Nogueira et al., 2008, Ferber et al., 
2012).  
 
The tumour suppressor TP53 (p53), which is best known for its checkpoint activity in 
the cell cycle transition from G1 to S-phase is furthermore involved in cellular redox 
metabolism. p53 responds to DNA damage through activation by ataxia telangiectasia 
mutated (ATM) and ataxia telangiectasia and Rad3-related protein (ATR) by stalling the 
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cell cycle through upregulation of the inhibitory protein p21. p21 binds to and inhibits 
the cyclin dependent kinase 2 (CDK2), leading to arrest of the cell cycle in G1 and 
providing time for DNA repair mechanisms to be activated. If the damage exceeds 
beyond repair, p53 is able to induce either senescence or apoptosis to remove the faulty 
cell from the system. This is accomplished, amongst other mechanisms, by enhancing 
ROS production through induction of p53-induced gene 3 (PIG3) (Polyak et al., 1997), 
mitochondrial proline dehydrogenase (PRODH) (Rivera and Maxwell, 2005), BAX, 
PUMA (Liu et al., 2005) and p66SHC (Trinei et al., 2002) and by downregulation of 
aldehyde dehydrogenase 4 (ALDH4) (Yoon et al., 2004), SOD2 and GPX1 (Johnson et 
al., 1996, Drane et al., 2001). At the same time, p53 has the capacity of inducing a ROS-
elimination programme by positively regulating GPX1 and SOD2 (Hussain et al., 2004, 
Tan et al., 1999) and inhibiting COX2 (Subbaramaiah et al., 1999) and NOS2 (Ambs et 
al., 1998, Forrester et al., 1996). Hence, in the context of ROS, p53 acts as a double–
edged sword (Figure 5.2). 
  
Despite the prevalent notion that ROS are ‘all bad’ and that their accumulation will 
result in severe and irreversible damage of DNA, proteins and lipids, eventually causing 
cell death (Figure 5.2) and therefore needs to be eliminated or prevented at all costs. 
However, certain ROS at low to moderate concentrations are important signalling 
components that act as second messengers reporting back on altered and aberrant 
metabolic activities and influence signalling cascades to bring about adaptations to 
maintain the cellular redox balance and homeostasis to guarantee cell survival, 
proliferation and/or differentiation (Gough and Cotter, 2011) (Figure 5.2). It has been 
shown that H2O2, for example, can activate pro-survival transcription factors such as 
HIF-1α (Chandel et al., 1998, Chandel et al., 2000a), c-JUN N-terminal kinase 1(JNK1) 
(Chandel et al., 2000b, Nemoto et al., 2000), nuclear factor κ-light-chain-enhancer of 
activated B-cells (NF-κB) (Chandel et al., 2000b, Gloire et al., 2006) and p53 (Chandel 
et al., 2000c) in response to stress (Veal et al., 2007). Moreover, H2O2 has been 
implicated in modulating growth factor, cytokine and mitogen signalling through 
oxidative alteration of key cysteine residues on signalling molecules, particularly protein 
tyrosine phosphatases (PTPs) (Tonks, 2005, Xu et al., 2002) such as phosphatase and 
tensin homologue (PTEN) (Leslie et al., 2003) and MAPK phosphatases, which inhibits 
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their phosphatase activity and stabilises growth factor signalling (Figure 5.2). 
Furthermore, overexpression of SOD, CAT, PRXs and GPX1 resulted in depletion of 
H2O2 and negatively interfered with growth factor-mediated proliferation and growth 
(Shi et al., 2004). Many of these findings were discovered in the context of cancer 
initiation and survival, highlighting an important role for ROS in tumourigenesis. Cancer 
cells work at an enhanced metabolic rate in order to meet the high demand of anabolic 
processes required for fast proliferation, and enhanced ROS production is a by-product 
of increased metabolic activity. This initial increase in ROS could thereby enhance cell 
proliferation through increased activation of the PI3K/AKT pathway due to H2O2-
mediated inactivation of PTEN. At the same time, induction of anti-oxidant mechanisms 
in cancer cells is needed to prevent excess accumulation of ROS to prevent cellular 
damage. For example, a recent study by Mitsuishi and colleagues has shown that the 
PI3K/AKT pathway also leads to nuclear NRF2 accumulation. NRF2 promotes PPP and 
glutamine metabolism in addition to cytoprotective antioxidant genes (Mitsuishi et al., 
2012). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Positive or negative effect of ROS on cell survival is concentration dependent  
The cell generates and needs a basal level of ROS for homeostasis. ROS are mainly generated as 
metabolic by-products and their accumulation up to a certain level induces signalling cascades to restore 
the balance. Once ROS accumulation exceeds another certain threshold, it becomes cytostatic and/or 
cytotoxic as it can cause severe damage to proteins, lipids and nucleic acids. Cancers found adaptation 
mechanisms to not only cope with the increased ROS levels that result from high metabolic rates but also 
to make use of it for their high proliferation rates.  
 
In conclusion, cancer cells seem to have hijacked the cellular ROS scavenging system to 
maintain and promote proliferation and survive in an unfavourable environment by 
enhanced ROS accumulation together with upregulated ROS scavenging molecules and 
enzymes to counteract detrimental macromolecule damage.  
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5.1.2 GPX gene family and protein synthesis 
GPXs are enzymes with the ability of neutralising peroxides such as H2O2 or lipid 
peroxides. In most cases, GSH is used as a co-substrate for the catalytic reaction. In 
humans, eight GPX isoforms have been identified (GPX1-GPX8) but GPX1-4 are the 
best studied of the family members. The different isoforms are highly conserved but 
differ in their expression pattern and substrate specificity, although some overlap.  
GPX1 is the most abundant isoform and functions as a homotetramer. It is ubiquitously 
expressed and can be found in the cytoplasm, mitochondria and peroxisomes. Apart 
from H2O2, GPX1 can also reduce lipid hydroperoxides. GPX1 knockout mice are 
viable but extremely sensitive to exogenous ROS stimuli (e.g. Paraquat or Diquat 
treatment) and oxidant-induced injury (de Haan et al., 1998).  
GPX2, which also functions as a homotetramer, is mainly expressed in the epithelium 
of the gastrointestinal tract (Chu et al., 1993). GPX2 knockout mice are also viable.  
GPX3, also known as plasma GPX, is the only extracellular GPX isoform. Although 
GPX3 mRNA can be found in many different tissues, plasma-derived GPX3 is mainly 
produced in and secreted by the kidney (Avissar et al., 1994, Chu et al., 1992).  
GPX4 differs from other GPX proteins in its substrate specificity as it mainly reduces 
phospholipid hydroperoxides such as tri- or diacylglycerol hydroperoxides (Marinho et 
al., 1997, Seiler et al., 2008, Toppo et al., 2009). With phospholipids being the main 
component of biological membranes, GPX4 is located to membranes to protect them 
from oxidative damage. Unlike the other GPXs, GPX4 is monomeric and, when 
systemically knocked out in a mouse model, results in embryonic lethality in 
midgestation (Yant et al., 2003), confirming an essential role for GPX4 in organismal 
development. 
 
The GPX protein family belongs to a specific class of proteins, namely the 
selenoproteins. Selenoproteins are relatively rare (only ~25 have been identified so far 
(Kryukov et al., 2003)) and are characterised by containing a selenocysteine (Sec, U) in 
their protein sequence. In selenoproteins with enzymatic functions, Sec is localised to 
the catalytic centre where it catalyses redox reactions. Sec is the rare 21st amino acid 
and a cysteine (Cys, C) analogue in which the sulphur-containing thiol group is replaced 
by a selenium-containing selenol group. This alteration lowers both its pKa and its 
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reduction potential compared to cysteine giving it a distinct antioxidant activity, as it is 
deprotonated even at physiological pH. Interestingly, incorporation of this special 
amino acid provides a basis for the unique regulatory mechanism in GPX synthesis. Sec 
does not have its own genetic code but is encoded as ‘UGA’ - generally known as 
STOP codon. Hence, so-called SECIS (Sec insertion sequences) elements, additional 
regions in the 3’ untranslated region (UTR) that form stem-loop structures, are 
necessary to recruit specific RNA-binding proteins (e.g. SECIS binding protein 2 
(SBP2)) that facilitate an event cascade eventually resulting in Sec incorporation (Berry 
et al., 1991a, Berry et al., 1991b, Copeland et al., 2000, Fagegaltier et al., 2000). 
Contrary to all other amino acids, there is no Sec pool, as it is too reactive, but it is 
synthesised on its specific tRNA (tRNAsec) just before incorporation into the protein. 
tRNAsec synthesis occurs in a three-step process: Firstly, tRNAsec becomes 
aminoacetylated with L-serine by seryl-tRNA synthetase (SerS). This seryl-residue is 
next converted to O-phosphoseryl-tRNAsec by O-phosphoseryl-tRNASec kinase (PSTK). 
Finally, O-phosphoseryl-tRNAsec is converted to selenocysteinyl-tRNAsec via the action 
of the Sep (O-phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase (SEPSECS) 
(Low et al., 1995, Low and Berry, 1996, Tujebajeva et al., 2000, Zavacki et al., 2003). 
Selenoprotein production is also dependent on the presence of selenium (Se). With Se 
being an essential nutrient, dietary Se restriction result in downregulation of 
selenoprotein mRNA and protein. However, not every selenoprotein is affected to the 
same extend by a reduction in available Se. There is a hierarchical separation - most 
likely depending on the importance of the respective selenoprotein. GPX4 and GPX2, 
for example, rank high and their mRNA is stable even at limiting Se concentrations 
while GPX1 and GPX3 mRNA, low in rank, get degraded already at moderate Se levels 
(Lei et al., 1995, Neve, 1995, Bermano et al., 1996, Wingler et al., 1999, Sunde et al., 
2009).  
 
5.1.3 GPX1 in tumourigenesis 
In the context of cancer, GPX1 is of particular interest. The GPX1 gene contains several 
oxygen response elements (ORE) (Cowan et al., 1993) as well as binding sites for the 
tumour suppressor p53 (Hussain et al., 2004) and pro-survival transcription factors, 
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such as NFκB, AP-1 and SP1 (Abate et al., 1990, Zhou et al., 2001). Furthermore, 
human GPX1 is located to chromosome 3p21, a region associated with frequent loss of 
heterozygosity (LOH) in a number of different cancer types including breast, colon, 
lung, head and neck and kidney cancer (Hardie et al., 2000, Hu and Diamond, 2003, Hu 
et al., 2004) suggesting a potential tumour suppressive role for GPX1 in humans. In 
addition, the GPX1 gene is prone to single-nucleotide polymorphisms (SNPs; 38 have 
been found so far), especially aggregating in the 3’ and 5’ flanking regions (Foster et al., 
2006). Within the protein coding region, there are two consistent SNP sites that are 
frequently found and alter the protein sequence: (a) leading to variations of in-frame 
GCG repeats (5, 6 or 7) resulting in varying numbers of alanines at the N-terminus and 
(b) amino acid 198 exchange (Pro -> Leu) due to a single-nucleotide substitution (CCC 
-> CTC). Both of these SNPs seem to render GPX1 less sensitive to increasing Se 
concentrations, at least in breast cancer (Hu et al., 2004) and cardiomyocytes (Jablonska 
et al., 2004, Lei et al., 2009). There have been several epidemiological studies carried 
out to link these polymorphisms with risks of breast, lung, prostate and bladder cancer, 
but no consistent trend towards increased or decreased cancer risk was detected 
(Ratnasinghe et al., 2000, Duffield-Lillico et al., 2003, Hu and Diamond, 2003, Cebrian 
et al., 2006, Gresner et al., 2007, Lippman et al., 2009). 
Although systemic GPX1 loss alone did not seem to affect cancer susceptibility in mice, 
GPX1/GPX2 double knockout mice developed spontaneous colon/intestinal tumours, 
most likely due to increased inflammation (Chu et al., 2004). Overexpression of GPX1 
has opposing effects on tumour initiation/progression: GPX1 overexpression alone or in 
combination with SOD2 in MIA PaCa-2 cells (human primary pancreatic 
adenocarcinoma cells), for example, decreased cancer cell proliferation in vitro and in 
vivo (Liu et al., 2004). In contrast, the same approach resulted in enhanced tumour 
numbers and growth kinetics due to inhibition of apoptotic mechanisms in a mouse skin 
cancer model (Lu et al., 1997, Kim et al., 2009), hinting to possible tissue-specific 
susceptibilities.  
 
Taken together, it can be concluded that GPXs are important regulators of cellular and 
organismal redox balance, which is necessary for normal tissue homeostasis. A 
deviation from this highly regulated redox state, either mediated through up- or 
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downregulation of GPXs and consequential decrease or increase of ROS levels, results 
in the development of disease-associated phenotypes. 
 
5.1.4 Glutathione biosynthesis and recycling 
Glutathione is the major endogenous antioxidant produced in the cell. Its production is 
regulated by NRF2 as many of the enzymes involved in GSH synthesis are. Glutathione 
is present in relatively high concentrations within the cell, reaching 1-11 mM in the 
cytoplasm, mitochondria and the nucleus compared to stromal (0.01 mM) or plasma 
(0.002 mM) concentrations (Carlson and Jones, 1998, Han et al., 2006). Furthermore, 
liver, kidney and lung contain high levels of glutathione, most likely as these tissues 
have the highest exposure to toxins. Interestingly, there is evidence for shuttling of 
glutathione at the organismal level, as glutathione can be transported via the blood 
stream from the glutathione-producing liver to the GSH-consuming kidney (Anderson 
and Meister, 1980).  
Glutathione occurs in two forms in the cell: as reduced glutathione (GSH) and as 
oxidised glutathione (GSSG). The ratio of GSH:GSSG is a common indicator of a cell’s 
redox state. During oxidative stress, when GSH is heavily used, more of it is converted 
into GSSG and the GSH pool becomes more and more exhausted. Although GSH is the 
predominant form in most of the cellular compartments (GSSG is found in 
concentrations around 5-50 µM only), this is not the case for the ER. In the ER, where 
folding and assembly of nascent proteins occur, GSSG provides the necessary 
environment to favour disulphide bond formation (Hwang et al., 1992). 
 
GSH is a tripeptide formed exclusively in the cytoplasm from L-glutamate, L-cysteine 
and glycine in a two-step, ATP-dependent, reaction. The first and rate-limiting reaction 
is the synthesis of γ-glutamylcysteine, which is mediated by γ-GCL under consumption 
of one ATP molecule. In the second step, monomeric glutathione synthetase (GSS) uses 
another ATP molecule to add glycine to the C-terminus of γ-glutamylcysteine to form 
GSH (Figure 5.3). γ-GCL is highly conserved in most eukaryotes and knockout of 
GCLC in mice is embryonic lethal (Dalton et al., 2000, Shi et al., 2000), indicating an 
essential role for this enzyme during development. In cancer, γ-GCL expression and 
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activity is often upregulated, most likely in response to enhanced demand for GSH due 
to enhanced ROS presence. 
 
Figure 5.3: Glutathione bio-
synthesis and recycling  
Glutathione (GSH) is synthesised in 
a three-step process from glutamine, 
cysteine and glycine. Once inside 
the cell, glutamine is converted to 
glutamate by glutaminase (GLS) and 
cystine is reduced to cysteine by 
thioredoxin reductase (TXNRD). 
Glutamate and cysteine are then 
ligated by γ-glutamylcysteine ligase 
(GCLC/M). Glutathione synthetase 
(GSS) adds a glycine to γ-glutamyl-
cysteine to form GSH. GSH is a co-
substrate for several ROS 
detoxifying enzymes such as 
glutathione peroxidase (GPX), 
glutaredoxin (GRX) and 
peroxyredoxin (PRDX). Oxidised 
GSSG can be recycled to reduced 
GSH by glutathione reductase 
(GSR), using NADPH as a reducing 
co-factor. NADPH can be sourced 
from the PPP, where it is produced 
by glucose-6-phosphate dehydro-
genase (G6PD). 
 
Cysteine is the rate-limiting substrate in GSH production and is reabsorbed from the 
stroma in the precursor form cystine, an amino acid formed by the covalent binding of 
two cysteine molecules via a disulphide bond. Cystine is taken up through either 
SLC7A11 or, especially in kidney tubules, by the cystine transporter SLC7A9 and 
subsequently reduced to cysteine intracellularly by TRDX or GSH (Figure 5.3). 
Expression of SLC7A11 and its stabilising cell surface glycoprotein CD44 have both 
been found to positively influence cancer cell proliferation (Ishimoto et al., 2011, Zhang 
et al., 2012). 
The second amino acid required for GSH synthesis is glutamate, which is taken up as the 
precursor glutamine by several transporters, including the solute carrier family 1 
member 5 (SLC1A5). Once in the cell, glutamine can be hydrolysed to glutamate and 
ammonia by glutaminase (GLS) (Figure 5.3). There are two isoforms of glutaminase: 
brain/kidney GLS1 and mitochondrial/liver GLS2. Expression of GLS1 is controlled by 
the oncogene c-MYC (Gao et al., 2009), while GLS2 is regulated by the tumour 
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suppressor p53 and has already been implicated to play a role in ROS metabolism 
(Suzuki et al., 2010). 
 
In the course of reducing ROS, GSH becomes oxidised and dimerises with a second 
GSH molecule to form GSSG via a disulphide bond. This GSSG can be recycled to two 
molecules of GSH by glutathione reductase (GSR). GSR activity is dependent on FAD 
and NADPH, two important cofactors. One source of cytoplasmic NADPH is the 
pentose phosphate pathway (PPP) (Figure 5.3 and 1.4). Firstly, NADPH is generated 
through the conversion of glucose-6-phosphate to 6-phosphoglucono-δ-lactone by 
glucose-6-phosphate dehydrogenase (G6PD). Secondly, two steps further down, 6-
phosphogluconate dehydrogenase (6PGD) converts 6-phosphogluconate into ribulose-5-
phosphate, generating another NADPH molecule (Figure 1.4). Because of this 
dependency, GSH maintenance is coupled to the PPP activity. 
 
5.1.5 Drugs perturbing GSH biosynthesis and maintenance 
With GSH occupying such a central position in cellular redox regulation, it is not 
surprising that several nodes of GSH biosynthesis have been targeted for anti-cancer 
treatment. Figure 5.4 gives an overview of inhibitors and drugs that interfere with 
glutathione biosynthesis and maintenance. The drug Sulfasalazine targets the 
cysteine/glutamine antiporter SLC7A11 and has been approved for the treatment of 
pancreatic and lung cancer (Lo et al., 2010, Guan et al.). The enzyme L-asparaginase 
depletes glutamine and has been approved for the treatment of leukaemia and pancreatic 
cancer (Dufour et al., 2012, Pieters et al., 2011). The small molecule 968 
(dibenzophenanthridine) and BPTES inhibit glutamine to glutamate conversion through 
inhibition of GLS and the small molecule 968 was approved to treat lymphoma and 
breast cancer (Wang et al., 2010, Le et al., 2012). Further down the line, the GCLC 
inhibitor L-buthionine sulphoximine (BSO) is used in the treatment of ovarian and 
breast cancer as well as in melanoma treatment (O'Dwyer et al., 1996). Finally, there 
have been successful attempts to pharmacologically alter the GSH:GSSG ratio (a) by 
inhibiting G6PD and thus GSH recycling with 6-anicotinamide (6-AN) (approved for 
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colon cancer treatment (Belfi et al., 1999)) and (b) through the GSSG mimetic NOV-
002 (approved for treatment of lung, breast and ovarian cancer (Montero et al., 2012)). 
In contrast, augmentation of GSH synthesis can be achieved by providing external 
supplements. The synthetic small-molecules N-acetyl-L-cysteine (NAC) and L-2-
Oxothiazolidine-4-carboxylic acid (OTC) are cysteine derivatives that can fuel GSH 
production when converted into L-cysteine. NAC is a widely used nutritional 
supplement (antioxidant) and pharmacological substance used as mucolytic agent, 
nephron-protective agent and to treat paracetamol overdose amongst others. Another 
stimulator for GSH production is the soy isoflavone Genistein, which positively 
regulates γ-GCL and GPX1/GPX2 via activation of NRF1 and NRF2 (Myhrstad et al., 
2002, Suzuki et al., 2002, Hernandez-Montes et al., 2006). 
 
  
 
Figure 5.4: Overview of inhibitors and drugs that interfere with glutathione biosynthesis 
and maintenance 
BSO, L-buthionine-S,R-sulfoximine; OTC, L-2-oxothiazolidine-4-carboxylate; NAC, N-acetyl-L-
cysteine; 2-ME, 2-methoxyestradiol; PEITEC, phenethyl isothiocyanate; 6-AN, 6-aminonicotinamide; 
DHEA, dehydroepiandrosterone; 2-DG, 2-deoxy-D-glucose 
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5.2  Depletion of ROS scavenging enzymes is detrimental for 
ccRCC proliferation – independent of pVHL-status 
As indicated in the previous chapter, analysis of the targeted metabolic screen in ccRCC 
cells (both the initial and the validation screen) identified several members of the GPX 
family (GPX1, GPX3, GPX4, GPX7) as well as SOD1 within the top 10% of genes that 
seemed to be essential for ccRCC cell proliferation (Table 4.1 and 4.2). This 
predominance of ROS scavenging enzymes amongst all other genes showing 
detrimental cell number loss when ablated led us to investigating their presumably 
fundamental role in ccRCC further. 
 
5.2.1 Deconvolution of GPX siRNAs in isogenic ccRCC cell lines 
As a second validation step, the SMARTpools for the eight GPX family members were 
deconvoluted in the RCC4 and 786-O isogenic cell line pairs and the non-malignant 
HK-2 cells. All eight GPX isoforms were positively deconvoluted as ≥ 2 of the four 
individual sequences showed a correlative decrease in cell number similar to that of the 
siRNA pool. Silencing of GPX1, GPX3, GPX4 and GPX7 showed the most negative 
effect on ccRCC cell viability. Moreover, in many of the cases, this negative effect was 
cancer-specific as HK-2 cells were hardly affected by depletion of these proteins. This 
was particularly the case for GPX1, GPX3, GPX6, GPX7 and GPX8. Interestingly, 
silencing of GPX1, GPX3 and GPX4 resulted in a stronger cell number loss in RCC4 
cells compared to 786-O cells, suggesting that depletion of these enzymes could be 
partially selective for cells expressing both HIF-α isoforms as opposed to cells that have 
lost HIF-1α expression.  
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Figure 5.5: Deconvolution of Dharmacon GPX1-8 SMARTpools 
The pVHL-isogenic cell line pairs RCC4 and 786-O and HK-2 cells were reverse transfected for 96 h 
with 37.5 nM of the 4 individual siRNA sequences comprising the SMARTpool in addition to the pool 
(P) against the 8 GPX isoforms. UBB and PLK1 served as positive and RISC-free (RF) and siC1-4 as 
negative controls. Bar graphs represent cell number means ± SD of triplicate wells normalised to RF. 
Significance of differential GPX siRNA effect in ccRCC cells compared to HK-2 cells was assessed by 
performing a 2-way ANOVA analysis including a Dunnett multiple comparison test (*, p ≤ 0.05). All 8 
SMARTpools deconvoluted successfully with ≥ 2 individual siRNA sequences having a similar 
(differential) effect as the pool. 
 
5.2.2 Knockdown efficiency of siGPX1-8 
Having successfully deconvoluted all eight GPX SMARTpools, knockdown efficiency 
of each SMARTpool and potential ‘cross-reactivity’ with any of the other isoforms was 
assessed. 786-O EV cells were transfected with each of the eight GPX SMARTpools 
and analysed for mRNA expression 48 h post transfection (Figure 5.6). Silencing of 
SEPSECS, the third and last enzyme in tRNAsec biosynthesis, was also included. 
It seems as if all of the siRNA SMARTpools affected mRNA levels of the other 
isoforms at least to some extent (Figure 5.6B). Surprisingly, silencing of SEPSECS had 
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only a minor effect on GPX mRNA levels in general. GPX1, GPX4 and GPX8 mRNA 
species were the least affected by siRNAs targeting the other isoforms, while GPX2, 
GPX5, GPX6 and GPX7 mRNA species were the most affected. It seemed, though, that 
sensitivity of GPX2, GPX5 and GPX7 mRNA to RNAi of the other isoforms correlated 
with low mRNA abundance, as control transfected 786-O pVHL-null cells had a ΔCT 
value ≥ 30 for GPX2, GPX5 and GPX7 (Figure 5.6A). Low basal mRNA levels make 
the analysis of siRNA knockdown efficiency for these genes less reliable.  
 
 
Figure 5.6: siRNA SMARTpools against the individual isoforms show ‘cross reactivity’ 
against each other. 
(A) 786-O pVHL-null cells were reverse transfected for 48 h with 37.5 nM siRNA against all 8 GPX 
isoforms and SEPSECS respectively. Total RNA was analysed for mRNA expression of GPX1-8, CAT, 
SOD1 and SOD2 and SEPSECS using RT-qPCR. Bar graphs represent average ± SD of duplicate 
measurements normalised to respective ACTB levels and are displayed relative to scramble silencing 
(siC1-4). Number above siC1-4 bars indicates mean ΔCT value. (B) Heat map summarising the fold-
change differences in mRNA abundance relative to siC1-4 shown as bar graphs in (A). (C) Knockdown 
efficiency for siSEPSECS relative to siC1-4. Numbers above C1-4 indicate average ΔCT value for 
comparison. 
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As GPX1 and GPX3 are the isoforms most likely to be important for cancer cells, 
knockdown efficiency of the individual GPX1 and GPX3 siRNA sequences of the 
SMARTpool and their cross-reactivity with each other was assessed (Figure 5.7). In 
both RCC4 and 786-O pVHL-null cells, mRNA depletion upon GPX1 and GPX3 
silencing was > 90% (Figure 5.7A,B). In HK-2 cells, silencing with the GPX3 
SMARTpool was equally effective and resulted in ~90% mRNA depletion (Figure 
5.7B). The GPX1 SMARTpool was less efficient on mRNA level with only a 50% 
knockdown (Figure 5.7A), but efficient depletion of the protein was detected in both 
RCC4 EV and HK-2 cells (Figure 5.7C). Due to its nature as a secreted protein, 
monitoring GPX3 on protein level remained unsuccessful with the methods available.  
Some GPX1 and GPX3 siRNA sequences showed a mutual effect on the other genes’ 
mRNA levels. Two of the four siRNAs targeting GPX1 also negatively affected GPX3 
mRNA levels in 786-O EV cells (Figure 5.7A, right-hand panel); while two of the four 
siRNAs targeting GPX3 induced GPX1 mRNA expression in RCC4 EV cells (Figure 
5.7B, right-hand panel). 
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Figure 5.7: GPX1 and GPX3 knockdown is good and efficient 
(A-B) RCC4 EV, 786-O EV and HK-2 cells were reverse transfected for 48 h with 37.5 nM of the 4 
individual siRNA target sequences (♯1-4) comprising of the SMARTpool and the pool (P) against (A) 
GPX1 and (B) GPX3. Total RNA abundances for GPX1 and GPX3 were examined using RT-qPCR. Bar 
graphs represent average of duplicate measurements normalised to respective ACTB levels and are 
displayed relative to scrambled siRNA (siC1-4). Error bars represent SD. (C) RCC4 EV and HK-2 cells 
were transfected as above with the deconvoluted siRNA sequences against GPX1. siSEPSECS was 
included. Whole cell lysates were subjected to SDS/PAGE and were analysed for GPX1 protein 
expression to check for knockdown efficiency. β-Actin serves as loading control. 
	  
5.3  Transfer from VHL-isogenic cell line to parental cell lines 
As ablation of GPXs did not show pronounced and consistent differential effects 
between VHL-null and -reconstituted cells, it seemed more appropriate to continue the 
study in the parental RCC4, UMRC2, A498, 786-O and 769-P cell lines. Moreover, for 
a better representation of the heterogeneity of ccRCCs, all twelve ccRCC cell lines were 
included for all further investigations. 
 
Reassuringly, GPX knockdown had similar detrimental effects in the parental cell lines 
and the isogenic cell line pairs (Figure 5.8). Silencing of CAT, SOD1 and SOD2 as well 
as the ROS-defence master regulator NRF2 was included to cover a broader spectrum 
of the ROS scavenging system. All ccRCC cell lines were highly sensitive not only to 
ablation of the different GPXs, but also to silencing of CAT, SOD1, SOD2 and NRF2 
(Figure 5.8B). Furthermore, ablation of especially GPX1, GPX3, GPX7 and SOD1 
revealed strong cancer-specific effects with HK-2 cells being hardly affected through 
ablation of any of the proteins tested but NRF2 and TXNRD2 (Figure 5.8).  
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Figure 5.8: Ablation of ROS detoxifying enzymes is detrimental for ccRCC but not for HK-
2 cells 
(A) Indicated ccRCC cell lines were transfected with 37.5 nM siRNA against the indicated genes for 
96 h. Bar graphs represent average endpoint cell numbers relative to RISC-free (RF) of 3 independent 
experiments performed in triplicates ± SEM. Asterisks indicate ccRCC cell lines with significant cell 
number loss compared to HK-2 cells upon ablation of the respective protein (2-way ANOVA analysis 
including Dunnett multiple comparison testing; *, p ≤ 0.05; ns, not significant). (B) Heat map 
summarising relative cell number data from (A). 
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In contrast to the ccRCC cell lines, which are maintained in DMEM, HK-2 cells are 
maintained in KSFM medium. Hence, the effect of different media on the sensitivity to 
silencing of components of the anti-oxidant system was addressed in RCC4, 786-O and 
HK-2 cells. While the observed GPX silencing effect hardly differed in the two 
different media for RCC4 cells, 786-O cells were more susceptible to cell number loss 
following ablation of GPXs in DMEM compared to KSFM medium (Figure 5.9). With 
regard to ablation of GPX1 and GPX3, 786-O cells seemed to encounter a proliferation 
boost in KSFM compared to DMEM medium (Figure 5.9). HK-2 cells showed higher 
cell number loss following ablation of only GPX1 and GPX4 in DMEM medium, but as 
transfection with scrambled siRNA (siC1-4) showed a similar effect, a potential media 
effect on knockdown efficiency in these cells was neglected (Figure 5.9).  
 
 
Figure 5.9: Media effect on knockdown efficiency of GPXs is negligible  
RCC4, 786-O and HK-2 cells were reverse transfected for 96 h with 37.5 nM siRNA against the 8 GPX 
isoforms, UBB as positive and C1-4 as negative control in either complete DMEM/10% FBS or KSFM 
medium. Bar graphs represent cell number means of 3 wells normalised to RISC-free (RF) ± SD. 
Asterisks indicate significant differences in cell number upon RNAi in the different media (two-tailed 
paired t-test, *, p ≤ 0.05). 
 
5.4  GPX1 and GPX3 ablation does not induce apoptosis 
To analyse the mechanisms leading to the observed reduction in cell number following 
ablation of ROS-scavenging enzymes, a subset of cell lines from the cell line panel 
(RCC4, A498, 769-P, TK10, ACHN and HK-2) was monitored for their growth kinetics 
in an IncuCyte life cell imaging system. The growth curves depicted in Figure 5.10A 
indicated that ccRCC cells grew slower rather than underwent cell death upon ablation 
of GPX1-8. This was particularly obvious by comparison with UBB ablation, which 
induces apoptosis. Ablation of most GPX isoforms resulted in significant cell number 
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loss compared to scrambled RNAi, whereby GPX1, GPX3, GPX 7 and SOD1 had the 
strongest growth inhibitory effects (Figure 5.10B). 
 
Figure 5.10: Ablation of GPX1, GPX3, GPX7 and SOD1 inhibit ccRCC proliferation 
(A) ccRCC and HK-2 cells were reverse transfected with 37.5 nM siRNA against the indicated genes and 
were monitored for cell proliferation in an IncuCyte live cell imaging system. siUBB serves as positive 
apoptosis-inducing control, siOTP1-4 as negative control. Curves show average cell proliferation over 
time generated from confluence measurements every 2 h for 120 h in total of ≥ 2 replicate wells ± SD.  
(B) Bar graphs represent average endpoint cell numbers of the ≥ 2 wells from (A) normalised to RISC-
free (RF) ± SD. Highlighted are genes (GPX1, GPX3, GPX7 and SOD1) that when silenced were 
particularly detrimental in most ccRCC but not so much in HK-2 cells. Asterisks indicate significant 
effects on endpoint cell numbers of respective GPX isoform ablation compared to transfection with 
scrambled siRNA (siOTP) (2-way ANOVA analysis with Dunnett multiple comparison testing,  
*, p ≤ 0.05). 
 
Further analysis confirmed the initial observation that GPX ablation was not cytotoxic, 
as upregulation of any common inducers of the apoptotic process were not obvious. It 
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was not possible to detect increased caspase3/7 enzymatic activity upon GPX1 or GPX3 
knockdown (Figure 5.20A, C) and no accumulation of cleaved poly (ADP-ribose) 
polymerase (PARP) could be observed (Figure 5.11A). In addition, no changes in B-cell 
lymphoma 2 (Bcl-2) and Bcl-2 associated X protein (BAX) mRNA could be observed 
in RCC4 or HK-2 cells (Figure 5.11B). Only expression of the p53 upregulated 
modulator of apoptosis (PUMA) mRNA seemed to be increased. However, a 2-/3-fold 
increase in p21 mRNA levels upon ablation of GPX1/GPX3 suggested that the cells 
were in distress (Figure 5.11B). 
 
 
Figure 5.11: GPX1 and GPX3 ablation does not induce apoptosis 
(A) RCC4 and HK-2 cells were reverse transfected with siRNA against GPX1 and GPX3 or with 
scrambled siRNA (siC1-4, Ctr.). Whole cell lysates were prepared 24, 48, 72 and 96h post transfection 
and analysed for GPX1, (activated, i.e. cleaved) PARP and Bcl-2 protein expression. β-Actin serves as 
loading control. (B) RCC4 (red) and HK-2 (green) cells were reverse transfected for 48h with siRNA 
against GPX1 and GPX3. mRNA levels of stress and cell death marker p53, PUMA, BAX, NOXA1 and 
p21 were determined using RT-qPCR. Bar graphs represent average of duplicate measurements 
normalised to respective ACTB mRNA levels ± SD and are displayed relative to the respective scramble 
siRNA (siOTP1-4). 
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5.5  GPX1 and GPX3 ablation prolong cell cycle duration in 
RCC4 cells 
Depletion of GPX1 and GPX3 resulted in a severe cell number loss compared to control 
silencing in the different ccRCC cell lines. However, no obvious induction of apoptotic 
cell death was observed (Figure 5.11). Another route of comparative cell number 
reduction following 4 days of siRNA treatment could be caused by prolonged cell 
cycling or cell cycle arrest, leading to reduced proliferation. 
RCC4 EV cells were subjected to an 8 h BrdU pulse-chase analysis to assess cell cycle 
duration following GPX1, GPX3 and SOD1 ablation (Figure 5.12). In contrast to 
control-silenced cells, where BrdU-positive cells showed a prominent G1-phase peak 
after 6 h (Figure 5.12A), cells with GPX1, GPX3 and SOD1 knockdown reached this 
peak with a 2 h delay (Figure 5.12B - D). RCC4 EV cells treated with 1 µM cdk4/6 
inhibitor as positive control remained in G1-phase over the experimental duration of 8 h, 
while vehicle treated cells cycled similarly to control siRNA treated cells (Figure 
5.12E - F). 
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Figure 5.12: Ablation of GPX1, GPX3 and SOD1 results in prolonged cell cycle in RCC4 
EV cells 
To analyse cell cycle duration 96 h post (A) scrambled (siOTP1-4), (B) GPX1, (C) GPX3 and (D) SOD1 
silencing, RCC4 EV cells were pulsed for 15 min with 30 µM BrdU and fixed immediately (0 h), after 
2 h, 4 h, 6 h or 8 h. Histograms show PI profile of BrdU-positive RCC4 EV cells. (E) 72 h treatment with 
(E) 1 µM cdk4/6 inhibitor served as positive control for cell cycle arrest in G1. (F) Vehicle treatment 
served as negative control for (E).  
 
To assess cell cycle progression over the course of a regular 4 d silencing experiment, 
changes in cell cycle distribution following siGPX1 and siGPX3 transfection were 
monitored every 24 h in RCC4 EV cells (Figure 5.13). RNAi in general seemed to have 
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a cell cycle attenuating effect, as silencing of either GPX1 or GPX3 or scrambled 
caused an increase in cells in G1-phase and a decrease in cells in S- and G2/M phase 
over the 4 days (Figure 5.13A). However, GPX1 and GPX3 silencing for 72 h caused a 
higher increase in G1 or G2/M cell populations compared to scrambled silencing 
(Figure 5.13B). 
 
 
Figure 5.13: GPX1 and GPX3 ablation prolong G1- and G2/M- phase in RCC4 cells 
(A-B) RCC4 EV cells were reverse transfected with 37.5 nM siRNA against GPX1 and GPX3. Cells 
were harvested every 24 h post transfection for 4 d and analysed for cell cycle progression using FACS 
analysis of incorporated propidium iodide (PI). Stacked bar graphs represent fractionation of analysed 
cell population in different cell cycle phases at time of fixation. (A) Cell cycle phase progrssion following 
scrambled (siC1-4), GPX1 and GPX3 silencing over time. (B) Cell cycle phase distribution following 
GPX1 or GPX3 ablation for 72 h (extracted from (A)). siC1-4, negative transfection control. (C) 
Schematic illustrating the regulating factors behind cell cycle progression. The proteins aligned in the 
centre are negative regulators of cell cycle progression and inhibit the positive regulators aligned on the 
outside of the circle in the respective phases of the cell cycle (G1->S->G2->M). The MAP kinase 
pathway as well as β-catenin can directly influence cell cycle progression by activation of cyclin D, while 
under cellular stress conditions (e.g. severe DNA damage) p14/ARF activates p53, which activates p21 
subsequently, leading to cell cycle arrest in G1. (D) Cells were transfected as in (A-B) and harvested after 
24, 48, 72, 96 and 120 h for cell lysis. Whole cell lysates were subjected to SDS/PAGE and analysed for 
the indicated cell cycle proteins. β-Actin serves as loading control. 
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RCC4 pVHL-null and HK-2 cells were also analysed for changes in protein expression 
of key cell cycle regulators over a 5 d period of GPX1 and GPX3 ablation (Figure 
5.13D). Over the 5 days, increased levels of cyclin D1 and p27 could be observed in 
both RCC4 and HK-2 cells; changes in p16 were only present in HK-2 cells. However, 
cyclin D1 was consistently reduced in cells where GPX1 or GPX3 was ablated (of the 
two genes, GPX3 had the strongest effect on cyclin D1 repression) compared to control-
silenced cells, even in HK-2. Furthermore, p53 and cyclin A protein levels oscillated in 
synchronisation in RCC4 cells, while in HK-2 cells it was p16 that was synchronised 
with cyclin A. p16 was undetectable in RCC4 and p53 was beyond detection levels in 
HK-2 cells (Figure 5.13D). 
 
Taken together, these results indicate that ablation of GPX1 or GPX3 in RCC4 cells 
causes a delay in cell cycle progression with an extended G1-phase compared to 
scrambled-silenced cells. This effect seemed to be stronger after silencing of GPX1 
compared to GPX3. However, further analysis is necessary to confirm these results. 
 
5.6  Silencing of GPX1 and GPX3 causes a mild DNA damage 
phenotype 
The preliminary cell cycle analyses pointed to a slowing down of cell cycle progression 
due to a prolonged G1-phase. A common reason for cell cycle stalling is damaged DNA 
that needs to be repaired before the cell can progress through S-phase and mitosis. 
Indeed, ccRCC cells show increased basal p21 mRNA levels as compared to HK-2 cells 
(Figure 5.14A), indicating higher basal stress levels in ccRCC as compared to HK-2 
cells. Accumulation of p53 protein was noticed (Figure 5.14B) as well as a 2- and 3-
fold increase in p21 mRNA levels following depletion of GPX1 and GPX3 respectively 
in RCC4 cells (Figure 5.14E). Both observations support the idea for increased DNA 
damage being causative. Hence, RCC4, 786-O, CAKI1 and HK-2 cells were analysed 
for DNA damage following knockdown of GPX1, GPX3 and SOD1 by simultaneous 
detection of immunofluorescence (IF) against γH2.AX and the DNA damage response 
(DDR) component 53BP1. Quantification of nuclear γH2.AX foci in RCC4 and 786-O 
cells showed a tendency towards increased foci number upon GPX1, GPX3 or SOD1 
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ablation compared to control, whereby GPX3 depletion had the strongest effect (Figure 
5.14C). CAKI1 and HK-2 cells did not show any alteration from control cells after GPX 
silencing. 53BP1 accumulates at sites of double strand breaks (DSB) on the DNA and 
recruits factors involved in DDR of the homologous recombination type (amongst 
others Ku70:Ku80 and RAD51). An increase in 53BP1 foci could be observed after 
GPX1 and GPX3 silencing in the cancer cells, but not in HK-2 cells (Figure 5.14D), 
although the variability between the three replicate experiments was considerable. 
Surprisingly, RAD51 and Ku70 mRNA levels were not increased in RCC4 cells and in 
case of HK-2 cells was even reduced by 30% upon GPX1 and GPX3 ablation compared 
to control (Figure 5.14E). However, an explanation for this discrepancy might be the 
experimental timing: mRNA levels were examined 48 h post transfection while 53BP1 
foci were assessed 96 h post transfection. As 53BP1 accumulation is the first event that 
recruits RAD51 and Ku70:Ku80, the appropriate detection window of induced RAD51 
and Ku70 might have been missed.  
In summary, these data suggest that loss of GPX1 and GPX3 result in at least mild 
DNA damage, quite possibly involving DSBs. These could be caused by ROS 
accumulation leading to oxidative damage of DNA. 
 
Chapter 5: The glutathione redox system is essential for ccRCC cell survival 
 177 
 
Figure 5.14: Ablation of GPX1, GPX3 and SOD1 induce mild DNA damage 
(A) Basal p21 mRNA expression in ccRCC and HK-2 cell lines. Bars represent average of duplicate 
measurements normalised to respective ACTB mRNA levels and are displayed relative to control 
silencing (siOTP1-4). Error bars represent SD. Number above HK-2 bar indicates average ΔCT value for 
comparison. (B) RCC4 and HK-2 cells were reverse transfected with scrambled (siC1-4, Ctr.), GPX1 
(G1) and GPX3 (G3) siRNA for 24, 48, 72 and 96 h before lysis. Whole cell lysates were analysed for 
GPX1, p53 and 53BP1 protein expression. β-Actin serves as loading control. (C-D) RCC4, 786-O, 
CAKI1 and HK-2 cells were reverse transfected for 96h with 37.5 nM siRNA targeting GPX1, GPX3 and 
SOD1.(C) γH2.AX and (D) 53BP1 foci formation was analysed simultaneously using immunofluorescent 
cytochemistry. Treatment with 250 nM Doxirubicine for 6 h prior to fixation was used as positive control 
for induction of DNA damage. Bar graphs represent average number of (C) γH2.AX and (D) 53BP1 foci 
per cell normalised to the respective negative RISC-free (RF) control from 3 independent experiments 
performed in triplicates. Error bars represent ± SEM. Asterisks indicate significant induction of either 
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γH2.AX or 53BP1 foci upon GPX1/3 and SOD1 ablation or Doxirubicine treatment compared to control 
(siOTP or DMSO, respectively) (2-way ANOVA analysis including Dunnett multiple comparison test; *, 
p ≤ 0.05; ns, not significant). (E) RCC4 and HK-2 cells were transfected as in (C) and lysed 48h post 
transfection for total RNA extraction. mRNA abundance of DNA damage response inducers p53, p21, 
p27 as well as the effectors RAD51 and Ku70 were determined using RT-qPCR. Bar graphs represent 
average of duplicate CT measurements normalised to respective ACTB mRNA levels ± SD and are 
displayed relative to control silencing (siOTP1-4). 
 
5.7  GPX1 and GPX3 silencing positively affects SOD2 
expression 
The effect of GPX1 and GPX3 silencing on the expression of other components in the 
main ROS detection system was investigated next in RCC4 and HK-2 cells. Therefore, 
mRNA levels of SOD1, SOD2, CAT, PRDX6 (a lipidperoxide reducing peroxiredoxin) 
as well as the ROS defence regulator NRF2 were evaluated (Figure 5.15). Silencing of 
GPX1 showed a mild downregulation of CAT and PRDX6 mRNA to similar extent in 
both RCC4 and HK-2 cells (Figure 5.15B). Furthermore, GPX1 loss increases SOD2 
mRNA levels ≥ 2-fold in both cell lines (stronger in RCC4 cells) and also induces 
NRF2 slightly in RCC4 cells. Ablation of GPX3 also caused NRF2 mRNA upregulation 
in both RCC4 and HK-2 cells while reducing SOD1 and PRDX6 mRNA levels to a 
similar extend (Figure 5.15B). Interestingly, GPX3 silencing had a major negative 
effect on SOD2 mRNA levels (50% reduction) in RCC4 but not in HK-2 cells. 
However, no SOD2 protein reduction could be detected following siGPX3. In contrast, 
increased levels of SOD2 mRNA following ablation of GPX1 also translated into 
increased SOD2 protein levels (Figure 5.15C). 
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Figure 5.15: GPX1 depletion induces SOD2 mRNA and protein expression. 
(A) Schematic illustrating the enzymatic network for ROS detoxification. (B) RCC4 and HK-2 cells were 
reverse transfected with 37.5 nM siRNA against GPX1 and GPX3 and analysed for mRNA expression of 
the indicated genes 48 h later. Bar graphs represent average of duplicate CT measurements normalised to 
ACTB and relative to the respective scramble control siRNA (siOTP1-4) ± SD. (C) RCC4, CAKI1 and 
HK-2 cells were reverse transfected with siRNA against GPX1 (SMARTpool, P and deconvoluted: 
siRNA ♯1-4) or GPX3 (SMARTpool) for 96 h. Whole cell lysates were subjected to SDS/PAGE and 
analysed for GPX1 and SOD2 protein expression. β-Actin serves as loading control. 
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5.8  Co-silencing of GPX1 and FOXO4 synergistically slow 
down cell proliferation 
As a stalling of the cell cycle in G1 and upregulation of SOD2 could be observed upon 
GPX1 ablation, interplay between GPX1 and FOXO factors was considered and further 
investigated. FOXO factors are known regulators of both cell cycle and ROS 
metabolism and directly control the expression of SOD2 (van der Horst and Burgering, 
2007, Kops et al., 2002a, Kops et al., 2002b, Nogueira et al., 2008, Ferber et al., 2012). 
RCC4 and HK-2 cells were monitored for their growth kinetics using the IncuCyte life 
cell imaging system following GPX1, FOXO1, FOXO3 and FOXO4 silencing alone or 
as combination of GPX1 and one of the three FOXO isoforms respectively (Figure 
5.16). In HK-2 cells, ablation of FOXO1, FOXO3 or FOXO4 alone or in combination 
with GPX1 did not have any significant effect on cell growth (Figure 5.16A, B). In 
RCC4 cells, knockdown of the individual FOXO isoforms also did not have an effect on 
proliferation. However, combined silencing of GPX1 and FOXO3 schowed a small, 
GPX1 and FOXO4 a significant synergistic effect on cell proliferation (Figure 
5.16A, B). Furthermore, upregulation of GPX1 and FOXO1 mRNA following FOXO3 
ablation in both RCC4 and HK-2 cells was observed, indicating cross-talk between 
different anti-oxidant control systems (Figure 5.16C). In addition, silencing of FOXO3 
or FOXO4 together with GPX1 increased mRNA levels of FOXO1 by approx. 2.5-fold 
in HK-2 cells, suggesting a compensatory mechanism in these cells. Contrary to RCC4 
cells, co-silencing of GPX1 with any of the three FOXO isoforms resulted in a 2- to 3-
fold increase in SOD2 mRNA in HK-2 cells (Figure 5.16C). This is surprising, as 
depletion of FOXO factors should result in a reduced expression of this target gene. 
However, increased oxidative stress caused by combined depletion of GPX1 and 
FOXOs could activate SOD2 expression via other pathways.  
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Figure 5.16: Co-silencing of GPX1 with FOXO4 has an additive negative effect on ccRCC 
proliferation 
(A-B) RCC4 and HK-2 cells were reverse (co-)transfected with 37.5 nM siRNA (i.e. 18.75uM of each of 
the 2 SMARTpools) targeting GPX1 and FOXO1 (F1), FOXO3 (F3) or FOXO4 (F4) and monitored for 
cell proliferation using an IncuCyte live cell imaging system. siUBB (ubiquitin B) serves as positive, 
siC1-4 as negative control. (A) Curves show average cell proliferation over time generated from 
confluence measurements every 2 h for 92 h in total of triplicate wells ± SD. (B) Bar graphs represent 
average endpoint cell number of triplicate wells from (A) normalised to RISC-free (RF) ± SD. Asterisks 
indicate statistically significant difference in cell number loss upon co-silencing of GPX1 and FOXO4 
compared to ablation of either alone (2-way ANOVA analysis with Dunnett multiple-comparison testing; 
*, p ≥ 0.05). (C) Knockdown efficiency of GPX1/FOXO co-silencing 48 h post transfection. Bar graphs 
represent average of duplicate CT measurements normalised to respective ACTB mRNA levels ± SD and 
are displayed relative to control silencing (siC1-4). 
 
5.9  Silencing of GPX1, GPX3 and SOD1 leads to ROS 
accumulation in RCC4 but not in HK-2 cells 
As GPX proteins are important regulators of cellular anti-oxidant response, the effect of 
GPX1, GPX3 and SOD1 depletion on ROS accumulation was determined in RCC4, 
CAKI1 and HK-2 cells using an H2DCFDA fluorescence-activated cell-sorting (FACS) 
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assay. Only RCC4 cells showed a 1.5-fold increase in DCFDA immunofluorescence 
upon GPX1 and SOD1 ablation and a 1.25-fold increase upon GPX3 ablation compared 
to scrambled control. In CAKI1 cells, only siGPX1 ♯4 lead to a significant ROS 
accumulation compared to control, wheras there was no significant change detectable in 
HK-2 cells (Figure 5.17). 
 
Figure 5.17: Ablation of GPX1 and SOD1 causes accumulation of ROS in RCC4 but not in 
CAKI1 and HK-2 cells 
(A) RCC4, CAKI1 and HK-2 cells were reverse transfected with 37.5 nM siRNA targeting GPX1 
(SMARTpool and the 4 individual siRNA sequences). Treatment with 1 mM H2O2 for 10 min prior to 
H2DCFDA addition served as positive control. 48 h post transfection, cells were analysed for 
accumulation of DCFDA fluorescence using FACS. Bars represent mean cellular DCFDA intensities 
normalised to the respective negative siOTP control of three independent experiments. Error bars 
represent ± SEM. (B-C) Cells from the same experiment as in (A) treated in the same way but with 
siRNA SMARTpools against (B) GPX3 and (C) SOD1. Asterisks indicate statistically significant 
increase in fluorescent DCFDA accumulation for each cell line when compared to scrambled silencing 
(2-way ANOVA analysis with Dunnett multiple comparison testing; *, p ≤ 0.05).  
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Next, RCC4 and HK-2 cells were subjected to a FACS assay that allows simultaneous 
detection of O2- and other ROS species (H2O2, ONNOO-, HO, NO, ROO). Comparing 
untreated RCC4 and HK-2 cells for basal oxidative stress, the non-tumourigenic HK-2 
cells seemed to have higher ROS and slightly lower O2- levels than the RCC4 cells 
(Figure 5.18A). GPX1 knockdown caused a 3-fold increase of ROS and a 1.5-fold 
increase in O2- in RCC4 cells but not in HK-2 cells compared to control silencing. This 
increase in ROS but not the increase in O2- was attenuated by addition of either NAC or 
GSH in RCC4 cells, though not statistically significant. Surprisingly, supplementation 
of HK-2 cells with GSH following siGPX1 seemed to increase ROS levels (Figure 
5.18B). Ablation of GPX3 resulted in an almost 2-fold increase in ROS in both RCC4 
and HK-2 cells compared to control silencing. Supplementation with NAC seemed to 
have an inhibitory effect on ROS accumulation, though this trend needs further 
investigation. O2- levels also increased 1.5-fold after GPX3 silencing compared to 
control in both cell lines, but NAC achieved rescue only in the HK-2 cells (Figure 
5.18C). Interestingly, silencing of cytosolic SOD1 only increased ROS and O2- levels in 
RCC4 cells but not in HK-2 cells (Figure 5.18D). 
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Figure 5.18: ROS accumulation following GPX1 and GPX3 depletion can be partially 
rescued by small-molecule inhibitors.  
(A) Control conditions for (B-D). RCC4 and HK-2 cells were treated with 200 µM Pyocyanin (ROS 
inducer) and Antimycine A (O2- inducer) respectively as positive controls. Bars represent mean raw 
intensities of ROS (dark grey) and O2- (light grey) fluorescent dye per treated or untreated cell of ≥2 
independent experiments ± SEM. (B) RCC4 and HK-2 cells were reverse transfected with 37.5 nM 
siRNA against GPX1 and treated with 1 mM NAC or 5 mM GSH the next day. Accumulation of 
ROS / O2- was determined 72 h later via FACS analysis. Bars represent mean intensities of ROS and O2- 
fluorescent dye per cell normalised to control treatment (siOTP1-4) of 3 independent experiments. Error 
bars represent ± SEM. (C-D) Same conditions and treatment strategies (where applicable) as in (B) but 
for (C) siGPX3 treatment and (D) siSOD1 treatment. Bar graphs represent mean intensities of ROS and 
O2- fluorescent dye per cell normalised to control treatment (siOTP1-4) of 3 independent experiments 
± SEM. RFU, relative fluorescent units. Asterisks indicate statistically significant changes in ROS / O2- 
accumulation upon GPX1, GPX3 and SOD1 ablation compared to control (siOTP) or following 
antioxidant treatment compared to untreated (2-way ANOVA analysis with Dunnett multiple comparison 
test; *, p ≤ 0.05). 
 
In summary, it can be concluded that RCC4 cells accumulated comparatively more 
ROS and O2- following silencing of GPX1, GPX3 or SOD1 than HK-2 cells. 
Furthermore, ROS accumulation could be, at least partially, rescued through 
supplementation with the antioxidant NAC and in some cases also through addition of 
GSH. These results suggest that GPX1, GPX3 and SOD1 are important components of 
the anti-oxidant system in ccRCC cells. In contrast, non-tumourigenic HK-2 cells, 
although having slightly elevated basal ROS levels compared to RCC4 cells, do not 
seem to be dependant on these proteins for maintenance of their redox balance. 
 
5.10  Antioxidants have only limited effect on cell number loss 
following GPX1, GPX3 and SOD1 depletion in RCC4 cells 
As NAC and GSH were able to partially rescue ROS levels in RCC4 and HK-2 cells it 
was assessed whether these or other antioxidants could also prevent the cell number loss 
phenotype upon silencing of GPX1, GPX3 or SOD1. Hence, RCC4 and HK-2 cells 
were treated with increasing amounts of GSH, NAC, TEMPOL and the GPX-mimetic 
Ebselen following transfection with siGPX1, siGPX3 and siSOD1. TEMPOL (4-
Hydroxy-TEMPO, a TEMPO derivative) is an antioxidant that specifically catalyses the 
disproportionation of O2- thereby acting as a SOD mimetic (Wilcox and Pearlman, 
2008). Ebselen is a Se-containing small-molecule that, similarly to Se-dependent GPXs, 
neutralises H2O2 and (phospho-) lipid hydroperoxides using thiols (e.g. GSH) as 
cofactors (Maiorino et al., 1988).  
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Within the concentration range tested, hardly any positive effect on cell number could 
be seen upon treatment with any of the four antioxidants. Only treatment with 5 mM 
GSH (Figure 5.19A) and 10 µM TEMPOL (Figure 5.19C) following SOD1 ablation in 
RCC4 cells was able to significantly increase enpoint cell number. In contrast, treatment 
of control silenced RCC4 cells with 5 mM GSH, 1 mM NAC or 10 µM TEMPOL 
resulted in a small but significant cell number loss, suggesting that under control 
conditions RCC4 cells are in a redox balanced state, which is perturbed by external 
addition of antioxidants resulting in cell number loss due to reductive stress. 
Interestingly, HK-2 cells seem to be generally sensitive to GSH, NAC and Ebselen 
supplementation, as a prominent cell number loss was observed with increasing 
concentrations of any of these antioxidants and independent of the protein ablated 
(Figure 5.19A, B, D), while TEMPOL supplementation had a milder negative effect and 
was significant only upon ablation of GPX1 and GPX3 (Figure 5.19C). 
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Figure 5.19: Antioxidants have only a limited effect on cell number loss upon ablation of 
GPX1, GPX3 and SOD1 in RCC4 cells and are detrimental for HK-2 cells 
(A-D) RCC4 and HK-2 cells were reverse transfected with 37.5 nM siRNA against GPX1, GPX3 and 
SOD1 in a 96-well format. The next day, increasing doses of (A) glutathione (GSH), (B) the ROS 
scavenger N-acetylcysteine (NAC), (C) the superoxide scavenger TEMPOL and (D) the GPX mimetic 
Ebselen were added. Dose response curves (respective left-hand panel for each cell line) represent 
average endpoint cell numbers of triplicate wells normalised to the respective vehicle control (0 mM) 
72 h post treatment. Error bars represent ± SD. Bar graphs (respective right-hand panel for each cell line) 
depict average cell numbers from the most effective concentration extracted from the respective dose 
response curve in (A-D). Bars represent average cell numbers of triplicate wells normalised to the control 
silenced (siOTP) vehicle treated condition. Error bars represent ± SD. Asterisks represent statistically 
significant changes in cell number for the indicated antioxidant treatment compared to vehicle control (2-
way ANOVA analysis with Bonferroni multiple comparison test; *, p ≤ 0.05).  
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The experiment was repeated in RCC4 and HK-2 cells with the most promising 
antioxidant concentrations and under monitoring cell proliferation and death  in an 
IncuCyte live-cell imaging system. Figure 5.20A-F summarises growth curves and 
accumulation of apoptotic cells. Reassuringly, the mostly neutral effect of NAC and 
TEMPOL on GPX1, GPX3 and SOD1 ablation could be at least maintained if not 
strengthened to a positive effect on cell number as compared to vehicle treatment. In 
contrast, the previously neutral to positive effect of GSH and Ebselen following 
ablation of GPX1, GPX3 and SOD1 observed in RCC4 cells was reversed (Figure 
5.20G). Treatment with these antioxidants resulted in increased apoptosis in these cells 
compared to treatment with vehicle as an accumulation of the fluorescent Caspase-3/7 
substrate was observed (Figure 5.20A-F centre and right-hand panel graphs). 
Furthermore, the negative effect of the tested antioxidants on cell number in HK-2 cells 
could be confirmed and was due to increased apoptosis (Figure 5.20A-F centre and 
right-hand panel graphs) hinting further to a potential reductive stress that the normal 
cells might face and have difficulty to cope with. Although TEMPOL, which showed no 
difference in endpoint cell number compared to vehicle, was an exception (Figure 
5.20H). 
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Figure 5.20: Antioxidants cannot rescue cell number loss phenotype upon siGPX1, 
siGPX3 and siSOD1 
(A-F) RCC4 and HK-2 cells were reverse transfected with 37.5 nM siRNA targeting (A, B) GPX1, (C, D) 
GPX3 and (E, F) SOD1 in a 96-well format. 12 h post transfection, glutathione (GSH, 5 mM), the ROS 
scavenger N-acetylcysteine (NAC, 1 mM), the superoxide scavenger TEMPOL (10 µM) and the GPX 
mimetic Ebselen (1 µM) was added together with 5 µM of a fluorescent Caspase-3/7 substrate (ESSEN 
BioScience) to monitor real time cell death in an IncuCyte live cell imaging system. siUBB (targets 
ubiquitin B) serves as positive apoptosis-inducing control, siOTP as negative control. Left-hand panel 
line graphs represent average confluence measurements of triplicate wells ± SD generated every 2 h for 
120 h in total. Center panel graphs represent number of cells that accumulate the converted and now 
fluorescent Caspase-3/7 substrate; average of triplicate wells ± SD. Right-hand panel graphs depict the 
ratio of apoptotic cells normalised to measured confluence; average of triplicate wells ± SD. (G-H) Bar 
graphs represent average endpoint cell numbers 5.5 d post transfection of the triplicate wells from (A-F) 
normalised to vehicle treated control silenced cells (siOTP) ± SD. Asterisks indicate statistically 
significant cell number changes upon treatment with Ebselen, GSH, NAC or TEMPOL compared to 
vehicle control (2-way ANOVA analysis with Dunnett multiple comparison test; *, p ≤ 0.05). 
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In summary, although NAC and GSH treatment attenuated ROS/O2- levels to some 
extent in RCC4 cells, their ability to alleviate also the cell number loss phenotype 
resulting from GPX1, GPX3 or SOD1 knockdown was only limited and variable. This 
was unexpected, as the GPX mimetic Ebselen should substitute for the reduced 
expression of GPX enzymes while TEMPOL should replace SOD1 function. However, 
interpretation of the results was compromised by the high toxicity observed with the 
compounds used. In particular, it became apparent that the non-tumourigenic HK-2 
cells are highly sensitive to treatment with GSH, NAC and Ebselen, pointing to 
increased sensitivity towards reductive stress. Furthermore, the exact timing of gene 
silencing and compound addition could also affect the outcome of the experiment. 
Overall, it seems that deregulation of antioxidant metabolism, either by depletion of 
GPX/SOD proteins or by addition of antioxidants, can perturb the cellular redox 
balance, ultimately negatively influencing cell survival. 
 
5.11  GPX expression is heterogeneous in ccRCCs 
Expression of different ROS detoxifying enzymes in the different ccRCC cell lines on 
mRNA levels was very heterogeneous and did not follow a clear pattern as can be seen 
from Figure 5.12. RCC4, 786-O, UMRC3, TK10 and ACHN cells seemed to be most 
compromised in their expression of antioxidant enzymes, judging from their mRNA 
levels relative to HK-2 cells. UMRC2, A704, CAKI2 and A498 cells showed higher 
levels of anti-oxidant gene expression compared to HK-2 cells. GPX2, GPX3, GPX5, 
GPX6 and SOD2 mRNA levels were generally lower in ccRCC cell lines compared to 
HK-2 cells, while GPX8, CAT and SOD1 showed a tendency to have marginally higher 
expression levels in the cancer cells. In contrast to SOD1 and SOD2, where mRNA 
levels were a good indicator of protein levels, GPX1 mRNA levels did not reflect 
protein expression in most cell lines (Figure 5.21C). GPX1 protein expression was 
generally reduced in ccRCC cells compared to non-malignant HK-2 cells (Figure 
5.21C). This discrepancy might be due to the extensive post-transcriptional regulatory 
mechanisms that control GPX mRNA and protein levels (see section 5.1.2). 
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Figure 5.21: GPX, SOD and CAT expression is heterogeneous in ccRCC 
(A) Basal mRNA expression of indicated ROS detoxifying enzymes analysed via RT-qPCR of total 
mRNA samples. Bar graphs represent average of duplicate measurements normalised to respective ACTB 
levels ± SD and are displayed relative to HK-2 cells. Numbers above HK-2 bars represent mean ΔCT 
value for comparison. (B) Heat map summarising fold-change differences in mRNA abundance relative 
to HK-2 cells shown as bar graphs in (A). Numbers in HK-2 column represent average ΔCT value for 
comparison. UD, undetermined. (C) Whole cell lysates were subjected to SDS/PAGE and analysed for 
basal GPX1, SOD1 and SOD2 protein expression levels. β-actin serves as loading control. 
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5.12  GPX activity is reduced in ccRCC cell lines compared to 
HK-2 cells  
To assess total GPX activity across the cell line panel, an enzymatic assay that measures 
the ratio of GSH-dependent peroxidation of cumene hydroperoxide over time was used. 
This assay showed that GPX activity is substantially (approx. 4-fold) lower in the 12 
cancer cell lines compared to non-malignant HK-2 cells (Figure 5.22B).  
 
 
Figure 5.22: ccRCC cells have significantly less basal GPX activity than HK-2 cells 
(A) Schematic of working principle of the Abcam GPX activity assay. GPX uses reduced glutathione 
(GSH) as cosubstrate to neutralise Cumene hydroperoxide (H2O2). The generated oxidised glutathione 
(GSSG) is recycled to GSH by glutathione reductase (GSR) under consumption of NADPH. Hence, GPX 
and GSR activity are supposedly proportional to each other and the decrease in auto-fluorescence emitted 
by NADPH at OD = 340nm should be proportional to GPX activity. All components but GPX are 
provided in excess in the reaction mix. (B) Basal GPX activity as measured with the GPX activity assay 
explained in (A). Bars represent mean calculated converted NADPH in nM/min/ml normalised to 
complete protein content assayed of three independent experiments. Error bars represent SEM. Asterisks 
indicate statistically significant reduction in GPX activity in ccRCC compared to HK-2 cells (One-way 
Anova, ****, p ≤ 0.001); Pos. Ctr. = purified GPX protein. 
 
Irrespective of expression and basal activity of GPX proteins, the results so far indicated 
that depleting GPX1 or GPX3 causes oxidative stress and compromises cell viability in 
ccRCC cells. In contrast, depletion of individual GPX proteins in HK-2 cells may not 
substantially impact on total GPX activity in HK-2 cells, therefore explaining the fact 
that these cells can tolerate the silencing of GPX1 and GPX3.  
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5.13  ccRCCs show mixed sensitivity to different ROS stimuli 
and inducer 
With four times less GPX activity compared to the non-tumourigenic HK-2 cells, 
ccRCC cells should be more susceptible to oxidative stress. To assess this, the cell line 
panel was treated with increasing doses of H2O2, tert-Butyl hydroperoxide (tBuOOH, an 
organic peroxide), Pyocyanin, Rotenone or Antimycin A. Pyocyanin, a toxin produced 
and secreted by Pseudomonas aeruginosa, a pathogen involved in respiratory 
complications in cystic fibrosis, has strong redox activity and generates ROS (Hassan 
and Fridovich, 1980). In the cystic fibrosis lung, cytoplasmic pyocyanin reduces 
NADPH to NADP+ to convert molecular oxygen to superoxide radicals (O2) causing a 
double negative effect: a) generating highly reactive ROS and b) depletion of the 
NADPH pool necessary to reduce GSSG to GSH. Hence, the lung upregulates CAT and 
SODs to keep the increased ROS in check (Ran et al., 2003). Furthermore, pyocyanin 
negatively regulates CAT via both direct interaction and inhibition of gene transcription. 
Reduced catalase activity results in H2O2 accumulation, which has a negative impact on 
the glutathione pool as GSH gets depleted (Muller, 2002). Rotenone, a herbal ketonic 
compound, and Antimycin A, a secondary metabolite produced by Streptomyces, affect 
components of the mitochondrial ETC, indirectly leading to the generation of ROS. 
Rotenone inhibits electron transfer from complex I to ubiquinone (CoQ) causing an 
accumulation of electrons in the mitochondrial intermembrane space such that NADH 
cannot be reduced any more and molecular oxygen gets converted into highly reactive 
O2-. Antimycin A has similar effects but its target is complex III, where it binds to 
cytochrome c reductase, inhibits oxidation of ubiquinol and causes an electron 
accumulation and subsequent O2- generation.  
The rational behind stimulating O2- production is, to have a more constant endogenous 
source of H2O2 accumulation, as O2- is quickly converted to H2O2 by one of the SOD 
isoforms. Furthermore, this experiment was designed to delineate which source of ROS 
would be most detrimental for ccRCC cells. 
Surprisingly, ccRCC cells seemed to be less sensitive to external ROS assault compared 
to HK-2 cells (Figure 5.23). CAKI2 and TK10 cells seemed to be particularly resistant 
to hydrogen peroxide species challenge (Figure 5.23A, B). Pyocyanin treatment evoked 
Chapter 5: The glutathione redox system is essential for ccRCC cell survival 
 194 
a similar reaction pattern as do the two hydrogen peroxide species - although RCC4 and 
ACHN cells displayed higher sensitivity, while HK-2 cells were more tolerant to this 
ROS inducer compared to the hydrogen peroxides (Figure 5.23B). Rotenone seemed to 
be tolerated only by RCC4, A704 and TK10 cells, while HK-2 cells showed high 
sensitivity towards this compound (Figure 5.23D). Antimycin A had the most 
detrimental effect of all ROS inducers tested on HK-2 cell survival compared to ccRCC 
cells. RCC4, A704 and TK10 cells are more, ACHN cells are less sensitive to inhibition 
of complex III compared to inhibition of complex I (Figure 5.23E). This observation is 
also in accordance with the findings of the screen, where ablation of ND3 and ND6, two 
components of complex I, emerged as detrimental for ccRCC cell survival (Figure 4.16).  
Taken these results together, it seems that ccRCC cell lines can tolerate increased levels 
of cytoplasmic ROS (induced by treatment with H2O2, tBuOOH or Pyocyanin) 
relatively well; on average better than the non-transformed HK-2 cells. In contrast, 
counteracting endogenous O2- generation caused by inhibitors of respiratory complexes 
in the mitochondria is more problematic for all kidney epithelial cell lines tested, 
irrespective of their tumourigenic or non-tumourigenic status.  
The decreased sensitivity of ccRCC cells towards cytoplasmic oxidants could indicate 
increased activity of GPX proteins, as this type of ROS is generally neutralised by the 
GPX reaction. In contrast, detoxification of mitochondrial ROS requires the activity of 
CAT and SOD2, two enzymes for which no selective dependency between ccRCC and 
non-malignant cells was detected. 
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Figure 5.23: ccRCC cells are less sensitive to ROS/ O2- stress than HK-2 cells 
ccRCC cells were treated with increasing concentrations of (A) H2O2, (B) tert-Butyl hydroperoxide, (C) 
Pyocyanin, (D) Rotenone and (E) Antimycine A for 72 h. Dose response curves (respective left-hand 
panel) represent mean endpoint cell numbers of 3 independent experiments performed in triplicates 
± SEM and result from non-linear regression modelling in GraphPad Prism 6. Accuracy of curve fitting 
(respective R2-values) to determined endpoint cell numbers for each cell line is depicted in respective 
center-panneled tables. Bar graphs (respective right-hand panel) represent IC50 values for each ROS/O2- 
inducer that were extracted from the dose response curves.  
 
5.14  ccRCC cells have higher GSH:GSSG ratio compared to 
HK-2 cells 
Knowing that ccRCC cell lines have lower GPX activity than HK-2 cells but, at the 
same time, are less sensitive to peroxide species as well as O2--inducers, it was 
considered whether this phenomenon could be explained by variations in the 
glutathione pool as glutathione is a co-factor for GPX functionality. Therefore, basal 
glutathione levels were determined in all cell lines of the panel. Total amount of 
glutathione (GSH + GSSG) did not show major differences between the different cell 
lines (Figure 5.24A). The same was true for the amount of oxidised GSSG (Figure 
5.24B). However, GSH levels derived by subtraction of oxidised GSSG from total 
glutathione, showed a trend towards higher levels in most of the ccRCC cell lines as 
compared to HK-2 cells (Figure 5.24C). Comparison of the ratio of reduced GSH and 
oxidised GSSG revealed a trend towards in average higher GSH:GSSG ratios in ccRCC 
cells than in HK-2 cells (Figure 5.24D), despite considerable variation between 
different experiments. This difference could indeed explain the increased tolerance of 
cancer cells to the ROS inducers tested compared to non-malignant HK-2 cells (Figure 
5.23). As the amount of total glutathione (GSH + GSSG) was similar in both ccRCC 
and non-malignant cells, the increased GSH:GSSG ratio is indicative of lower levels of 
basal oxidative stress in cancer cells, which deplete the GSH pool. However, it is more 
likely that the processes that lead to the restoration of GSH could be more efficient in 
the cancer cells, resulting in higher GSH levels and increased resistance to oxidative 
insults. 
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Figure 5.24: ccRCC cells have higher GSH levels and higher GSH:GSSG ratio as HK-2 
cells 
(A) Total glutathione (GSH + GSSG) and (B) oxidised glutathione (GSSG) were determined using a 
glutathione fluorometric assay kit (Biovision). (C) GSH levels were determined through subtraction of 
measured GSSG from measured total glutathione (GSSG + GSH). In each of the three independent 
experiments, the determined values were divided by the average value of all cell lines in order to being 
able to cross-compare between experiments. Error bars indicate ± SEM. (D) Calculated GSH:GSSG ratio 
from values determined in (A) and (B). Bar graphs represent average of ratios formed in each of the 3 
individual experiments ± SEM. Asterisks indicate significant difference of respective ccRCC cell line 
compared to HK-2 cells in total glutathione, GSSG, GSH and GSH:GSSG (2-way ANOVA analysis with 
Dunnett multiple comparison testing.. *,p ≤ 0.05). 
 
For the maintenance of an active glutathione pool, oxidised GSSG can be recycled to 
reduced GSH. This reaction is accomplished by glutathione reductase (GSR) under 
consumption of NADPH. One cytosolic source of NADPH is the oxidative arm of the 
PPP (Figure 1.4 and 5.3). Hence, mRNA expression levels for GSR and G6PD, one of 
the two NADPH producing enzymes of the PPP, were examined. Indeed, HK-2 cells 
showed comparatively high levels of GSR mRNA, which is exeded only in UMRC2, 
769-P and CAKI2 cells. G6PD mRNA expression was more variable in the cell line 
panel and did not reveal an obvious trend (Figure 5.25A). 
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Importantly, depletion of GSR or G6PD in ccRCC cell lines severely diminished their 
survival (Figure 5.25B). Indeed, most ccRCC cell lines showed more than 50% 
reduction in cell number following depletion of GSR or G6PD. In contrast, HK-2 cells 
were hardly impacted by silencing of these enzymes. This result indicated that the 
glutathione recycling system in the cancer cells could be more vulnerable to 
perturbations than that of HK-2 cells.  
 
 
Figure 5.25: ccRCC cells have a less efficient GSH recycling system than HK-2 cells 
(A) Total mRNA was extracted from untreated cells and analysed via RT-qPCR for glutathione reductase 
(GSR) and glucose-6-phosphate dehydrogenase (G6PD) expression levels. Bar graphs represent average 
of duplicate measurements normalised to respective ACTB levels ± SD and are displayed relative to HK-
2 cells. Numbers above HK-2 bars represent average ΔCT values for comparison. (B) ccRCC and HK-2 
cells were reverse transfected with 37.5 nM siRNA against GSR or G6PD for 96 h in a 96-well format. 
Bar graphs represent average endpoint cell numbers normalised to RISC-free (RF) of 3 individual 
experiments performed in triplicates ± SEM. Asterisks indicate statistically significant cell number 
reduction in the respective ccRCC cell line compared to HK-2 cells (2-way ANOVA analysis with 
Dunnett multiple comparison testing; *, p ≤ 0.05). 
 
Unfortunately, due to time restrictions, complementary evaluation of the cellular 
NADP+/NADPH pool to fully elucidate the reductive potential of ccRCC cells relative 
to HK-2 cells could not be carried out yet, but is an imminent future objective. 
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5.15  Perturbation of the active GSH pool is not tolerated by 
ccRCC cells and causes ROS accumulation 
As mentioned in more detail in the introduction, GSH is a tripeptide composed of three 
amino acids, glutamate, cysteine and glycine and it is generated in a two-step process 
mediated firstly by the GCLC/GCLM complex and then by GSS (Figure 5.3). 
Glutamate is generated by GLS from L-glutamine, a nutrient contained in food. During 
the cell characterisation process, it was established that ccRCC cells are highly sensitive 
to glutamine deprivation (Figure 3.11). Hence, it was considered that glutamine 
addiction could be linked to GSH production in ccRCC cells. 
Knockdown of GLS, GSS or GSR in a selection of ccRCC cell lines and HK-2 cells 
was performed and cell proliferation was monitored using an IncuCyte live cell imaging 
system. Contrary to HK-2 cells, all of the ccRCC cell lines tested showed reduced 
proliferation rates with significant endpoint cell number loss following ablation of GLS, 
GSS or GSR compared to control silencing. Loss of GSS had the strongest negative 
effect on ccRCC proliferation and overlapped in most cases with the dependency on 
GPX1, confirming the importance of glutathione for a functional GPX pathway in 
ccRCC cells. Furthermore, UMRC2, UMRC3 and ACHN cells were particularly 
sensitive to GLS ablation, suggesting a strong dependency on glutamate in these cells 
(Figure 5.26). 
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Figure 5.26: RNAi-mediated ablation of components of GSH biosynthesis and its 
recycling system negatively affect ccRCC proliferation 
Indicated cell lines were reverse transfected with 37.5 nM siRNA targeting GPX1, glutathione reductase 
(GSR), glutathione synthetase (GSS) and glutaminase (GLS) in a 96-well format and cell proliferation 
was monitored using an IncuCyte live cell imaging system. siUBB (ubiquitin B) served as positive, 
siOTP as negative control. Respective left-hand growth curve graphs represent mean confluence values 
from triplicate wells ± SD recorded every 2 h for 120 h in total. Respective left-hand bar graphs represent 
average endpoint cell numbers normalised to RISC-free (RF) of the triplicate wells ± SD 120h post 
transfection. Asterisks indicate significant cell number loss upon ablation of GLS, GSS, GSR or GPX 
compared to scrambled silencing (2-way ANOVA analysis with Dunnett multiple comparison testing; 
****, p ≤ 0.001; ns, not significant). 
 
Knockdown of GLS and GSS in the whole cell line panel confirmed the cancer-specific 
negative effect on cell number and, although not significantly, GCLC ablation also 
showed a trend towards preferential cell number loss in ccRCC compared to HK-2 cells 
(Figure 5.27A).  
Next, the cell line panel was treated with the GLS inhibitor BPTES and the GCLC 
inhibitor BSO to see if chemical inhibition would have a similar phenotype as RNAi-
mediated ablation of these genes. Dose response curves and extracted IC50 values 
pointed to higher sensitivity towards BPTES for ccRCC cells compared to HK-2 cells 
(Figure 5.27B). Furthermore, apart from UMRC3, A704 and ACHN cells, the profile of 
the IC50 values matched the sensitivity of the cells towards GLS silencing (Figure 
5.27A-B), confirming that cancer cells are indeed addicted to glutamate. BSO on the 
other hand, was less effective with IC50 values well above 100µM for the majority of 
the cell lines including HK-2 cells (Figure 5.27C). Also, a discrepancy between 
extracted IC50 values and GCLC RNAi results could be observed for the respective cell 
lines (Figure 5.27A, C). 
Comparison of GLS, GCLC and GSS mRNA levels showed that there is a tendency of 
ccRCC cells expressing in average higher levels of GLS and lower levesl of GSS 
compared to HK-2 cells, possibly explaining the increased sensitivity of ccRCC cells 
towards GLS and GSS ablation/inhibition. GCLC expression on the other hand was 
highly variable across the cell line panel (Figure 5.27E). However, at least in UMRC2, 
A498 and CAKI2 cells, high GCLC mRNA levels correlated with reduced BSO 
sensitivity. In contrast, RCC4, 786-O and UMRC3 cells, which expressed low GCLC 
mRNA levels, appeared to be more sensitive to BSO treatment (Figure 5.27C-E). 
 
Chapter 5: The glutathione redox system is essential for ccRCC cell survival 
 202 
 
Figure 5.27: Ablation or inhibition of enzymes involved in GSH biosynthesis decreases 
ccRCC survival 
(A) ccRCC cells were reverse transfected with 36.5 nM siRNA targeting glutathione synthetase (GSS), 
the catalytic subunit of glutamate-cysteine ligase (GCLC) and glutaminase (GLS) for 96 h in a 96-well 
format. Bar graphs represent mean endpoint cell numbers normalised to RISC-free (RF) of 3 independent 
experiments performed in triplicates ± SEM. Asterisks indicate statistically significant cell number loss 
upon GLS, GCLC or GSS ablation for the respective ccRCC cell line compared to HK-2 cells (2-way 
ANOVA analysis with Dunnett multiple comparison testig; *, p ≤ 0.05). (B-C) ccRCC cell were treated 
for 72 h with increasing doses of (B) the GLS inhibitor BPTES or (C) the GCLC inhibitor BSO. Drug 
response curves (left-hand panel) represent mean endpoint cell numbers of 3 independent experiments 
performed in triplicates ± SEM and result from non-linear regression modelling in GraphPad Prism 6. Bar 
graphs (right-hand panel) represent IC50 values extracted from the dose response curves. UD, 
undetermined, i.e. 50% cell number reduction was not reached. (D) Table depicting R2 values for the 
respective cell lines and drugs, which are indicative of goodness of fit of dose response curves to 
measured endpoint cell numbers. (E) Basal GLS, GCLC and GSS mRNA levels determined from total 
mRNA extraction by RT-qPCR, normalised to ACTB and displayed relative to HK-2 cells. Bars represent 
average of duplicate measurements ± SD. Numbers above HK-2 bars indicate average ΔCT value for 
comparison. 
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Taken together, these data provide evidence that ccRCC cells rely on GSH production 
and maintenance for cell survival. Furthermore, they reiterate glutamate being an 
essential metabolite for these cancer cells but not so much for HK-2 cells. 
 
To see if perturbation of GSH production phenocopied GPX1 and GPX3 ablation by 
slowing down the cell cycle, RCC4 and HK-2 cells were treated with increasing BSO 
concentrations. 48h BSO treatment resulted in distressed cells expressing increased p21 
and p53 protein levels (Figure 5.28). Furthermore, cyclin A, cyclin D1, p27, cdk2 and 
cdk6 protein expression was elevated compared to vehicle control, indeed indicative of 
cell cycle arrest. A similar expression pattern could be observed upon silencing of 
GPX1 and GPX3 (Figure 5.13). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.28: BSO phenocopies the 
cell cycle arrest phenotype caused by 
GPX1/GPX3 depletion 
RCC4 EV, RCC4 and HK-2 cells were 
treated with increasing 50 µM and 100 µM 
BSO for 72 h; DMSO served as vehicle 
control (0 µM). Whole cell lysates were 
subjected to SDS/PAGE and analysed for 
expression of the indicated cell cycle 
regulators. β-actin serves as loading control. 
 
 
 
Next, ROS levels were measured in RCC4 and HK-2 cells after BSO and BPTES 
treatment or after glutamine withdrawal to see if the cell cycle arrest phenotype 
correlates with ROS accumulation. A tendency towards increased ROS/O2- levels 
following BPTES treatment or glutamine withdrawl could be observed in RCC4 cells 
(Figure 5.29). However, in both cases, statistical significance was not reached due to 
high variability of the data. BSO treatment had no obvious effect on ROS but slightly 
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reduced O2- levels in RCC4 cells. Interestingly, both ROS and O2- induction following 
BPTES treatment could be rescued by NAC supplementation in RCC4 cells (Figure 
5.29). Surprisingly, BSO caused substantial ROS accumulation in HK-2 cells, which 
could not be attenuated by NAC treatment. Although BPTES treatment alone did not 
alter ROS levels too much in HK-2 cells, in combination with NAC, however, a 2-fold 
increase in ROS levels could be observed. This ROS increase might be due to reductive 
stress - an assumption that needs further investigation.  
 
 
Figure 5.29: Inhibition of GSH production causes ROS accumulation in RCC4 and HK-2 
cells 
RCC4 and HK-2 cells were treated for 72 h with 100 µM BSO or 10 µM BPTES including 1 mM NAC 
(where applicable). Cellular ROS and O2- accumulation was measured via FACS. Treatment with 200 µM 
Antimycine A/Pyocyanin served as positive control. Bars represent mean cellular ROS/O2- intensities 
normalised to the respective untreated control of three independent experiments ± SEM. A 2-way 
ANOVA analysis with Dunnett multiple comparison testing was performed to check for statistically 
significant accumulation of ROS/O2- following BSO or BPTES treatment compared to untreated or 
ROS/O2- attenuation upon NAC addition. RFU, relative fluorescent units. 
 
5.16  Glutamine and cysteine are essential nutrients for ccRCC 
Ablation or inhibition of enzymes involved in GSH biosynthesis or recycling resulted in 
severe cell number loss in ccRCC cell lines compared to HK-2 cells. To see whether 
restriction of replenishment of GSH components has a similar effect on ccRCC cell 
proliferation, perturbation of glutamine and cystine uptake was examined. Glutamine 
and cystine uptake is facilitated by SLC1A5 and SLC7A9, respectively. Moreover, the 
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SLC7A11 antiporter shuttles extracellular cystine in exchange for intracellular 
glutamate. 
Comparison of mRNA levels for these transporters revealed that ccRCC cells expressed 
on average lower levels of SLC1A5 mRNA, but higher levels of SLC7A11 and 
SLC7A9 mRNA compared to HK-2 cells. SLC7A9 is particularly highly upregulated in 
these cancer cell lines (Figure 5.30A). Knockdown of SLC1A5 and SLC7A11 resulted 
in significant cell number loss of ≥50% in most ccRCC cell lines, while HK-2 cells 
were only majourly affected by SLC7A11 (Figure 5.30B). Silencing of SLC7A9 caused 
a mixed result: about half the cancer cell lines showed a tendency towards increased cell 
number loss compared to HK-2 cells, while the other half remained relatively 
unaffected (Figure 5.30B).  
 
 
Figure 5.30: Ablation of glutamine or cystine transporters is detrimental to ccRCC cells  
(A) Basal mRNA levels for SLC1A5 (glutamine transporter), SLC7A9 (cystine transporter) and 
SLC7A11 (glutamate/cysteine antiporter) determined via RT-qPCR and normalised to respective ACTB 
levels. Bars represent average of duplicate measurements ± SD and are displayed relative to HK-2 cells. 
Numbers above HK-2 bars indicate average ΔCT value for comparison. (B) ccRCC and HK-2 cells were 
reverse transfected for 96 h with 37.5 nM siRNA targeting SLC1A5, SLC7A9 and SLC7A11 in a 96-well 
format. Bar graphs represent average endpoint cell number normalised to RISC-free (RF) of 3 
independent experiments performed in triplicates ± SEM. Asterisks indicate statistically significant cell 
number loss in the respective ccRCC cell line compared to HK-2 cells resulting from SLC1A5, SLC7A9 
or SLC7A11 knockdown (2-way ANOVA analysis with Dunnett multiple comparison testing; *, 
p ≤ 0.05). 
 
These results confirmed the previous observation that glutamate is a limiting factor for 
ccRCC cell proliferation. In addition, transporter-mediated uptake of cystine was also 
revealed as an essential process for both cancer and non-cancer cells.  
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In addition to its function as a precursor for GSH synthesis, glutamine can also be 
converted to α-KG and shuttled into the TCA cycle, thereby contributing to 
mitochondrial NADH and ATP synthesis, a process termed anaplerosis (Kovacevic and 
McGivan, 1983). Glutamate-derived α-KG can also contribute to lipid synthesis through 
reductive carboxylation (Figure 1.4) (Holleran et al., 1995, Metallo et al., 2012, Mullen 
et al., 2012). In an attempt to delineate whether in ccRCC cells glutamine is 
preferentially used for energy production or GSH synthesis, RCC4, 786-O, CAKI1 and 
HK-2 cells were starved off glutamine or treated with BPTES and supplemented with 
increasing amounts of GSH, L-cysteine, NAC and α-KG. Rescue of cell number loss 
with one or more of the antioxidants would suggest a preferred shuttling of glutamine 
into the GSH biosynthesis pathway, while rescue with α-KG would indicate that 
glutamine is mainly used to supplement the TCA cycle. Figure 5.31 illustrates the dose 
response curves for the respective treatments.  
Supplementation of glutamine-deprived cells with increasing amouts of either GSH or 
NAC resulted in an upward trend with regard to cell proliferation in both cancer and 
HK-2 cells, although statistical significance could not be reached for the cancer cells 
due to high variability. Interestingly, HK-2 cells grown in glutamine-deprived DMEM 
displayed the strongest positive effect upon GSH and NAC addition. Supplementation 
with increasing doses of L-cysteine or α-KG on the other hand did not affect the cell 
number loss phenotype much in any of the four cell lines (Figure 5.31A).  
In contrast, addition of GSH and NAC to all BPTES treated cells improved cell survival 
significantly (almost) in a dose dependent manner. Except for RCC4 cells, low 
concentrations of L-cysteine increased proliferation, while higher concentrations of L-
cysteine were detrimental to 786-O, CAKI1 and HK-2 cells in the presence of 7.5 µM 
BPTES. Interestingly, all four cell lines responded similarly positive to α-KG 
supplementation independent of increasing doses (Figure 5.31B). 
These results suggest that in ccRCC and HK-2 cells a fair amount of glutamine is 
needed for antioxidant purposes and point to the possibility of shunting a majour part of 
the generated glutamate into GSH production for antioxidant supply and only to a lower 
extend into the TCA cycle for energy production. However, a more extended 
examination, for example by using isotopomer flux analysis of stable isotope labelled 
glutamine, will be necessary to confirm this hypothesis.  
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Figure 5.31: BPTES-induced cell number loss can be partially rescued by antioxidants 
and α-KG 
(A) RCC4, 786-O, CAKI1 and HK-2 cells were treated for 72 h with increasing concentrations of GSH, 
L-cysteine, NAC and α-KG in glutamine-depleted growth medium. Curves represent average cell 
numbers normalised to untreated standard growth medium of 3 independent experiments performed in 
triplicates ± SEM. (B) RCC4, 786-O, CAKI1 and HK-2 cells were treated as in (A) in full growth 
medium supplemented with 7.5 µM BPTES. Curves represent average cell number of triplicate wells 
normalised to vehicle treated cells ± SD. Asterisks indicate statistically significant change in cell number 
upont GSH, L-cysteine, NAC or α-KG treatment compared to vehicle treatment for the respective cell 
line (2-way ANOVA analysis with Dunnett multiple comparison testing; *, p ≤ 0.05). 
 
5.17  Deregulation of GPX1, GLS, GCL, GSR, SLC1A5 and 
SLC7A9 correlates with clinical parameters in ccRCC  
In order to examine whether expression of GPXs or enzymes involved in GSH 
biosynthesis are deregulated in clinical samples of human ccRCC, mRNA levels of 
these genes were examined in a public gene expression dataset. In 2013, a 
comprehensive study on ccRCC was published by The Cancer Genome Atlas (TCGA) 
consortium, which summarised DNA copy number, RNA and protein expression data 
from almost 450 individual ccRCC patient samples. This data set was used to decipher 
potential connections between the processes identified in this study and clinical 
parameters in renal cancer. Initial analysis of DNA copy number data revealed a 
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significant copy number loss for GPX1 and a copy number gain for GPX3 in ccRCC 
samples compared to samples of unaffected kidney tissue (Figure 5.32). 
 
 
 
Figure 5.32: ccRCCs show DNA 
copy number loss for GPX1 and 
gain for GPX3 compared to 
normal adjacent tissue 
Box plots summarise DNA copy 
number data ± range for GPX1 and 
GPX3 extracted from the Oncomine 
TCGA renal2 dataset (Cancer Genome 
Atlas Research, 2013). 
 
 
 
Next, a detailed analysis of the RNA sequencing data provided within the TCGA 
dataset was performed by Richard Mitter from the LRI Bioinformatics and Biostatistics 
Service (BABS). Kaplan-Meier Plots were generated that correlate patient survival with 
low, medium and high expression of GPX1, GPX3, SOD1, GLS, GCLC, GCLM, GSS, 
GSR, G6PD, SLC1A5, SLC7A9 and SLC7A11 mRNA, respectively (Figure 5.33). 
Interestingly, poor survival correlates with high mRNA expression levels of GPX1 and 
SLC1A5 but with low mRNA levels of GLS, GCLC, GCLM, GSR and SLC7A9.. 
 
Additional analysis of protein expression of the different enzymes by 
immunohistochemistry or measurement of in situ GPX activity complemented with 
GSH and NADPH levels will be needed to establish the exact activation state of this 
pathway in ccRCC tissue. 
 
Chapter 5: The glutathione redox system is essential for ccRCC cell survival 
 209 
 
Figure 5.33: Deregulation of GPX1, GLS, GCL, GSR, SLC1A5 and SLC7A9 correlate with 
patient survival 
(A-D) Analysis of RNA sequencing data from ccRCC patient samples (n = 419) published by The Cancer 
Genome Atlas Research Network (Cancer Genome Atlas Research, 2013) to identify associations of 
expression levels with poor survival. Kaplan-Meier survival curves for the indicated genes were 
produced. For each gene, the associated expression scores across all patients were split into tertiles 
representing high (red), medium (grey) and low (blue) expression. p-values/q-values represent the 
significance of difference between the three curves. Highlighted in bold are genes where mRNA 
expression levels correlate statistically significant with survival. (A) ROS detoxifying enzymes, (B) GSH 
biosynthesis enzymes, (C) enzymes involved in GSH recycling and (D) glutamine and cystine 
transporters. 
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5.18  Discussion 
The aim of this study was to identify genes associated with metabolic functions, 
including enzymes, nutrient transporters and metabolic regulators that are essential for 
proliferation and survival of ccRCC cells. RNAi-mediated gene silencing in a panel of 
12 ccRCC cell lines revealed that depletion of members of the GPX family, in particular 
GPX1 and GPX3, resulted in reduced cell proliferation. Moreover, depletion of the 
cytoplasmic SOD1, which also contributes to the detoxification of cytoplasmic ROS, 
but not the mitochondrial SOD2 isoform negatively influenced cell proliferation. 
Importantly, it was found that this effect was independent of pVHL status of the cells 
but was specific to cancer cells, as the non-transformed kidney epithelial cell line HK-2 
was not affected by ablation of these genes (Figure 5.8). The observed loss in cell 
number was not due to induction of apoptosis, as no apoptotic markers could be 
detected (Figure 5.10 and 5.11). Instead, loss of cell number is more likely to be caused 
by inhibited cell cycle progression leading to a G1 cell cycle arrest (Figure 5.12 and 
5.13). A likely cause for the G1 cell cycle arrest upon GPX1, GPX3 and SOD1 ablation 
is ROS-induced DNA damage, as both, a moderate increase in ROS levels and focal 
accumulation of the DDR proteins γH2.AX and 53BP1 were observed in RCC4 cells 
but not in HK-2 cells following GPX1 or GPX3 ablation (Figure 5.14, 5.17 and 5.18). 
Further evidence is required to substantiate these findings, for example confirmation of 
ROS-induced DNA damage could be provided by the detection of increased levels of 
7,8-dihydro-8-oxo-2'-deoxyguanosine (8-oxo-dG), a biomarker of oxidative DNA 
damage (Mangal et al., Valavanidis et al., 2009). 
Initial analysis of the cell line panel for mRNA expression of several components of the 
antioxidant system (GPX1-8, SOD1/2, CAT, NRF2) revealed an overall heterogeneous 
expression pattern (Figure 5.21). This could be due to the heterogeneity of the ccRCC 
cell line panel and the disease itself. However, no correlation of expression with 
sensitivity towards RNAi targeting different antioxidant enzymes or the response to 
exogenous ROS-insults (i.e. treatment with H2O2, tert-Butyl, Rotenone, AntimycinA or 
Pyocyanin) could be observed (Figure 5.23). This could be due to compensatory 
mechanisms carried out by other antioxidant enzymes not investigated in this study, 
such as components of the PRX or TRX system. Furthermore, it was found that, 
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especially with regard to GPX1, mRNA levels in ccRCC cells did not correlate with 
protein expression (Figure 5.21). However, the GPX activity analysis clearly showed 
that ccRCC cells were severely restricted in their GPX activity compared to the non-
tumourigenic HK-2 cells, when measured using an enzymatic assay (Figure 5.22). In 
contrast, ccRCC cells were found to have higher levels of GSH than HK-2 cells (Figure 
5.24), which could provide reducing capacity not only for the GPX reaction but also for 
other GSH-dependent antioxidant enzymes. Moreover, GSH on its own with its thiol 
group is already a potent antioxidant and can contribute to the antioxidant activity in 
ccRCC cells. The vital role of GSH in ccRCC homeostasis was revealed by the finding 
that perturbation of the GSH biosynthesis pathway was detrimental to most ccRCC cell 
lines, while proliferation of HK-2 cells was unaffected (Figure 5.26 and 5.27). The most 
severe effect on ccRCC cell viability was seen upon disruption of glutamate and 
cysteine supply. In particular, ablation of the glutamine transporter SLC1A5 or the 
glutamate/cystine antiporter SLC7A11 diminished ccRCC cell proliferation. However, 
the effect of silencing of SLC7A11 was not cancer specific, as HK-2 cells were affected 
to the same extent as the ccRCC cell lines (Figure 5.30). This suggests that SLC7A11 
could be essential for kidney epithelial function in general. In fact, the kidney shows 
high expression of SLC7A11 as this antiporter is needed for the maintenance of acid-
base balance. In the ccRCC cell line panel used here, SLC7A11 was highly expressed in 
about half of the cell lines, with these lines showing higher expression levels compared 
to HK-2 cells (Figure 5.30). Cell number loss upon ablation of GLS and GSS was not 
due to apoptosis but due to decreased cell proliferation (Figure 5.26), indicating that 
perturbation of GSH synthesis is growth inhibitory rather than cytotoxic, at least under 
the experimental conditions used. It would be interesting to see if this growth arrest is 
only transient or will eventually lead to cell death or senescence in longer term assays. 
 
It seems that most of the ccRCC cell lines might also have a compromised GSH 
recycling system, as all but UMRC2, A498, 769-P and CAKI2 cells express lower 
levels of GSR and G6PD mRNA compared to the non-tumourigenic HK-2 cells (Figure 
5.25). Interestingly, ablation of GSR or G6PD resulted in reduced proliferation to 
similar extent in all ccRCC cell lines, independent of mRNA expression levels, while 
HK-2 cells were unaffected (Figure 5.25). One explanation for the detrimental effect of 
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GSR and G6PD depletion might be that the GSH recycling system is in constant 
demand in ccRCC cells, potentially due to increased ROS production. If this limited 
recycling capacity is further reduced by gene silencing it cannot provide sufficient ROS 
detoxification, resulting in compromised proliferation. It is possible that increased 
levels of GSH and the strong dependency on components of the GSH biosynthesis 
pathway provide an alternative for ccRCC cells to circumvent an impaired GSH 
recycling capacity. However, changes in the levels of GSH and GSSG as well as 
alterations in the rate of NADPH synthesis upon GSR, G6PD or GSS silencing would 
need to be determined to confirm this hypothesis. 
 
The study of cellular ROS is challenging due to the lack of tools to accurately measure 
not only distinct/specific ROS species but also their temporal and spatial distribution. 
To compound matters further, ROS are highly dynamic in their formation and 
distribution. Furthermore, the cellular system is highly buffered not only with regard to 
pH but also with regard to redox potential. Using ROS reagents based on electron 
interference, poses the risk of unspecific reactivity, while subtle but biologically 
potentially highly relevant changes in the nM range might be beyond the detection limit. 
The H2DCFDA ROS probe, for example, can react with a wide range of ROS species 
and has low substrate affinity, making it easily reducible, which accounts for 
accumulative probe enrichment. However, as the importance of ROS in cellular 
homeostasis and disease development is becoming more appreciated, novel ROS 
reporters are being developed. There are now probes available that are species-specific 
and allow the simultaneous tracing of more than one ROS species at a time. Moreover, 
probes that locate to different organelles allow the detection of spatially separated ROS 
(Woolley et al., 2013). These tools could be used for a more detailed study of ROS 
accumulated upon GPX1, GPX3 or SOD1 ablation. Moreover, the effect of ROS on 
different macromolecules such as proteins, DNA and lipids, could be established. 
Finally, it would be interesting to see whether ROS accumulate only within the 
cytoplasm or in specific organelles.  
 
It is also important to consider that oxidative stress can alter the expression and activity 
of different components of the antioxidant system. To better understand the full impact 
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of ROS on the antioxidant system in ccRCC cells, protein and activity levels would 
need to be evaluated upon external ROS assaults using diverse agents (e.g. H2O2, 
Rotenone, Antimycin A, Paraquat). For comparison of basal response with antioxidant-
perturbed response, this should be also done following GPX1, GPX3 and SOD1 
ablation. Moreover, the effect of GSH depletion using chemical agents such as PEITEC, 
BITC or Imexon should be investigated. These analyses could give valuable insights 
into potential novel drug regimens, i.e. the combinatorial delivery of a ROS-inducing 
agent (i.e. chemotherapy) with simultaneous or time-delayed delivery of an antioxidant-
depleting compound to achieve synergistic effects.  
 
The findings from this study also suggest that increased antioxidant intake, for example 
in the form of dietary supplements, could provide a growth advantage to cancer cells. 
Indeed, studies exploring the benefits of antioxidant intake for both cancer prevention 
and cancer treatment have so far provided controversial results. The first large-scale 
randomized Linxian General Population Nutrition Intervention Trial investigated 
potential beneficial effects of daily intake of an antioxidant mix (β-carotene, α-
tocopherol and selenium) for 5 years for prevention of gastrointestinal cancer in 
Chinese men and women at risk. Although initial results were promising in that 
antioxidant supplementation reduced the mortality rates of gastric but not oesophageal 
cancer, without lowering the risk of either, though. In the final results, however, 
published 10 years after supplementation ended, the beneficial effect of antioxidants on 
mortality risk was no longer visible (Blot et al., 1995, Qiao et al., 2009). The Selenium 
and Vitamine E Cancer Prevention Trial (SELECT), which investigated potential 
beneficial effects of dietary supplementation with selenium, vitamin E or the 
combination on prostate cancer risk, was stopped ~ 5 years earlier than planned as 
antioxidant supplementation did not reduce cancer risk. An updated report after 7 years 
(5.5 years ‘on’ plus 1.5 years ‘off’ supplementation) even showed a 17 % increase in 
prostate cancer incidents following vitamin E supplementation as compared to the 
control group. Selenium supplementation on its own and the combination of both 
vitamins did not have any effect (Klein, 2009, Lippman et al., 2009). These and similar 
results reiterate that the presumption that ROS are disease promoting and have to be 
prevented is not necessarily true. It also highlights that ROS regulation is far more 
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complicated and caution has to be applied when considering it as anti-cancer treatment 
(Lau and Chiu, 2009).  
 
Importantly, while all experiments indicating a role for GPX proteins and the GSH 
biosynthesis pathway were performed using in vitro systems, analysis of copy number 
and mRNA expression from human tissue suggests clinical relevance of the findings. 
High levels of GPX1, SOD1 and SLC1A5 mRNA or low levels of GLS, GCLC, GCLM, 
GSR and SLC7A9 mRNA are associated with poorer overall survival of patients 
harbouring ccRCC. However, these findings should be substantiated by the analysis of 
protein levels using immunohistochemistry or in situ enzymatic activity in ccRCC 
tissue samples. 
 
Overall, it can be concluded that the GPX system and the processes involved in the 
synthesis and restoration of GSH are highly relevant for the proliferation of ccRCC 
cells and could represent interesting targets for the development of novel therapeutic 
strategies, especially as they seem to be cancer specific.  
 
 
 
 
 
 
 
 
 
Figure 5.34: Proposed model 
HK-2 cells showed high GPX activity and perturbation of neither GSH biosynthesis or recycling, nor 
GPX ablation had a major effect on their cell proliferation. In contrast, despite slightly higher GSH levels 
seen in most ccRCC cell lines tested, ablation of GPXs, especially GPX1 and GPX3, as well as 
perturbation of GSH biosynthesis and recycling had severe negative effects on ccRCC cell proliferation.  
The following assumption could offer a plausible explanation for the observations described in this 
chapter: In basal conditions, ccRCC cells already seem to work on the edge of their GSH-dependent 
antioxidant capacity and any perturbation that interferes with the highly optimised redox system drives 
these cancer cells over the edge causing e.g. unhealthy ROS accumulation accompanied by loss of 
proliferation. In contrast, HK-2 cells seem to have a relatively stable GSH-dependent antioxidant buffer 
capacity with enough leeway to allow for coping with exogenous perturbations before being 
overburdened and crashing. 
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The study presented here gives a more detailed insight into clear cell renal cell 
carcinoma (ccRCC) biology, especially with regard to the metabolic aspect. A panel of 
12 ccRCC cell lines was examined for commonalities and differences with regard to 
their metabolic requirements and dependencies. Furthermore, a non-tumourigenic renal 
epithelial cell line, HK-2, was incorporated into the analysis to reveal cancer specific 
traits from common kidney physiology.  
It could be shown, that ccRCC cells present a good example of the Warburg Effect, as 
these cancer cells showed characteristically high glycolytic activity, despite the 
presence of ample oxygen. This behaviour is mainly triggered by the constitutive 
activity of HIF due to functional loss of its negative regulator pVHL. Loss of functional 
pVHL is the central characteristic of ccRCC disease. HIF-dependency on the glycolytic 
phenotype was confirmed by the observation that reconstitution of functional pVHL 
expression was efficient in repressing HIF-α accumulation (Figure 3.3) and sufficient in 
decreasing glycolytic activity and increasing respiratory capacity as shown by decreased 
ECAR and increased OCR, respectively (Figure 3.6 and Figure 3.7). Furthermore, it 
was revealed that ccRCC cells are fairly stress-resistant with regards to metabolic 
perturbations. Oxygen deprivation (Figure 3.5), serum starvation (Figure 3.12) and lipid 
depletion (Figure 3.14) for several days compromised ccRCC cell proliferation only 
moderately, if at all, suggesting that this cancer type developed a highly dynamic 
metabolic network that allows quick adaptation to changes in nutrient availability. 
Having said that, there are two exceptions to the rule: glutamine and glucose withdrawal 
had severe negative effects on ccRCC cell proliferation (Figure 3.11). Glucose fuels the 
glycolytic pathway, which can serve as both, ATP/energy production or supply of 
precursors for anabolic pathways, such as the generation of nucleotides, phosphatidic 
acids or the biosynthesis of serine. Indeed, we established that ccRCC cells display high 
proliferation rates, which require high amounts of nucleotides for DNA replication. 
Glucose withdrawal could decrease nucleotide production to a critical level resulting in 
inhibition of proliferation. Glutamine is the most abundant amino acid, which can 
provide precursors for several anabolic pathways. Although Glutamine is a non-
essential amino acid, i.e. can be synthesised by the cell, it has been established as an 
essential nutrient supplement for cancer cells as glutamine withdrawal from the medium 
severely compromises cell proliferation (De Berardinis et al., 2010). c-MYC-driven 
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tumours, including ccRCC, were found to be particularly sensitive to impaired 
glutamine supply (Fuchs and Bode, 2006, Garcia-Cao et al., 2012). However, the exact 
mechanism of how glutamine supports cancer cell survival and proliferation, i.e. 
whether it is its contribution to ATP/energy production via anaplerosis, its shunt into 
lipogenesis via reductive decarboxylation or its input to glutathione biosynthesis and 
redox homeostasis is not yet determined and provides room for investigation. 
 
In an attempt to delineate the ccRCC-specific dependencies in the core glucose, amino 
acid and fatty acid metabolism and to identify associated metabolic vulnerabilities, a 
functional genomics approach was undertaken. Therefore, five ccRCC cell lines, 
including counterparts with reconstituted pVHL expression, were subjected to a 
functional siRNA screen targeting 240 genes that encode metabolic enzymes, regulators 
and nutrient transporters. This approach aimed at identifying not only general ccRCC 
metabolic vulnerabilities but also potential VHL-synthetic lethality. Furthermore, as the 
five isogenic cell lines that were chosen for the screen differ in their HIF-α isoform 
expression, putative correlations between metabolic essentialities and HIF-α isoform 
expression could also be elucidated. 
Intriguingly, although we identified few cell line-specific VHL-synthetic lethal genes, 
none of the genes tested showed a strong, consistent cell number loss in all five cell 
lines upon silencing. Initially, this finding was puzzling, because it did not fit in with 
the assumptions that were made when planning the screen. Apart from functional pVHL 
loss, a prominent Warburgian metabolism is the other common feature in ccRCC. 
Hence, these two features could be expected, at some level, to influence each other. 
Several reasons could explain the lack of positive VHL-synthetic lethal genes. The 
screen only analysed 240 genes and it could be possible that the library did not contain 
the relevant VHL-synthetic lethal genes. Similarly, the readout used for this screen may 
have biased the results. Loss of cell number is a rather crude, though most definite 
readout, which, when exchanged by comparative analysis of more refined features such 
as changes in migration or redox-flux might have yielded more promising differential 
hits. 
Recently, there is accumulating evidence for ccRCC to be a genetically highly instable 
disease. In addition to fractional LOH on chromosome 3p, fractional LOH of 
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chromosome 14q and gain of chromosome 5q as well as focal gene losses and gains 
across the genome were identified implicating substantial intertumour heterogeneity 
(Zbar et al., 1987, Presti et al., 1991b, Semenza, 2003, Shen et al., 2011, Cancer 
Genome Atlas Research, 2013, Sato et al., 2013). Indeed, although the ccRCC cell lines 
share some commonalities such as high glycolytic flux and growth inhibition upon 
glucose and glutamine withdrawal when compared to HK-2 cells, they show differences 
when compared amongst each other. In other words, despite having adapted to a 
metabolic switch from oxidative phosphorylation to glycolysis as a whole tumour 
subtype, the fine-tuning of this adaptation could be different in individual cell lines as 
consequence of their distinct genetic backgrounds. Hence, genetic heterogeneity 
between the different cell lines might not allow for one and the same VHL-synthetic 
lethal relationship. In line with this, pVHL is only one amongst many genes that is 
heterozygously lost upon fractional LOH of chromosome 3p, the initiating step in 
ccRCC tumourigenesis (Gerlinger et al., 2012a), and this could be another good reason 
for failing to identify metabolic genes that are exclusively synergistic-lethal with VHL. 
In fact, a systems biology approach that applied genome-scale metabolic modelling of 
cancer cells, revealed that the unique metabolic phenotype that distinguishes ccRCCs 
from other cancer types is due to recurrent LOH in multiple metabolic genes adjacent to 
VHL, such as choline dehydrogenase (CHDH), glycerol-3-phosphate dehydrogenase 1-
like (GPD1L) or pyruvate dehydrogenase B (PDHB) (Gatto et al., 2014), putting the 
exclusivity of VHL into perspective, at least from a metabolic point of view.  
 
We were also interested in identifying HIF-α isoform specific dependencies in ccRCC. 
However, correlation of loss of viability upon gene silencing and HIF-α expression was 
found in only few cases, probably because of the small number of cell lines analysed, 
and occurred almost predominantly in a HIF-2α specific manner. c-MYC was amongst 
the differential genes, which is in line with reports of HIF-2α/c-MYC cooperation in 
driving cell cycle progression in hypoxia (Gordan et al., 2007a). Indeed, when exposed 
to severe oxygen deprivation, the cell lines expressing only the HIF-2α isoform, 786-O 
and 769-P, showed steeper growth curves compared to the other cell lines expressing 
both HIF-α isoforms (Figure 3.5). 
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Given the heterogeneity that ccRCCs display, identifying vulnerabilities that are shared 
throughout the tumour subtype could provide leads for novel therapeutic windows. The 
screen described in this study was able to identify a number of genes whose silencing 
resulted in severe cell number loss in most, if not all, ccRCC cell lines. Amongst these 
‘general ccRCC killers’ were many genes that belonged to the cholesterol or fatty acid 
biosynthesis pathway, genes that encoded glycolytic enzymes and also two AKT 
isoforms, AKT1 and AKT2. Intriguingly, these results are in line with the recently 
published comprehensive molecular characterisation of over 400 ccRCC patient 
samples within the TCGA network. The TCGA study highlighted that in ccRCCs the 
PI3K/AKT pathway is frequently mutated and that induced lipogenesis correlates with 
poor survival (Cancer Genome Atlas Research, 2013). These vulnerabilities were not 
only successfully recapitulated with the in vitro screen described in this study, but we 
were also able to identify specific targets in these metabolic processes that cause loss of 
viability upon ablation.  
 
In addition, the screen identified a further metabolic vulnerability not addressed by the 
TCGA study: the strong dependency of ccRCC cells on a solid glutathione redox 
system. Loss of GPX1, GPX3 and SOD1 were identified to be detrimental in all tested 
ccRCC cell lines. Furthermore, comparison with the non-tumourigenic renal epithelial 
HK-2 cell line revealed that the observed effect was cancer-specific, as ablation of these 
proteins did not affect HK-2 cells. SOD1 is a cytosolic superoxide dismutase that 
converts highly reactive superoxide (O2-) to hydrogenperoxide (H2O2). GPXs, are a 
family of peroxidases that use glutathione (GSH) as co-factor to neutralise H2O2 to 
water. Subsequent analyses showed that although the different ccRCC cell lines showed 
heterogeneous expression of the different GPXs (Figure 5.21), all of them were found to 
have much lower GPX activity compared to HK-2 cells (Figure 5.22). This suggests 
that ccRCC cell lines must operate at the limit of GPX activity, as perturbing the 
already compromised GPX activity even further through ablation of GPX1 or GPX3 
had severe consequences for cell proliferation (Figure 5.8 and Figure 5.10). In contrast, 
HK-2 cells must be able to accommodate GPX1 and GPX3 ablation easily as they were 
hardly affected in their proliferation (Figure 5.8 and Figure 5.10). Subsequent analysis 
to determine if availability of the co-substrate GSH is limited in ccRCC and contributes 
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to the impaired proliferation pattern seen upon GPX silencing, revealed that in 
comparison to HK-2 cells, ccRCC cells displayed higher levels of GSH with similar 
basal total glutathione levels across all cell lines (Figure 5.24). This accumulation of 
GSH in ccRCC cells seems to be partially dependent on GSH recycling but possibly 
more dependent on GSH production. Ablation of GSR, the enzyme that reduces 
oxidised GSSG to 2x GSH, using NADPH as co-factor, resulted in severe cell number 
loss in most ccRCC cells but not in HK-2 cells. The same result was obtained upon 
ablation of G6PD, a PPP enzyme that generates NADPH. Interestingly, two thirds of the 
cell lines displayed decreased GSR and half of them reduced G6PD mRNA levels 
compared to HK-2 cells (Figure 5.25), suggesting that activity of these enzymes, too, is 
close to the lowest limit tolerated in ccRCC cells while HK-2 cells have buffer capacity. 
Depletion of enzymes within the glutathione biosynthesis pathway, especially the first 
(GLS) and the last enzyme (GSS) in the cascade, though, not so much the actual rate 
limiting enzyme GCLC also resulted in severe cell number loss (Figure 5.27) 
implicating GSH biosynthesis to be essential for ccRCC proliferation. Interestingly, 
GLS, the enzyme that converts glutamine to glutamate, seemed to be induced in ccRCC 
cells at least on mRNA levels (Figure 5.27), suggesting a potential adaptation to 
increased glutamine utilisation. Intriguingly, ccRCC cells showed higher sensitivity to 
treatment with the GLS inhibitor BPTES (Figure 5.27), too. These findings tie in nicely 
with the observed sensitivity of ccRCC cells to glutamine withdrawal (Figure 3.11). In 
line with this, depletion of both the glutamine transporter SLC1A5 and the 
glutamate/cystine antiporter SLC7A11 resulted in ≥ 50% cell number loss in ccRCC 
cells, while depletion of the cystine transporter SLC7A9 showed this effect in only half 
the cell lines (Figure 5.30), reiterating the notion that glutamine is an essential nutrient 
for ccRCC proliferation. As mentioned above, glutamine is a universal amino acid that 
can be shunt into several anabolic pathways, the TCA cycle being one of them, GSH 
biosynthesis being another one. The data obtained so far strongly suggest an essentiality 
for glutamine in GSH production. Initial experiments support this idea, as 
supplementation of GSH, L-cysteine, NAC had a stronger positive effect on cell 
proliferation than α-KG following BPTES treatment (Figure 5.31). With the help of 
glutamine tracing techniques, it should be possible to delineate the contribution of 
glutamine to ATP/energy production, lipogenesis or GSH biosynthesis. This approach 
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could help to make a more informed call of whether, at least in ccRCC cells, glutamine 
addiction is due to an increased need for GSH production to maintain increased anti-
oxidant capacity. This increased redox buffer is needed to accommodate increased ROS 
accumulation, which comes with high metabolic flux. 
Finally, the inability to detect cell death upon silencing of GPX1, GPX3, SOD1 as well 
as genes encoding for enzymes in the GSH biosynthesis and recycling pathway suggests 
that loss of these proteins is not essential for survival but rather for proliferation, at least 
in the time frame analysed. Cell cycle analysis confirmed this assumption as RCC4 cells 
showed prolonged cell cycling upon silencing of GPX1, GPX3 and SOD1 as compared 
to control silencing (Figure 5.12). It will require further long-term assays to see whether 
this initial cytostatic effect seen in ccRCC during the four days of treatment will 
eventually result in senescence or cell death. 
One reason for the delay in cell cycle progression could be due to the need to repair 
DNA damage (Figure 5.14) caused by accumulated ROS upon depleting GPX1, GPX3 
and SOD1 (Figure 5.17, Figure 5.18) and possibly other enzymes involved in the GSH-
ROS-detoxification system. And, although the antioxidant NAC was able to partially 
rescue ROS accumulation (Figure 5.18), cell proliferation upon ablation of GPX1, 
GPX3 or SOD1 could not be rescued with any of the antioxidants tried (Figure 5.19). 
Further analyses will be necessary to determine in more detail to what extend ROS 
accumulation and/or DNA damage response contribute to the phenotype seen upon 
GPX1, GPX3 and SOD1 depletion.  
 
In conclusion, the presented study provides a detailed insight into the metabolic 
dependencies of ccRCC cells. It also provides evidence that the until recently prevailing 
dogma that ccRCC is exclusively caused by and defined as ‘loss of functional pVHL’ 
should be revised. Furthermore, the performed screen was not only able to recapitulate 
clinically relevant vulnerabilities of ccRCC, but also to identify the importance of the 
GSH-dependent anti-oxidant system for ccRCC cell proliferation, which provides also a 
novel lead for the development of diagnostic and/or therapeutic applications as it seems 
to be a cancer specific feature and does not affect normal cells. 
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Appendix 
Table 7.1: siRNA oligonucleotides used in customised Dharmacon siRNA library 
Gene 
Symbol Gene ID Plate Well Pool Number 
Duplex 
Number Sequence 
HK1 3098 1 A03 MU-006820-01 D-006820-01 GGAAGGAGAUGAAGAAUGG 
         D-006820-03 GAAGUUACCUGUGGGAUUC          D-006820-04 GCACAACAAUGCCGUGGUU           D-006820-05 GACCGAGAAUGGUGACUUC 
HK2 3099 1 A04 MU-006735-01 D-006735-05 GCGGAUGUGUAUCAAUAUG 
         D-006735-02 GAAGUUGGCCUCAUUGUUG          D-006735-03 GCAGAAGGUUGACCAGUAU           D-006735-04 CAAGCUACAUCCUCACUUU 
GCK 2645 1 A05 MU-010819-01 D-010819-05 CCACGAUGAUCUCCUGCUA 
         D-010819-01 GCAAGCAGAUCUACAACAU          D-010819-02 GCUCAUAGGUGGCAAGUAC           D-010819-04 GCACGAAGACAUCGAUAAG 
PKLR 5313 1 A06 MU-006780-01 D-006780-01 GUGAAGAGGUUUGAUGAAA 
         D-006780-02 GGGCAAGCCUGUUGUCUGU          D-006780-03 GUGGAGAGCUUUGCAGGUU           D-006780-04 GAAGGACACGGCAUCAAGA 
PKM2 5315 1 A07 MU-006781-02 D-006781-05 GCAUUGAGAUUCCUGCAGA 
         D-006781-01 GAAAGAACAUCAAGAUUAU          D-006781-02 UUAGGAAGGUCCUGGGAGA           D-006781-03 GCAAGAAGGGUGUGAACCU 
PC 5091 1 A08 MU-008950-02 D-008950-01 GAAAGCAGAUGAAGCCUAU 
         D-008950-03 GAGCUGAUGUGGUGGAUGU          D-008950-18 GGAUAAUGCUUCCGCCUUC           D-008950-19 UCUCUGAGCGAGCGGACUU 
PDHA1 5160 1 A09 MU-010329-02 D-010329-02 GCUCUAGCCUGUAAGUAUA 
         D-010329-04 GCUCACGGCUUUACUUUCA          D-010329-05 AAGCAGAUCAGCUGUAUAA           D-010329-06 AAUAAUCGCUAUGGAAUGG 
PDHA2 5161 1 A10 MU-023925-01 D-023925-01 UAAGAGGGAUCCUAUAAUA 
         D-023925-02 GAUGAGAUCUGUUUGACUU          D-023925-03 GCAGAUAGCCGAAGCUUUC           D-023925-04 GCUCAUGGUGUGUGCUAUA 
PDHB 5162 1 A11 MU-008803-01 D-008803-01 CAAAUCAUCUUGUAACUGU 
         D-008803-02 GGUCAAAGACAUCAUAUUU          D-008803-03 GAAAGGCAAGGAACACAUA           D-008803-04 GAGAAUGAAUUGAUGUAUG 
DLD 1738 1 A12 MU-009509-01 D-009509-04 GUACAAAGUUGGGAAAUUC 
         D-009509-01 GAAGUUCGCUUGAAUUUAG          D-009509-02 UAUUAAAGCUGCCCAGUUA          D-009509-03 CAAUGGAUAUGGAAAGAUA DLAT 1737 1 B03 MU-008490-00 D-008490-01 GCACAGCGAUUAAUGCAAU 
         D-008490-02 CAACCGAAGUAACAGAUUU          D-008490-03 GGAUUGAUCUUACACAAGU           D-008490-04 GUACGGAAAGAACUUAAUA 
ACACA 31 1 B04 MU-004551-02 D-004551-01 GAAAGCAGGUCAACUAUGA 
         D-004551-03 CAGCAAACCUGGAUUCUGA          D-004551-04 GCAGAUGACUUCCCUAAUC           D-004551-09 GCAAUUAGAUUCGUUGUCA 
LDHA 3939 1 B05 MU-008201-01 D-008201-01 GGAGAAAGCCGUCUUAAUU 
         D-008201-02 GGCAAAGACUAUAAUGUAA          D-008201-03 GAAGAGGCCCGUUUGAAGA           D-008201-04 CUACGUGGCUUGGAAGAUA 
LDHB 3945 1 B06 MU-009779-01 D-009779-01 GAAAGUCUCUGGCUGAUGA 
         D-009779-02 GGAAGGAAGUGCAUAAGAU          D-009779-03 GAACUGACAAUGAUAGUGA           D-009779-04 CAUGGGAGCUUAUUUCUUC 
LDHC 3948 1 B07 MU-008759-02 D-008759-01 GGAUUUGGCUGAUGAACUU 
         D-008759-03 GUUAAGGGAUUAUAUGGAA          D-008759-04 GGAAUGGUGUCUCAGAUGU           D-008759-05 CGUAAUGUGGCUAUAAUGA 
CS 1431 1 B08 MU-009334-01 D-009334-01 GCAAAGAUCUACCGAAAUC 
         D-009334-03 GGACUGGUCUCACAAUUUC 
         D-009334-04 GCAAAGCUACCUUGUGUUG 
          D-009334-17 GGAAGACUGAUCCGCGAUA 
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Gene 
Symbol Gene ID Plate Well Pool Number 
Duplex 
Number Sequence 
ACLY 47 1 B09 MU--004915-00 D-004915-01 CCAACGAGCUCAACAAUAU 
         D-004915-02 GACCAAAGAUGGAGUCUAU          D-004915-03 UCAACGAGCUGGCAAACUA           D-004915-04 CCACUCCUCUGCUCGAUUA 
G6PD 2539 1 B10 MU-008181-02 D-008181-05 UGACCUACGGCAACAGAUA 
         D-008181-01 GAGAGUGGGUUUCCAGUAU          D-008181-02 CAACAUCGCCUGCGUUAUC           D-008181-03 CGUGAGGCCUGGCGUAUUU 
FASN 2194 1 B11 MU-003954-04 D-003954-01 GAGCGUAUCUGUGAGAAAC 
         D-003954-03 UGACAUCGUCCAUUCGUUU          D-003954-04 CCAUGGAGCGUAUCUGUGA           D-003954-08 GCAACUCACGCUCCGGAAA 
CHKA 1119 1 B12 MU-006704-01 D-006704-01 GAAUUAAGUUUGCCAGAUA 
         D-006704-02 CAGAUGAGGUCCUGUAAUA          D-006704-03 GAGCAAACAUCCGGAAGUA           D-006704-04 GAAUACAGCAGUUACAAUU 
CHKB 1120 1 C03 MU-006705-00 D-006705-01 GGAAUGGCCUUUCUACAAA 
         D-006705-02 GUGAGUGGGUUUAUGAUUA          D-006705-03 CCACGAAGAUGGCGCAAUU          D-006705-04 CAUAGAAUUUGGUUACUUG 
HMGCS1 3157 1 C04 MU-009808-01 D-009808-01 GAAGACACCUACUUUGAUA 
          D-009808-04 GAUAUUAACUCUCUUUGCA 
          D-009808-17 GCCAAAUGUACUCGAAUGA 
          D-009808-18 CAGAGACAAUCAUCGACAA 
HMGCS2 3158 1 C05 MU-010179-01 D-010179-01 AAACUGACCUGGAGAAGUA 
         D-010179-02 ACACAAACCAGCUUAUAUA          D-010179-03 AGAGAGCAAUUCUACCAUA           D-010179-04 GGGCAUAGAUACCACCAAU 
HMGCR 3156 1 C06 MU-009811-02 D-009811-03 UGAAGAAUGUCUACAGAUA 
         D-009811-04 CCAGAAAUGUGAUUCAGUA          D-009811-06 GAGCAGUGACAUUAUAAUU           D-009811-19 GAUGGAAACUCAUGAGCGU 
SLC2A4 6517 1 C07 MU-007517-02 D-007517-01 CAGAUAGGCUCCGAAGAUG 
         D-007517-02 GCAUGGGUUUCCAGUAUGU          D-007517-03 UCAACCAACUGGCCAUUGU           D-007517-05 ACAGAUAGGCUCCGAAGAU 
SLC2A1 6513 1 C08 MU-007509-01 D-007509-02 CCAAGAGUGUGCUAAAGAA 
         D-007509-03 CAUCGUGGCUGAACUCUUC          D-007509-04 GAGCAUCGUGGCCAUCUUU           D-007509-05 GUAUGUGGGUGAAGUGUCA 
SREBF1 6720 1 C09 MU-006891-01 D-006891-01 UGACUUCCCUGGCCUAUUU 
         D-006891-02 ACAUUGAGCUCCUCUCUUG          D-006891-03 GCGCACUGCUGUCCACAAA           D-006891-04 ACACAGACGUGCUCAUGGA 
SREBF2 6721 1 C10 MU-009549-00 D-009549-01 GAGCGGAGCUGGUCUGUGA 
         D-009549-02 GAAGAGAGCUGUGAAUUCU          D-009549-03 GCACAAGUCUGGCGUUCUG           D-009549-04 AAACUCAGCUGCAACAACA 
PRKAA1 5562 1 C11 MU-005027-02 D-005027-01 CAAAGUCGACCAAAUGAUA 
         D-005027-02 GUAGAGCAAUCAAACAAUU          D-005027-03 GACAAGCACUUACUCCAAA           D-005027-05 ACAAUUGGAUUAUGAAUGG 
PRKAA2 5563 1 C12 MU-005361-02 D-005361-02 GUACCUACGUUAUUUAAGA 
         D-005361-03 GGAAGGUAGUGAAUGCAUA          D-005361-04 GACAGAAGAUUCGCAGUUU           D-005361-05 ACAGAAGAUUCGCAGUUUA 
HIF1A 3091 1 D03 MU-004018-05 D-004018-01 GGACACAGAUUUAGACUUG 
         D-004018-06 UCACCAAAGUUGAAUCAGA          D-004018-03 GAUGGAAGCACUAGACAAA           D-004018-05 CGUGUUAUCUGUCGCUUUG 
AKT2 208 1 D05 MU-003001-02 D-003001-05 GUACUUCGAUGAUGAAUUU 
         D-003001-06 GCAAAGAGGGCAUCAGUGA          D-003001-07 GGGCUAAAGUGACCAUGAA           D-003001-08 GCAGAAUGCCAGCUGAUGA 
AKT3 10000 1 D06 MU-003002-02 D-003002-09 GAAAGAUUGUGUACCGUGA 
         D-003002-10 GGACUACUGUUAUAGAGAG          D-003002-11 UGAGACAGAUACUAGAUAU           D-003002-12 GCUCAUUCAUAGGAUAUAA 
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ILVBL 10994 1 D07 MU-009658-02 D-009658-03 UGACUGCGGUGAAGAAUGC 
         D-009658-20 CCUGGUAUUUAGAGAAUUA          D-009658-21 CGUCAAUCGUAAUCGGGAA           D-009658-22 GCUACAGCCUCAUCGAAUU 
PHGDH 26227 1 D08 MU-009518-01 D-009518-01 GAACAUCCCUGAAGAAUGC 
         D-009518-02 GAACUCACUUGUGGAAUGA          D-009518-03 GGAAAGACCCUGGGAAUUC           D-009518-04 GGAAGGGCAUCUUGGUUAU 
MDH1 4190 1 D09 MU-009264-00 D-009264-01 CAAAGGAACUGACAGAAGA 
         D-009264-02 CAUCAAGGCUCGAAAACUA          D-009264-03 GUUGAAGGUCUCCCUAUUA           D-009264-04 AAGGUGAAAUUGCAAGGAA 
MDH2 4191 1 D10 MU-008439-00 D-008439-01 CCAGAACAAUGCUAAAGUA 
         D-008439-02 CAACACCAAUGCCACGAUU          D-008439-03 CAAGAAGCAUGGAGUGUAC           D-008439-04 CCUGAAAGGUUGUGAUGUG 
GPD1 2819 1 D11 MU-008782-01 D-008782-02 AGAAAGAGUUGCUGAAUGG 
         D-008782-04 GAUCGUGGGUGGCAAUGCA          D-008782-17 AGAUGAUAGCCUUCGCCAA           D-008782-18 CCCAUCAGUUCAUCGGCAA 
GPD2 2820 1 D12 MU-009843-02 D-009843-01 UGAAUGAAGUGCGUAAUUA 
         D-009843-02 GAACCUGGCCUAUGUUAAA          D-009843-03 GAUAUGAUUUCACGUCGUA           D-009843-05 GAGAGUGGCCUUAUUACUA 
PRPS1 5631 1 E03 MU-006784-00 D-006784-01 GCAAAUAUGCUAUCUGUAG 
         D-006784-02 UGGAGGAACUGCACUAUUG          D-006784-03 GUGAUUGACAUCUCUAUGA           D-006784-04 CCAUGCAGCUGACAAACUU 
PRPS2 5634 1 E04 MU-004877-02 D-004877-05 GAUCUUGGCCGAAGCAAUC 
         D-004877-01 AUACAGGGAUUCUUUGAUA          D-004877-03 CAAAGUGUAUGCUAUCCUU           D-004877-04 CAGAGUAACUGCCGUGAUC 
PPAT 5471 1 E05 MU-006003-01 D-006003-01 GAAAUGGUCUGGAAUGUUU 
         D-006003-02 GGUAAAUGCUGCUCGAUUA          D-006003-03 GGGAAUGGGUCUUGUAAAU           D-006003-05 GAAUGGGUCUUGUAAAUCA 
UMPS 7372 1 E06 MU-009828-01 D-009828-02 GAACUAAGCGUCUUGUAGA 
         D-009828-04 GAAGACUCAUGUAGAUAUU          D-009828-17 AUUUCUGGCUCCCGAGUAA           D-009828-18 UGAUAUUUGAAGACCGGAA 
SLC1A5 6510 1 E07 MU-007429-01 D-007429-02 GGAUGUGGGUUUACUCUUU 
         D-007429-03 GUUCUGGUCUCCUGGAUCA          D-007429-17 GAGAGGAAUAUCACCGGAA           D-007429-18 CAGUCAACCUCCCGGUCGA 
SLC7A5 8140 1 E08 MU-004953-01 D-004953-01 GAUCCCAACUUCUCAUUUG 
         D-004953-03 UGACCAACCUGGCCUACUU          D-004953-17 GUGAACUGCUACAGCGUGA           D-004953-18 UGAAAACUCUGGUACGAAU 
PFKL 5211 1 E09 MU-006822-00 D-006822-01 UGAAGAUGCUGGCACAAUA 
         D-006822-02 GCACAAUACCGCAUCAGUA          D-006822-03 CACAAUACCGCAUCAGUAU           D-006822-04 UGCUGAAGAUGCUGGCACA 
GAPDH 2597 1 E10 MU-004253-02 D-004253-01 CAACGGAUUUGGUCGUAUU 
         D-004253-03 GACCUCAACUACAUGGUUU          D-004253-04 UGGUUUACAUGUUCCAAUA           D-004253-05 GUCAACGGAUUUGGUCGUA 
GAPDS 26330 1 E11 MU-009671-01 D-009671-01 CAAGGGAAGUGUGGAAUUC 
         D-009671-02 GGACAACCAUGAGAUCUCU          D-009671-03 UGGUGUACAUGUUUAAGUA           D-009671-04 CCAUGAACAUUGUGAGCAA 
PGK1 5230 1 E12 MU-006767-01 D-006767-05 GAAGCGGGUCGUUAUGAGA 
         D-006767-01 CAAAAUUGAUGAUCCAUUA          D-006767-02 UUGAUGAUCCAUUAAGUAA           D-006767-04 GCACAGCAUCUCAGCUCAU 
PGK2 5232 1 F03 MU-006768-02 D-006768-05 GGAAUGGGCCGUUAGGAGU 
         D-006768-02 GCAGACAAGAUCCAACUUA          D-006768-03 CAAGAUCCCUCUGGAAAGA           D-006768-04 UGACAAAUAUUCCUUAGCA 
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ENO1 2023 1 F04 MU-004034-02 D-004034-03 CAAACUGAUGAUCGAGAUG 
         D-004034-04 AAUGAUAAGACUCGCUAUA          D-004034-01 GAACGUCACAGAACAAGAG           D-004034-02 GAUAAGACUCGCUAUAUGG 
IDH1 3417 1 F05 MU-008296-00 D-008294-03 GUACAUAACUUUGAAGAAG 
         D-008294-04 CAAGAUAAGUCAAUUGAAG          D-008294-01 GAGCAAAGCUUGAUAACAA           D-008294-02 GGACUUGGCUGCUUGCAUU 
IDH2 3418 1 F06 MU-004013-00 D-004013-01 CAAGAACUAUGACGGAGAU 
         D-004013-02 GCGCCACUAUGCCGACAAA          D-004013-03 AACGAGCACUUCCUGAACA           D-004013-04 GACAUCCAGCUAAAGUAUU 
OGDH 4967 1 F07 MU-009679-02 D-009679-03 GCUAGGACAUUUCAACAGA 
         D-009679-05 CAGACAAACUUGGGUUCUA          D-009679-18 UCUAGAAGGCUGCGAGGUA           D-009679-19 CUGAUGAGGGCUCCGGAGA 
SDHA 6389 1 F08 MU-009398-02 D-009398-01 GAGGGAGGCAUUCUCAUUA 
         D-009398-03 CGAAGGACCUGGCGUCUAG          D-009398-04 UGAGAAAGAUCACGUCUAC           D-009398-14 CGAAAGGUUUAUGGAGCGA 
SDHB 6390 1 F09 MU-011773-02 D-011773-01 GGUAUUGGAUGCUUUAAUC 
         D-011773-02 GAACAUCAAUGGAGGCAAC          D-011773-19 GUGAGAAACUGGACGGGCU           D-011773-20 GCUACUGGUGGAACGGAGA 
SDHC 6391 1 F10 MU-011385-01 D-011385-17 GGGCUUAGAUAGAAAGUCU 
         D-011385-18 AGUUAAAGCUGUGGGUCGA          D-011385-19 GAAAAGAAGUGACGCAUGU           D-011385-20 UCGAAGUAAUGUACCCUUU 
SDHD 6392 1 F11 MU-006305-00 D-006305-01 GGACCGACCUAUCCCAGAA 
         D-006305-02 GCUUUGCUAUUUCAACUAU          D-006305-03 ACUUUCAGCUUUAACCUUU           D-006305-04 CAGACCUGCUCAUAUCUCA 
FH 2271 1 F12 MU-009512-00 D-009512-01 GAUCUACGAUGAACUUUAA 
         D-009512-02 UCAACAAGCUGAUGAAUGA          D-009512-03 GCACAGAUCAUCAAGAUUG           D-009512-04 AGCCAGAGCUCAAAUGAUA 
CHPT1 56994 1 G03 MU-009775-02 D-009775-01 GAACUUAUCCUGACUGGUU 
         D-009775-06 UUUCAGGCAUGUUGAGAUU          D-009775-19 GCGCUCAUUGGCAGACUUA           D-009775-20 CUUCAUUUGAUAUGGUGAU 
MVK 4598 1 G04 MU-006749-00 D-006749-01 UGGAAGAGCUCAUUGACAU 
         D-006749-02 ACACCAAAGUCCCUCGCAA          D-006749-03 GCUCAAGUUCCCAGAGAUC           D-006749-04 ACCAAAGUCCCUCGCAAUA 
PMVK 10654 1 G05 MU-006782-01 D-006782-01 UUUAUCCGCUCCAGACUUU 
         D-006782-02 CGAGAACCAUGGAGUUGAA          D-006782-03 GCGAAACCCUGCCAUAUCC           D-006782-04 AAUGUGGCCUGGACAACUU 
MVD 4597 1 G06 MU-006748-00 D-006748-01 GACCGGAUUUGGCUGAAUG 
         D-006748-02 ACAUCGCGGUCAUCAAGUA          D-006748-03 GCCCAUCUCUUACCUCAAU           D-006748-04 CAGCAUCGCUCGGCAAGUG 
GGPS1 9453 1 G08 MU-016477-02 D-016477-03 CAAAUUAGGGAUGAUUAUG 
         D-016477-04 UAAAACCGCUACUUAAUAC          D-016477-20 GGGACAAGGCCUAGAUAUU           D-016477-21 CCAAUUGGGAAGCGGAAAA 
LSS 4047 1 G09 MU-008624-00 D-008624-01 GGACUGCGCUCAACUAUGU 
         D-008624-02 GCAGAAGGCUCAUGAGUUC          D-008624-03 GAAGCUGUAUGAACACAUU           D-008624-04 UGCAGGCGCUUAAGUAUUU 
DHCR7 1717 1 G10 MU-020182-01 D-020182-01 GGCCAAGACUCCACCUAUA 
         D-020182-02 GAACAAGUAUCAGAUCAAC          D-020182-03 CAUCAUGGCUUGUGACCAG           D-020182-04 GCCCAGCUCUAUACCUUGU 
PRKAG2 51422 1 G11 MU-009693-01 D-009693-02 GCAAUAAGCUGGAAAUACU 
         D-009693-03 CCACAACAUUGCCUUCAUA          D-009693-17 CGGAGUGACCGCCGUGAAU           D-009693-18 CCACAGAUUGCCCGUUAUU 
 
Appendix 
 240 
Gene 
Symbol Gene ID Plate Well Pool Number 
Duplex 
Number Sequence 
PRKAG3 53632 1 G12 MU-009859-01 D-009859-01 UCUAUGAGAUUGAACAACA 
         D-009859-02 GGGAAGUGAUCGACAGGAU          D-009859-03 ACAAACGCCUGCUCAAGUU           D-009859-05 GCUCCAAGCUAGUCAUCUU 
PRKAB1 5564 1 H03 MU-007675-00 D-007675-01 CAGAAGCCACAAUAACUUU 
         D-007675-02 CAACAACUGGAGUAAACUU          D-007675-03 UGUCUGAGCUGUCCAGUUC           D-007675-04 GGAAGGAGAGCAUCAGUAC 
PRKAB2 5565 1 H04 MU-007672-00 D-007672-01 GUUCGAUGCUUUAAAGUUA 
         D-007672-02 UAAGAGCCAUAAUGACUUU          D-007672-03 GCAAGGAGGUCUUCAUCUC           D-007672-04 GCACCAAGAUUCCACUGAU 
PRKAG1 5571 1 H05 MU-009056-01 D-009056-01 GGACAUCUACUCCAAGUUU 
         D-009056-02 GAUGCUGUCUCUUCAUUAA          D-009056-03 CAACAUCGAUCACAUUACU           D-009056-04 GUGUAUACUUCCUUCAUGA 
EPAS1 2034 1 H06 MU-004814-01 D-004814-05 ACACAUCUUUGGAUAACGA 
         D-004814-02 GCAAAUGUACCCAAUGAUA          D-004814-03 GAGCGGGACUUCUUCAUGA           D-004814-04 AGACGGAGGUGUUCUAUGA 
MT-ND1 4535 1 H07 MU-012827-00 D-012827-01 UAACCUCCCUGUUCUUAUG 
         D-012827-02 UGAUUUAUCUCCACACUAG          D-012827-03 CUAAUAAGUGGCUCCUUUA           D-012827-04 CCGAAUACACAAACAUUAU 
MT-ND2 4536 1 H08 MU-012828-00 D-012828-01 GCGCUAAGCUCGCACUGAU 
         D-012828-02 UAACCAAUACUACCAAUCA          D-012828-03 CAAUAUACUCUCCGGACAA           D-012828-04 CCAUAUCUAACAACGUAAA 
MT-ND3 4537 1 H09 MU-012829-00 D-012829-01 CAACUAACCUGCCACUAAU 
         D-012829-02 CCGCGUCCCUUUCUCCAUA          D-012829-03 CUUAGUAGCUAUUACCUUC           D-012829-04 CAACUCAACGGCUACAUAG 
MT-ND4 4538 1 H10 MU-012830-00 D-012830-01 CUAGGCGGCUAUGGUAUAA 
         D-012830-02 GACCUAAAAUCGCUCAUUG          D-012830-03 GAGCCAAUAACUUAAUAUG           D-012830-04 UAACCACGUUCUCCUGAUC 
MT-ND5 4540 1 H11 MU-012831-00 D-012831-01 UGAGAGGGCGUAGGAAUUA 
         D-012831-02 GCCUAUAGCACUCGAAUAA          D-012831-03 CUAGGACUCAUAAUAGUUA           D-012831-04 CUACUCCACUCAAGCACUA 
MT-ND6 4541 1 H12 MU-012832-00 D-012832-01 GGUCGGGUGUGUUAUUAUU 
         D-012832-02 GAAUGAUGGUUGUCUUUGG          D-012832-03 CGAUGGCUAUUGAGGAGUA           D-012832-04 GAUUAUGGGCGUUGAUUAG 
GALK1 2584 2 A03 M-007728-01 D-007728-03 GACCAGUUCAUCUCACUUA 
         D-007728-04 GCGCCAAUGUGAAGAAGUG          D-007728-05 GGGAACACACGGACUACAA           D-007728-06 GAGCCAAGGUGCUGUGCUU 
GALK2 2585 2 A04 M-006725-00 D-006725-01 GCUAAUAACAUCCAGAUUG 
         D-006725-02 GCACAACUAUUUCUUAUGU          D-006725-03 GGAAAUAUCCCACCAAGUU           D-006725-04 GGACCAGUCUAUAUCAUUU 
GALT 2592 2 A05 M-010327-00 D-010327-01 AAACAAAGGUGCCAUGAUG 
         D-010327-02 GAUCUAGCCUCCAUCAUGA          D-010327-03 GAUCUCAGCAGGCCUAUAA           D-010327-04 GCAAACGACCAUCAGCAUA 
PGM1 5236 2 A06 M-010925-00 D-010925-01 CGAAUCGUCUUCCGACUGA 
         D-010925-02 GUACAUCGAUAGCUAUGAG          D-010925-03 CGACUGAAGAUCCGUAUUG           D-010925-04 GGAAAUUGUGGAUUCGGUA 
PGM3 5238 2 A07 M-013912-00 D-013912-01 GAGGUCAAUUCCAUGAUUA 
         D-013912-02 GGAUUUAGGUGCUAUUACA          D-013912-03 GGGCAAACUCAAUCAUUUA           D-013912-04 GACAAGAUAGCAACGUUAA 
GLUD1 2746 2 A08 M-004032-02 D-004032-01 GCAACCAUGUGCUGAGUCU 
         D-004032-02 UAAAUCAUGUCAGCUAUGG          D-004032-05 CAAUGAAGCUUCUUACAUG           D-004032-19 GAAAUUAAGGUUAGCGGAU 
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GLUD2 2747 2 A09 M-009067-02 D-009067-01 CAAUGAAGCUUCUUACAUG 
         D-009067-04 GGACGCAUCUCUGCUACUG          D-009067-05 CAAGGGAGGUAUCCGUUAC           D-009067-18 CUUUAUUGGUCCUGGCGUU 
HK3 3101 2 A10 M-006736-00 D-006736-01 GGAAUGCGAUGUCUCCUUA 
         D-006736-02 GCAGUUGACUCGUGUCUGA          D-006736-03 GACAGGAGCACCCUCAUUU           D-006736-04 UCACGUUCCUGCAGUCAGA 
GPI 2821 2 A11 M-004900-01 D-004900-01 GGAAAUACAUCACCAAAUC 
         D-004900-03 CAACCAAAGUGAAGGAGUU          D-004900-04 GAUGAUACCCUGUGACUUC           D-004900-05 UCACGACGCUUCUACCAAU 
PFKM 5213 2 A12 M-006765-01 D-006765-01 UCAAGAAUCUGGUGGUUAA 
         D-006765-03 GAUCAUGGAAAUUGUAGAU          D-006765-04 CAGAAGACAUCAAGAAUCU           D-006765-05 GGAUAUGACACCCGGGUUA 
PFKP 5214 2 B03 M-010253-01 D-010253-01 GAAAUCGGCUGGACAGAUG 
         D-010253-02 CAACGUAGCUGUCAUCAAC          D-010253-03 GAAGAGAUCGCCACACAGA           D-010253-05 GGAACGGCCAGAUCGAUAA 
PFKFB1 5207 2 B04 M-006761-01 D-006761-01 UAAAGAGAAUUGAGUGCUA 
         D-006761-03 UAAUGACCCUGGCAUAAUU          D-006761-04 GCUAUGAGGUCAACUACCA           D-006761-17 UACCAGAGAACGACGGUCA 
PFKFB2 5208 2 B05 M-006762-02 D-006762-01 GAACUUUGCUGAACAGAAU 
         D-006762-02 GAACAGAGAGAACGUGAUG          D-006762-03 CCAAUAUUCUGGAGGUUAA           D-006762-18 CGGCAUGGAGAAAGCGAGU 
PFKFB3 5209 2 B06 M-006763-01 D-006763-01 GGACCUAACCCGCUCAUGA 
         D-006763-02 GAGGAUCAGUUGCUAUGAA          D-006763-03 AAAGCUACCUGGCGAAAGA           D-006763-17 ACAAGUACUAUUACCGCUA 
PFKFB4 5210 2 B07 M-006764-01 D-006764-01 GAGCGACCAUCUUUAAUUU 
         D-006764-02 GAAAUGACCUACGAGGAAA          D-006764-04 CAUCGUAUAUUACCUCAUG           D-006764-17 GGGACAGGCCUCAGAACGU 
ALDOA 226 2 B08 M-010376-01 D-010376-02 GGACAAAUGGCGAGACUAC 
         D-010376-03 UUGAAGCGCUGCCAGUAUG          D-010376-04 GGCGUUGUGUGCUGAAGAU           D-010376-05 UGACAUCGCUCACCGCAUC 
ALDOB 229 2 B09 M-010990-01 D-010990-01 CCAAAGCCCUGGAAACUAA 
         D-010990-02 GGACAUGCCUGCACCAAGA          D-010990-04 GAAGAAGGAGCUCUCAGAA           D-010990-05 CCAAAGGACAGUAUGUUCA 
ALDOC 230 2 B10 M-012697-01 D-012697-01 GAAAGAUGAUAAUGGUGUU 
         D-012697-02 GCGCUUACCUUCUCCUAUG          D-012697-03 GCACAGUCACUCUACAUUG           D-012697-04 AAACGUUGUCAGUAUGUUA 
TPI1 7167 2 B11 M-009776-02 D-009776-01 GCAAGGUCGUCCUGGCCUA 
         D-009776-02 GCUCAGAGCACCCGUAUCA          D-009776-05 AGAGAGAAGGCAUGUCUUU           D-009776-06 GAUCAAAGACUGCGGAGCC 
PGAM4 441531 2 B12 M-034271-00 D-034271-13 GCACAGGUUCUCAGUCUAA 
         D-034271-14 CCUCAUACCAAUAUAGGAU          D-034271-15 CAUGCUAAGCCACGACCAA           D-034271-16 CAGAAGAGAGUGAUCCGGA 
PGAM1 5223 2 C03 M-008883-01 D-008883-02 GGACAAGAACUUGAAGCCU 
         D-008883-03 CCAUGCAGUUUCUGGGGGA          D-008883-04 UGAAGAGACGGUGCGCAAA           D-008883-05 GGUCUAACCGGUCUCAAUA 
PGAM2 5224 2 C04 M-008712-02 D-008712-01 GAUCAAGGCCGGCAAGCGA 
         D-008712-03 CCAAGAUGGAGUUUGACAU          D-008712-18 UGUCAGACCAGGCGAUCAU           D-008712-19 GGAUGUCAGACCAGGCGAU 
BPGM 669 2 C05 M-008917-02 D-008917-02 GAAAGCUCCUGGCGUCUAA 
         D-008917-03 GGAAUAAGGAGAACCGUUU          D-008917-04 GGAGGAAGCUCGGAACUGU           D-008917-18 CAACUGCCACGGUCGGAAA 
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ENO2 2026 2 C06 M-009777-01 D-009777-04 CUGAACGUCUGGCUAAAUA 
         D-009777-17 GGACAUAACUUCCGUAAUC          D-009777-18 CCACUGAUCCUUCCCGAUA           D-009777-19 CCUCAGAGUUUUAUCGUGA 
ENO3 2027 2 C07 M-009718-02 D-009718-02 CUAUGAGGCUCUGGAACUA 
         D-009718-03 GGGUGAACAUCCAGAUUGU          D-009718-04 GCAAUGGGAAGUACGAUCU           D-009718-05 CGGAGCGUCUGGCCAAAUA 
LDHAL6A 160287 2 C08 M-008760-01 D-008760-01 GGAGAAACACGCCUUGAUU 
         D-008760-02 CCAGAUAUAGGAACUGAUA          D-008760-03 GGAGUGGUGUGAACAUUGC           D-008760-04 GAAGAGGAGGCCAUUCAUC 
LDHAL6B 92483 2 C09 M-008908-02 D-008908-01 UGGAAUAGAUGAAGAAGUA 
         D-008908-03 AGUAAGGUCUCCAUCAUAG          D-008908-04 GACGAUGGAUCUUCAACAU           D-008908-17 GAGUGAGCUUAUUGAGCGU 
PDK3 5165 2 C10 M-005021-02 D-005021-02 GUUGGUAUAUGCAGAGUUU 
         D-005021-03 UAAGAUCAGUGACCUAGGU          D-005021-05 CGGGAGAGAUAAUGCAUGU           D-005021-06 GUUCAGAGUUGGUAUAUGC 
PDK4 5166 2 C11 M-019425-02 D-019425-01 AAAGAAGACCUUACCAUUA 
         D-019425-02 GAAAUAGACACCAUAAUGU          D-019425-03 CGACAAGAAUUGCCUGUGA           D-019425-04 GACCGCCUCUUUAGUUAUA 
PDP1 54704 2 C12 M-008718-00 D-008718-01 CGACUGAUAUUGAUGUUAA 
         D-008718-02 GAACUGAGCAGGAUCUAUG          D-008718-03 GCAUCCAAAUUGUACUUUA           D-008718-04 GCAAGUUGGUGAUCCUAAU 
PDP2 57546 2 D03 M-022572-00 D-022572-01 CAACAGAGGAAGAUGAUUU 
         D-022572-02 GCAAACCAAUGGACUGAUG          D-022572-03 GGAACAGCAUUGCCACAUU           D-022572-04 GAAGAAGCAUUAAUGUACU 
ACO1 48 2 D04 M-010037-00 D-010037-01 GCAAACAGGUCGUGAUGAA 
         D-010037-02 GAACAUAGAAGUGCCAUUU          D-010037-03 GUAGGAAUGUUUCGAGAUU           D-010037-04 GAGAUUCGGUAACAACUGA 
ACO2 50 2 D05 M-009566-00 D-009566-01 CAAUCUAGCUGAUGAAUUC 
         D-009566-02 CCACUUCCGUGUUCCCUUA          D-009566-03 GCAGUGCCCUCAACAGAAU           D-009566-04 GGACGGCUAUGCACAGAUC 
LOC441996 441996 2 D06 M-035153-01 D-035153-09 CAGGCAAGGAUGGCAAGAA 
         D-035153-10 GGUCAGUUGCACAGAAAGG          D-035153-11 GCAGGAGAAGAACAUAAUU           D-035153-12 GCAGAUCCGUGCCUCCAUU 
IDH3A 3419 2 D07 M-008753-00 D-008753-01 GCAGAAAGCUGUAAAGAUA 
         D-008753-02 GAACGUCACUGCCAUUCAA          D-008753-03 GGAAAGAGCUUGACAAAAG           D-008753-04 GCUAAAGAGUCCAUGGAUA 
IDH3B 3420 2 D08 M-009596-00 D-009596-01 UGAAGAAGGUGAUCAAAGU 
         D-009596-02 GCAUCUUAAUCUUGAGUAU          D-009596-03 GCAGUGGGCAGGAAUAUAG           D-009596-04 UUGAGACAAUGAUCAUAGA 
IDH3G 3421 2 D09 M-009361-00 D-009361-01 GCAAGAGUAUCGCCAAUAA 
         D-009361-02 GGACAUAGACAUCCUCAUU          D-009361-03 GCACGUGAGUUCCAAUGCU           D-009361-04 GAACACAGAGGGCGAGUAC 
DLST 1743 2 D10 M-009941-02 D-009941-01 GCAGGAAGGUUGUCAUUAA 
         D-009941-02 GCAGAGAGGCUGUGACUUU          D-009941-05 GAUGAGGGCUCGGCACAAA           D-009941-19 CAAAAUCAAGGCAGCGGUA 
LOC283398 283398 2 D11 M-026908-01 D-026908-01 UAAAGGAAGCUCAAGUAUA 
         D-026908-02 CAAAUUACGAAGCUGUAUA          D-026908-03 GGACGACAAAUCAGAGAAU           D-026908-04 ACUAGAAACUUCCAGUCAA 
SUCLG2 8801 2 D12 M-008918-01 D-008918-01 AAAGGAAGCUCAAGUAUAU 
         D-008918-02 AAAUGAAGCUGCCAAAUAU          D-008918-04 GGACUAGAUGGGAACAUUG           D-008918-17 GGUACAAUCUAGCGACAAA 
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SUCLG1 8802 2 E03 M-008677-01 D-008677-01 GAAAUUCCCUUGGUUGUGU 
         D-008677-02 AGAGAAUGCUGCAGAAUUU          D-008677-03 GGGCUUACCUGUCUUUAAU           D-008677-04 GAUCUGGCACCCUGACUUA 
SUCLA2 8803 2 E04 M-008237-00 D-008237-01 GCAAAGGAAUCUCUCACUA 
         D-008237-02 GGAUGAAGCUGCUAGAAUG          D-008237-03 UCAAGGUCCUGUAUUAAUA           D-008237-04 GGGAAGUUCUGGAUUGUUU 
GOT1 2805 2 E05 M-011673-01 D-011673-01 GAGCAUAUCGCACGGAUGA 
         D-011673-02 UUAAAGACAUUCGGUCCUA          D-011673-03 UAGCCUAAAUCACGAGUAU           D-011673-17 GAACAGGUGCACUUCGAAU 
GOT2 2806 2 E06 M-011674-02 D-011674-01 GCAUGCAGCUACAAGGUUA 
         D-011674-03 AACAUGGGCUUAUAUGGUG          D-011674-04 CUUGAAGAGUGGCCGGUUU           D-011674-18 UGAGAAACAGCACACGUUA 
SLC25A11 8402 2 E07 M-007470-00 D-007470-01 GGACUCAGGCUACUUCUCU 
         D-007470-02 GGGAUGGGAGCUACAGUUU          D-007470-03 CAGAACAUGCGGAUGAUUG           D-007470-04 UCUAUACCGUGCUGUUUGA 
GPD1L 23171 2 E08 M-008514-01 D-008514-01 GGAAGACCAUUGAAGAGUU 
         D-008514-02 GGCUGAAGCUCAUUUCUGA          D-008514-03 GUUGCCAUGUCAAAUCUUA           D-008514-04 GCAGACCAGUUCAAGAGAU 
ME3 10873 2 E09 M-008499-01 D-008499-01 CAACAAUGCUGAAUUCUUG 
         D-008499-02 ACAAAUACCGUAACAAGUA          D-008499-03 GGAGCCACCUGAACCAUGA           D-008499-04 CUAAAGGGCUCAUUGUCAA 
GLUL 2752 2 E10 M-008228-01 D-008228-01 GCACGUGUCUUCUCAAUGA 
         D-008228-02 GAAGAAGGGUUACUUUGAA          D-008228-03 GCACACCUGUAAACGGAUA           D-008228-04 CAUGAAACCUCCAACAUCA 
GPT 2875 2 E11 M-031622-00 D-031622-01 GAAGAAGCCUUUCACCGAG 
         D-031622-02 GAACAUGGACGCUGCAGUG          D-031622-03 GCGCAGUGCAGGUGGAUUA           D-031622-04 CCGAGCAGGUCUUCAAUGA 
GPT2 84706 2 E12 M-004173-02 D-004173-01 UCAAAUGGCUCCAGACAUG 
         D-004173-03 GUGAAAGACUUCCACAUCA          D-004173-04 UCAAGAAGGUGCUGUACGA           D-004173-18 GUGAAAAGGUUAAAUCGUA 
DDO 8528 2 F03 M-009311-01 D-009311-02 CAGCACGGAUUGCAGUUGU 
         D-009311-03 UCAGAGAAACCUUUAAUCA          D-009311-17 GGACCUAUGCAGAUUUAUA           D-009311-18 GGUGUAACAUGUAAGCUGA 
AGXT 189 2 F04 M-008925-01 D-008925-01 GGAGAGACAUCGUCAGCUA 
         D-008925-02 GCAAGGAUAUGUACCAGAU          D-008925-04 UAGACCACUUCGACAUUGA           D-008925-05 GGUCAUCUCUGGCUCGGGA 
AGXT2 64902 2 F05 M-009818-00 D-009818-01 GGAAAGAAGAGCUAAGUAA 
         D-009818-02 GGACCUACAUGUUACUAAA          D-009818-03 GGAAGCAGAUACCUGGAUU           D-009818-04 CAUAACCACUCCAGAGAUU 
PSAT1 29968 2 F06 M-010398-02 D-010398-21 UUUAAGAGUGCCAGGCGAA 
         D-010398-22 GAGAAUCUUGUGCGGGAAU          D-010398-23 GCGCAAAUGAGACGGUGCA           D-010398-24 GGACUAUAAAUAUCGUUCA 
CAD 790 2 F07 M-009471-01 D-009471-01 GAGGGUCUCUUCUUAAGUA 
         D-009471-17 GGAAGGAGAUUGAGUACGA          D-009471-18 CCAACAGAUAAGCGGAUUU           D-009471-19 AUUAAGACUCCACGGGUAU 
ODC1 4953 2 F08 M-006668-00 D-006668-01 GAGCAGACCUUUAUGUAUU 
         D-006668-02 CGAAAGAGCUAAAUAUCGA          D-006668-03 GAAGUUGAGUUGAUGAAAG           D-006668-04 GAAGAGAUCACCGGCGUAA 
SHMT1 6470 2 F09 M-004617-00 D-004617-01 GAGCUGGCAUGAUCUUCUA 
         D-004617-02 GGAGAACGCACGCCUCUUC          D-004617-03 CCUAGGCUCUUGCUUAAAU           D-004617-04 UACGGAAGAUUGCAGAUGA 
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SHMT2 6472 2 F10 M-004906-01 D-004906-01 GGAGAUCCCUUACACAUUU 
         D-004906-02 GGUCAGGGCUCAUCUUCUA          D-004906-03 GGACAGUGAUCCUGAGAUG           D-004906-04 AAACUGGCCUCAUUGACUA 
TKT 7086 2 F11 M-004734-01 D-004734-01 GAAAAUGCCAUCAUCUAUA 
         D-004734-03 GAACUAGCCGCCAAUACAA          D-004734-04 CUGCCGAACUGCUGAAGAA           D-004734-05 GGAACUAGCCGCCAAUACA 
TKTL1 8277 2 F12 M-004736-01 D-004736-01 GCAAGUACCGCUCUAAUUU 
         D-004736-02 GGAAUUCCCUUCGCUGUUU          D-004736-03 GCAGAAAGUUGGCAUGCAA           D-004736-04 GGAAUUAGUGCCAGACAUA 
DKFZP 84076 2 G03 M-004735-01 D-004735-01 CGACAGAGCAUGCUAUUUA 
434L1717        D-004735-02 GUGAAUUGCUGGAUAUGUU          D-004735-03 GAUAAAGUCACAGUAAUUG           D-004735-04 GUAAUUGGAGCUGGAGUUA 
PGLS 25796 2 G04 M-020023-00 D-020023-01 GAUUGUGGCUCCCAUCAGU 
         D-020023-02 CACACUACCUGUCCUGAAU          D-020023-03 GCAAGGCAGCUGUUCUGAA           D-020023-04 CGGCUGAGGACUACGCCAA 
H6PD 9563 2 G05 M-004692-01 D-004692-01 CCGAGGAGCUGAUCUCUAA 
         D-004692-02 GCAGCCCUCUGUCCGAUUA          D-004692-03 GGACAUGUCUCCAUAAUCC           D-004692-04 GGGCUACGCUCGGAUCUUG 
PGD 5226 2 G06 M-008371-00 D-008371-01 GAUCAUCUCUUACGCUCAA 
         D-008371-02 UAAUAGGACUGUCUCCAAA          D-008371-03 GAAAUCACAGCCAAUAUUC           D-008371-04 GAAAUUGGUACCAUUGUUG 
RPIA 22934 2 G07 M-016428-01 D-016428-01 GGAAGUGGUUCUACAAUUG 
         D-016428-02 GCGAAUAGCUGAAAGGGUG          D-016428-03 GCUAGUCGCUUCAUCGUGA           D-016428-04 CAAAUGGAGUGAAGUGAAU 
PRPS1L1 221823 2 G08 M-006804-00 D-006804-01 GCAAAUAUGCUCUCUAUAG 
         D-006804-02 GAAAUCAACGACAGUCUAA          D-006804-03 CAACACUGCAUGCUUUGAA           D-006804-04 CAACCAGAGUUUAUGCUAU 
GPAM 57678 2 G09 M-009946-01 D-009946-01 GGAAAGAUGUUCUCUAUAG 
         D-009946-02 GAUAAUACCUGUUGGAAUC          D-009946-03 GUUCAUAGAUCCCAUAUUG           D-009946-04 AGAAAGAAAUGUUGCAGUA 
AGPAT1 10554 2 G10 M-003810-01 D-003810-01 AUGAAGAUCUUGCGUCUAA 
         D-003810-03 CGUGGCGCCUUCCAUCUUG          D-003810-04 UCGAGAACAUGAAGAUCUU           D-003810-05 UCAAAUACCUGUACGGGAU 
AGPAT2 10555 2 G11 M-003811-02 D-003811-01 GUGCGAAGCUUCAAGUACU 
         D-003811-03 GCCGGACGGUGGAGAACAU          D-003811-21 CGGCCGAGUUCUACGCCAA           D-003811-22 GCGCUGUGCUUCACGGUGU 
AGPAT6 137964 2 G12 M-010300-00 D-010300-01 GAAAUUGGAGCCACAGUUU 
        D-010300-02 UUAAGGAGUUCAUGAGUAA          D-010300-03 GAACCUGCAUCAAUAAUAC           D-010300-04 GAGAAGAACCACCAGCUUU 
UNQ1849 253558 2 H03 M-010307-00 D-010307-01 GGAAUUGCCUGAUGCGAUA 
         D-010307-02 UCGAAGACAUGAUUGAUUA          D-010307-03 GCCUAUAUCUUCAUUCAUA           D-010307-04 GAAAGAAGUGUCAUUAUCA 
AGPAT3 56894 2 H04 M-008620-00 D-008620-01 GCUCCAAGGUCCUCGCUAA 
         D-008620-02 GGGAGCAGCUUCCUUUGGA          D-008620-03 UCCAGGAGAUAUAUAAUCA           D-008620-04 GCAGCUGUCUAUGAUGUAA 
AGPAT4 56895 2 H05 M-009283-01 D-009283-01 AGAAAGAGCUGGCCUAUGU 
         D-009283-02 GGAGUUCGAUGGAUGAUUG          D-009283-03 GCACACGGUUCACGGAGAA           D-009283-04 AAAUGUAGUUUCAGCUGUA 
PPAP2A 8611 2 H06 M-019098-01 D-019098-01 GAGGAGGACUCUCAUACAA 
         D-019098-03 CUACAUAUGUCGAGGGAAU          D-019098-04 CAACAACUGGGAAUCACUA           D-019098-17 CUGUAUAUGUAUCGGAUUU 
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PPAP2C 8612 2 H07 M-011500-00 D-011500-01 UGACAGACCUGGCCAAGUA 
         D-011500-02 GCACGACUCUGUUGGAAGU          D-011500-03 GCUCGGACUUCAACAACUA           D-011500-04 CCGCGUGUCUGAUUACAAA 
PPAP2B 8613 2 H08 M-017312-01 D-017312-01 GGGACUGUCUCGCGUAUCA 
         D-017312-02 UCUAUUACCUGAAGAAGUC          D-017312-03 CAGUUCACCUUGAUCAUGA           D-017312-05 GGAAUUCUACCGGAUCUAU 
PCYT1A 5130 2 H09 M-008642-01 D-008642-01 GGAGAGGGUUGACAAAGUA 
         D-008642-02 UGAAACAUAUGCUGAAAGA          D-008642-04 GGAGAAGUCCCGAGAAUUC           D-008642-17 UGUGAGAGUUUAUGCCGAU 
PCYT1B 9468 2 H10 M-009611-01 D-009611-02 GGACAUCAUUACCAGAAUU 
         D-009611-03 AAAGAGCCAUGAUCUAAUU          D-009611-17 GGAAAUAACUAAUGCCUAU           D-009611-18 CUUAGUCACCUGUGCGAAA 
PLD1 5337 2 H11 M-009413-00 D-009413-01 UAACUGAGCUUAUCUAUGU 
         D-009413-02 GAAGAACAAUUCCUUGGUA          D-009413-03 GAAGAUUACUUGACAAAGA           D-009413-04 GGUAAUCAGUGGAUAAAUU 
PLD2 5338 2 H12 M-005064-01 D-005064-01 GGACAACCAAGAAGAAAUA 
         D-005064-02 GGACCGGCCUUUCGAAGAU          D-005064-03 GACCUGCACUACCGACUGA           D-005064-04 CAGCAUGGCGGGACUAUAU 
ACAS2L 84532 3 A03 M-008549-00 D-008549-01 CCACCAAGAUCGCCAAAUA 
         D-008549-02 GAUCGGAGCUGUCCACACA          D-008549-03 GAAGAUCAAUCAGUUCUAU           D-008549-04 UGAGGAAGAUCAUCACUAG 
ACAS2 55902 3 A04 M-010396-00 D-010396-01 GAGAAGGGUUUCCCAGUAA 
         D-010396-02 GAGACAACCUACUUUAAGA          D-010396-03 CCACAACCUUCAAGUAUGU           D-010396-04 GCACCUGGCUUGCCUAAAA 
ACACB 32 3 A05 M-004759-02 D-004759-01 GAACAUCCCUGCACAGAAA 
         D-004759-05 CCACAAAGGAUUUAAAUAC          D-004759-18 GAACUUAACCGGAUGCGUA           D-004759-19 AGAUACAUGAUCACGGAUA 
MT 27349 3 A06 M-014204-01 D-014204-01 GAAGAAUUCCUCUAAGUUU 
         D-014204-02 UAAAGGCAGUCGACAUUAA          D-014204-04 AGACGAUGCAUGCCAUAUA           D-014204-17 GCUGGCCGCUGUCGAGAAA 
THEDC1 55301 3 A07 M-004796-01 D-004796-01 GGGCAGAUCUGAACAUUGU 
         D-004796-02 GGAUAAACCAUUUGCAUUU          D-004796-04 CCAAGGAAUUUGUGAAACA           D-004796-17 GGAUCCUGCGAACGAGAAA 
FLJ20604 54995 3 A08 M-031860-00 D-031860-01 GGAGACUCAUUUAGAUUUA 
         D-031860-02 GGUCAGCAUUCGAUAUAAA          D-031860-03 GCAAUUGGCAUGGGAAUGA           D-031860-04 UCUCAACUAUGUUCCACUA 
ELOVL6 79071 3 A09 M-008861-01 D-008861-01 CAAUGGACCUGUCAGCAAA 
         D-008861-02 GGUCGGCACCUAAUGAAUA          D-008861-03 CGAACUAGGAGAUACAAUA           D-008861-17 GGGUGUAUAUCUAGAACGA 
SCD 6319 3 A10 M-005061-01 D-005061-02 GAUAUGCUGUGGUGCUUAA 
         D-005061-04 AGAAUGAUGUCUAUGAAUG          D-005061-05 CGACAUUCGCCCUGAUAUA           D-005061-06 GGAGUACGCUAGACUUGUC 
SCD5 79966 3 A11 M-008416-03 D-008416-03 CAUAUUGGGUGGCUGUUUG 
         D-008416-20 AGAACAUCGUCUGGAGGAA          D-008416-21 GAGAAAGCUUGACGUCACU           D-008416-22 CAGAAUGACAUCUUCGAGU 
ACAT1 38 3 A12 M-009408-00 D-009408-01 GAAAUGAACAGGACGCUUA 
         D-009408-02 GGGUAAAGCUUGAAGAUUU          D-009408-03 GCAAAGAAGCUGAAUAUUG           D-009408-04 GCGAAGAGGCUCAAUGUUA 
ACAT2 39 3 B03 M-010001-01 D-010001-01 UCACUUGGCUUACUUGAGA 
         D-010001-02 GGAAUUCCCUACUCUGUUC          D-010001-03 GAAGCCAUGUCCAAGCUAA           D-010001-04 GCAUCUGGCUGUCGAAUUC 
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AACS 65985 3 B04 M-009458-01 D-009458-02 CGAAAGGAAUCGCAGAUGU 
         D-009458-04 GGCAAGAAGUGGCUUUGUU          D-009458-17 CGUAUACGCUCAACGGCAA           D-009458-18 GGAACGAUGAGAACGGCAA 
IDI1 3422 3 B05 M-009357-00 D-009357-01 GAACAUUGAGAAAGGAUUA 
         D-009357-02 GAGGAAGAAUGUAACUUUG          D-009357-03 UAAGAUAACGCCAUGGUUU           D-009357-04 UAAAUGGUGGGAUAACUUA 
IDI2 91734 3 B06 M-008463-00 D-008463-01 GUAGUAGCCACCCAUUAUA 
         D-008463-02 GGAAUUGCCAUCUGAACGA          D-008463-03 UGGAGGAAAUGCUGAUUGU           D-008463-04 UCACGUUUCCUGGGUAUUU 
FDFT1 2222 3 B07 M-009442-02 D-009442-01 GGAAGAGAUUUAUCAUAGA 
         D-009442-03 GGACAAGUACUGCCACUAU          D-009442-04 CCACUUUGGCUGCCUGUUA           D-009442-05 GUUUGGAGCAGGUAUGUUA 
SQLE 6713 3 B08 M-009646-01 D-009646-04 UAUUGAAGGUGUUGUGUUA 
         D-009646-17 UUUCAAACUUGGUGGCGAA          D-009646-18 CAAACUUGGUGGCGAAUGU           D-009646-19 GAGAUACAGUGGAAGGUCU 
CYP51A1 1595 3 B09 M-009215-01 D-009215-01 CAGCAUACAUCCUCAACUA 
         D-009215-02 CCACUAUGCUUCGUUUAUA          D-009215-03 GAAGGGAGUUGCAUACGAU           D-009215-17 GGUAGGGAAUAAUCGAACA 
NSDHL 50814 3 B10 M-008448-00 D-008448-01 UGACAGGCCUCAAUUAUGA 
         D-008448-02 GCCAAGAGAUGCACAGUGA          D-008448-03 GAUAUGCUGUCAAUGUAUU           D-008448-04 GCAGUUAGCGAGCCAAUGA 
HSD17B7 51478 3 B11 M-008140-02 D-008140-02 GAAGAUGGACCUAGAUGAA 
         D-008140-03 GGAAUUCUGCCUCCGUUUA          D-008140-18 CAAUAUUGCUACUUCGCUU           D-008140-19 GCAUUCACUUUGACACCAU 
EBP 10682 3 B12 M-012282-01 D-012282-01 GAAAGAGUAUGCCAAGGGA 
         D-012282-03 GCCGAUACAUCCUGGGUGA          D-012282-04 ACGAAGACCUGCUUGGAGA           D-012282-17 CCCACAGUUUGGAGGGACA 
SC5DL 6309 3 C03 M-009745-01 D-009745-01 CAAAUUACAUGAUGACCUA 
         D-009745-02 GAAGAUUCCUACUCCAUUU          D-009745-03 GGAAGGGACCGCUCAGUUA           D-009745-04 GUGCAACACUGAGCUAUUA 
DHCR24 1718 3 C04 M-010222-01 D-010222-01 CAACACAUCUGCACUGCUU 
         D-010222-02 GAAAUGAGGCAGAGCUCUA          D-010222-03 GGAGUACAUUCCCUUGAGA           D-010222-04 CAUCAUCCCUGCCAAGAAG 
SOD1 6647 3 C05 M-008364-01 D-008364-05 UCGUUUGGCUUGUGGUGUA 
         D-008364-06 ACAAAGAUGGUGUGGCCGA          D-008364-07 GUGCAGGGCAUCAUCAAUU           D-008364-08 UUAAUCCUCUAUCCAGAAA 
SOD2 6648 3 C06 M-009784-02 D-009784-03 AAAGAUACAUGGCUUGCAA 
         D-009784-04 GUAAUCAACUGGGAGAAUG          D-009784-19 ACCAGGAGGCGUUGGCCAA           D-009784-20 GGAUUGAUGUGUGGGAGCA 
SOD3 6649 3 C07 M-009741-01 D-009741-01 GCGCCAAGCUCGACGCCUU 
         D-009741-02 ACGCCAAGGUCACGGAGAU          D-009741-03 GCGGAGUGGAUCCGAGACA           D-009741-04 AAGAAGCGGCGGCGCGAGA 
CAT 847 3 C08 M-010021-01 D-010021-01 CACAUGACAUUACCAAAUA 
         D-010021-02 GGAAUCCAGUUAAUUACUU          D-010021-03 GAGCACAGCAUCCAAUAUU           D-010021-04 GGACAUCGCCACAUGAAUG 
GPX6 257202 3 C09 M-019309-00 D-019309-01 GCAAGCACGUCCUGUUUGU 
         D-019309-02 GCAGUUCAAUACCCACUAG          D-019309-03 GCGAGGAGUACAUCCAAUU           D-019309-04 AUAGGAAGGUGGAUUGCAA 
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GPX1 2876 3 C10 M-008982-00 D-008982-01 GCAAGGUACUACUUAUCGA 
         D-008982-02 UGAAUUCCCUCAAGUACGU          D-008982-03 GGAGAACGCCAAGAACGAA           D-008982-04 GCAACCAGUUUGGGCAUCA 
GPX2 2877 3 C11 M-011675-00 D-011675-01 GAACGAGCAUCCUGUCUUC 
         D-011675-02 GAAGGUAGAUUUCAAUACG          D-011675-03 CAGGAGAACUGUCAGAAUG           D-011675-04 GCAGGGCCGUGCUGAUUGA 
GPX3 2878 3 C12 M-006485-01 D-006485-01 GUACGGAGCCCUCACCAUU 
         D-006485-02 GGAUGUCAAUGGAGAGAAA          D-006485-03 AGGAAGAGCUUGCACCAUU           D-006485-04 GAGGCUUUGUCCCUAAUUU 
GPX4 2879 3 D03 M-011676-01 D-011676-01 CAACGUGGCCUCCCAGUGA 
         D-011676-03 GUAACGAAGAGAUCAAAGA          D-011676-04 CGUCAAAUUCGAUAUGUUC           D-011676-17 GCUGCGUGGUGAAGCGCUA 
GPX5 2880 3 D04 M-009445-01 D-009445-03 GCAAGCACAUCCUCUUCGU 
         D-009445-04 UGGCGUACUUGAAGCAAUU          D-009445-17 AGGCCAUCGCACUUAAUAA           D-009445-18 GGGAGGAUUUGUACCUAGU 
GPX7 2882 3 D05 M-009875-01 D-009875-01 GAAGCGAGAAGACUUAUAA 
         D-009875-02 ACAAGGAGAUUGAGAGCUU          D-009875-03 GCACCUACAGUGUCUCAUU           D-009875-04 GGACUUCUACGACUUCAAG 
SCO2 9997 3 D06 M-011987-01 D-011987-01 GCAGAUCGGCUGAGCAGAU 
         D-011987-02 GAACAGAAGCCCUGCGCCA          D-011987-03 GAACCCGGCUGCUGAUCAC           D-011987-04 ACAGUUACCGCGUGUACUA 
ATPIF1 93974 3 D07 M-017220-00 D-017220-01 AAGAAGAAAUCGUUCAUCA 
         D-017220-02 AGAGAGAGCAGGCUGAAGA          D-017220-03 GCCAUAAGCAGAAGAUCAA           D-017220-04 GGGCGUGAGGACCAUGCAA 
COX4I1 1327 3 D08 M-011625-00 D-011625-01 UGUACGAGCUCAUGAAAGU 
         D-011625-02 GCAGAAGCACUAUGUGUAC          D-011625-03 CGAGUUGUAUCGCAUUAAG           D-011625-04 CCAAGUGGGACUACGAAAA 
COX4I2 84701 3 D09 M-013590-00 D-013590-01 GCACAGAACUCAACGCUGA 
         D-013590-02 UCGCAGCUCUGGUGAUUUG          D-013590-03 GCAGCGGGUCUACGUAUUU           D-013590-04 GAUGAACCGUCGCUCCAAU 
COX5A 9377 3 D10 M-011940-00 D-011940-01 GAACUUAGACCAACUUUAA 
         D-011940-02 ACACACUUGUUACCUAUGA          D-011940-03 GCAUGCAGACGGUUAAAUG           D-011940-04 GAUAUAGAUGCCUGGGAAU 
C12ORF5 57103 3 D11 M-020597-01 D-020597-01 AAUCACAGCUCUAAAGUUA 
         D-020597-02 GAUAUGACGGUAAAGUAUG          D-020597-03 GAAAUACGGGGUUGUAGAA           D-020597-04 GAGUCACGGUGCUUACAUG 
OXCT1 5019 3 D12 M-004045-00 D-004045-01 GAACGACAGUACUUAUCUG 
         D-004045-02 UUAUGUACAUCGCCUUAUA          D-004045-03 UGUGUCAACCGCAUUAUUA           D-004045-04 UCAACCGCAUUAUUACUGA 
OXCT2 64064 3 E03 M-013881-00 D-013881-01 UUAUGUAGAUCGCGUGAUA 
         D-013881-02 CCAAGAUCAUGGAGAAAUG          D-013881-03 ACGCGCAGCUCUGGAAUUU           D-013881-04 GCGCUUAACGAUCCUGAAA 
SLC16A7 9194 3 E04 M-007409-01 D-007409-01 GGAUUUAACUGGAGAAUAU 
         D-007409-02 GAUAGCAGGAGGCUUAUUA          D-007409-04 CAGCAAAUAUUCCACACUA           D-007409-17 CGGAAGAUGUUAACGUCAA 
SLC16A3 9123 3 E05 M-005126-03 D-005126-03 GGCAACUUCUUCUGCAUUA 
         D-005126-04 CGACCCACGUCUACAUGUA          D-005126-05 CAUGGUGGCUGCGUCCUUU           D-005126-06 GCUCACCUCCUCCCUGAUU 
SLC16A8 23539 3 E06 M-007410-01 D-007410-02 GCACGUCCCGUAUCUGUUC 
         D-007410-03 CCAAAGCCGUGAGCGUCUU          D-007410-04 UGUACGCCGUCACCAAGUU           D-007410-17 CUGCCUGCGUUGUGCUAAA 
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SLC16A4 9122 3 E07 M-007406-00 D-007406-01 GACAGGAGCCCUUAUAUUA 
         D-007406-02 GAAACACACUGCCAUGAGA          D-007406-03 GAAGAAAGUGAUAAGGUUA           D-007406-04 UGACAUACUUGGAGAGAAA 
TALDO1 6888 3 E08 M-008996-02 D-008996-01 GAGCAGAAAUACUAAAGAA 
         D-008996-02 CAGCACAGAUGCCCGCUUA          D-008996-05 CACAAGAGGACCAGAUUAA           D-008996-18 CCACAGAAGUAGACGCAAG 
RPE 6120 3 E09 M-012767-00 D-012767-01 GGGCUAAUCAGAUAGAUAU 
         D-012767-02 GAGCUAACAUGAUUGUGUC          D-012767-03 GUUCCCAUCUUUGGAUAUA           D-012767-04 CCAUAAAUGUGCAGAGGCA 
GFPT1 2673 3 E10 M-008833-01 D-008833-02 GGACGAGGCUAUCAUUAUG 
         D-008833-03 UGAAACGGCUGCCUGAUUU          D-008833-17 GAGCAUGGAUGACGAAAUU           D-008833-18 CAUGCAAGAAAGACGCAAA 
GFPT2 9945 3 E11 M-010390-01 D-010390-01 UCGCCAAGCUGAUUAAAUA 
         D-010390-03 GAUCAUCCGUGGCUUGAGA          D-010390-04 AGACAAAGGCAACGAAUUU           D-010390-17 CGAUGGGAAUAAUCACGAA 
GNPNAT1 64841 3 E12 M-005239-01 D-005239-02 CGGCAACUCUGAUUAUAGA 
         D-005239-03 CUACAUGUGUCGGAGGUUU          D-005239-04 GUACUGCUGACUUAAAUAG           D-005239-17 GGAUUACAUAUGUCGGCUA 
UAP1 6675 3 F03 M-017160-01 D-017160-01 GAACAAAGUUUCUAUGGCU 
         D-017160-02 UGAGAGAUGUUGUCAAUGU          D-017160-03 CUACUACGUUUCUGGAAUG           D-017160-04 ACCCAAGGACAGUUAAUUA 
OGT 8473 3 F04 M-019111-00 D-019111-01 GCAGUUCGCUUGUAUCGUA 
         D-019111-02 CGACAUGCAUUGCGUCUCA          D-019111-03 GAUUAAGCCUGUUGAAGUC           D-019111-04 CCGAGAAAUUGGCUUAUAU 
PGM1 5236 3 F05 M-010925-00 D-010925-01 CGAAUCGUCUUCCGACUGA 
         D-010925-02 GUACAUCGAUAGCUAUGAG          D-010925-03 CGACUGAAGAUCCGUAUUG           D-010925-04 GGAAAUUGUGGAUUCGGUA 
PGM3 5238 3 F06 M-013912-00 D-013912-01 GAGGUCAAUUCCAUGAUUA 
         D-013912-02 GGAUUUAGGUGCUAUUACA          D-013912-03 GGGCAAACUCAAUCAUUUA           D-013912-04 GACAAGAUAGCAACGUUAA 
WBSCR14 51085 3 F07 MU-009253-00 D-009253-01 GACACUCUCUUCACCAUGAUU 
         D-009253-02 ACAAGUGGCGCAUCUACUAUU          D-009253-03 GGGCACAUCUACCAGUAUCUU           D-009253-04 GCCCAUGCCUUCAAACUUCUU 
SLC25A10 1468 3 F08 MU-007469-00 D-007469-01 GCAGACAGAUGACCUACUCUU 
         D-007469-02 GUACCUCUCUGACAACAUCUU          D-007469-03 CCGCGUAGCUCGUGAAGAGUU           D-007469-04 CUGAAGACUCGCCUGAUGUU 
ME1 4199 3 F09 MU-009348-02 D-009348-02 CAUCUGACAUUGAGAAAUU 
         D-009348-03 AGUAAGAGGUUCUGAAUAU          D-009348-19 CCUUGCAGCUCUUCGAAUA           D-009348-05 GGUAAAUUGGCUCUAUAUA 
ME2 4200 3 F10 MU-009461-00 D-009461-01 GAAGAAGCAUAUACACUUAUU 
         D-009461-02 UGAAAGGCCUGUAAUAUUUUU          D-009461-03 GAACAUGGCGGAGUGAAUAUU           D-009461-04 GAAACGAGAUCGCACACAAUU 
GLS 2744 3 F11 MU-004548-00 D-004548-01 AGACAUGGUUGGUAUAUUAUU 
         D-004548-02 UGAAUAAGAUGGCUGGUAAUU          D-004548-03 GGUGGUUUCUGCCCAAUUAUU           D-004548-04 GAAUAACACUCCCAUGGAUUU 
GLS2 27165 3 F12 MU-012500-00 D-012500-01 UCAAACUGCUUCAAGAUUAUU 
         D-012500-02 GAACUUAGAAAGCAUGGUAUU          D-012500-03 CAAGUGGCCUGCGCUACAAUU           D-012500-04 GCCAUCGGCUAUUAUCUCAUU 
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PIK3CA 5290 3 G03 MU-003018-03 D-003018-07 GGACAACUGUUUCAUAUAG 
         D-003018-08 GCCAGUACCUCAUGGAUUA          D-003018-24 CUUGAAGAGUGUCGAAUUA           D-003018-25 GCUUGAAGAGUGUCGAAUU 
MYLCD 23417 3 G04 MU-009626--01 D-009626-01 GGAAUGAACUCUUUACAGA 
         D-009626-02 GAACAUCCUCCAUCAGAAA          D-009626-03 UGAAAGGAAUGCUCUCAGA           D-009626-04 UCAACUGGAUGGCGGAUGU 
IRS1 3667 3 G08 MU-003015-01 D-003015-05 AAAGAGGUCUGGCAAGUGA 
         D-003015-06 GAACCUGAUUGGUAUCUAC          D-003015-07 CCACGGCGAUCUAGUGCUU           D-003015-08 GUCAGUCUGUCGUCCAGUA 
PTEN 5728 3 G12 MU-003023-01 D-003023-05 GUGAAGAUCUUGACCAAUGUU 
         D-003023-06 GAUCAGCAUACACAAAUUAUU          D-003023-07 GGCGCUAUGUGUAUUAUUAUU           D-003023-08 GUAUAGAGCGUGCAGAUAAUU 
MYC 4609 3 H03 MU-003282-07 D-003282-14 AACGUUAGCUUCACCAACA 
         D-003282-15 GGAACUAUGACCUCGACUA          D-003282-16 GAACACACAACGUCUUGGA           D-003282-35 CUACCAGGCUGCGCGCAAA 
RPTOR 57521 3 H04 MU-004107-00 D-004107-01 GAAACCAUCGGUGCAAAUUUU 
         D-004107-02 AGAAGGGCAUUACGAGAUUUU          D-004107-03 UGGAGAAGCGUGUCAGAUAUU           D-004107-04 GCCCGUCGAUCUUCGUCUAUU 
RICTOR 253260 3 H05 MU-016984-01 D-016984-01 UCAACGAGCUCACAUAUGAUU 
         D-016984-02 GUACGAAGACUACUUUAUUUU          D-016984-03 UGACCGAUCUGGACCCAUAUU           D-016984-04 GUACUUGGGCUCAUAGCUAUU 
SLC16A1 6566 3 H06 MU-007402-02 D-007402-01 GCAGUAUCCUGGUGAAUAA 
         D-007402-02 AGAGGAAGCUUUCUAAUUC          D-007402-05 GGUAAUUGGAGCUUUCAUU           D-007402-18 GCCAAUAAGACCUCGAAUU 
SLC25A1 6576 3 H07 MU-007468-01 D-007468-01 CCAUAGUGUUUGUCAUCUA 
         D-007468-02 GCCUGGAGGCGCACAAAUA          D-007468-05 GCGCACAAAUACCGGAACA           D-007468-06 UGAAGCUGCUCAACAAAGU 
PDK1 5163 3 H08 MU-005019-00 D-005019-01 GGAAGUCCAUCUCAUCGAAUU 
         D-005019-02 GGAACACCAUGCCAACAGAUU          D-005019-03 GAUCAGAAACCGACACAAUUU           D-005019-04 GAUCAGUGAAUGCUUGUGAUU 
PDK2 5164 3 H09 MU-005020-00 D-005020-01 CAAAGAUGCCUACGACAUGUU 
         D-005020-02 GCACGGAGCCCAAGAACACUU          D-005020-03 GCUCCUGUGUGACAAGUAUUU           D-005020-04 CCAGCACACCCUCAUCUUUUU 
CPT1a 1374 3 H10 MU-009749-02 D-009749-01 GAGAGAACCUCAUCAAUUU 
         D-009749-02 GAAGAAGGAUACAGAAGUG          D-009749-05 GGACAGCUACGCCAAAUCU           D-009749-18 UGACAACGAUGUACGCCAA 
CPT1b 1375 3 H11 MU-010266-01 D-010266-04 CAAGUAACUAUGUGAGUGA 
         D-010266-17 GAUCAUGUAUCGCCGUAAA          D-010266-18 GGACUGAGACUGUGCGUUC           D-010266-19 CAUGAUUGCAGGCGAGAAC 
AKT1 207 3 H12 MU-003000-03 D-003000-05 GACAAGGACGGGCACAUUA 
AKT2 208     MU-003001-02 D-003000-07 GCUACUUCCUCCUCAAGAA 
AKT3 209     MU-003002-02 D-003000-08 GACCGCCUCUGCUUUGUCA 
 
